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ABSTRACT 
Non-Hodgkin’s Lymphomas (NHL) represent the eighth most common cancer in Western Europe. 
Yet despite their widespread prevalence and high mortality rate relatively little is known about the 
aetiology of these hematological malignancies. Consequently NHL represents an ideal candidate for 
the discovery of biomarkers lying along the causal pathway. Such biomarkers would allow the 
improved identification of risk factors and high risk individuals, as well as an enhanced understanding 
of lymphomageneisis.  However, to date there has been little progress in determining validated 
predictive biomarkers of NHL.  
This thesis attempts to address some of the issues that have previously hampered the study of NHL 
through novel strategies of biomarker identification utilising novel methodologies, technologies and 
statistical techniques.  The thesis comprises a nested case-control study within the European 
Prospective investigation into Cancer (EPIC) cohort and is split into two parts: the ‘validation of 
biomarkers’ and the ‘integration of biomarkers’.  The most exciting finding was the identification of a 
novel biomarker for Follicular lymphoma based on the t(14;18) translocation which comprises a 
previously unknown pre-disease condition. Although no other predictive biomarkers were identified 
this work represents a ‘proof-of-principle’ for the use profile regression in the study of highly 
dimensional complex datasets, and the possibility of using mass-spectrometry derived metabolic 
profiles in the study of lymphoma. Part two of the thesis confirmed that the use of the ‘meet-in-the-
middle’ approach was a valuable and feasible method for studying the complete causal pathway from 
risk factor to disease. 
Together these results highlight potential avenues for further study of NHL and confirm the utility of 
a number of novel strategies that can aid such work. Additionally it informs on some of the likely 
challenges that will be involved. 
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NPV Negative Predictive Value 
NSAID Non-Steroidal Anti Inflammatory Drugs 
NSHDS Northern Sweden Health and Disease Study 
OPLS-DA Orthogonal Partial Least Squares Discriminant Analysis 
OR Odds Ratio 
Pb Lead 
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PCA Principal Components Analysis 
PCBs Polychlorinated Biphenyls 
PCR Polymerase Chain Reaction 
PLS Partial Least Squares 
POP Persistent Organic Pollutant 
PPV Positive Predictive Value 
PRoBE Prospective-Specimen-Collection-Blinded-Evaluation 
QC Quality Control 
REMARK REporting recommendations for tumor MARKer prognostic studies 
RNA Ribonucleic Acid 
ROC curve Receiver Operator Characteristic Curve 
rt Retention Time 
SCALE Scandinavian Lymphoma Aetiology Study 
SNP Single Nucleotide Polymorphism 
STROBE-ME STrengthening the Reporting of OBservational studies in Epidemiology: Molecular Epidemiology 
TCDD 2,3,7,8-Tetrachlorodibenzodioxin  
TCE Trichloroethylene   
ttd Time to Diagnosis 
UPLC-MS Ultra-high Performance Liquid Chromatography Mass Spectrometry  
UV Ultraviolet 
VIP Variable Importance in the Projection 
  
B-cell NHL Subtypes  
MALT lymphoma Mucosa-Associated Lymphoid Tissue Lymphoma 
DLBCL Diffuse Large B-cell Lymphoma 
BCLL B-cell Chronic Lymphocytic Leukaemia  
FL Follicular Lymphoma 
MM Multiple Myeloma 
MCL Mantle Cell Lymphoma 
LPL Lymphoplasmacytic Lymphoma 
MZL Marginal Zone B-cell Lymphoma 
HCL Hairy Cell Leukaemia 
BALL B-cell Acute Lymphatic Leukemia 
SLL Small Lymphocytic Lymphoma 
BNOS B-cell NHL Not Otherwise Specified 
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1 INTRODUCTION 
Non-Hodgkin Lymphomas (NHL) represent the eighth most common cancer in Western Europe 1. Yet 
despite their widespread prevalence and high mortality rate relatively little is known about the 
aetiology of these hematological malignancies, and they remain largely incurable 2.  The incidence of 
NHL, particularly the more highly aggressive subtypes, has been reported to be on the increase in the 
UK and most other Western countries since the 1980s and although this observed increase has 
recently begun to plateau, the evidence suggests worldwide incidence and mortality rates are still 
rising 3-5. The causes of this increase have yet to be identified and are thought to be larger than can be 
explained by the diagnostic improvements and changes to the classification procedures which have 
occurred within the same time period 4,6. Few definitive risk factors have been identified and NHL 
remains a poorly understood malignancy for which the elucidation of its aetiology is further 
complicated by the existence of multiple heterogeneous subtypes. These factors combine to make 
NHL a prime candidate for biomarker discovery.  
 
Biomarkers are indicators in a biological system or sample, which include any objectively 
measureable characteristic that provides information on a physiological or pathological state.  There 
are three major types of biomarkers (Figure 1): biomarkers of susceptibility, biomarkers of exposure 
and biomarkers of effect. 
Figure 1: Schematic describing the different types of biomarker categories commonly employed 
in molecular epidemiology, their uses and specific examples 
Adapted from: Vineis and Perera, CEBP. 2007 7, Gallo et al. PLOS Medicine 2011 8 
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Biomarkers of susceptibility include multiple categories and are used to identify ‘at risk’ individuals  
where risk is either acquired (as measured by markers of previous disorders) or more usually, 
inherited (as measured by genetic markers) 
8
. Biomarkers of exposure are used to capture the initiating 
events in the causal pathway and therefore are most commonly used to identify risk factors and to 
understand the casual mechanisms by which they may cause disease 9. Finally, biomarkers of effect 
reflect the interaction between the risk factor and the individual 8 . Consequently they tend to be used 
in screening, diagnosis and disease progression monitoring 9.   
This thesis attempts to address some of the issues that have previously hampered the study of NHL 
through the use of novel strategies of biomarker identification, utilising a nested case-control design 
within the European Prospective investigation into Cancer (EPIC) cohort.  The thesis will be split into 
two parts: the ‘validation of biomarkers’ and the ‘integration of biomarkers’. In part one various 
datasets within the EPIC-Lymphoma subcohort will be utilised in order to define potential biomarkers 
of susceptibility, of internal dose, of biologically effective dose and of early biological effect (figure 
1). The clinical utility of these biomarkers will be assessed by validating their ability to predict future 
risk of NHL. Then, to provide a more global overview of the disease process, in the second part of the 
thesis two biomarker categories will be integrated in order to explore the extra information and the 
improved utility that can be obtained by considering them in combination. Together these analyses 
will provide an increased understanding of the mechanistic pathways involved in lymphomagenesis 
and the aetiology of NHL. In addition it will provide an overview of the current role of biomarkers in 
NHL, as well as possible research avenues for the future.  
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1.1 Histology 
NHL comprises a heterogeneous collection of lymphoproliferative B or T-cell malignancies that 
typically present as a solid tumour of lymphoid cells 10.  The cells differentiate from hematopoietic 
stem cells within the bone marrow and mature into high affinity antibody producing cells through a 
number of stages involving genetic recombination and mutation. This inherent capacity to generate 
specific antibody-mediated immunity through immunoglobulin gene rearrangement leaves the cell 
open to mutations if the rearrangement goes awry 11. The progressive accumulation of particular 
genetic lesions and translocations can deregulate certain oncogenes and disrupt homeostasis leading to 
proliferation, blocked differentiation and immortalisation, creating malignant T- or B-cells capable of 
clonal expansion.  Further modulation by environmental, epigenetic, pathogenic or genetic factors 
may then lead to the development and progression of lymphoma 3,12. Non-Hodgkin’s lymphomas are 
distinguished from Hodgkin’s lymphomas (HL) by the type of lymphocyte from which they arise; 
with Reed/Sternberg cells being the hallmark of HL 13.   
The majority of NHL develop in lymph nodes, with primary extranodal disease, most commonly in 
the stomach, intestine or skin, accounting for only 20–30% of cases 4. Lymphomas can be subdivided 
into two prognostic groups: indolent (slow growing) or aggressive (fast growing) which although they 
have a shorter natural history are frequently curable, unlike the indolent tumours which have a long 
median survival, but tend to be ultimately fatal 14.  
NHL was first evaluated as a separate entity in the late 1940s, and by the 1960s was characterized as 
either lymphosarcoma or reticulosarcoma 6. Medical advances and increased understanding of the 
immune system, the bone marrow and of the genetic and cellular basis of malignant transformation 
provided the ability to subdivide these malignancies further 15.  A number of differing classification 
systems including the Rappaport formulation, the Working Formulation, the Kiel classification and 
the Revised European-American Lymphoma (REAL) classifications were subsequently introduced. 
These were superseded by the WHO classification of haematological malignancies which were most 
recently updated in 2008 16. These criteria marked a substantial change in the classification of 
haematological malignancies, representing an international consensus for the first time and addressing 
the issue of the lack of compatibility between the different classification systems that had been used 
previously 15. The WHO classification refined and extended the definitions of existing haematological 
malignancies, incorporated clinical characteristics into disease criteria and identified new malignant 
conditions, based on biologically sound underlying principles to ensure clinical relevance, practicality 
and reproducibility 17,18. Currently more than 50 different subtypes of B and T-cell NHL have been 
defined, differing in both clinicopathological and biological characteristics 18 and potentially in 
aetiology.  
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Recently Morton et al. 19 proposed a classification system for the epidemiologic analysis of 
lymphoma subtypes based on a hierarchical system which groups subtypes according to pathologic 
features including morphology,  immunophenotype, genotype and stage of differentiation, and clinical 
features such as the site of occurrence. This was developed in order to address the challenges inherent 
in the epidemiological analysis of lymphoma. Evidence suggests etiological heterogeneity between 
the subtypes, but the various clinical and pathological schemes used over time and across the world 
complicate the study of individual subtypes. Standardising the groupings for epidemiologic research 
facilitates the comparison of subtype-specific literature, the harmonisation of cases diagnosed using 
differing systems and the pooling of cases for meta-analyses. All of these effects will further the 
elucidation of aetiology. The system, based on the WHO classification of lymphoid neoplasms 20 and 
the International Classification of Diseases – Oncology, Third edition (ICD-O03) 21, suggests that 
analyses are focused on the highest hierarchical group possible within the limit of the sample size of 
that study. This thesis will be focussed on hierarchical group four: peripheral B-cell neoplasms (from 
here on NHL will be taken to refer only to B-Cell NHL). The Morton et al. classification system was 
chosen for this thesis first to reflect the diversity of subtypes included, some of which pre-date the 
WHO 2001 classification. Second, within EPIC there is insufficient power to investigate each sample 
individually due to sample size. The Morton et al. system enables the grouping of pathologically and 
clinically similar neoplasms within EPIC, maximising the power and the likelihood of producing 
biologically relevant findings in this thesis, as well as thirdly allowing comparisons with the existing 
literature. 
 
 
 
 
 
 
 
 
 
 
25 
1.2 Incidence 
The worldwide age-standardised incidence of NHL as a group (ICD-10 codes C82-85, C96) was 
estimated to be 5.1 cases per 100,000 persons in 2008.  Risk increases with age from 1.7 cases per 
100,000 in those aged 15-39 years to 28.1 in the 70-74 years age group and 40.2 in those aged 75 
years and older 22. The average age at diagnosis is between 60 and 70 years, although this differs 
markedly by subtype 2,15. Precursor T- and B-cell malignancies are primarily diseases of children and 
young adults, while in adults most hematological malignancies arise from mature immunocompeptant 
B-cells.   This is likely explained by the transition from an immune system rich in precursor cells in 
the young to one increasingly dominated by germinal centre and memory B-cells with increasing age. 
Overall incidence rates are roughly 1.5 times higher in males than females 15 (Figure 1.2a), with an 
age standardised rate of 6.0 cases per 100,000 compared to 4.2 in females. This gender-disparity has 
been hypothesised to relate to gender-specific differences in immune system regulation 15.  It has been 
observed to differ by subtype 15, but overall to increase with age, and it is particularly apparent over 
the age of 50 years 23. 
Figure 1.2a: Estimated Incidence of NHL by sex and age group, per 100,000 persons 
Created based on data from GLOBOCAN 2008 (IARC) http://globocan.iarc.fr/map.asp  Accessed 06.04.20141 
NHL International Classification of Disease Codes (ICD) C82-85, C96. Includes HIV disease resulting in malignant neoplasms 
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Geography 
In common with many cancers, overall incidence rates for NHL are higher in the Western world, 
namely North America, Europe and Oceania (Figure 1.2b). Again subtype plays a role, in particular 
diffuse and follicular lymphomas are very common in the Western world but rare in developing 
countries and the far-east, while Endemic Burkitts’ lymphoma, which is related to infection with the 
Epstein Barr virus (EBV), occurs almost exclusively in Africa 1,4,24,25. The extent to which these 
geographical differences represent true effects as oppose to a reflection of the better awareness and 
reporting of NHL in Western nations remains to be established. This is of particular interest as the 
burden of HIV/AIDs in much of the developing world would be expected to have a strong impact on 
prevalence. A proportion of the difference is likely to be attributable to the quality of the cancer 
statistics available from resource poor settings, which may not be entirely comparable to those from 
more developed nations.  Although reporting can be problematic for all malignancies, it is particularly 
difficult for lymphomas due to the evolving classification, the poor standardisation of data, and the 
fact that unlike many other cancers, haematological neoplasms are diagnosed using multiple 
parameters. These include a combination of histology, cytology, immunophenotyping, cytogenetics, 
imaging and clinical data in addition to clinical and biological prognostic factors. This information 
can be difficult to access systematically and in enough detail to be able to implement the WHO 
classification 15. These factors will undoubtedly impact the variation in global incidence, nevertheless 
given the strong association between age and risk, an even larger percentage is likely to be attributable 
to the differing age distributions between the developed and developing world, and the competing 
risks in developing nations. 
Figure 1.2b: Estimated global age-standardised incidence rate of NHL per 100,000 persons: 
Males and females, all ages 
 
GLOBOCAN 2008 (IARC) http://globocan.iarc.fr/map.asp Accessed 13.10.20131 
NHL International Classification of Disease Codes (ICD) C82-85, C96. Includes HIV disease resulting in malignant neoplasms 
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Incidence increase 
The increase in incidence of NHL since the 1980s is well referenced in the literature 2  and has been 
observed to be particularly marked in developed nations. It has been reported in both males and 
females, across most ethnic and age groups and in nearly all subtypes, although it has been notably 
larger for aggressive NHL 4,26.  The rise has now begun to plateau, however the reasons for the 
changing trends remain unknown 3,27.  Interestingly, the incidence trend of NHL is not mirrored by 
that for HL or Leukaemia, which have remained relatively stable during the same time period despite 
the fact the three malignancies are believed to share a number of risk factors 28. 
 
A large body of research has been dedicated to the investigation of the observed increase and to 
determining whether it represents a true effect or merely a data artefact. Changes in classification 
methods, advances in diagnostic technology and improvements in cancer registrations have all been 
postulated to play a role 5,29. The impact of the WHO classification on incidence trends and disease 
burden should also not be underestimated. These criteria resulted in the inclusion in incidence data of 
previously unrecognized lymphoma types, such as mantle cell lymphoma, MALT lymphoma, and 
various T-cell lymphomas. Further, refinements in the histomorphological understanding of HL led to 
a large number of HL cases being reclassified as NHL 15. 
 
Overall the weight of the evidence suggests that although such factors have inflated the incidence of 
NHL, the magnitude of its change is too large to be explained by data artefact alone 5,30. This is 
supported by the fact that an increase was been reported in a variety of diverse nations with different 
diagnostic and reporting procedures 5,30. In 1992 an international workshop concluded NHL 
constituted an “emerging epidemic” 31 implicating a pivotal role for an increase in causal 
environmental, lifestyle or other risk factors 4,5,26,32,33.  The subsequent levelling off of this increase 
has been attributed to cancer preventative measures and to changes in the prevalence of putative risk 
factors, such as restrictions in the use of certain chemicals, particularly in Western countries 34. 
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1.3 Aetiology  
The specific mechanisms for the development of NHL have yet to be determined, however chronic 
antigenic stimulation, the induction of an immunosuppressive state or the disruption of normal cell 
proliferation are likely candidates 3. It is similarly unknown what co-factors may interact with the 
normal regulation of lymphocytes to precipitate these malignant pathways, however the global rise in 
the incidence of NHL suggests that exposure to, or the prevalence of  such factors may also be on the 
increase 33. Genetic, viral, environmental and biological factors are all likely to play a role. 
1.3.1 Immune dysfunction 
Immunosuppression 
NHL is a malignancy of the immune system and the most consistently and strongly associated risk 
factor is congenital or acquired immunodeficiency 35,36. This is supported by the elevated incidence 
rates in immunosuppressed populations 2. A quarter of patients with congenital immunodeficiency 
will develop a tumour at some point during their lifetime, of which NHL comprise about 50%. AIDS 
patients (excluding those in Africa) show an up to 100-fold higher risk of NHL than the general 
population 4. The majority of AIDS-related NHL are high-grade tumors involving extra nodal sites, 
some of which are specific to HIV/AIDs patients and other which also manifest in HIV negative 
patients 37. In fact, the onset of the AIDs epidemic in the 1980s was one of the postulated reasons for 
the observed increase in NHL incidence, however accumulated evidence suggests this is unlikely to 
the be case 32. The immunosuppressive state is a result of the down regulation of the T-cell response 
to compensate for chronic antigenic stimulation 3. This characteristic antigenic stimulation which 
induces immunosuppression also increases B-cell proliferation and consequently the probability of a 
random genetic mistake. Such mistakes are particularly prevalent in immunoglobulin gene 
rearrangement during lymphopoiesis 38, thereby increasing the risk of lymphomas. Risk increases with 
the degree of immunodeficiency and there is no evidence of a threshold 39.   
The use of immunosuppresive drugs following organ transplantation or for the treatment of 
autoimmune disorders has also been associated with a dose-dependent increase in risk 4. However it 
appears to be only a temporary effect with a high rate of tumour regression observed following the 
withdrawal of the drugs 3.  
Autoimmunity 
Autoimmune disorders themselves, which manifest in an imbalance of the immune system towards 
the T-helper 1-cell mediated response 40, have also been frequently associated with NHL risk 
independently of treatment. In particular Rheumatoid arthritis, systemic lupus erythematosus, Coeliac 
disease and Sjögren’s syndrome have been implicated 40. Some estimates suggest the risk of NHL 
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may be increased by up to 44 times in people with Sjögren’s syndrome compared to the normal 
population 4,41.  The effect of autoimmunity appears to impact multiple subtypes, in particular 
DLBCL, FL and MZL, as well as NHL overall 
32
, and to be stronger in females than in males 
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. 
Allergy and Atopy 
In comparison, the relationship between NHL and atopy is less well understood, and the literature less 
consistent 35,42 with positive 43,44, null 35,45 and negative associations 46,47 reported.  Two conflicting 
hypotheses have been put forward to support the contradictory findings. The ‘immune surveillance 
hypothesis’ proposes that the atopic conditions may be protective against NHL due to the dominance 
of the humoral T-helper 2 response which heightens response to foreign antigens and thereby 
enhances the ability of the immune system to detect and eliminate malignant cells 46,48,49. Conversely,  
‘ The Antigenic stimulation hypothesis’  suggests that atopy may in fact lead to an increased risk of 
malignancy 48 by creating a subchronic state of inflammation 42 which results in a higher possibility of 
random mutations occurring in dividing cells 35. Epidemiological evidence relating to number of 
siblings, birth order and household crowding is inconsistent, and again appears to differ by subtype 
35,50-52.  The relationship is further complicated by that fact that NHL itself has been associated with a 
reduction in atopic symptoms and in low levels of immunoglobulin subclasses including IgE 53. 
Therefore the ‘protective’ effect, which has mainly been observed in case-control studies and only 
rarely in cohorts 35, may in fact be a result of reverse causation. Contrary to this, decreased levels of 
plasma cytokines such as Interleukin-2 and Tumor necrosis factor-α and down regulation of T helper-
1 cytokines have been observed to be associated with future risk in prospective studies 27. 
 
Infectious agents 
Finally in addition to HIV which induces an immunosuppressive state though the depletion of CD4+ 
37, a number of other infectious agents have also been implicated in risk 54. This is thought to be 
mediated through their induction of cell proliferation, inflammatory cytokine release, stroma 
activation, and DNA damage 3,4. Certain viruses are known to be able to directly transform 
lymphocytes. The most well-characterised is the relationship between EBV and Burkitts Lymphoma.  
Burkitt’s tumour cells almost universally display a t(8;14) translocation which activates c-myc a 
potent oncogene 54.  EBV is also thought to be associated with NHL through immunosuppression and 
the resulting proliferation of transformed B cells normally controlled by T-cell-mediated immunity. 
Roughly half of HIV-associated DLBCL cases are EBV positive. EBV has further been hypothesized 
to increase risk through infectious mononucleosis, which has also been associated with NHL and of 
which EBV is a major cause 32,55. 
More recently additional viruses and pathogens have been implicated in a number of NHL subtypes. 
HTLV-1 has been associated with the risk of adult T-cell Leukemia/lymphoma in a Japanese 
population 56, and H.pylori has reported to be causal for gastric MALT lymphoma due to chronic 
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inflammation 57. Hepatitis B and C infection, herpes zoster, Campylobacter jejuni, Chlamydia psittaci 
and Borrelia burgdorferi have all also been implicated, although the evidence is inconsistent 32,5058.  
Further the high prevalence of some of these infections relative to the incidence of NHL suggests they 
are interacting cofactors, and alone do not represent a sufficient cause 4. In general the explorations of 
previous infection as a risk for future NHL is limited by the self-reported nature of the data and 
problems of recall bias, particularly among adults interviewed about their health in childhood, few of 
the existing studies use medical records for confirmation and for many infections and conditions 
differing definitions are used between different studies 55. 
In summary, the overwhelming weight of the evidence supports immune dysfunction as the 
underlying basis of lymphomagenesis27,59. Nevertheless, although individuals with 
immunosuppressive and autoimmune disorders display a large increase in risk of NHL, in fact they 
account for only a small proportion of cases 2 . For the majority of cases, although pathogenesis may 
act through pathways of the immune system, immune dysfunction itself is not the cause.   
1.3.2 Occupational Exposures 
Epidemiological studies have noted some apparent associations between certain occupations and 
NHL. Meta-analyses and systematic reviews have most consistently found farmers, teachers, dry 
cleaners, butchers, car repairmen and workers in the wood and printing industries to be at an increased 
risk 60,61. However to date, no workplace exposures have been conclusively identified as risk factors 
for NHL, and occupation is unlikely to represent a major risk factor in most populations 62. 
For some of the implicated occupations, in particular the ‘white collar’ occupations, there is no 
obvious causal link with NHL. However, for others there is a biological rationale; the association with 
teaching, animal husbandry and farming is supportive of a viral or bacterial aetiology of NHL 32,60,61, 
while the relationship with farmers has also been used as evidence for a link with UV radiation 
exposure due the large amount of time farmers spend outdoors 3. In fact, for the vast majority of 
observed associations the relationship with NHL is likely to be linked to exposure to the specific 
pesticides, solvents, oils, organic and inorganic dusts, aromatic amines, paints and varnishes 
associated with the particular occupation of interest 3,4,32,60,61. 
1.3.3 Environmental pollutants 
Despite evidence from occupational studies and plausible mechanisms, including genetic mutations 
and immunosuppressive effects 3,  the role of environmental pollutants in NHL remains uncertain. 
Studies tend to be marked by small study populations with poorly characterized exposures leading to 
limited statistical power, poor quality of exposure measurements, minimal efforts to control for 
confounding, and lack of information on dose-response and temporality 3.  Occupational studies have 
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often been conducted in extremely high exposure settings, such as in the aftermath of an industrial 
disaster, and so are difficult to interpret in terms of actual population risk 63.  
The Seveso disaster was an industrial accident in a chemical manufacturing plant in the Lombardy 
region of Italy. It resulted in the highest ever known human exposure to 2,3,7,8-
Tetrachlorodibenzodioxin  (TCDD) and has formed the basis of the evidence linking dioxins to NHL 
risk. Follow-up of the exposed population noted an almost doubling of the risk of lymphohemopoietic 
neoplasms 64, and these findings are supported  by similar study of an industrial accident in a Dutch 
cohort 65 and by evidence from animal models 66. Dioxin toxicity is mediated through binding to the 
aryl hydrocarbon receptor (AHR), a ligand-dependent transactivating factor which is expressed by 
major cell types of the immune system 67,68. TCDD has been shown to target cells in the immune-
haematopoietic system and consequently the observed association with NHL is thought to be 
mediated through its immunosuppressive effects 67,69.  
A vast number of other chemicals with either known effects on the immune system or associations 
with other haematological malignancies, such as leukaemia, have similarly been explored. The dioxin-
like properties of certain congeners is also, in part, the rationale behind the exploration of the 
polychlorinated biphenyls (PCBs) 70-72 which are mixture of synthetic chlorinated hydrocarbons 
produced directly or indirectly by multiple industrial and agricultural processes. Agricultural exposure 
to pesticides has been suggested as a further explanation for the increased risk of NHL observed in 
farmers. Of the most commonly used pesticides phenoxy herbicides and the herbicide 2,4-
Dichlorophenoxyacetic acid (2,4-D) have been associated with the greatest risk however the lack of 
evidence for a dose–response relationship has raised doubts about the significance of these findings 3.  
Multiple other pesticides which have demonstrated tumour initiating and/or promoting effects in 
animals have been studied 67,73-75, however data is scant and, like the study of PCBs, subject to 
problems of exposure measurements and classification, as exposure is frequently based on self-report 
or the use of job exposure matrices  3,4,32. Duration of follow-up could also be an issue for 
epidemiological studies of NHL given that many subtypes represent indolent disease. Therefore 
although associations cannot be ruled out, to date neither PCBs, pesticides as a general group, nor 
specific chemicals have been defined as definitive risk factors 32,73,76-86. Some of the strongest data 
relates to solvent exposure, in particular Benzene and Trichloroethylene (TCE). Yet despite a large 
number of studies the evidence is largely inconsistent, a causal association is yet to be established, 
and if it does exist appears to be restricted to FL and CLL 87-90.  
1.3.4 Other environmental, lifestyle and anthropometric risk factors 
A number of other environmental and lifestyle variables have been suggested as NHL risk factors.  A 
history of blood transfusion has been associated with an up to four-fold increase in risk of NHL, 
which may be due to oncogenic virus transmission, transfusion-induced immunosuppression or 
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engraftment of malignant lymphoma cells from the donor 3,91. A number of medications including 
statins, NSAIDs, antibiotics and antidepressants have been implicated by some studies 32, although it 
is difficult to separate their effects from those of the underlying condition they were prescribed for, 
particularly for antibiotics. Postmenopausal hormone therapy and an increasing number of 
pregnancies has been associated with a decreased risk, while long term (>5 years) use of hormonal 
contraception has been observed to increase risk 92-94. In both instances these effects appeared to be 
specific to FL and DLBCL. The known carcinogenic effects of smoking, coupled with the evidence 
that tobacco can alter the immune response and that cigarettes contain substances known to be 
leukemogenic has led to smoking being suggested as a risk factor. The evidence supports an 
association but, again, suggests it is restricted to FL 95.The use of hair dyes, particularly before 1980 
has been observed to increase the risk of FL and CLL/SLL  96.  Exposure to ionizing radiation, 
therapeutic radiation and ultraviolet radiation/sunlight 97,98 have all also been widely studied. However 
the data remain inconclusive 32. 
Anthropometry 
The global rise in obesity has been postulated as an explanation for the reported increase in NHL 99, 
given that obesity is also known to cause chronic low-grade inflammation and specific immune 
alterations 32. Obesity has previously been associated with a number of other malignancies however it 
appears that the relationship with NHL, if real, may be restricted to DLBCL 100. Height has been 
associated with overall NHL risk, but only in females 101. 
Dietary factors 
A high intake of fat, particularly animal and saturated fat, and of red meat has been suggested to 
increase risk of NHL, although previous studies have found it hard to disentangle the dietary effects 
from their strong correlation with obesity 99,102,103. Conversely an inverse association with vegetables 
has been reported in a number of studies. This may be related to the high content of isothiocynates, 
which are hypothesised to induce apoptosis and growth arrest in preneoplastic and neoplastic cells 99.  
Evidence is also suggestive but insufficient for a protective effect of wholegrains, fish, fruits, 
antioxidants and one-carbon nutrients 99,102. Vitamin C intake has been reported to be inversely 
associated with FL risk 104. Moderate physical activity is thought to similarly be associated with a 
reduced risk 99, and again it is hard to establish whether one, or all, of these associations are causal or 
whether they are merely proxies for a healthier lifestyle and therefore a lower risk of malignancy.  
 
Perhaps at odds with the healthy lifestyle argument is the recent meta-analysis which provides 
quantitative evidence for a protective role of alcohol on NHL risk in both sexes and across all 
subtypes; the risk in alcohol drinkers is reduced by 15% compared to non-drinkers 105. It has been 
suggested that alcohol may act through its immunomodulatory effect, the improvement of insulin 
sensitivity or via the antioxidants present in most alcoholic beverages. However at present such 
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mechanisms are merely postulations and there is a lack of a biological rationale for an association, as 
well as a risk of reverse causation if the onset of disease symptoms is associated with an increase in 
abstinence 
105
. In general diet is a complicated risk factor to study given such possible confounding 
and the fluctuating nature of dietary patterns over time, and further studies are needed to investigate 
putative associations with NHL.   
1.3.5 Genetics of NHL 
A family history of any hematopoietic malignancy has been found to be associated with a 2-4 fold 
increased risk of NHL 106 suggesting a heritable component to risk. Aggregation of NHL in certain 
families has been observed, although this is rare  107.  In general, familial lymphomas account for 
around only 5% of all cases 3 and it is unclear to what extent such clustering is due to an increased 
awareness of the symptoms of this malignancy or to shared environmental factors. There does appear 
to be some non-uniformity in heritability by subtype, sex and the relationship to the affected relative. 
Siblings have been shown to confer the greatest risk, but overall the pattern of heritability remains 
poorly understood 106. The primary congenital immunodeficiency disorders which are strongly 
associated with NHL such as Ataxia telangiectasia and Wiscott–Aldridge syndrome also impart a 
heritable component of NHL risk, although again such disorders are rare 3.  
The role of a genetic component in risk has been supported by evidence from candidate gene studies 
considering germline mutations 108,109, and more recently by a number of genome-wide studies of 
NHL and its subtypes 110,111.  Due to the importance of immune dysfunction in aetiology, some of the 
most commonly explored pathways are those involved in the immune and inflammation response. 
Within these pathways studies have identified variants in genes which appear to be associated with 
NHL as a whole including toll-like receptor genes 112, TRAF1, RIPK3, BAT2, MAP3K5, DUSP2, 
CREB1, B3GNT3, SELPLG, LSP1, FGG, ITGB3 113, as well as those associated with particular 
subtypes. Genes involved in the TH1/Th2 balance have been shown to affect overall risk of NHL 114, 
but the findings are particularly strong for DLBCL with specific variants in TNF and IL10 associated 
with a doubling of risk 
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. Similarly genetic variation in the major histocompatibility complex, which 
is within the 6p21.3 region, although found to be associated with all subtypes 116, has been observed to 
be of particular importance in FL 110,117, DLBCL 118 and CLL 119 susceptibility. Risk of CLL has 
additionally found to be associated with a further gene involved in the immune response, the 
transcription factor IRF4 120. 
Variants in the one-carbon metabolism pathways genes such as TYMS, MTHFR, MTR, BHMT, CBS, 
FPGS, FTHFD, and SHMT1 have also been implicated, and it is thought this may be mediated 
through the role of this pathway on immune function 2,121.  Genes involved in the oxidative stress 
pathway 122, DNA repair 123, the xenobiotic metabolism pathway 124 and a number of pro-apoptotic 
genes such as BCL2L11125 have been similarly associated with risk. More recently, a new region of 
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interest on chromosome 9 has been identified. This region includes SYK, which encodes a kinase and 
is known to be of importance in B-cell development 116 . Furthermore, emerging evidence suggests a 
potentially important role for interactions between certain genetic variants and lifestyle and 
environmental variables in risk 126. A number of gene-environment interactions, involving both the 
aforementioned and additional pathways such as vitamin D and leptin, have been reported in the 
literature (see chapter 2 for details).  
However, studies considering a role for constitutional genetics in the aetiology of NHL are hampered 
by a lack of reproducibility, and therefore it is difficult to determine causal associations. This failure 
to replicate findings between studies has been attributed to inherent technical variability, 
heterogeneity between the studied populations and population stratification, issues of multiple testing 
and limited power, particularly when considering subtypes 2. An International consortium of 22 
lymphoma studies known as InterLymph is now addressing this by conducting the largest subtype-
specific GWAS of NHL to date. The first paper to emerge from this consortium GWAS considered 
CLL and was able confirm a number of previously reported associations, as well as identifying nine 
novel loci. These loci were in close proximity to genes involved in apoptosis 87, supporting their 
biological plausibility, and also therefore the power of the InterLymph GWAS. The findings for 
DLBCL, FL and MZL are due to be published soon. Nevertheless, these studies are still limited by 
their focus on individual markers 2. The most likely genetic basis of NHL seems to consist of multiple 
common variants each with only incremental individual effects influencing risk in combination 12.   
Further information on the pathology of NHL and therefore potentially greater understanding of 
genetic susceptibility may also be explored by considering the tumour genome and the temporal 
sequence of somatic mutations in lymphoma tumours. Such studies have revealed that tumour 
phenotypes are a result of multiple oncogenic abnormalities acting synergistically 109.  Chromosomal 
translocations, including t(2;5)(p23;q35), t(3;22)(q27;q11), t(11;14)(q13;q32) and t(14;18)(q32;q21), 
are a genetic hallmark of NHL and have been shown to play a particularly important role in the 
pathology of lymphomagenesis through the inappropriate expression of certain crucial genes at 
reciprocal breakpoints  2. The disruption of chromatin biology has also been suggested to be an 
important factor based on the observation that genes with roles in histone modification are mutated in 
some tumours 127. While mutations in genes that play a vital role in the survival of B-cell, such as 
BCR and its co-receptors, are thought to enable lymphoid tumor cells to avoid apoptosis and have 
been associated with disease prognosis 128.  
 
Again, while some of these mutations appear to pertain to multiple subtypes, others are specific. This 
has been observed to be particularly true for the translocations such as t(14;18) which is strongly 
associated with FL (see chapter 7 for further details). In fact, some of the most interesting findings to 
emerge from the study of tumour biology are those revealing the extensive genetic heterogeneity 
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between the subtypes, particularly between the germinal centre and non-germinal centre derived 
malignancies. Even within the subtypes gene-expression profiling and next generation based 
sequencing technologies have identified further molecular subgroups 
129
. For example DLBCL has 
been shown to be comprised of at least two molecularly and clinically distinct diseases: a germinal 
center B cell-like (GCB) and an activated B cell-like (ABC) form.  These two disorders arise from B 
cells at different stages of differentiation and are associated with specific genetic alterations, 
differentially expressed regulatory factors, different molecular signaling pathways, and different 
clinical outcomes 23,109,130. Gene expression signatures tend to reflect the intrinsic properties of 
tumours cells as well as the tumour microenvironment and as such have provided a number of other 
novel insights into the pathobiology of human lymphomas, including predictions of response to 
therapy and of survival 109.  Such insights inform on aetiology and provide promising new therapeutic 
molecular targets for NHL 131. Consequently their findings should not be overlooked, rather they 
should be utilized to help to refine the search for underlying genetic susceptibility markers. 
 
1.3.6 Summary 
In summary despite multiple studies, causal associations between environmental, lifestyle, dietary or 
genetic factors and NHL remain elusive. This may imply that causal associations do not exist with the 
risk factors explored to date, or alternatively it may be that genuine causal relationships have been 
obscured by bias or confounding in the study designs utilised.  
A particular problem relates to the difficulty of accurately assessing environmental exposures and lifestyle 
factors. In NHL, a large number of the positive associtions with suspected risk factors arise from case-
control studies. These are commonly cited dspite the fact the fact that such findings are subject to the 
problems of reverse causation as well as selection and recall bias 71.  Reverse causation in the case-control 
setting is also particularly problematic for putative NHL risk factors such as PCBs, as treatment or the 
disease itself has been reported to affect metabolism and blood concentrations of exogenous exposures 
82,132
.  Case-control studies additionally allow no measure of temporality. This may be a particular 
problem in occupational studies, which form a sizeable majorotiy of NHL research,  where long-term 
exposure may be difficult to objectively quantify and where workers may be more aware of the 
harzardous nature of their exposure environments.  Results from cohort studies can be considered as more 
definitive proof, however even here duration of follow-up is likely to be an issue given that many 
subtypes represent indolent disease and may be not be symptomatic for many years after exposure.  
As discussed below, the heterogeneity of NHL is also problematic when considering aetiology as 
rather than representing a single disease NHL encompasses a heterogeneous group of malignancies 
varying in histological characterization and clinical manifestation 20, which may not share the same 
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aetiological pathway. Correct case-subtype classification is vital, but often lacking, particularly 
among older studies, given the multiple classification systems employed over time.  Furthermore a 
large number of the putative risk factors are not specific to NHL and have been linked with other 
malignancies such as dioxins and prostate cancer 133, hormonal and reproductive factors and breast 
cancer 134, smoking and lung cancer 135, red meat consumption and obesity with colorectal cancer 136.  
Similarly the ‘protective’ effect observed for certain dietary factors may simply be reflective of a 
lower overall risk of malignancy. Even for some of the strongest findings such as benzene, often more 
consistent evidence exists for these exposures with other haematological malignancies 137. Hair dye 
usage appears to be one of the few risk factors specific to NHL 138. Similarly, the weight of the 
evidence suggests NHL may be the most common malignancy in immunocompromised individuals, 
but alone these factors account for only a small proportion of disease.    
Consequently the identification of validated risk factors for NHL is challenging. In fact, it is likely 
that, in common with most complex diseases, the majority of cases of NHL have a multifactorial 
aetiology, with each variable conferring only a small increase in risk. The incidence trend of NHL 
over recent decades suggests that exogenous factors including lifestyle and environment, play a 
particularly important role 4, but are associated with only small effect sizes 32 making their accurate 
measurement even more vital. However in the context of large epidemiological studies this can be 
extremely difficult; there is often a lack of consistency between studies in terms of how putative risk 
factors are measured. Furthermore, rather than being measured directly they are often inferred from 
occupation or area of residence. Finally, many studies consider single risk factors and even when 
confounding variables are taken into account, such univariate exposure is unlikely to reflect real world 
experience. Consequently in order to identify the factors contributing to risk, it is vital to have 
improved way of measuring them in the context of large epidemiological studies. The use of validated 
quantitative biomarkers could have the multi-beneficial impact of standardising risk factor 
assessment, improving definition of its relationship with NHL, and providing insights into potential 
mechanistic pathways. 
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1.4 Subtype heterogeneity  
According to the WHO classification, which represents the international standard for clinical practice 
and research there are at least 50 different subtypes of NHL 16. Even within the subtypes gene-
expression profiling has revealed further subdivision, particularly for DLBCL and FL 117. These 
different subtypes differ in genetics, morphology, immunophenotype, molecular signalling pathways 
and clinical outcomes, particularly regarding survival 2,17. The incidence of NHL differs by subtype; 
the two most common subtypes are diffuse large B-cell lymphoma (DLBCL) and Follicular 
lymphoma (FL) which account for roughly 40% and 20% of all cases, respectively. 
 
The heterogeneous nature of NHL complicates the study of lymphomagenesis. Differences in 
aetiology have not, to date, been well characterised, with both common and subtype-specific risk 
factors reported, and it is still not clear whether the existing subtype definitions are optimal for 
determining aetiology 19. Lymphoid neoplasm subtypes all arise from the malignant transformation of 
normal lymphoid cells at various stages of differentiation, however what causes the original 
transformations is largely unknown and it could well be that there are common underlying risk factors 
for all subtypes. Similarly common susceptibility loci pertaining to all subtypes have been identified, 
although it is recognised these are less common than subtype specific loci 139.  
 
In fact, some of the strongest evidence for causal risk factors to date pertain to particular subtypes, 
rather than NHL as a whole, and an increasing number of studies are demonstrating the importance of 
subtype specific studies. A large study 52 specifically designed to explore aetiological heterogeneity 
observed that late birth order and a high BMI only increased the risk of DLBCL, while autoimmune 
conditions and meat consumption appeared only to effect MZL and CLL respectively. A number of 
factors, such as HIV and Hepatitis C. infection, were also observed to increase the risk of multiple 
subtypes, and there were also common protective factors including alcohol consumption, sunlight, and 
consumption of cruciferous vegetables. In fact, some subtypes were found to be more closely related 
than others in terms of risk factors. They hypothesised that this related to the cell of origin which are 
thought to be germinal center or post–germinal center B cells for FL, DLBCL and MZL, while the 
cells of origin for CLL/SLL are not thought to have undergone germinal center transit 52. In particular 
DLBCL and MZL both shared a number of risk factors that act through the immune response, which 
is consistent with these subtypes arising in the phases of B-cell differentiation that are most dependent 
on immune stimulation.  
 
These findings may in part explain the observed differences in incidence rates by gender, age, country 
and time period. Understanding patterns of etiologic commonality and heterogeneity for non-Hodgkin 
lymphomas will additionally help to illuminate lymphomagenesis 52. Consequently subtype 
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heterogeneity, should be taken into account, as much as possible in all studies of NHL. Given the 
discussed difficulties with defining subtypes in certain settings, again easily measurable biomarkers, 
which can help to distinguish subtypes and subtypes within subtypes, may prove useful here. 
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1.5 Biomarkers of NHL 
NHL is a prime candidate for biomarker discovery given its high incidence, subtype heterogeneity and 
poorly understood aetiology with a lack of validated risk factors. Those factors that have been 
identified have little, if any, practical ability to predict disease risk of progression 2. A wealth of 
emerging data is slowly beginning the address these issues, and some important successes have been 
reported 26. Nevertheless, the risk factors identified to date can explain only a proportion of the 
incidence and progression of NHL and particularly for the genetic factors, replication and validation 
of findings is lacking 2.  
 
It has been stated that the incorporation of objective molecular markers into epidemiological research 
can help to standardise risk and prognostic factors. This allows the pooling, interpretation and 
standardization of findings between multiple disparate studies and populations, ultimately increasing 
the ability to determine true effects 23. Furthermore as stated, the diagnosis and classification of NHL, 
particularly in resource poor settings, is difficult, due to the multiple indices employed. Here again 
biomarkers could prove useful by representing a quicker, easier, and therefore most likely cheaper 
means of diagnosis 140. In terms of the study of NHL, the use of biomarkers as a surrogate endpoint 
could decrease the required sample size, which is particularly important for the rare subtypes, as well 
as potentially circumnavigating ethical issues related to measuring true endpoints 140. Consequently, 
biomarkers have multiple purposes and can take many forms 7, most of which would be advantageous 
to the study, prevention and treatment of NHL.   
The different subgroups of biomarkers can be categorised as outlined in figure 1. Although there is 
some overlap, in general biomarkers of internal dose, biologically effective dose, early biological 
effect and altered structural function, can be considered as a temporal sequence of events between a 
risk factor and a disease outcome, and therefore in theory biomarkers can be identified at any stage 
along this causal pathway (although not every risk factor/disease relationship may follow this pattern). 
Additionally biomarkers of susceptibility can act at any of these stages. A number of biomarkers 
falling under each of these subgroups have been studied with relation to NHL, however substantial 
challenges remain, as discussed below.  
 
1.5.1 Biomarkers of susceptibility 
Biomarkers of susceptibility provide an indication of an individual’s underlying susceptibility to a 
disease or its risk factors that may be inherited or acquired 8,141. Given the role of immunodeficiency 
in NHL aetiology, immune disorders have been widely studied but as discussed, due to the small 
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proportion of cases arising in such susceptible individuals, these are normally treated separately from 
immunocompetant individuals.  What is less well understood are more subtle changes in the immune 
system such as infection with EBV which has been demonstrated to interact with environmental 
exposures including organochlorines to modify risk 83.  
Inherited genetic variants in the germline which predispose to risk through the modification of certain 
pathways, are likely to account for a larger proportion of cases.  As discussed in section 1.3.5, the 
most likely candidate pathways include immune and inflammation response 112-114, one-carbon 
metabolism 2,121, oxidative stress 122, DNA repair 123, and xenobiotic metabolism 124. However, the 
associations identified to date represent low penetrance variants, and a number may not be causal as 
studies have tended to be limited by problems of population stratification, improper control selection, 
genotyping errors, population size and failure to consider sex-, subtype-, or stage- specific effects 12,87. 
Furthermore the majority of associations remain to be replicated 2.   
Nevertheless, there is a vital need to consider genetic biomarkers of susceptibility in studies of risk 
factor-disease relationships as intra-population differences in such variants may explain some of the 
inconsistent associations observed for NHL identified to date. A number of such studies have been 
performed (see chapter 2). However it seems that the candidate gene approach taken to such studies 
may have reached its limitations and new methodologies considering interactions between multiple 
genes are required.  
1.5.2 Biomarkers of internal dose 
Dose represents the amount of a contaminant actually deposited within the body and so biomarkers of 
dose bear a quantitative relationship to previous and potentially cumulative exposure. Internal dose of 
suspected risk factors, often referred to simply as body burden, has been widely studied due to the 
suspected role of environmental pollutants in the aetiology of NHL, and the relative ease of accurate 
measurement. Among these, dioxins and PCBs are some of the most commonly investigated, but the 
results have been contradictory. This has been attributed to the use of case-control studies and the 
resulting potential for reverse causation bias, which is particularly important for the exploration of 
NHL, as the treatment or the disease itself has been reported to affect metabolism and blood 
concentrations of exogenous exposures 77,132. 
1.5.3 Biomarkers of biologically effective dose  
The biologically effective dose represents the dose at the site of toxic action. Biomarkers of 
biologically effective dose typically encompass interactive products, or interactions that change the 
status of the target molecule 141. The most commonly used measures include DNA adducts and 
oxidative damage 142. Such biomarkers are vital as they can provide an indicator of the potency of the 
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causal risk factor, established using biomarkers of internal dose. However this is a relatively 
unexplored area in NHL research and to date only oestrogen-DNA adducts have been investigated, 
with higher levels being observed in male NHL cases compared to controls 
143
. Consequently novel 
approaches are required to fully exploit the potential of these biomarkers.  
1.5.4 Biomarkers of early biological effect 
Biomarkers of early effect indicate the presence and strength of a biological response to exposure to 
an environmental agent on the subcellular level 141. By far the most widely studied in NHL aetiology 
is the t(14;18)(q32;q21) translocation, which is found in 70-90% of FL cases, 20-30% of DLBCL 
cases and 5-10% of the less common subtypes 20,144,145. This chromosomal aberration increases cell 
proliferation and effectively immortalises lymphocytes 66,146, however it is also present in up to 80% 
147,148  of healthy individuals, albeit at much lower frequencies 149. This renders presence of the 
translocation alone an insufficient biomarker. Nevertheless its strong association with NHL and FL in 
particular, suggests this translocation could still be of some utility if exploited in a different way.  
A number of other early effect biomarkers have also been explored in relation to NHL aetiology, 
including replicative index and mitotic index as measures of cell proliferation, and micronucleus 
frequency as an indicator of chromosomal damage. This has been determined mainly through their 
association with putative risk factors such as 2,4-D and Carbofuran 150-152. Similarly the hypothesis 
that TCE and TCDD may induce NHL by suppressing the immune system is based on reported 
decreases in C4+ levels and major lymphocyte subsets, particularly sCD30 and sCD27 153.  
Consequently, although they provide some mechanistic insights, they are not specific to NHL and, as 
such, again are of little clinical utility. The problem of the inconsistency of the evidence for the 
association between NHL and most postulated risk factors makes their utility even more challenging.  
Therefore methods which integrate the risk factor, the biomarker and the disease are required to 
determine whether these relationships follow a temporal pathway, and therefore if the biomarker can 
be of predictive use.   
1.5.5 Biomarkers of altered structure or function 
Biomarkers of altered structure and function are the final stage in the pathway before clinical 
manifestation of disease. They are used to indicate subclinical changes in morphology or function, 
most commonly altered gene expression or a decrease in organ function are used 141.  Immune system 
function can be considered a good proxy in the investigation of lymphoma and a number of exciting 
results have been reported in this context. A recent study found that circulating immune markers 
including BCA-1, sTNFR2, and sVEGFR2 are associated with NHL risk well in advance of diagnosis 
154. While prediagnostic levels of  IFNγ, TNF-α, sICAM-1, IL2 27, IL10, sCD27 and sCD30 155,156 
have also been observed to be upregulated in NHL patients.    
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Similarly, the study of altered gene expression is perhaps currently one of the most promising areas in 
NHL aetiology. Accordingly a number of studies have reported differences in both epigenetic 
regulation 
157
  and gene expression 
158
 in NHL cases compared to healthy controls, which could 
represent potential candidate biomarkers. However, the majority of these studies, both of immune 
function and of altered gene expression tend to be case-control in design which may lead to issues of 
reverse causation, particularly for late stage biomarkers.  
1.5.6 Summary 
As with the risk factors themselves, multiple biomarkers have been explored to try and better 
characterise potential causal relationships between suspected risk factors and disease. Although there 
are some promising candidates, the majority of the available studies lack sufficient evidence to 
definitively identify biomarkers. There has also been a lack of a concentrated effort to replicate the 
findings in independent populations, which is the gold standard for determining utility.   
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1.6 The future of NHL research 
Together these findings support investing in the study of biomarkers. Given that so much remains 
unknown regarding the mechanisms and aetiology of NHL, the issue of subtype heterogeneity, the 
difficulty of classifying disease and of standardising its classification, and the problem of recruiting 
large enough sample sizes, biomarkers, which could help to address all these issues, are paramount to 
the future of NHL research. This requires novel approaches in terms of methods, technologies and 
analysis. It also suggests a new way of thinking is needed, which should consider biomarkers not as 
single discrete entities, but as stages on a continuum between a risk factor and disease. These can be 
integrated in order to assist in the elucidation of aetiology and of mechanisms, in disease prediction 
and in the identification of targets for treatment and ultimately for prevention.  
In this thesis, this will be performed using the methodologies and concepts detailed below. 
1.6.1  Gene-environment interactions 
Although well-established, gene-environment interaction models remain a relatively unexplored area 
in NHL research (see chapter 2: literature review for details). Gene-environment interaction or GxE is 
defined as "a different effect of an environmental exposure on disease risk in persons with different 
genotypes," or, alternatively, "a different effect of a genotype on disease risk in persons with different 
environmental exposures” 159. Current GxE studies in NHL have all employed a candidate-gene 
approach (Chapter 2), which does not take into account the fact that multiple variants (and multiple 
environmental factors) may be jointly contributing to disease risk. Additionally, by only exploring 
genes from pathways with biological a priori hypotheses, there is the risk of missing novel variants 
and pathways which may be pivotal to lymphomageneisis. Furthermore, considering Figure 1, any 
stage of the causal pathway can be modified by host susceptibility factors and so the concept of GxE 
can also be expanded to include gene-biomarker interactions.  New methodologies to deal with high 
order interaction analyses combining multiple risk factors, multiple genetic variants and potentially 
multiple biomarkers, are therefore required. 
1.6.2 The ‘meet–in-the-middle’ approach 
The numerous epidemiological studies of NHL to date provided little mechanistic evidence for the 
aetiology or pathways of lymphomagenesis. What is required is a more holistic approach combining 
both the risk factor and disease in order to visualise the causal pathway. The “meet-in-the-middle” 
(MITM) approach 7 combines a retrospective search for biomarkers in those who develop disease, 
with a prospective search for associations with these biomarkers to past environmental exposures 
suspected to be risk factors. By linking exposure information with biological data measured on the 
same human biosample the mechanisms and events occurring along the theoretical continuum 
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between exposure and disease can potentially be identified, providing targets for both early diagnosis 
and therapy 7.  
1.6.3 High throughput –omics technologies 
The advent of the 'omics' era, together with improved bioinformatics and systems biology tools, has 
enabled a new generation of biomarker discovery allowing for the simultaneous quantitative analysis 
of tens of thousands of biological markers to differentiate between cases and controls. The 
combination of multiple –omics technologies including epigenomics, transcriptomics, proteomics and 
metabolomics provides a global picture of the functional state of an organism at the levels of DNA, 
RNA, proteins and metabolites. These measurements are co-informational, each shedding light on 
complementary biological process 160 and together they provide a holistic view of the effect of the 
environment on cellular pathways.  In this way -omics technologies provide unique opportunities for 
the discovery of biomarkers of exposure to exogenous environmental compounds, diet, lifestyle 
factors, pathogens and anything else that perturbs the steady state of the human body. Consequently 
these technologies can also be used to identify biomarkers of the early effects of exposures that can be 
considered predictive for disease risk.  
1.6.4 New statistical techniques 
The advent of these new technologies introduces a range of new challenges. GxE utilising a GWAS 
approach and –omics analyses involve hundreds of thousands of potentially highly correlated 
variables, and no reasonable threshold for minimising false-positives has yet been agreed 161. 
Similarly, to elucidate fully the role that a risk factor or interacting risk factors play in disease 
aetiology as is proposed in the MITM approach, it is necessary to determine the temporal sequence of 
initiation and the subsequent stages involved. Most biostatistical models such as multivariate 
regression are insufficiently able to take these levels of complexity into account 162. Therefore to 
exploit these advances fully also requires novel statistical techniques 2.  
A novel Bayesian methodology – profile regression – offers a potential solution 163,164165 (methods 
section 3.3.4 and chapter 4). Profile regression clusters individuals according to their genetic and 
environmental covariate pattern and simultaneously associates these patterns with the disease 
outcome, allowing for the identification and quantification of the effect of the genetic and 
environmental factors which jointly influence risk.  Profile regression is a Bayesian technique which  
is optimally designed to deal with highly dimensional and highly correlated data, and which has 
previously been shown to be well suited to the analysis of genome-wide data in a study of lung cancer 
165.    
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1.7 Conclusions 
The end of the 1990s coincided with a reported decline or levelling off of the incidence of NHL in 
most Western countries 34, however despite encouraging developments in understanding the 
pathogenesis and mechanisms of disease 166 particularly from studies of tumours and NHL patients, 
determining aetiology and predicting risk remain challenging 167. Immune dysfunction and related 
conditions continue to represent the most well defined risk factors while putative associations with 
occupational, environmental and dietary factors remain controversial. Similarly genetic studies have 
been promising but few causal variants have been identified to date. The limitations of traditional 
epidemiological studies have led to a shift in focus to more molecular epidemiology-based approaches 
characterised by the search for biomarkers of exposure and disease. However, to date this work has 
been hindered by the same factors as the conventional studies and again very little conclusive, 
validated evidence is available. What is agreed upon is that the aetiology of B-cell NHL is complex 
and largely unexplained. Consequently further research into the causal pathways of NHL is vital and 
methods of analyses which are able to take these levels of complexity into account must be employed 
In the following chapters a number of these issues will be addressed and novel biomarkers on the 
causal pathway will be identified. These will help to better characterise risk-disease relationships and 
additionally to inform on disease mechanisms. This will be achieved utilising a nested case-control 
design within pre-existing cohorts with prediagnostic blood samples that can be used to precisely 
measure potential markers in a manner that allows temporal determination and is free from bias. The 
findings will then be integrated to build upon the current knowledge in this field to better understand 
the aetiology of this malignancy for which so little is currently known.  
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1.8 Objectives 
The objectives of this thesis are as follows: 
1. To identify and validate novel biomarkers of NHL including biomarkers of susceptibility, 
exposure and effect 
2. To integrate two different biomarker categories using the “meet-in-the-middle” approach, to 
consider temporal causal pathways 
3. To explore the utility of the identified biomarkers and the biomarker “meet-in-the-middle” 
approach in understanding NHL aetiology and in predicting risk in individuals 
4. To consider how the findings of this thesis may inform future studies of NHL 
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2. GENE-ENVIRONMENT INTERACTION STUDIES 
IN NHL EPIDEMIOLOGY: A REVIEW OF THE 
LITERATURE  
2.1 Introduction 
As outlined in the previous chapter the aetiology of NHL remains largely unknown despite a 
multitude of studies investigating potential environmental, as well as genetic causes.  Where putative 
associations have been observed the effect sizes tend to be small, rendering them of little value for 
clinical prediction. Consequently the population attributable risk for these factors is unclear. 
It is now widely accepted that a majority of complex disorders including cancers arise, not from single 
gene-mutations or single risk factors but rather from the interplay between an individual’s genetic-
make up and their personal exposure and lifestyle histories. This renders elucidation of the aetiology 
of such disorders difficult. It is also thought to explain in part why, when considering environmental 
or genetic risk factors in isolation few significant associations have been observed. Those that have 
been identified, have been small in magnitude, as the observed associations tend to be shifted to the 
null 168.  It is hypothesised that by restricting the analysis of an environmental risk factor to those who 
are genetically susceptible, the power to identify associations will be increased 169. Furthermore the 
identification of interactions also provides evidence on the pathways and mechanisms by which an 
environmental factor may be exerting its risk 170.  
Consequently GxE studies have become popular in the study of complex diseases such as NHL. 
However, to date there are no existing literature reviews which consolidate all the available studies of 
GxE in the aetiology of B-cell NHL and which report the results of these studies in detail.  
2.1.1 Objectives of this review 
In order to fill this gap in the literature the objectives of this review are to identify, summarise and 
critique all the current published literature considering the interactions between specified genetic 
variants and specified environmental variables, including lifestyle, anthropometric, medical, 
exogenous and dietary factors, which affect the risk of B-cell NHL and its subtypes. The review was 
restricted to B-cell NHL in line with the recommendations by Morton et al. 19 regarding the proposed 
classification of lymphoid neoplasms for epidemiologic research, to reflect the higher prevalence of 
B-cell NHL in Western populations which comprise the population studied in this thesis, and in 
keeping with the overall focus of this thesis. 
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2.2 Search Strategy 
PubMed, EMBASE and Web of Science were searched for peer-reviewed articles using the search 
term combinations described in figure 2.2 up until 14th April 2013. The population of interest was 
adult (aged 18 years and older) males and females from any country. The inclusion and exclusion 
criteria are described in table 2.2. The references of selected articles were also screened for potential 
inclusion, as were the references from any existing reviews of GxE in NHL 171.  
Figure 2.2: Flowchart describing the  results of the literature search  
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Table 2.2: Search Strategy Inclusion and Exclusion Criteria 
 
 
 
 
 
 
 
 
2.3 Included articles 
A total of 25 articles which met the inclusion criteria were selected following the screening process. 
These articles are described in table 2.3. 
 
 
 
 
Inclusion criteria 
 
 English-language articles published in per-
reviewed journals 
 Articles published before April 2013 
 B-cell NHL or a specified subtype as disease 
outcome 
 Specified polymorphism and specified 
environmental, lifestyle, dietary or anthropometric 
variable as  an exposure 
 Quantified measure of interaction 
 Studies in humans 
 
 
 
Exclusion criteria 
 
 T-cell NHL as the disease outcome 
 AIDs associated B-cell NHL cases  
 Articles in languages other than English 
 Articles not reporting original results 
 Articles considering mortality or treatment effects as 
outcome 
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Table 2.3: Description of the Included Articles from the Literature Search 
Study population Year Authors 
No. 
cases 
No. 
controls 
Gene(s) 
No. 
SNPs 
Environmental variable Subtype analyses 
         
Population based Case-control study, 
UCSF2, San Francisco, USA (1988-
1995) Age: 21-74 2004 
Skibola C. 
et al 
458 812 
Leptin (LEP), Leptin-Receptor 
(LEPR) 
3 Body Mass Index 
All NHL, DLBCL, 
FL, Other 
Population based Case-control Study 
(matched on sex and date of birth), 
England (1998-2001) Age: 18-64 2005 
Willett E. 
et al 
593 754 
Leptin (LEP), Leptin-Receptor 
(LEPR) 
4 Body Mass Index 
All NHL, DLBCL, 
FL 
2010 
Kane E. et 
al 
471 468 Melanocortin 1 receptor 9 
Sun exposure, eye colour, skin colour, hair colour, 
history of sun burn 
All NHL, DLBCL, 
FL 
Population based Case-control study 
(frequency-matched on age, sex, race, 
and registry) NCI-SEER, USA (1998-
2000) Age 20-74 
2006 
Morton L. 
et al 
1136 922 
N-acetyltransferase 1 (NAT1) and 2 
(NAT2) 
10 Cigarette smoke, dietary heterocyclic amines 
All NHL, DLBCL, 
FL, SLL, MZL, T-
cell NHL 
2006 
De Roos 
A. et al 
566 422 
11 genes involved in xenobiotic 
metabolism 
15 Smoking status 
Subtype specific data 
not shown 
2007 
Lim U. et 
al 
386 319 
18 genes involved in one-carbon 
metabolism 
30 107 food and beverage items  
All NHL, DLBCL, 
FL, SLL 
2007 
Morton L. 
et al 
566 422 
N-acetyltransferase 1 (NAT1) and 2 
(NAT2) 
10 Hair dye use 
Subtype specific data 
not shown 
2007 
Purdue M.       
et al 
551 462 
Vitamin D-receptor (VDR), 
Interleukin (IL4, IL10, IL12A, 
IL12B), Tumour necrosis factor 
(TNF) 
8 UV exposure 
All NHL, DLBCL, 
FL 
2007 
Wang S. et 
al 
1,172 982 
Interleukin-10 (IL10), Tumour 
necrosis Factor (TNF) 
2 
Autoimmune conditions, Education, BMI, Diet, 
Height, Weight, Smoking status, Ethanol, b6, Sun 
exposure, Eye colour, Termite treatment, Alpha-
chlordane, PCB180, Furans 
All NHL, DLBCL, 
FL 
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Table 2.3 continued 
Study population Year Authors No. cases No. controls Gene(s) 
No. 
SNPs 
Environmental 
variable 
Subtype analyses 
 
        
Population based Case-control study 
(frequency-matched on age, sex, race, and 
registry) NCI-SEER, USA (1998-2000) Age 
20-74 
2008 
Keleman L.     
et al 
371 311 
17 genes involved in pathways of ROS 
neutralization and detoxification and DNA repair 
28 
Multiple dietary 
variables 
All NHL 
2009 Colt J. et al 1321 1057 36 immune genes 61 
Organochlorine 
exposure 
All NHL 
2009 
Gathany A.                
et al 
990 828 IRF4 (MUM1) 
 
Sun sensitivity All NHL 
Population-based Case-control study 
(matched on sex, age, and study region) , 
Germany (1999-2002) Age: 18-80 
2008 
Hoeft B. et 
al 
710 710 
Prostaglandin-endoperoxide synthase-2 (COX2), 
prostaglandin E synthase (PTGES), interleukin-1 
alpha (IL1A), IL-1 beta (IL1B) IL-1 receptor 
antagonist (IL1RA) 
10 NSAID use 
All lymphoma, B-NHL, 
T-NHL, HL 
Females only. Population based Case-control 
study (frequency-matched by 5 -year age 
groups), YALE Study, Connecticut, USA 
(1996-2000) Age 21-84 
2009 
Kilfoy B. et 
al 
518 597 
glutathione S-transferases (GSTs) and cytochrome 
P450s (CYPs) 
5 Smoking status All NHL, DLBCL, FL 
2009 Han X. et al 513 591 18 genes involved in the oxidative stress pathway 137 
Fruit and 
vegetable intake  
All NHL, DLBCL, FL, 
SLL/CLL 
2009 
Zhang Y. et 
al 
461 535 9 xenobiotic genes 19 Hair dye use 
All NHL, DLBCL, FL, 
CLL/SLL, MZL, T-cell 
lymphoma 
2010 
KilfoyB. et 
al 
453 
(NAT1), 
456 (NAT2) 
528 
(NAT1),  
533 (NAT2) 
N-acetyltransferase genes NAT1 and NAT2 10 Smoking status 
All NHL, DLBCL, T-cell 
NHL 
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Table 2.3 continued 
Study population Year Authors 
No. 
cases 
No. 
controls 
Gene(s) 
No. 
SNPs 
Environmental variable Subtype analyses 
         
Females only. Population based Case-control 
study (frequency-matched by 5 -year age 
groups), YALE Study, Connecticut, USA (1996-
2000) Age 21-84 
2010 Li Y. et al 461 535 
11 Cytochrome P450s (CYPs), 
glutathione S-transferases (GSTs) and 
N-acetyltransferases (NATs)  
20 Alcohol consumption 
All NHL, DLBCL, 
MZL, T-cell NHL 
2010 
Barry K. et 
al 
518 597 
Cytochrome P450 2E1 (CYPE1), 
Epoxide Hydrolase 1 (EPHX1), 
NAD(P)H Dehydrogenase, Quinone 1 
(NQ01), Myeloperoxidase (MPO) 
6 
Organic, chlorinated solvents (Benzene, 
chloroform, carbon tetrachloride, 
dichloromethane, dichloroethane, 
methyl chloride, trichloroethylene) 
All NHL, DLBCL, 
FL, CLL, SLL, MZL, 
T-cell NHL 
2011 
Chen Y. et 
al 
785 868 Th1 and Th2 cytokine genes 5 Body Mass Index 
All NHL, DLBCL, 
FL, SLL/CLL, 
MZBCL 
2012 Jiao J. et al 518 597 16 DNA repair genes 30 
Chlorinated solvent, benzene and 
formaldehyde exposure 
All NHL, DLBCL, 
FL 
Population-based case-control study (frequency-
matched by 10 -year age groups, sex and 
country) The Scandinavian lymphoma aetiology 
study (SCALE), Denmark and Sweden (1999-
2002) Age: 18-75 
2010 
Ekström 
Smedby K 
et al 
2448 1981 vitamin D receptor (VDR) protein 10 UV exposure 
All NHL, DLBCL, 
FL, CLL 
2010 
Fernberg P.     
et al 
2449 1980 BCL2, CCND1, MYC, TNF, and IL10 11 History of autoimmune disorders 
All NHL, DLBCL, 
FL, CLL, Mantel 
cell, T-cell NHL 
Population based case-control study (matched 
on 5 year age group, sex and region) British 
Colombia, Canada (2000-2004) Age: 20-79 2010 Ng C. et al 422 459 AHR  5 Organochlorine exposure 
All NHL, DLBCL, 
FL, Other B-cell, T-
cell 
Four studies from the USA; Nebraska, NCI-
SEER, YALE Study, UCSF2.  Two from 
Europe; SCALE, EpiLymph (Spain, Germany, 
Ireland, Czech Republic, France, Italy). One 
from Australia; New South Wales  
2013 
Gibson T.  
et al 
5026 4630 
N-acetyltransferase genes NAT1 and 
NAT2 
10 Smoking status 
All NHL, FL, 
DLBCL, ll/SLL, 
MZL, MCL, 
PTCL,MF/SS 
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2.4 Historical context 
Many ‘gene-environment interactions’ have been known of since long before the advent of 
genotyping, although they may not have been identified as such. For example, the effect of sunlight 
exposure on fair as compared to dark skin, or the flushing response in certain individuals following 
alcohol consumption 169 . The formal study of the interaction between genes and the environment in 
the aetiology of disease has been suggested to extend back to as early as 1902 169,172. However the first 
studies which attempted to quantify interaction  did not appear until the late 1960s as one of the 
fundamental concepts of the developing field of genetic epidemiology 159. There has since been an 
explosion in the number of publications which cite ‘gene-environment interaction’ in the title, and this 
field now represents a major research theme which continues to grow with the development of newer 
and cheaper technologies for sequencing the genome. 
Despite this, the study of GxE remains a relatively unexplored area in NHL aetiology, as evidenced 
by the small number of articles identified by this review (n=25).  Nevertheless, the selected articles 
also reflect the general trend for an increase in studies of this type and suggest this is a growing field 
which will only expand. The first article was not published until 2004, and almost half were published 
from 2010 onwards.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
2.5 Included populations 
Although 25 unique articles were selected for review these in fact represent only seven independent 
study populations and one pooled study which encompasses four of these populations. This pooled 
study was included as it additionally contained unpublished results 126. Two thirds (n=17) of the 
selected articles originated from two studies: the National Cancer Institute-Surveillance Epidemiology 
and End-Results (NCI-SEER) study 173 and the YALE study 174. This may limit the generalizability of 
these findings to other populations and suggest further GxE analyses are hampered by the lack of 
available genotype data for NHL cases and suitable controls within large- scale epidemiological 
studies. Although there are a number of multi-study consortiums specifically considering NHL, 
notably InterLymph and EpiLymph, in common with a large number of epidemiological studies, 
many other studies of NHL lack the funds and infrastructure to collect biological samples. 
Of the selected articles, all included very similar age ranges spanning from 18-84 years.  They were 
all conducted in comparable time periods around the late nineties, early 2000s. Eight of the articles: 
those based within the YALE study, included only female participants while the rest considered both 
males and females. Where reported, the ratio of included males to females was similar except in the 
two articles from the SCALE study 175,176 and in Morton et al. 2007 177 where a much higher 
percentage of males and of females, respectively, were included. Again when considering the 
generalizability of these studies it should be noted that they do not reflect the overall higher burden of 
NHL among males worldwide.  In all studies cases and controls were matched by sex.   
Although the included populations for the articles originated from the same few overall studies there 
was between-article heterogeneity in terms of the sample size (table 2.3), particularly within the NCI-
SEER study. This was on account of the availability of environmental or genetic data for the specific 
variables investigated, or due to exclusions based on technical issues. 
Ethnicity is of particular importance in studies of genetics, due to well-defined issues of population 
stratification 168,169. However only four of the articles: those based within the English study and the 
Scandinavian SCALE study, utilised ‘genetically homogenous’ populations. The other studies contain 
a mixture of ethnic groups in their analyses, although these were not always specified or quantified.  
As well as the potential for ethnic differences arising through differing inherited allele frequencies, 
observed differences between different ethnic groups, may also be a reflection of cultural and societal 
differences, which will influence environment and lifestyle. This is also true of the different 
geographical populations investigated by the selected articles. Nineteen of the articles were based in 
North America including Canada, two in Scandinavia and the UK respectively and one in Germany.  
The pooled Study by Gibson et al. 126 additionally included a further North American population, six 
more European countries and an Australian study. It is of note that there were no studies conducted 
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outside Europe, North America and Australia, and all populations were either entirely or majority 
Caucasian. Given the recent findings of differences in genetic susceptibility to lymphoma among 
different ethnic groups 
178,179
, this may be an issue for the wider generalisability of these results.  In 
any case the problems faced by main effects studies (i.e. the gene-disease or risk factor-disease 
relationship), in terms of ethnicity/race and geography, are potentially doubled in GxE studies. The 
currently available studies are most generalisable to a Western Caucasian population, and caution 
should be applied when considering their results in other populations and contexts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
2.6 Investigated environmental and lifestyle factors 
Few definitive risk factors have been identified for NHL, which complicates the study of GxE as there 
are few obvious environmental variables to focus on.  Although some studies have employed what 
they define as an ‘Environment-wide Study design’180, these are not entirely analogous to a GWAS as 
they cannot measure all possible environmental exposures and lifestyle factors, and so a targeted 
approach must be taken. The most well characterised risk factor for NHL is immune dysfunction 36, 
and accordingly two studies 106,176 investigated the interaction with a history of autoimmune 
conditions, which have been previously been associated with an increased risk of NHL 40.  
For all other included factors (Table 2.3) there exists a body of literature considering their association 
with NHL, but the evidence is far from unequivocal.  The most commonly investigated variable in the 
selected articles was smoking status (n=6), followed by UV/sun exposure (n=5), organochlorine 
exposure (n=5) and BMI (n=4). Despite multiple studies on the association with NHL, the literature 
has failed to reach a consensus for any of these factors. Interestingly UV exposure has actually been 
hypothesised to be protective against risk 
181
. Three other articles, those by Han 
182
, Li 
183
 and Hoeft et 
al. 184 considered variables which are thought to be protective against NHL or which have shown 
inverse associations: fruit and vegetable consumption 99,  alcohol intake 105 and NSAID (non-steroidal 
anti-inflammatory drug) use 185 respectively.   
The main effect association between the investigated environmental factor and NHL was reported by 
16 out of the 25 studies, either explicitly or in reference to previous work performed by the same 
group on the same population. The majority of these reported a significant association with the main 
effect. The exceptions were variables related to sun exposure 186, NSAID use 184, dietary mutagens 187 
and one of the papers considering hair dye use 177. As with hair dye use, for some factors investigated 
in more than one study conflicting results were found. Gibson et al.’s pooled paper 126 observed a 
significantly positive association between FL and ever smoking which was not reported by Kilfoy et 
al (2009 and 2010) nor Morton et al. (2006), although all three agreed there was a null relationship 
with NHL overall. Similarly Gathany et al. 188 reported that eye colour and number of hours spent in 
the sun were both inversely associated with risk, while Kane et al. 186 found no effect.  In fact, such 
inconsistency in the literature may well be the result of GxE and therefore provides the very reason to 
conduct such analyses in the first place. The failure to report a main effect in the remaining studies 
complicates the interpretation of the interaction effect presented. 
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2.7 Investigated genes and pathways 
All of the included studies have taken a candidate approach to the selection of genes based on known 
functions, biological processes or biological networks. Or based on the known mode of action of the 
environmental factor and therefore the pathways through which it may work 170,171.  
 
The most commonly investigated single genes were Interleukin10 (IL10) and Tumour necrosis factor 
(TNF), both of which were investigated by the same five studies 176,189-192.  Three of these were based 
on the same overall population from the NCI-SEER study 189,190,192. IL10 and TNF are involved in the 
immune response as part of a regulatory feedback network that controls inflammation, and both have 
been frequently associated with NHL risk 189. In fact genes of immune pathways are some of the most 
frequently explored with regard to lymphoma risk, and a number of significant findings have been 
reported 12. Within this review in addition to TNF and IL10 many other genes involved in the immune 
response were also explored including Th1/Th2 191, COX2 184, IFNG 192 and IRF4 188. Most were 
chosen on the basis of previously reported associations in the literature, but in the few studies where 
main effects were reported, the only replicated associations were for TNF in Fernberg et al. 176 and 
IRF4 in Gathany et al. 188. Again, this may be taken as evidence for the role of GxE. Alternatively it 
may be reflective of the problems with the candidate gene approach and the lack of replication that 
has characterised such studies to date. 
The most commonly explored pathway was xenobiotic metabolism, which was considered in ten 
articles 126,177,183,187,189,193-198. Polymorphisms in this pathway resulting in a lowered capacity to 
detoxify and eliminate carcinogens from the body, have also previously been associated with risk of 
NHL 199. Interestingly among these studies, more main effects were reported and replicated, compared 
to those investigating immune pathways.  
In addition to genes involved in xenobiotic metabolism Keleman et al. 195 also studied a number of 
DNA repair genes, as did Jiao et al. 200. Two studies considered Leptin (LEP) and Leptin receptor 
(LEPR) genes which are involved in body weight homeostasis 201,202 and two studies considered 
polymorphisms in the Vitamin D receptor gene 175,190. The remaining articles considered genes 
involved in metabolism 203, one-carbon metabolism 204, oxidative stress 182 and pigmentation 186.  
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2.8 Methods 
There are considerable methodological challenges, both including and extending beyond those for 
main effects studies, in the design and analysis of GxE studies 168. This partly stems from the fact that, 
although many studies define themselves as GxE studies, they actually represent a wide range of 
statistical models that present different information in different ways, and which are often not 
comparable 169. 
However, the included studies in this review were fairly homogenous: all employed a case-control 
design. Incident cases were identified and suitable unrelated, population-based controls selected, most 
commonly by population registries and random digit dialling. The only exceptions were the Irish, 
Czech and French EpiLymph studies from Gibson et al. which utilised hospital based controls 126.  
This may introduce some of the well-defined bias associated with the use of such controls.  
2.8.1 Sample size 
There are a number of different approaches for calculating the required sample size to obtain optimum 
power in GxE studies 205. However it is commonly accepted that the sample size of an interaction 
study needs to be at least four times the size required to calculate the main effect of each included 
variable with disease 205. Allele frequency, the type of genetic model employed and the strength of the 
interaction will also affect sample size 206. A high probability of misclassification of the risk factor 
will further increase the numbers required 169.  
The samples sizes utilised in the articles range from nearly 700 195 to over 4500 175,176, and a total of 
5026 cases and 4630 controls in Gibson’s pooled study. Most authors recognised that the main 
limitation of their study design was a lack of statistical power due to sample size, although some made 
no mention of power and none reported a quantified measure of the actual power of their study to 
detect an interaction. This lack of statistical power was a particular problem for those studies 
reporting subtype analyses, and there is a strong probability that, especially for the weak interactions,  
and in those studies reporting multiple comparisons, some of the presented findings represent spurious 
associations 169.  
The most effective way to increase power is by the pooling of studies as was done by Gibson et al., 
but even here it was not feasible to recruit enough cases and controls to perform GxE studies with 
high power. Particularly when considering subtype-specific analyses, SNPs with low minor allele 
frequencies or difficult to classify environmental and lifestyle factors. 
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2.8.2 Statistical methods 
Many models and methodologies have been proposed to assess GxE 207. However all the selected 
articles in this review used the same statistical model, the inclusion a multiplicative term in the 
logistic regression model and the calculation of a p-value for interaction based on either the Wald’s 
test or the likelihood ratio test. The only exceptions were Morton et al. (2006) and Kilfoy et al. (2010) 
who calculated the risk associated with hair dye use and smoking, respectively, stratified by NAT1 and 
NAT2 variants, but did present a quantified measure of interaction.  
All the studies made assumptions about the underlying genetic model for their variant of interest. A 
dominant model was chosen by the majority of papers, most likely to simplify the interpretation of the 
interaction model through the use a binary ‘G’, as well as to retain power. Although the use of a 
dominant model may be justified for some of the investigated variants, none of the studies provided a 
biological justification for their choice. If another genetic model would be more appropriate then there 
is a risk of misleading odds ratio and interaction estimates, which have been shown to be sensitive to 
model assumption 208. 
2.8.3 Environmental variable assessment methods 
The lack of definitive risk factors identified for NHL to date has been suggested, in part, to reflect the 
difficulty of accurately measuring exposure, lifestyle and environmental factors in large scale 
epidemiological studies. This is a problem for any such study but the extent to which the included 
studies are subject to ‘measurement error’ varies according to the investigated variable and the study 
design employed. Blood measurements and clinically diagnosed medical conditions which, although 
still prone to measurement error, are in theory more objective than those such as sun exposure, which 
rely strongly on participant recall. Only eye colour, which was considered in two articles 186,189, as one 
of a range of variables, should be exempt.  
Articles from the same ‘parent’ study by definition employed the same methodology to assess the 
environmental and lifestyle factors, and all used in-person or telephone interviews to complete the 
questionnaire data. Factors measured by more than one study tended to be ascertained in uniform 
ways. Nearly all relied on self-report, including height and weight from which BMI was calculated. 
Sun/UV exposure was calculated from self-reported time spent in the sun, taking geographical 
residence and use of sunbeds into account, and sun sensitivity was estimated from a variety of 
questions such as history of sunburn.  Lim 204, Keleman 195, Morton (2007) 19 and Han et al. 182 used 
variations of food frequency questionnaires and calculated nutrient intake from these using 
standardised databases. Smokers were classified as never, former or current except in Kilfoy et al. 
(2009) 196 which included only two categories (smokers and non-smokers). 
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Only organochlorines were objectively measured in serum samples by Ng 193, Wang 189 and Colt et al. 
192. Colt additionally measured the levels in carpet dust from the homes of the participants. In Jiao et 
al. 
200
 and Barry et al. 
203
 a standardised job exposure matrix assessing occupational history, was used 
as a proxy for exposure.  
2.8.4 Genotyping 
DNA was extracted from blood or buccal cell samples in all studies, with the exception of the SCALE 
study 175,176 and Hoeft et al. 184 which used blood only. The majority of studies utilised Taqman 
(Applied Biosystems) for genotyping. Han et al. 182 used a custom-designed Illumina assay (Illumina, 
San Diego, CA), while Hoeft et al. 184 employed Pyrosequencing Restriction- Fragment-Length-
Polymorphism (Biotage, Uppsala, Sweden) analysis for certain SNPs. The SCALE study175,176 used 
Sequenom matrix-assisted laser desorption/ionization time-of-ﬂight mass spectrometry (Sequenom 
Inc, San Diego, CA) and in Kane et al. 186 MC1R genotypes were determined via direct sequencing  
(DxS Ltd., Manchester, UK). 
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2.9 Results 
Eighteen of the 25 studies stated that they found evidence of at least one interaction between a defined 
SNP and a defined environmental or lifestyle factor in the aetiology of B-cell NHL or one of its 
subtypes. Some interactions were consistent across subtypes, while others were specific, although in 
actual fact all studies were underpowered to explore by subtype, particularly the rarer ones. Crucially 
though, the definition of success differed between the articles; for some a difference in risk estimate 
between different genotype strata was sufficient, in others a significant p-value for interaction was 
required. The confidence level required to denote significance also varied, and interactions reported as 
significant in some studies would be considered insignificant in others. A number of studies used the 
conventional level of statistical significance, a p-value of 0.05, to denote an interaction, despite the 
fact that most were considering multiple factors and genetic variants and some presented main effects 
as well as interactions. The majority of the studies did acknowledge this, although only nine corrected 
for multiple testing 175,182,191,193,195,198,200,203,204. Additionally three studies argued that, although not 
robust for multiple testing, the consistency of their findings renders false-positives unlikely 177,190,192. 
Table 2.9 describes the p-value for interaction in those studies where success was declared and the p-
value was smaller than 0.05.  
Jiao et al. 200 observed significant interactions between DNA repair genes and chlorinated solvents 
and benzene in the risk of NHL that remained significant after correction for multiple testing.  This 
was also apparent when analysis was restricted to FL and DLBCL.  Both Wang et al. 189 and Colt et 
al. 192 considered the joint effects of polymorphisms in IL10 and TNF with organochlorine exposure in 
the NCI-SEER study. However, within the two differing subsets of the population different 
conclusions were drawn. Wang et al. stated they observed evidence of a joint effect of IL10 with 
exposure to termite treatment/chlordanes; although the p-value was non-significant they observed 
consistent results across subtypes. Colt et al., who explored a different polymorphism in IL10 found 
no evidence of this but did report a significant interaction between PCB180 and IL10 that was not 
observed by Wang et al. 189.  Colt et al. 192 additionally observed a significant interaction between 
IL16 and PCB180 plasma levels and concluded that their results provide one of the ‘first examples of 
potential gene-environment’ interactions in NHL aetiology. Both Colt et al. 192 and Wang et al. 189 
agreed that there was no significant interaction between TNF and organochlorines.   
Ng et al. 193 considered organochlorines and variants in the Aryl hydrocarbon receptor gene (AHR). 
They did observe interactions with PCB118, oxychlordane and transnonachlor that were consistent 
across all subtypes, but not robust for their defined FDR threshold (0.01).  Nevertheless, they 
conclude that the consistency of their findings does suggest a role for the AHR gene in mediating the 
risk of NHL with exposure to organochlorines. Similarly Barry et al.203  reported a significant 
interaction between solvent exposure and CYP2E1 and EPHX1 in the risk of NHL. 
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Three studies considered dietary variables 182,195,204; among the multiple genes investigated five were 
common between the articles by Han et al. 182 and Keleman et al. 195 both of whom considered 
vegetable consumption (GPX1, MPO, NOS2A, NOS3 and SOD2).  Overall Keleman et al. concluded 
that, despite observing some interactions, these were likely false-positives, and that the examined 
genes in the pathways of reactive oxygen species neutralisation, detoxification and DNA repair were 
not modifiers of the association between vegetables or zinc intake and NHL risk.  In contrast Han et 
al. noted a number of interactions with vegetable consumption mainly for genetic polymorphisms in 
NOS1, MOP and SOD 3. Most interactions were observed for DLBCL, but a number for FL, CLL and 
NHL overall were also reported.   
Lim et al. 204 reported significant gene-nutrient interactions in the one-carbon metabolism pathway 
which may be aetiologically involved in lymphomagenesis. In particular they found a protective 
interaction between vitamin B6 with FPGS, MTHFS and MTR, and for methionine with FTHFD, 
MTHFR and MTRR.  
 
Four studies reported on potential interactions with variables relating to UV exposure and sun 
sensitivity175,186,188,190. Among these, two 175,190 reported on polymorphisms in the vitamin D receptor.  
Purdue et al.’s 190 results suggested that the inverse association between UV exposure and NHL risk 
may be mediated by the vitamin D pathway, and this was particularly evident in FL. In contrast 
Smedby et al. 175  reported no evidence of interaction between VDR variants and UVR exposure on 
risk of overall NHL or B-cell lymphoma subtypes, although they did observe a potential interaction 
with T-cell risk.  Both Kane 186 and Gathany et al.188, neither of whom observed a significant 
interaction with sun exposure, considered a number of related variables including hair and eye colour. 
While Kane et al. reported that the joint effects of MC1R genotypes and skin colour influenced DLCL 
risk, Gathany et al. observed no significant interactions with IRF4 for any of the investigated 
variables.  
 
Morton et al. (2006) 
187
 concluded that there was an increased risk of smoking-associated NHL in 
NAT2 intermediate/rapid-acetylators compared to NAT2 slow-acetylators, but no interaction with 
NAT1 and smoking for NHL overall.  In contrast Kilfoy et al. (2010) 197 suggested that the association 
between NHL and smoking status may be modified by genetic variation in NAT1 but not in NAT2, 
although they did not present p-values for interaction. Gibson’s 126 pooled study included both these 
articles in addition to unpublished results on NAT polymorphisms and smoking from 5 other studies. 
They did not report significant interactions for either NAT1 or NAT2 and concluded that the positive 
association between risk of FL and smoking status is not modified by genetic variation in the N-
acetyltransferase enzymes. However the exact variants explored differed slightly between the articles. 
Three other articles also considered smoking status 189,194,196; Wang et al.  189 reported that IL10 and 
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TNF genotypes had no effect on the relationship between smoking and NHL. Similarly Kilfoy et al. 
(2009) 196 did not report significant interactions for polymorphisms in GSTs or CYPs. De Roos et al 
194
, who explored a number of different genes of the xenobiotic metabolism pathway, including GSTs 
and CYPs, reported significant interactions for former smoking and EPHX1 H139R and PON1 
Q192R, but concluded these had no realistic biological interpretation and were likely to represent 
false-positives.   
Both Skibola et al. 201 and Willet et al. 202 considered the potential that genetic polymorphisms in 
Leptin or its receptor may be modifying the association between obesity and NHL. However neither 
reported evidence of a significant interaction. Conversely Chen et al. 191 reported that common genetic 
variation in Th1/Th2 pathway genes may modify the association between BMI and NHL risk. Wang 
et al. 189 found that risk differed by TNF genotype, although this was not supported by Fernberg et 
al.’s study 176.  
Of the remaining articles Morton et al. (2007) 177 presented evidence suggesting that the risk of hair 
dye use may differ by genetic variation, although they do not quote an interaction statistic. Zhang et 
al.  supported Morton’s findings for NAT2, as well as observing interaction effects for hair dye use 
with  CYP2C9, CYP2E1, GSTM3 and GSTP1. They did quote interaction statistics, and conceded they 
were not robust to correction for multiple testing. Hoeft et al. 184 reported evidence for the joint effects 
of NSAID use and IL1RN and IL1B on B-cell NHL risk. Finally Li et al. 183 reported interactions for 
multiple GSTs and NATs with alcohol intake on the risk of DLBCL, although again the reported p-
values are unlikely to be robust for correction for multiple testing. These findings are summarised in 
table 2.9. 
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Table 2.9; Summary of the results of the selected publication reporting significant interactions with a p value<0.05 
The table shows the interacting variant and environmental variable, the subtypes affected, the variant genotype and the direction of risk effect   
Pathway Genetic variant Exposure Subtypes variant genotype Risk  
DNA 
Repair, 
Oxidative 
Stress, 
Xenobiotic 
Metabolism  
MGMT  rs12917 Chlorinated Solvents NHL**; DLBCL**; FL** CT+TT Increased risk with exposure 
NBS1 rs1805794 Chlorinated Solvents NHL** CG+CC Increased risk with exposure 
BRCA2  rs144848 Benzene NHL** AC+CC Decreased risk with exposure 
GSTP1  rs1138272 (A114V) Alcohol
∞ 
 MZL* CT or TT Decreased risk with exposure 
    Vegetables≠ NHL* CC Decreased risk with higher intake 
  rs1695 Alcohol∞  MZL*  AG or GG Decreased risk with higher intake 
GSTM3  rs1799735 Alcohol
∞ 
 DLBCL*  +- or -- Increased risk with higher intake 
    Vegetables≠ NHL* AGG/AGG Decreased risk with higher intake 
    Hair dye NHL*  +- and -- Increased risk with use pre-1980 
OGG1  S326C Nutrients NHL* CC Decreased risk with higher Zinc intake 
XRCC3  T241M Vegetables
≠
 NHL* CC or CT Decreased risk with higher intake 
AHR  IVS1 + 4640G/A Oxy-chlordane NHL* GA or AA Decreased risk in the highest quartile of exposure 
    Trans-nonachlor NHL* GA or AA Decreased risk in the highest quartile of exposure 
    PCB118 NHL* GA or AA Decreased risk in the highest quartile of exposure 
NAT1   smoking NHL**
, + without *10 Increased risk in current smokers 
NAT2   smoking NHL*
, + intermediate-/rapid-acetylators Higher risk in smokers 
MPO rs4401102 Vegetables
≠
 NHL**
, + CT + TT Increased risk with higher intake 
NOS1  rs2293054 Vegetables
≠
 NHL**, FL*** AG + AA Decreased risk with higher intake 
  rs545654 Vegetables≠ DLBCL*** CT + TT Increased risk with higher intake 
  rs11068446 Vegetables≠ DLBCL** CT + TT Decreased risk with higher intake 
  rs3782221 Vegetables≠ DLBCL** AG + AA Decreased risk with higher intake 
  rs7298903 Vegetables≠ DLBCL**; FL*** CT + CC Decreased risk with higher intake 
  rs12424669 Vegetables≠ DLBCL** CT + TT Increased risk with higher intake 
EPHX1 H139R smoking NHL* GG Increased risk among non-smokers 
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Table 2.9; cont. 
Pathway Genetic variant Exposure Subtypes variant genotype Risk  
DNA Repair, 
Oxidative Stress, 
Xenobiotic 
Metabolism  
PON1 Q192R smoking NHL* GG Increased risk among non-smokers 
SOD3  rs2284659 Vegetables
≠
 CLL/SLL*** GT + TT Increased risk with higher intake 
CYP1A1 rs1048943 Alcohol
∞
  DLBCL* AG or GG Increased risk with higher intake 
CYP2E1 rs2070673 Dichloromethane NHL** TT Increased risk with exposure 
    Carbon tetrachloride NHL* TT Increased risk with exposure 
    Methyl chloride NHL* TT Increased risk with exposure 
CYP2C9  rs1799853 Alcohol
∞
  DLBCL* CT or TT Increased risk with higher intake 
    hair dye use (pre-1980) NHL* CT + TT Increased risk with use pre-1980 
Immune response 
TNF  rs1799724 BMI NHL*; FL* CC Increased risk with BMI >25 
IL1RN  rs454078 NSAID use NHL** T Decreased risk with use 
 IL1B  rs16944 NSAID use NHL** A Decreased risk with use 
IL1  haplo-type 3 NSAID use NHL** AACC Decreased risk with use 
  haplo-type 5 NSAID use NHL*** TACC Decreased risk with use 
IL4 Ex1-168C>T TEQ NHL* CC Increased risk with exposure 
IL7R  rs1494555  BMI NHL*; MZL*; CLL/SLL* AA Increased risk with BMI >25 
IL12  rs568408 BMI FL* AG or AA Increased risk with BMI >25 
IL13  rs20541  BMI MZL* AG or AA Increased risk with BMI >25 
IL16  UTR, Ex871-A>G PCB180 NHL** AA Increased risk with exposure 
IFNGR2  rs9808753 BMI MZL** AA Increased risk with BMI >25 
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Table 9; cont 
Pathway Genetic variant Exposure Subtypes variant genotype Risk  
One-Carbon 
metabolism  
FPGS  Ex15-263T>C Vitamin B6 intake NHL** CC Decreased risk with high (>median) intake 
MTR  Ex26-20A>G Vitamin B6 intake NHL* AA Decreased risk with high (>median) intake 
FTHFD  Ex10-40G>T Methionine intake NHL* GG Decreased risk with high (>median) intake 
MTHFR  
Ex8-62A >C 
(1298A>C) Methionine intake NHL** CC Decreased risk with high (>median) intake 
MTRR Ex5+36T>C Methionine intake NHL* TT Decreased risk with high (>median) intake 
Vitamin D  Vitamin D  Ex11 + 32 T > C UV exposure FL** CC Increased risk with < 7 h/week of exposure 
Melanocortin  MC1R   Skin colour DLBCL***  carrier of D84E, R151C, R160W or D294H Increased risk in those with medium/dark skin 
 
Significance of the association; *<0.05, **<0.01, ***<0.001 +Not replicated in an independent study; \DLBCL – Diffuse Large B-cell Lymphoma; FL – Follicular lymphoma; MZL – Marginal 
zone lymphoma; MCL –Mantel cell lymphoma; CLL – Chronic Lymphocytic leukaemia (results for T-cell NHL not shown);  ∞ includes beers, spirits and wine ≠ Any variables considering 
vegetable intake (cruciferous, leafing etc)
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2.9.1 Biological Plausibility and Replication 
It is stated that a gene-environment interaction will only be accepted if it can be reproduced in two or 
more studies and if it is biologically plausible 169. Although all the studies presented here are 
biologically plausible, indeed this was the impetus for conducting the studies, to date none of the 
positive findings have been replicated.  
The existence of a statistical interaction between two factors does not necessarily inform 
understanding of the underlying biology of the joint effect of these factors on disease 168. It can be 
difficult to determine biological plausibility, and in many studies it is often determined post hoc after 
the analysis has been completed to explain the findings. The potential plausibility of an interaction is 
further complicated by the many remaining ‘grey areas’ in the pathways and functions of genes, and 
by the subjective nature of the definition of plausibility 169. 
One problem with the criterion of replication is that, as can be seen from this cross section of GxE 
studies, in such studies commonly multiple tests will be performed but ‘current models of publication 
of individual studies favour suppression of negative results’ 169,170. This means replication of the 
interactions presented here may have been attempted but not found to be significant and therefore not 
published. In fact a number of the studies did agree on null findings, such as for BMI and Leptin 201,202 
and TNF and organochlorines 189,192, but overall this is rare. The study of different SNPs within the 
same gene by different studies and the use of haplotype-tagging or linkage disequilibrium (LD) 
tagging SNPs to explore genetic associations further complicates the issue of replication and makes 
the identification of true causal associations even harder.  
The lack of replications or attempted replications among the included studies meant that it was not 
possible to perform meta-analyses or to determine the heterogeneity in estimates between studies in 
this review.  
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2.10 Bias, confounding and limitations 
All the included studies were case-control in design allowing detailed information, focussed on the 
variable of interest to be obtained and histology classification to be centralised. However, there are a 
number of unavoidable biases and limitations associated with GxE studies, in addition to the well-
characterised problems faced by all case-control studies. 
All participants were selected from larger parent studies, and were generally chosen based on the 
availability of both questionnaire data and DNA. If there is differential participation/availability by 
ethnicity, socioeconomic status or disease stage or grade, this may have an important impact on 
results. Selection bias was addressed in all studies by matching cases and controls on potential 
confounders, which tended to be uniform throughout the studies, in particular age and sex, and 
ethnicity where appropriate. However none reported on the grade or stage of disease at diagnosis, 
which may substantially affect results.  
All studies, excluding those reporting on organochlorines, relied on self-reported information and the 
extent to which recall bias influenced the findings is difficult to know, but is likely to be sizeable 
given many of the studies are attempting to quantify lifetime or historical exposures and experiences. 
The case-control design may also introduce bias if diseased people choose to change their lifestyle 
following diagnosis or if the variable is altered by the pathology of the disease. The latter is of 
particular interest for those studies which measured serum concentrations of organochlorines 189,192,193 
as there is some evidence to suggest that chemotherapy or NHL itself may affect body burden, and 
that therefore they may not be representative of exposure levels pre-diagnosis 132. Measurements of 
risk factors are also subject to influence by both age and geography. The studied age range in the 
selected populations is very homogenous but encompasses most of adulthood which could be 
important for factors that may be strongly associated with age, such as BMI. Similarly in terms of 
geographical setting environmental and lifestyle factors also vary between populations. This is 
probably most pertinent for the studies considering UV exposure and other sun-related variables. 
However it may also be important for those studying chemical exposures where local restrictions, 
policies and usage patterns dictate the population exposure, and for diet which tends to be 
geographically heterogeneous.  
Misclassified, noisy or biased information is likely to bias the risk estimate to the null 169, which may 
potentially explain the lack of strong findings in the included articles. All the studies used categorised 
variables, even when the underlying distribution was continuous. This is commonly done as it is much 
more straightforward to model and interpret joint effects, but it also loses information and introduces 
measurement error and further potential bias 209. In contrast germline variation is static and discrete 
and therefore in theory can be measured without error 168,171. However, there is still some potential for 
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bias when several polymorphisms in a gene contribute to altered function, or if the functional variants 
are not known and associations are identified through tagging SNPs 169. Only Kane et al. 186  used 
direct sequencing and a number of the polymorphisms considered in the study are of unknown 
function. Due to these potential biases, which cannot be quantified all findings  should be viewed with 
caution, although it should be noted that it has been shown that the presence of a biased main effect 
does not automatically imply a biased estimate of GxE 169.  
As discussed, GxE studies are also problematic due to the issues of multiple testing which arises from 
models including multiple genes, multiple risk variables and multiple interactions. This is a particular 
issue in the selected studies, given that many of the articles were based within the same population, 
and some considered the same SNPs. Consequently even the within-paper FDRs, where these were 
calculated and applied, may not be sufficiently stringent. Furthermore it can be difficult to choose the 
optimal method of analysis, and to translate the statistical finding of an interaction into biology. Such 
limitations were touched on, in varying detail, in the majority of the included articles, although few 
sufficiently accounted for them in their conclusions.  
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2.11 Conclusions 
Although the sequencing of the human genome has potentially been less successful than initially 
envisaged in terms of determining disease aetiology, it has provided the opportunity to explore 
environmental risk factors in the context of an individual’s susceptibility through the study of GxE. 
The 25 articles included here considered the joint effect of environmental or lifestyle factors with 
genetic variants in the risk of NHL. All the studies were similar in terms of design and methodology. 
In total, 18 of the studies reported that they found an interaction, and an even greater number 
concluded that their findings were of sufficient interest to warrant replication in larger studies. 
However, as discussed there are a number of ways of declaring a success in an interaction study, and 
the differing criteria employed by the different studies means that not all of the ‘successes’ can be 
considered equal.  
This disparity is perhaps not unexpected given that, to date, there are few agreed guidelines or 
standards for the best way to conduct and report GxE. Interestingly none of the selected articles 
employ some of the more advanced statistical techniques available to explore interactions 207. What is 
universally established is that to be confident that an observed interaction is a true effect it must be 
replicated in an independent population 169. This was not the case for any of the findings presented 
here, which perhaps also is not unexpected given that are almost no examples of robust, replicated 
GxE for any disease. The best example is that between  NAT2, smoking behaviour and bladder cancer 
risk 210, and a number of successes have also been noted in pharmacogenetics 169. These interactions 
are characterised by genetic variants with clearly defined phenotypes and environmental variables that 
can be accurately and objectively measured, and it has been suggested that the study of GxE may only 
possible under such conditions 117. The included studies here do not fulfil these criteria.   
There has been some criticism of the popularity of GxE studies in the literature, which states that they 
are often not performed or interpreted correctly 211. A statistical interaction does not necessarily 
correspond to a biological one. A biological interaction refers to an aspect of biological mechanism 
while a statistical interaction between two factors is a test of the ﬁt of a particular model of joint 
action, and the extent of deviation from a model on a predeﬁned scale 211.  Consequently the statistical 
model will almost always be a simplification of the underlying biology 209, and it has been argued that 
to date, a failure to grasp this has resulted in ‘widespread over-interpretation of “interaction” in 
logistic regression models’ 211. Such an argument could be made for the included studies here. They 
used a simplistic model of interaction, in studies lacking sufficient power, yet the majority made fairly 
bold conclusions regarding their findings.  
The ultimate goal of GxE studies can be said to be the development of individualised disease 
prevention or treatment 169. The results from the studies to date are insufficient to do so. Although 
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some promising results are presented, which may help to inform or guide future studies and lines of 
investigation, until replication in an independent population can be demonstrated they cannot be 
considered definitive. There are a number of limitations and likely biases in the GxE studies available 
to date. The use of self-reported data, a candidate approach, dominant genetic models and simplistic 
interaction models, coupled with inadequate sample sizes, and a failure to fully account for multiple 
testing all affect the validity of the findings. Furthermore the use of different thresholds to determine a 
an interaction renders between study comparisons difficult, and among those studies investigating the 
same factors consistency was weak. Therefore, at worst these GxE studies may add to the confusion 
and uncertainty regarding NHL aetiology. Consequently it is recommended that future studies take a 
different approach to the consideration of GxE, and better reflect the ethnic and subtype heterogeneity 
which are likely to play an important role. 
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2.12 Recommendations 
Although it is the approach chosen by the vast majority of the GxE studies for any disease, it could be 
argued that the main failing of the included studies is the candidate gene-approach taken. This is also 
the approach traditionally used for main genetic effect associations, but the success has been modest 
in these studies. This has been attributed to unfortunate choices of candidates and insufficiently 
stringent p-values. The same problems will therefore also plague GxE studies using this approach, and 
so other ways of identifying genes for study are required. 
The advent of high-throughput genotyping technologies, has opened the possibility of exploring GxE 
at a genome wide level using an agnostic approach 171.  This approach is gaining popularity, but is 
currently limited by the lack of appropriate methods for modelling such a large number of 
interactions, by the extremely stringent significance thresholds that would be required for so many 
high-order interactions and by the fact that prior knowledge on biological processes and pathways is 
not taken into account 170. It can be argued that in reality all disease arises from the interactions 
between our environment and our genome, and that therefore the benefit of GxE studies lies in 
determining the magnitude of these effects 209, identifying where they lie along the causal pathway, 
and how they relate to other casual pathways 171,209. New methodologies which are able to deal with 
these issues are required.  
This thesis will explore the use of one such methodology,  profile regression, and apply it to GWAS 
and environmental data to determine whether it can offer new insights and understanding to the study 
of GxE, and in particular the roles such interactions may be playing in the aetiology of NHL.  
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3. METHODS 
3.1 Study design 
This thesis is based on participants from the European Prospective Investigation into Cancer (EPIC) 
cohort. Additionally, as part of the EnviroGenoMarkers (EGM) study a number of participants from 
the Northern Sweden Health and Disease study (NSHDS), have also been utilised in some analyses, 
where specified. NSHDS incorporates a proportion of EPIC-Sweden. The participants included in 
each chapter, and the crossover in participants between the chapters is described in table 3.1.2c at the 
end of this section. 
3.1.1 EPIC 
epic.iarc.fr 
Ethics Statement 
This thesis involves human genetic material, human biological samples and collection of personal 
data. All participants were adults and were healthy at recruitment. All the projects detailed in this 
thesis which include EPIC participants have been approved by ethical review boards of each 
participating centre and of the International Agency for research on Cancer (IARC). All participants 
provided written informed consent at recruitment using centre-specific forms which were 
administered in the local language, agreeing to have their health status followed for the rest of their 
lives.   
Background 
The European Prospective Investigation into Cancer (EPIC) is a multi-centre prospective cohort 
following over half a million healthy participants from middle age onwards. It was established to 
investigate the relationships between diet, nutritional status, lifestyle and environmental factors with 
the incidence of cancer. Detailed information on these variables in addition to anthropometric 
measurements and blood samples taken at recruitment is available for all EPIC participants. EPIC 
represents the largest study of diet and health ever undertaken and the goals of this project have now 
expanded to consider other  risk factors and other chronic diseases 212.   
Study subjects 
EPIC was originally initiated in 1992 in seven countries but it has now been expanded to include a 
total of 23 centres from ten European countries: Denmark, France, Germany, Greece, Italy, The 
Netherlands, Norway, Spain, Sweden and the United Kingdom (Figure 3.1.1.a). It is planned to 
follow-up the study participants for at least another ten years.  
The choice of study population was country-specific determinant on practical considerations in that 
nation. Where follow up could be based on population cancer registries the general population was 
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targeted. Where cancer registries provide incomplete coverage, specific groups such as civil servants 
or members of health insurance plans were invited to participate. All countries included males and 
females aged 35-74 years with the exception of Norway, France and Utrecht (one of the two centres in 
the Netherlands) which included only females. Therefore women were over represented in the total 
epic cohort, accounting for ~70% of participants.  No French cases were included in this thesis due to 
incomplete coding for lymphoid neoplasms at this time. Forty two percent of subjects were aged 49 
years or younger at recruitment and more than 90% of participants were younger than 65 years. 
Potential study subjects were contacted via letter, phone or by personal contact dependent on the 
country.  
Figure 3.1.1a: Map of the EPIC Collaborating Centres  
The centres included in the EnviroGenoMarkers Project are indicated with a red box 
 
 
Adapted from; http://epic.iarc.fr/centers/epicmap.php 213 
 
Questionnaire and dietary data and anthropometric measurements 
Full details can be found in 214. In brief, a standardized self-completed questionnaire was used to 
collect information on history of tobacco smoking, history of alcohol consumption, occupation, 
socioeconomic status, age at puberty and reproductive history, use of contraception and of hormonal 
drugs, history of previous illnesses and current physical activity. Height (cm), seated height (cm), 
weight (kg) and waist and hip circumference (cm) were measured using standardised methods and 
quality control checks for between- and within- observer variability. 
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To assess diet a 24-hour diet recall questionnaire was administered on 12 days over the course of the 
year. A built-in calibration study was also used based on precise measurements of single day’s food 
intake in a subsample of 2% of the study population.  
Blood samples 
Blood samples were extracted in the centres at recruitment.  Fourteen millilitres of blood was 
collected and aliquoted into plasma, serum, white blood cells and erythrocytes. They were stored in 
0.5ml plastic straws in liquid nitrogen containers at -196°C.  
Follow up for incident cancer cases 
Cancer incidence data is obtained through population cancer registries, health insurance programs or 
though periodic personal contact dependent on the centre. Where possible, clinical data on anatomical 
localisation of the tumour, histology grade and stage has been collected for every cancer. Information 
on mortality is collected by record linkage with death certificate, health insurance or national health 
service files.   
Lymphoma within EPIC 
A total of 2116 incident cases of lymphoma have been identified to date of which 1921 have validated 
subtype information (table 3.1.1). Hodgkin Lymphomas (HL) comprise 94 cases. Of the Non-
Hodgkin’s Lymphomas 46 are of T-cell origin and 1757 are of B-cell origin. The diagnosis of cases in 
EPIC was initially based on the International Classiﬁcation of Diseases for Oncology, second edition 
(ICD-O-2). These cases were then reclassified upon the publication in 2008 of the WHO document on 
classification of tumours of the hematopoietic and lymphoid tissues 16 by applying a conversion 
program available on the Surveillance, Epidemiology, and End Results Web page 
(http://seer.cancer.gov/tools/conversion/ICDO2-3manual.pdf) 215. Those that could not be reclassified 
were termed “not otherwise specified” (NOS).  
Multiple myeloma was the most common malignancy in this cohort accounting for 21% of cases 
(table 3.1.1), followed by CLL (17%), DLBCL (13%) and FL (12%). DLBCL and FL are commonly 
cited as the two most common NHL, however these estimates do not include MM which is recognised 
as the second most common blood cancer after NHL. For the purposes of this thesis MM is included 
as an NHL as discussed. Of the 1757 B-cell NHL cases 1524 (86.7%) had an available blood sample 
and could be matched to two controls who were lymphoma-free at the time of diagnosis in the case. 
Cases and controls were matched on study centre, age (+/- 1 year), sex and blood collection date (+/- 
45 days). The characteristics of the eligible (n=1524) and non-eligible (n=233) participants are shown 
in appendix table 3.1.1. The non-eligible participants were more likely to be female and were slightly 
younger than the eligible participants. There were also some differences in country of origin, with a 
large percentage of Norwegians among the non-eligible cases.   
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Despite the overall higher prevalence of NHL in males worldwide, due to the overrepresentation of 
females in the EPIC cohort of the 1524 cases 765 (50.2%) were female and 759 (49.8%) were male. 
The age distribution and the year of diagnosis were very similar between males and females. CLL, LL 
and HCL were more common in males, while FL and MZL were more common in females in this 
cohort (figures 3.1.1b ad c).  
Table 3.1.1: Subtype Classification of 2116 Incident Lymphoma cases diagnosed within the 
EPIC cohort during follow-up 
Subtype n. % 
Non-Hodgkin’s Lymphoma  
  
 
B-cell  
  
 
    Multiple Myeloma 452 21.4% 
 
    Chronic Lymphatic Leukaemia  359 17.0% 
 
    Diffuse Large B-cell Lymphoma 284 13.4% 
 
    Follicular Lymphoma 243 11.5% 
 
    Lymphoplasmocytic Lymphoma 69 3.3% 
 
    Marginal Zone B-cell Lymphoma 22 1.0% 
 
    Hairy Cell Leukaemia 22 1.0% 
 
    B-cell Acute Lymphatic Leukaemia 21 1.0% 
 
    B-cell Lymphoma, Not Otherwise Specified 285 13.5% 
 
T-cell 
  
 
    Mycosis Fungoides 24 1.1% 
 
    T-cell Acute Lymphoblastic Leukaemia 3 0.1% 
 
    T-cell Lymphoma, Other 43 2.0% 
Hodgkin's Lymphoma 94 4.4% 
Histological Information Not Available 195 9.2% 
    Total   2116 100.0% 
This does not include any cases from EPIC-France, who were not involved in the Lymphoma working group 
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Figure 3.1.1b Year of Diagnosis for 1524 incident NHL cases who had an available blood sample 
and could be matched to two lymphoma-free controls: Stratified by sex 
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Figure 3.1.1c Number of Cases by Subtype and Age group in 1524 incident NHL cases who had 
an available blood sample and could be matched to two lymphoma-free controls: Stratified by 
sex 
 
 
MM- Multiple myeloma, CLL – Chronic lymphatic leukaemia, DLBCL-Diffuse Large B-cell lymphoma, FL- Follicular lymphoma, LL-
Lymphoplasmacytic lymphoma, MZL – Marginal Zone lymphoma, HCL – Hairy cell leukaemia, BALL- B-cell acute lymphatic leukaemia, B, 
NOS – B-cell NHL not otherwise specified. 
 
3.1.2 The EnviroGenoMarkers study  
www.envirogenomarkers.net 
Ethics Statement 
This study was approved by the committees on research ethics in Umea (Dnr 08-215M) and in 
Florence (ref 347/2009) in accordance with the Declaration of Helsinki of the World Medical 
Association. All participants provided written consent at recruitment agreeing to provide detailed 
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information on their dietary and lifestyle habits at recruitment and to have their health status followed 
for the rest of their lives.   
Background 
The EnviroGenoMarkers (EGM) Study 216 is a nested case-control study aiming at the development of 
a new generation of biomarkers to better characterise the relationship between exposure to 
environmental pollutants and adverse health effects.  
Study Subjects 
The EnviroGenoMarkers study is based on participants from two existing prospective cohort studies: 
EPIC-Italy and NSHDS (figure 3.1.1.3). All participants had blood samples collected prospectively at 
enrolment.  
EPIC-Italy 217 is a subset of EPIC. A total of 47,749 participants aged 35-70 years were enrolled in 
five participating centres across Italy: Varese, Florence, Turin, Naples and Ragusa, between 1993 and 
1998. Standardised procedures were used to identify newly diagnosed cases of cancer based on 
automated linkages to cancer and mortality registries, municipal population offices and hospital 
discharge systems. The only exception was Naples, where follow-up information was collected 
through periodic personal contact.  
The NSHDS 218 includes participants from the Västerbotten Intervention program, the Västerbotten 
Mammary Screening Program and the Northern Sweden MONICA project.  A total of 95,000 healthy 
individuals aged 40-60 were invited for inclusion in the project between 1990 and 2006.  Subjects 
were asked to complete a self-administered questionnaire to collect demographic, medical and 
lifestyle information and a separate self-administered food frequency questionnaire at recruitment. 
Invasive cancers occurring among cohort members during the study period were identiﬁed by linkage 
with the Swedish Cancer Registry and the local Northern Sweden Cancer Registry. A proportion of 
the NSHDS participants included in the EGM study (61 cases and 56 controls) were also participants 
in the Swedish subset of EPIC.  
Selection of cases and controls 
Lymphoma cases were classified into subtypes according to the SEER ICD-0-3 morphology codes 21. 
Incident cases occurring at least two years after blood draw were identified and a suitable cancer-free 
control was selected by incidence matching from the remaining populations for each case matched on 
sex, age (+/- 2.5 years), centre and date of blood collection (+/- 6 months). More than 95% of 
participants also had the same fasting status as their matched pair at blood extraction. Information 
from the two studies was integrated into a single database and calibrated. The baseline characteristics 
of cases and controls are described in table 3.1.2a. The time between sample extraction and diagnosis 
is shown in table 3.1.2b.  The majority of participants were from Sweden (69%). There were no 
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significant differences between cases and controls in terms of baseline factors. Despite the fact that 
the incidence of NHL is greater in males than females, the population selected for this study included 
a slightly higher proportion of females than males. The mean age at recruitment was 53 years and the 
mean time to diagnosis was 73 months. This was similar between males and females, but longer in 
Sweden than in Italy, as the NSHDS included more recent follow up (up to 2013).  The diagnosis by 
subtype is shown in figure 3.1.2, the most common diagnosis in all subgroups was MM. Roughly a 
quarter of the cases from NSHDS could not be assigned a subtype (BNOS). 
To reduce the impact of technically-induced variation, matched pairs were analysed in the same batch 
on the same day. As matching was performed by sample date each case therefore had the same 
storage time as its matched control.  
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Table 3.1.2a: Baseline characteristics of cases and controls in the EnviroGenoMarkers study 
Baseline variable Cases (n=270) Controls (n=270) Difference 
    [n (%)] [n (%)] (p-value)α 
Cohort EPIC-Italy 84 (31.1) 84 (31.1) 
 
 
NSHDS 186 (68.9) 186 (68.9) 
 Phase∞ One 100 (37.0) 100 (37.0)  
 Two 170 (63.0) 170 (63.0)  
Sex Male 133 (49.3) 133 (49.3) 
 
 
Female 137 (50.7) 137 (50.7) 
 Mean Age (yrs) 53.08 53.09 0.989 
Mean Height (cm) 169.55 168.24 0.120 
Mean Weight (kg) 76.48 75.09 0.267 
BMI Underweight (<18.5 kg/m
2
) 1 (0.4) 0 (0.0) 
 
 
Normal (18.5-24.9 kg/m
2
) 104 (38.5) 109 (40.4) 
 
 
Overweight (25-29.9 kg/m
2
) 121 (44.8) 118 (43.7) 
 
 
Obese (≥30 kg/m2) 40 (14.8) 39 (14.4) 
 
 
Unknown 4 (1.5) 4 (1.5) 0.883 
Smoking status Never 121 (44.8) 134 (49.6) 
 
 
Former 90 (33.3) 72 (26.7) 
 
 
Current 57 (21.1) 54 (20.0) 
 
 
Unknown 2 (0.7) 10 (3.7) 0.269 
Highest educational 
level None 4 (1.5) 1 (0.4) 
 
 
Primary 94 (34.8) 98 (36.3) 
 
 
Technical/professional 68 (25.2) 54 (20.0) 
 
 
Secondary 52 (19.3) 64 (23.7) 
 
 
University/college 47 (17.4) 42 (15.6) 
 
 
Unknown 5 (1.9) 11 (4.1) 0.202 
Cambridge physical 
activity index Inactive 80 (29.6) 75 (27.8) 
 
 
Moderately inactive 106 (39.3) 95 (35.2) 
 
 
Moderately active 69 (25.6) 76 (28.2) 
 
 
Active 14 (5.2) 23 (8.5) 
 
 
Unknown 1 (0.4) 1 (0.4) 0.510 
Mean time to 
diagnosis (years) 
6.1 (range: 2.0, 
16.0)   
 
α
 P-value for difference was calculated using the chi-squared test for categorical baseline variables and the student’s t-test for continuous 
variables                                                                                                                                                                                                                       
∞In phase 1 50 case-control pairs were from NSHDS and 50 were from EPIC-Italy. In phase 2 136 pairs were from NSHDS and 34 were 
from EPIC-Italy 
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Table 3.1.2b; Time between sample extraction and NHL diagnosis in cases from the 
EnviroGenoMarkers study; mean median, range and number of cases by 5 year interval 
Population 
Median 
(months) 
Mean 
(months) 
Range 
 n. ttd<5 
years (<60 
months) 
n. ttd ≥ 5 
years                 
( ≥ 60 
months) 
Total 70.13 73.41 (24.03, 191.08) 121 149 
Sweden 74.52 78.43 (24.03, 191.08) 70 116 
Italy 54.62 60.25 (24.33, 119.15) 51 33 
Men  66.16 73.70 (24.33, 191.08) 62 71 
Women 71.74 73.11 (24.03, 190.92) 59 78 
ttd – time to diagnosis 
 
Figure 3.1.2 Classification of Included Incident B-cell NHL cases in the EnviroGenoMarkers 
Study: Stratified by Cohort and Sex  
Percentage of the total cases classified into each subtype 
 
BALL- B-cell Acute Lymphatic Leukemia , BCLL- B-cell Chronic Lymphocytic Leukaemia, BNOS - B-cell NHL Not 
Otherwise Specified, DLBCL - Diffuse Large B-cell Lymphoma, FL – Follicular Lymphoma, ML - Marginal Zone B-cell 
Lymphoma, MM- Multiple Myeloma 
 
Schematic 
The study was conducted in two phases. An initial pilot phase (phase 1) included 100 matched case 
control pairs (50 pairs from EPIC-Italy and 50 from NSHDS). Upon successful completion a second 
83 
roll-out phase (phase 2) was implemented including 34 case-control pairs from EPIC-Italy and 136 
case-control pairs from NSHDS. 
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Table 3.1.2c Origin and number of included participants for each results chapter (4-8), and the between chapter crossover 
POPULATION CHAPTER 
PARENT 
STUDY 
DATA 
n. 
participants 
Cross Over between the Chapters (n.) 
FOUR FIVE SIX SEVEN EIGHT 
CASES 
      
 
Four EPIC Genotyping performed as part of the InterLymph Consortium 175 175 
    
 
Five EGM POPs and Heavy Metal Body Burden 270 25 270 
   
 
Six EPIC Metabolomic Profiling 210 10 210 210 
  
 
Seven  EPIC Translocation Frequency and Prevalence 165 44 34 24 165 
 
 
Eight EGM POPs and Heavy Metal Body Burden plus Metabolomic Profiling 210 10 210 210 24 210 
          CONTROLS 
      
 
Four EPIC Genotyping performed as part of the InterLymph Consortium 263 263 
    
 
Five EGM POPs and Heavy Metal Body Burden 270 53 270 
   
 
Six EPIC Metabolomic Profiling 210 16 210 210 
  
 
Seven  EPIC Translocation Frequency and Prevalence 336 45 11 3 336 
 
 
Eight EGM POPs and Heavy Metal Body Burden plus Metabolomic Profiling 210 16 210 210 3 210 
          TOTAL 
      
 
Four EPIC Genotyping performed as part of the InterLymph Consortium 438 438 
    
 
Five EGM POPs and Heavy Metal Body Burden 540 78 540 
   
 
Six EPIC Metabolomic Profiling 420 26 420 420 
  
 
Seven  EPIC Translocation Frequency and Prevalence 511 89 45 27 511 
   Eight EGM POPs and Heavy Metal Body Burden plus Metabolomic Profiling 420 26 420 420 27 420 
This table includes only those participants included in the final analysis (ie. excluded participants are not shown)                                                                                                    
EGM incorporates both a subset of EPIC-Italy and a subset of the NSHDS 
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3.2 Technical (laboratory) methodologies 
The following technical methodologies were conducted by other individuals, as specified. 
3.2.1 Exposure assessment  
Exposure to metals was assessed by measurements in stored erythrocytes, and exposure to persistent 
organic pollutants (POPs) was assessed using blood serum. Blood samples were collected without 
RNA preservative in citrate (EPIC-Italy) or heparin (NSHDS) tubes and processed by centrifugation 
on the same day of collection (EPIC-Italy) and within one hour of collection (NSHDS). Aliquots 
(0.5ml) were stored in liquid nitrogen tanks at -196°C in Italy and -80°C in NSHDS. 
Cadmium and Lead  
Included in chapters five and eight. Conducted as part of the EGM study by Thomas Lundh, 
Department of Occupational and Environmental Medicine, Lund University Hospital, Sweden.  
Erythrocyte concentrations of Cadmium (Cd) and Lead (Pb) were determined by inductively coupled 
plasma-mass spectrometry (ICP-MS; Thermo X7, Thermo Elemental, Winsford, UK) in samples 
diluted with an alkaline solution according to Barany et al.219. The detection limit was calculated as 
0.03 and 0.09 µg/L for Cd and Pb respectively based on the standard deviation (SD) of the blank 
multiplied by three. The analytical accuracy was checked against human blood reference material 
from Centre de Toxicologie du Quebec, International Comparison Program, Canada. The results 
(mean ± SD) obtained were for Cd (Lot. C0616 and C0912) 0.98 ± 0.04 and 5.0 ± 0.18 µg/L (n = 69) 
vs. recommended 1.0 ± 0.13 and 5.3 ± 0.43 µg/L, respectively and for Pb (Lot. L0909 and L0807) 23 
± 0.043 and 112 ± 3.9 µg/L (n = 69) vs. recommended 23 ± 1.1 and 112 ± 9.9 µg/L, respectively. All 
samples were prepared in duplicate and the method imprecision (calculated as the coefficient of 
variation for duplicate preparation measurements) was 5 and 3% for Cd and Pb respectively 216.  
PCBs, DDE, HCB 
Included in chapters five and eight. Conducted as part of the EGM study by Hannu Kiviranta, 
Chemical Exposure Unit, National Institute for Health and Welfare, Kuopio, Finland 
The concentrations of the POPs (PCBs, DDE, DDT, HCB and BDE-47) in blood serum were 
determined using gas chromatography - mass spectrometry (GC-MS) analysis.  
 
The quantification of POPs was performed by an Agilent 6890 gas chromatograph (GC) connected to 
a Waters Autospec Ultima high resolution mass spectrometer (HRMS). The GC column used was 
DB-5MS (J&W Scientific, 30m, ID 0.25 mm, 0.25 μm), and the splitless mode was used for injection. 
For the phase 2 EPIC-Italy samples a slightly different procedure was used involving  an  Agilent 
7000B gas chromatography triple quadruple mass spectrometry (GC-MS/MS) system, with a DB-
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5MS UI (J&W Scientific, 20m, ID 0.18 mm, 0.18 μm) GC column and the solvent vent mode.  For 
quality control purposes in each batch of samples (43 batches with HRMS, 20 batches with MS/MS) 2 
reagent blanks were additionally prepared and the average result of the blank samples subtracted from 
the results of the real samples. Furthermore two control samples of Standard Reference Material 
1589a (PCBs, Pesticides, PBDEs, Dioxins/Furans in Human Serum) from the National Institute of 
Standards and Technology, were also included in each batch.  
3.2.2 Metabolomic Profiling 
Included in chapters six and eight. Conducted as part of the EGM study by Alexis Siskos and Anas 
Kamleh in the laboratory of Hector Keun, Department of Surgery and Cancer, imperial College 
London  
Sample preparation 
50 μL aliquots of plasma were thawed on ice then diluted with 50 μl of UPLC (Ultra-High 
Performance Liquid Chromatography) grade water (Romil LTD, Code H949, Cambridge , UK) and 
treated for protein precipitation using 300 μL of cold methanol (MeOH was pre-chilled at -20 C for 1 
h). Samples were vortexed and kept in -80 C for a complete precipitation then centrifuged at 13000 
rpm for 10 minutes. The supernatant was carefully removed to a clean eppendorf which was stored in 
-40 C until analysis day. A QC sample representing all samples was prepared by pooling 25 μl of each 
sample in a falcon tube. The pooled QC was aliquoted in 1.0 ml portion and stored at -40 C. A blank 
sample was prepared by replacing the plasma with 50 μl of pure water. On analysis day, 35 μl of each 
sample was added to 25 μl of an aqueous cocktail of internal standards (Hippuric acid-[D2], 
Phenylalanine [13C], Methionine [13C] and Acetylcarnitine [D3], Tryptamine-aplha,alpha,beta,beta-
[D4]).  
 
All blanks, QCs and samples were loaded, in high recovery chromatography vials (Waters 
Corporation, Milford, MA, USA) into the UPLC-MS auto-sampler. Samples were run with UPLC-MS 
as matched pairs of cases and control, and QC was run every six injections (3 case/control pairs). 
 
UPLC-MS experiment 
Reversed-phased chromatographic separation of the plasma sample preparation was conducted using 
an Acquity UPLC system (Waters Corporation, Milford, MA, USA) on an Acquity HSS T3 C18 
column 10mm x 2.1mm, 1.8 um (Waters) and a binary gradient elution comprising water + 0.1% 
formic acid (Sigma) and acetonitrile + 0.1% FA . Mass spectrometric analysis of the chromatographic 
eluent was performed using a quadrupole time-of-flight (QtoF-Ultima) spectrometer (Waters), with 
data collected in centroid mode in the m/z range 70-1000. Analysis was performed using positive ion 
mode electrospray ionization.  
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Data processing 
Mass spectral profile data was converted to NetCDF format using the DataBridge software (Waters) 
before processing using the XCMS software package 
220
 running in the R computing environment. 
XCMS data processing typically comprised of peak picking (CentWave method, 
peakwidth=c(3,30),ppm=15,snthresh=12.5), peak grouping (group density, mzwid=0.07,bw=20), 
retention time alignment (rector method, f=”s”,p=”m”) and feature intensity filling and reporting 
(integrated peak intensity).  The pooled QC samples, injected at intervals throughout the analytical 
run were used to normalise across batches and also to assess the quality of metabolite features.  
Due to the untargeted nature of the methodology and the use of LCMS, only a proportion of 
metabolite features have been annotated.  Unambiguous assignment requires the determination of 
retention time. This can only be determined by running authentic standards of the putative metabolites 
corresponding to the metabolite features and comparing the MS/MS fragmentation data. Each 
metabolite feature could potentially correspond to multiple metabolites, therefore to obtain the 
authentic standards and run the analyses for every possible metabolite for all the features identified in 
this project would take many years and was not possible during the scope of this thesis.  
 
3.2.3 Screening for the t(14;18) translocation 
Included in chapter seven. Conducted on a subset of the EPIC cohort by Bertrand Nadal, Sandrine 
Roulland and colleagues at CNRS-INSERM, Université de la Méditerranée in Marseille, France  
DNA isolation   
DNA  samples  were  extracted  from  buffy  coats  using  the  QIAsymphony  DNA Midi Kit or the 
QIAamp DNA FFPE tissue kit for Formalin-fixed paraffin embedded (FFPE) tumor biopsies (Qiagen, 
Crawley, UK).  
Screening assay 
Quantitative real-time PCR (Q-PCR) was conducted using an ABIPRISM 7500 system and Sequence 
Detection software (Applied Biosystems). The laboratory was blind to the case-control status of the 
samples. t(14;18) frequency within the BCL2 major breakpoint region (MBR) was measured using 
buffy coat-extracted DNA samples. Three PCR replicates were performed with at least 0.5-1 µg DNA 
for t(14;18), two replicates for the reference GAPDH gene and two for control cell lines. The absolute 
frequency of lymphocytes carrying the translocation was calculated using the standard curve method 
and normalized to the number of total lymphocytes in the samples. Frequency  was  defined  as  the  
number  of  circulating  t(14;18)  copies  per  1,000,000  circulating  lymphocytes. Prevalence 
(t(14:18)+) was defined as more than 1 cell bearing the translocation per 1,000,000 circulating 
lymphocytes (≥1x10-6 ). 
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3.2.4 Genotyping 
Included in chapter four. Conducted as part of the InterLymph NHL GWAS in a subset of the EPIC 
cohort at the National Cancer Institute’s Cancer Genomics Research Laboratory, Bethesda, 
Maryland, USA 
Genotyping was performed using Illumina OmniExpress at the NCI covering 71,5530 SNPs. 
Genotypes were called using Illumina GenomeStudio software, and quality-control duplicates (for the 
entire InterLymph GWAS) showed >99% concordance. Further details are provided in 87, and details 
of the quality control criteria applied to the EPIC population for this study are provided in chapter 
four.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
3.3 Statistical methodologies 
The statistical analysis plan employed for each chapter is outlined in the individual methods sections. 
Overarching statistical methodologies applied in more than one chapter are described here. All 
analyses were run using STATA 12.1 (Stata Corporation, College Station, TX), R version 3.0.0 or 
PLINK version 1.07 as specified. All tests are two tailed and the level of statistical significance was 
set at 0.05. However the potential for spurious results arising from multiple testing was also 
considered and where alternative significance levels were used these are indicated.  
3.3.1 Unconditional and conditional logistic regression 
The vast majority of association analyses within this thesis were based on a nested case-control design 
and so effect estimates were calculated as odds ratios using a logistic regression model. Logistic 
regression models the relationship between a dependent variable, in this case incidence of NHL and 
one or more independent variables which are chapter specific, using a generalized linear model with a 
binomial response and logit link function 
The basic model considers occurrence of NHL as the binary dependent variable, the potential 
(chapter-specific) biomarker of interest as an independent variable and adjusts for the case-control 
study matching factors: age (+/- 1 year), sex, country and date of blood draw (+/- six months). In 
analyses based on the EGM study the basic model additionally includes study phase and processing 
batch.  
As the parent study populations used a matched design where possible conditional logistic regression 
was utilised, which conditions out the matching factors from the analysis in order to eliminate 
unwanted nuisance parameters from the estimate. In practice, on the same data the basic and the 
conditional model will show similar odds ratios. 
Additional included confounders for both the basic and the conditional model are described in the 
relevant chapters.  
3.3.2 Association analysis for GWAS data 
All genome-wide association analyses were conducted using PLINK version 1.07 utilizing all SNPs 
that passed the quality control thresholds (as detailed in chapter 4).  
The association command logistic, which compares allele frequencies between cases and controls, 
was used to test the association with the defined phenotypes (NHL or translocation) adjusting for a 
defined set of covariates specified in a separate text file and with the ci95 option to obtain 95% 
confidence intervals (95% CI) for the odds ratios. This command additionally provides the allele 
frequencies in cases and controls.  
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The logistic command reports a log-additive model so the resulting odds ratio describes the increase 
or decrease in risk associated with each extra copy of the variant (minor) allele.  
3.3.3 Receiver Operator Characteristic (ROC) curve analysis 
ROC curves are created by plotting the false-positive rate (1-specificity) against the true-positive rate 
(sensitivity) for a continuous predictor and a binary outcome.  
In this thesis, ROC analysis was performed using three commands in STATA: lroc which plots the 
graph and computes the area under the curve (AUC, also known as the concordance index), roctab 
which provides the nonparametric estimation of the ROC curve and the asymptotic normal confidence 
intervals for the AUC, and roccomp which allows statistical comparison of multiple ROC curves. 
3.3.4 Meta-analysis 
Where multiple subgroups were compared heterogeneity in effect estimates between the groups was 
assessed using meta-analyses. The metan command in STATA was used to calculate the I2 
inconsistency matrix as a measure of the amount of heterogeneity not due to chance, and the 
corresponding p-value.   The default fixed effects model was used, to account for the fact that the 
compared groups all came from the same parent population. 
3.3.5 Profile regression 
Profile regression is a novel Bayesian methodology specifically developed to analyse complex 
datasets in which multiple risk factors are likely to interact in the aetiology of common multifactorial 
diseases 163-165.  
The benefits of profile regression include its ability to identify effects which are too small to be 
picked up as significant by standard logistic regression, and additionally to show the joint effect of 
covariates combined. In contrast to standard methodologies, it works better the more covariates there 
are, and the more correlated they are. Profile regression can handle over 1000 covariates and can 
include potential confounders as fixed effects in its estimation.  
Profile regression acts to reduce dimensionality by using a profile formed of a sequence of covariate 
values, rather than individual risk factors, as its basic unit of inference. The covariate profile is used to 
cluster individuals into subpopulations, so that clusters are coherent with respect to risk factors among 
observations within clusters and dissimilar with respect to risk factors between clusters. 
Clusters are determined via an assignment submodel, which evaluates the probability that an 
individual is assigned to particular cluster. Simultaneously a disease submodel links the profiles to an 
outcome of interest via an estimated association parameter.  Both submodels are fitted jointly, in a 
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unified manner using Bayesian inference techniques and Monte Carlo Markov Chain (MCMC) 
sampling methods, so the allocation of individuals to clusters depends on both the covariate data in 
the assignment submodel and the outcome information in the disease submodel.  
The MCMC method outputs a different clustering of data at each iteration of the sampler, with 
flexible clustering using the Dirichlet process.  In Bayesian non-parametric models of data the prior 
and posterior distributions are not parametric distributions, but stochastic processes such as Dirichlet. 
The Dirichlet process is a probability distribution whose domain is itself a set of probability 
distributions which govern the relative chances of different outcomes. Therefore a draw from a 
Dirichlet process will return a theoretically infinite sequence of random variables. This makes it 
extremely flexible and an ideal candidate for clustering problems where the distinct number of 
clusters is unknown beforehand. In profile regression it allows the model to start with more clusters 
than needed and for the number of clusters to vary 221. The best partitioning of the data i.e. the optimal 
number of clusters, is determined based on a score matrix, which calculates the percentage of times 
two people were in the same cluster 222. The output of the MCMC sampler is exploited to assess 
parameter uncertainty and to compute the risk associated with specified profiles of interest. Each 
covariate is assigned a continuous selection weight (ρ) relating to its importance in the formation of 
clusters, relative to the outcome and all other covariates. 
The script as run in R is shown in the appendix (Methods 3.4.4), using the PReMiuM package 223. 
3.3.6 The “meet-in-the-middle” approach 
The “meet-in-the middle” (MITM) approach 7 has previously been successfully applied to the study of 
diet and colon cancer using (1)H NMR profiles from plasma samples collected before disease onset 224. 
The principle is to use a nested case-control design to combine a retrospective search for biomarkers 
of disease development with a prospective search for associations with these biomarkers to past 
environmental exposures.   
The MITM approach will be applied when combining biomarkers, and will be achieved using 3 steps 
to identify putative intermediate biomarkers: 
STEP A: From disease to exposure 
The ‘top’ (as defined by a biomarker specific threshold and significance level) disease-biomarker 
associations will be identified. 
STEP B: From exposure to disease 
The ‘top’ exposure-biomarker associations will be identified  
STEP C: Parallel analysis 
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Biomarkers identified in both Step A and Step B (i.e. the common biomarkers) will be taken forward 
for further analyses to consider biological plausibility including pathway analysis and performance 
against biomarker criteria if appropriate.  
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3.4 Pathway analysis 
SNP were mapped to genes using three different web-based programs (default settings): 
Brain array SNP function Portal 225 
(http://brainarray.mbni.med.umich.edu/Brainarray/Database/SearchSNP/snpfunc.aspx) 
BRISK (Biology related Information Storage Kit) SNP to gene function 
(http://genapha.icapture.ubc.ca/brisk/snpGene.do)  
pfSNP: Potentially Functional SNP Search Engine 226 
(http://pfs.nus.edu.sg)  
 
Genes which were identified by all three databases were then uploaded to the Database for 
Annotation, Visualization and Integrated Discovery (DAVID v6.7, http://david.abcc.ncifcrf.gov/) 227 
for functional annotation. All available functional categories were considered, including 
Gene_Ontology, Pathways, and Protein_Interactions. A functional annotation chart was used to 
identify the most important pathways using defined criteria; the EASE (Expression Analysis 
Schematic Explorer) score was set to less than 0.01 and the minimum number of genes per group to 5. 
Pathways were considered of importance if their Bonferroni corrected p-value was less than 10e-3 and 
their fold enrichment greater than 1.5. These are established default values for this methodology. 
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3.5 Biomarker assessment 
Although there exist a number of guidelines for the reporting of biomarkers including REMARK 228 
and  STROBE-ME 8. There is less formal agreement on the best way of actually evaluating their 
utility in an epidemiological manner, and any rules that exist tend to be underdeveloped and/or not 
routinely applied 229.  
Estimates of sensitivity, specificity, negative predictive value (NPV) and positive predictive value 
(PPV) are important measures of biomarker utility 230. However, the most objective and statistically 
valid method for the evaluation of biomarker prediction is the use of ROC curves. The corresponding 
AUC can be interpreted as the probability that a classifier (in this case, biomarker) will rank a 
randomly chosen positive instance higher than a randomly chosen negative one; an AUC of 0.5 
therefore is interpreted as having no practical utility 230. In this thesis, these measures will be reported 
as standard where possible, in addition to adhering to the reporting guidelines as outlined by 
REMARK and STROBE-ME (the full guidelines can be found at 228 and 8 respectively).  
As it will not always be possible to calculate AUC, sensitivity, specificity, PPV and NPV, and to 
enable a more holistic evaluation of biomarkers, a number of other guidelines and criteria will also be 
employed (Table 3.5). Standard epidemiological causation employs Bradford Hill’s nine causation 
criteria 231, which can provide evidence on whether biomarkers lie along the causal pathway. 
Nevertheless, as biomarkers are not necessarily part of a causal association, the “Venice Criteria” 232 
will additionally be employed. These criteria were developed for genetic studies as an alternative to 
the Bradford Hill Criteria, to reflect the fact that many of these guidelines are considered 
inappropriate for genetic associations, but they can also be well applied to molecular epidemiology 
studies. Finally, the themes addressed by Ransohoff in his paper 'Rule of evidence for cancer 
molecular-marker discovery and validation’ 229 will be discussed. There is some crossover between 
these guidelines, particularly the importance of replicating findings and of accounting for potential 
bias and confounding.  
The criteria for a successful screening test will also be discussed in this thesis and these are outlined 
in appendix box 3.5 233. 
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Table 3.5; Three different sets of criteria for assessing biomarker utility and determining their 
association with an outcome of interest  
Bradford Hill’s Causation 
Criteria 
231
 
Venice Criteria 
232
 
Ransohoff's Rules of evidence for 
cancer molecular-marker 
discovery and validation 
229
 
Consistency/replication of the 
finding 
Replication 
Assessment of the reproducibility of 
the finding in an independent data set 
Strength of the Association Amount of  Evidence Protection from overfitting 
Specificity of an association 
Protection of the 
association from bias 
Protection from bias 
Temporality of exposure and 
effect 
  Protection from confounding 
Analogy/consideration of 
alternative explanations 
  Generalisabilty 
Biological gradient/dose response 
effect 
  Clinical usefulness 
Biological plausibility of 
association 
  
Consideration of cost vs. effort and 
benefit vs. harm 
Coherence with existing 
knowledge 
    
Experimental evidence     
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PART 1: VALIDATING BIOMARKERS 
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4.PROFILE REGRESSION AS A TOOL FOR 
IDENTIFYING SUSCEPTIBILTY BIOMARKERS 
FROM GENETIC PROFILES  
BIOMARKER: SNP sets 
BIOMARKER TYPE: Biomarker of Susceptibility 
POPULATION: A subset of cases and controls from the EPIC cohort genotyped as part of the 
InterLymph consortium 
4.1 Introduction 
There is a wealth of data to support a genetic component to lymphoma aetiology 12, as evidenced by 
the increased risk observed for individuals with a family history  and results from various genetic 
studies of both germline and somatic mutations. A number of compelling findings have emerged from 
studies of lymphoma tumours, however, in order to identify genetic biomarkers of susceptibility 
which can be used in prediction, constitutional genetics are of more interest. Initial candidate gene 
studies mainly focused on associations with genes involved in DNA integrity and methylation, the 
immune response, B-cell survival and growth and in the pathways of xenobiotic metabolism 
108,123,124,187,234. More recently genome-wide scans have identified variants involved in the 
inflammatory, folate, apoptotic, energy production and hormone metabolising pathways as also being 
of potential importance 12,110,111,124. These findings have been discussed in more detail in chapter 1, 
section 1.3.5. Despite some success, to date both for the candidate and the genome-wide studies tend 
to have been characterised by modest effect sizes and low penetrance variants.  
Consequently in an attempt to address this through the use of larger sample sizes there has been a shift 
towards consortium-led GWAS encompassing thousands of subjects from multiple studies. One such 
initiative is the InterLymph NHL GWAS 87, which contains over 11,000 NHL cases and 15,000 
controls from 22 studies, including 9 prospective cohort studies, 8 population-based case-control 
studies and 5 clinic/hospital-based case-control studies. This represents the largest study to date 
enabling the investigation of individual subtypes with good power.  InterLymph have previously 
reported a large number of significant associations between genetic variants and the risk of NHL and 
its subtypes using a candidate approach 110,114,115,125,126. Many of which, particularly those involved in 
the immune response, have also been replicated in independent studies. Its more recent subtype-
specific GWAS has already published strong findings for chronic lymphocytic leukaemia (CLL) 87. 
Currently, the manuscripts for the remaining subtypes, including DLBCL, FL and MZL, are in 
preparation. Within the InterLymph NHL GWAS a total of 190 NHL cases and 265 controls from 
EPIC have been genotyped. 
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Although the emerging results from the consortium are very promising, it is hypothesised that a large 
proportion of genetic heritability remains unexplained. For CLL it is estimated that up to 46% of 
familial risk could be explained with common SNPS, while the identified variants explain only 17%.
 
It is therefore likely that further SNPs, probably with only marginal effect sizes, remain to be 
discovered 87 . Although there is a counter-argument to this which states that not all that is heritable is 
necessarily genetic, and a large component of the ‘missing heritability’ may represent shared 
environmental and social factors or the inheritance of environment-sensitive epigenetic states  235,236. 
Nevertheless, it has been observed that for most disorders GWAS can only detect a few common 
variants explaining only a fraction of the genetic component of risk 237. In general if disorders are 
caused by rare genetic variants with minor allele frequencies (MAF) less than 1%, or by variants with 
effect sizes less than 10% then these are unlikely to be identified by standard GWAS methods. 
Additionally, these univariate methods are unable to elucidate how multiple variants may be working 
in combination to affect risk 87,238. Consequently it has been proposed that GWAS may be better 
suited as a first preliminary step to prioritize information for additional analysis 237. 
In particular three different ways of performing secondary analyses on the findings resulting from 
GWAS have been suggested: meta-analyses, pathway analyses and interaction analyses. Meta-
analyses are now commonly used, mainly in systematic reviews, and the methods are well understood, 
although their application to GWAS data does introduce some novel challenges. These mainly relate 
to the heterogeneity between the contributing studies which, if too large, may obscure the association 
of interest.  Pathway analysis is a way of integrating the findings from genetic studies into known 
molecular pathways and determining whether they are plausibly associated with the disorder of 
interest. This is a less well developed area than meta-analyses and it has been observed that findings 
can be very dependent on the various databases and methodologies employed 239. Similarly the study 
of gene-gene interactions (GxG) is complex and currently it remains computationally and statistically 
implausible, if not impossible, to assess all the pairwise and higher order interactions involved in the 
context of a GWAS.  
This chapter focusses on a novel methodology, profile regression, for the exploration of GxG 
following GWAS analyses, as a way of considering the findings in a different context and of 
providing a more global overview. Profile regression is also particularly well suited to the situation 
where the number of variables far exceeds the number of subjects, as in this dataset. Given the limited 
sample size available, the likelihood of obtaining interpretable results using standard GWAS analyses 
in this population is low.  
Profile regression 163,165  is a dimension reduction technique that clusters individuals according to both 
their covariate pattern and an outcome of interest. The covariate profile in this instance is based on the 
genotype for each individual at each measured SNP, and the outcome is NHL.  This allows for the 
99 
identification of the SNPs which combine to influence risk and the quantification of risk in each 
cluster.  It is a Bayesian technique which incorporates flexible nonparametric clustering and a variable 
selection approach using a Dirichlet process to allow uncertainty to be taken into account. Each SNP 
is assigned a continuous selection weight which can be utilised to identify the variables most 
important for cluster formation and for determining outcome, relative to all other variables. Further 
details of the methodology are provided in methods chapter 3.3.5. 
Here the results of profile regression analyses are presented for the strongest NHL associated SNPs in 
participants from the EPIC cohort.   
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4.2 Methods 
4.2.1 Study population 
The study population was drawn from the EPIC cohort (see methods 3.1.1 and table 3.1.2c). Blood 
samples from incident cases of NHL and two matched lymphoma-free controls, were sent to the 
Cancer Genomics Research Groups at the National Cancer Institute in Washington. Here, a subset of 
these cases (n=190) and controls (n=265) were selected for screening and the remainder saved for the 
taqman replication of promising findings from the total consortium.  
4.2.2 Genotyping 
Details of the genotyping and quality control (QC) procedure are in methods section 3.2.4. The data 
was received in its raw format so QC procedures were run independently on the EPIC dataset utilising 
the same thresholds applied by the InterLymph consortium in the pooled analysis87. 
4.2.3 Quality control in EPIC 
First sample quality was checked. Samples with a call rate <93%, those with a mean heterozygosity 
<0.25 or >0.33 (based on the autosomal SNPs), those showing a discordant sex to that stated in the 
questionnaire (on the X chromosome >5% heterozygosity for males and <20% heterozygosity for 
females), unexpected duplicates (>99.9% concordance) and first-degree relatives (on the basis of 
identity-by-descent (IBD) with Pi-hat > 0.40) were excluded. The SNP QC criteria were then applied 
to the remaining samples. Monomorphic SNPs, SNPs with a call rate <93%, SNPs with a MAF <1% 
and those with a Hardy-Weinberg equilibrium p-value <1x10-6 were excluded.  
4.2.4 Association analyses 
Association analyses were run including all individuals and SNPs that passed the QC criteria using 
PLINK: whole genome association analysis toolset 240. The logistic command was used to produce an 
odds ratio, 95% confidence interval and p-value for each SNP, adjusted for age, sex, country and 
significant MDS (multidimensionality scaling) components. MDS is a dimensionality reduction 
technique that is a means of determining the levels of similarity between participants in a dataset. 
Components based on IBD were calculated using the genome command in PLINK.  
SNPs were then ranked according to their p-value, with the smallest p-value ranked as one, and the 
strongest 5000 associations taken forward for profile regression analyses. To avoid simply picking up 
population substructure this list of 5000 SNPs was then thinned (meaning the number of SNPs were 
reduced) using purpose built code (Appendix 4.2.4). When the top 5000 SNPs are ordered by 
chromosome and then base-pair position, this code picks up the top SNPs for each region, according 
to p-value, by assuming that SNPs within 100kb of each other are in the same region and those more 
than 100kb apart are independent. In this way the top 1000 independent SNPs can be selected for 
profile regression 
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4.2.5 Profile regression 
The top 1000 SNPs were analysed by profile regression adjusting for age, sex, country and significant 
MDS components by including these variables as fixed effects. SNPs were coded as 0, 1 or 2 
depending on their minor allele count. Sex and country were included as binary and categorical 
variables, and age and MDS components were continuous. The MCMC output, in tandem with the 
model averaging approach, assigned individuals into clusters based on their covariate profile. Latent 
selection weights were used to identify the most important SNPs for the formation of these clusters. 
Results were obtained from 285,000 iterations, with a filter of one hundred after a burn-in sample of 
285,000 iterations (in total 570,000 iterations). Burn-in refers to the process of discarding an initial 
proportion of the Markov Chain sample. This is performed to minimise the effect of the initial pre-
convergence values on posterior inference, and to start the chain in, or near equilibrium. A filter of 
100 was applied to the model, so that the simulated sample is recorded every 100th iteration. This is 
performed to speed up subsequent computations and to reduce autocorrelation within the sample, 
because within the Markov chain high correlation between adjacent samples may be present. These 
values (the number of burn-ins and iterations) were chosen after multiple sensitivity analyses were run 
to determine the number of iterations required to produce consistent results. Further details on profile 
regression are detailed in the methods section 3.3.5. 
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4.3 Results 
4.3.1 Study population and quality control 
A total of 455 participants, 190 incident NHL cases and 265 controls from the EPIC cohort, were 
genotyped as part of the InterLymph NHL GWAS.  These were selected by the genotyping lab from 
the 1524 B-cell NHL cases within EPIC with a blood sample and two matched controls. Selection was 
based on the numbers required for the subtype specific analyses of the whole consortia population. 
Those cases and controls not genotyped were saved for use in the replication stages of the promising 
signals emerging from the GWAS. Fourteen cases of T-cell NHL were excluded from further 
analysis. One case with a call rate <93% (90%) and two female controls with an X-chromosome 
heterozygosity >20% (21% and 24%) were also excluded. The remaining participants met all other 
sample QC thresholds and a total of 175 cases and 263 controls were included in the analysis. The 
baseline characteristics of these participants are shown in table 4.3.1. Before the QC thresholds were 
applied genotype data were available for 715,530 SNPs in the 438 remaining participants. After 
frequency and genotype pruning and the exclusion of heterozygous haploid genotypes and SNPs 
which failed Hardy-Weinberg Equilibrium (HWE), a total of 609,456 markers were included in the 
analysis.  
Cases and controls displayed no differences with respect to gender age, BMI or smoking status (table 
4.3.1). However, they did differ significantly by country with the majority of controls (76.8%) 
originating from Italy. This is despite the fact that Italy accounted for only 11% of EPIC cases overall 
(appendix table 3.1.1). Again, women were overrepresented in this study compared to global 
incidence and the age at diagnosis was younger than the European average. Almost three quarters of 
cases and of controls were overweight or obese and roughly half were former or current smokers. 
However due to the large number of different European countries included, and the fact that obesity 
and smoking prevalence have changed throughout the recruitment period, it is difficult to determine 
whether these values are higher than expected. The most common subtype was CLL (40.6%) followed 
by DLBCL and FL (both 26.3%). These were also the three most common subtypes in EPIC overall, 
excepting MM which was not included in the InterLymph GWAS.  
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Table 4.3.1: Baseline characteristics of EPIC NHL cases and controls with available genotype 
data from the InterLymph Consortium 
Demographic characteristics 
  Controls   Cases   
Difference 
(p-value) 
N 
 
263 
 
175 
  Age at blood draw in yrs, mean (range)  
 
62.5 (44, 84) 
 
61.4 (41, 83) 
 
0.171 
Sex - n (%)                                        Male 
 
120 (45.6) 
 
86 (49.1) 
 
0.470 
Female 
 
143 (54.4) 
 
89 (50.9) 
  
BMI category - n(%)            Underweight 
 
2 (0.8) 
 
2 (1.1) 
 
0.158 
                                                       Normal 
 
118 (44.9) 
 
61 (34.9) 
                                                  Overweight 
 
109 (41.4) 
 
80 (45.7) 
                                                           Obese 
 
34 (12.9) 
 
32 (18.3) 
  
Smoking status - n(%)                     Never 
 
106 (40.3) 
 
81 (46.3) 
 
0.061 
                                                       Former 
 
77 (29.3) 
 
61 (34.9) 
                                                        Current 
 
73 (27.8) 
 
30 (17.1) 
                                                     Unknown 
 
7 (2.7) 
 
3 (1.7) 
  
Country - n(%)                                   Italy 
 
202 (76.8) 
 
37 (21.1) 
 
<0.001* 
                                                          Spain 
 
10 (3.8) 
 
24 (13.7) 
                                          United Kingdom 
 
14 (5.3) 
 
48 (27.4) 
                                          The Netherlands 
 
15 (5.7) 
 
26 (14.9) 
                                                          Greece 
 
6 (2.3) 
 
13 (7.4) 
                                                      Germany 
 
15 (5.7) 
 
26 (14.9) 
                                                      Denmark 
 
1 (0.4) 
 
1 (0.6) 
  
Age at diagnosis in yrs, mean (range)  
   
61.5 (42, 83) 
  
Subtype  - n(%)                                  CLL 
   
71 (40.6) 
                                                        DLBCL 
   
46 (26.3) 
                                                                FL 
   
46 (26.3) 
                                                            MZL 
   
8 (4.6) 
                                                            MCL 
   
3 (1.7) 
                                        B-cell NHL, NOS       1 (0.6) 
  
∞t-test for age, chi-squared test for all other analyses                                                                                                                                     
*Significant at the 95% level                                                                                                                                                                                  
CLL-Chronic Lymphocytic leakemia, DLBCL-Diffuse Large B-cell Lymphoma, FL-Follicular Lymphoma, MZL-Marginal Zone Lymphoma, 
MCL – Mantle Cell lymphoma, NOS- Not Otherwise Specified 
 
4.3.2 Population stratification 
To evaluate population substructure MDS components were calculated in PLINK which uses identical 
by state distance to perform hierarchical clustering. Plots for the first ten components are shown in 
figure 4.3.2. There was some evidence of clustering by country for the first two components. 
Additionally four components were associated with case-control status at the p<0.1 level (C1: 
p<0.001, C2: p=0.093, C8: p=0.065, C12: p=0.073), and were adjusted for in the association analysis. 
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Due to the large number of controls from Italy, country was also retained in the model, to further 
attempt to attenuate the potential effect of population stratification.   
Figure 4.3.2: Plots of the first ten MDS components to evaluate population substructure in the 
total NHL EPIC genotyped population (cases=175, controls=263). Plots are coloured according 
to country of residence of the participants  
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4.3.3 Association analysis 
No SNPs achieved genome wide significance in this population (p<5x10-8), although this was not 
unexpected given the modest sample size, and there was no evidence of an enrichment of SNPs with 
small values compared to the null distribution in the quantile-quantile plot (Figure 4.3.3). The SNPs 
that almost met the threshold for a ‘suggestive association (p<1x10-5) are highlighted on the 
Manhattan plot. In total 48 SNPs had a p-value <10-4. 
Figure 4.3.3: Quantile-Quantile (QQ) Plot and Manhattan Plot for the NHL-GWAS Association 
Analyses in the total NHL EPIC genotype population 
In the QQ Plot the expected null distribution is shown as a diagonal red line. In the Manhattan Plot, 
the red horizontal line represents the genome-wide significance level (5x10-8) and the blue line, the 
suggestive association level (10-5) 
 
 
After thinning, a final 2263 SNPs, all of which are independent and represent the top SNP for each 
region were selected. The p values for these 2263 SNPs ranged from 1.04x10-5 to 8.47x10-3. The top 
1000 of these SNPs (according to p-value) were taken forward for profile regression.  
4.3.4 Profile regression 
The SNPs were coded as 0, 1, and 2, according to the count of their minor allele. Latent selection 
weights were used for the detection of important genetic markers. Sensitivity analyses using different 
numbers of iterations were run to determine the number needed to obtain consistent results (appendix 
table 4.3.4). The final results are based on 285,000 iterations, after a burn-sample of 285,000.  The 
MCMC output, in tandem with the model averaging approach assigned the subjects to two sub-
populations (table 4.3.4a). There was a significant difference in risk between the two clusters. Cluster 
one contained 413 participants of whom 150 were NHL cases. Cluster 2 comprised 25 participants of 
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whom 25 were cases and membership of this group was associated with more than double the risk of 
cluster one according to the profile regression computed estimates of risk (OR: 2.29 (95% credible 
interval: 2.00, 2.44). 
 
Table 4.3.4a; Assigned clusters for 438 NHL EPIC genotyped participants after 285,000 
iterations of the sampler 
Cluster 1 2 
No. Participants 413 25 
Risk (No. cases/no. participants in cluster) 0.363 1.00 
Risk parameters computed by profile regression 
(95% CI) 
0.371 (0.339, 0.402) 0.850 (0.678, 0.961) 
Relative risk (95%CI)  1.00 (ref) 2.29 (2.00, 2.39) 
CI – Credible Interval                                                                                                                                                                                   
Relative risk computed according to risk parameters computed by profile regression: RR in cluster2 =0.850/0.371 
 
The estimates of cluster-specific risk are computed using post-processing of the whole MCMC output, 
in which the subjects may cluster slightly different at each iteration. At every iteration of the sampler, 
the risk parameters corresponding to the 25 subjects is averaged to obtain the distribution, therefore as 
some of the 25 participants may be in lower risk clusters at different iterations the computed risk is 
less than one.   
 
The computed estimates should be robust to confounders, however the majority (n=22) of participants 
in the high risk cluster were from Italy, with the remaining cases from the United Kingdom (n=1), 
Spain (n=1) and Greece (n=1). Consequently there was a significant association between country of 
origin and allocation to the highest risk cluster (Chi-squared p=0.044). The effects of the confounder 
covariates are shown in table 4.3.4b.  
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Table 4.3.4b: Posterior estimates of the effects of the confounders included in the logistic 
regression model 
Confounder Posterior Median 95% Credible Interval 
age -0.017 (-0.045,0.009) 
Italy -2.095 (-3.921,-0.503) 
Spain 1.117 (-0.514,2.875) 
UK 1.713 (0.029,3.348) 
The Netherlands 0.951 (-0.64,2.529) 
Greece 1.055 (-0.647,2.786) 
Germany 0.988 (-0.583,2.598) 
Denmark 0.125 (-2.449,2.824) 
sex 0.013 (-0.47,0.492) 
c1 0.281 (-3.932,5.277) 
c2 -0.026 (-4.843,3.819) 
c8 -0.378 (-5.361,3.27) 
c12 -0.926 (-6.035,3.473) 
 
The sex ratio was similar in both clusters: 47% and 48% of the population were male in cluster 1 and 
2 respectively (p=0.920). There were additionally no significant differences between the clusters in 
terms of MDS components 2 (p=0.267), 8 (p=0.693) or 12 (p=0.762), height (p=0.059), weight 
(p=0.054), BMI (p=0.417), educational level (p=0.152), activity level (p=0.700) or smoking status 
(p=0.629). Among the NHL cases there was no significant difference between the clusters in terms of 
time between blood draw and diagnosis (p=0.825).  Individuals in the high risk cluster comprised 
diagnoses of all subtypes: CLL n=8, DLBCL n=4, FL n=8, MCL n=2, MZL n=3. 
 
A total of 12 SNPs have a latent selection weight greater than 0.45 and two had a selection weight of 
1, ranking them as the SNPs of greatest importance in the formation of clusters.  Of the 12 SNPs three 
were located in chromosome 5, two were in chromosome 9, two were in chromosome 11 and there 
was one in each of chromosomes 1, 2, 6, 14 and 15. For 867 SNPs the selection probability was 0.  
 
The posteriors medians of the latent selection weights for the top 1000 SNPs, ordered according to the 
strength of their association (ranked by p-value from 1-1000) with NHL, are shown in figures 4.3.4a 
and 4.3.4b.  Of the SNPs with a variable selection weight >0.45 only two also had p-values in the top 
100 in terms of association with NHL: rs10511476 on chromosome 9 which ranked 21st using 
classical methods (p=6.19x10-5, posterior median: 0.46) and rs7402445 on chromosome 5 which 
ranked 32nd (p=9.82x10-4, posterior median: 0.50). For the remaining SNPs with a weight >0.45 the p-
values ranged from 1.7x10-4 to 0.0032. 
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Figure 4.3.4a; Posterior medians for the latent selection weights obtained using profile 
regression for the top 1000 SNPs associated with NHL in the logistic regression analyses 
To compare the findings from the profile regression to the classical logistic regression method SNPs 
are ordered from 1-1000 based on the significance (p-value) of the association using the logistic 
regression model  
 
 
Figure 4.3.4b; Top 12 SNPs according to Posterior Median Latent Selection Weight obtained 
from the profile regression analyses and the associated p-values from the logistic regression 
analyses 
The top 12 SNPs identified using profile regression are highlighted in black 
 
 
Figure 4.3.4c shows the top 12 SNPs and the associated genotypes which most contributed to the 
formation of the high risk cluster.  The results show that individuals in the high risk cluster are 
significantly more likely to carry the rare homozygote for rs1384483 and rs11207160. Although the 
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differences were not significant for the remaining SNPs, individuals in the low risk cluster were more 
likely to carry the common homozygote, as would be expected.   
 
Figure 4.3.4c: Profile of the top 12 SNPs influencing NHL risk cluster formation identified using 
the profile regression analyses  
 
The bottom left hand plot displays the number of participants in the two clusters and the top left hand graph displays 
the proportion of these participants who were cases. The next plot shows the risk in the high risk (red) cluster relative 
to the average risk in the rest of the population. The remaining plots each represent one of the top 12 SNPs 
contributing to cluster formation, one column per SNP. The plots within the column represent the genotypes 
0=common homozygote, 1=heterozygote, 2=rare homozygote. For each genotypes the boxplots show the likelihood of 
participants cluster 1 and cluster 2 (high risk) carrying this genotypes. Red indicates significantly more likely to, blue 
significantly less likely to, and green no significant difference. 
There were no carriers of the rare homozygote for rs17085103 
 
Biological plausibility of the findings 
Of the top 12 SNPs (rs11241627, rs6730045, rs17085103, rs1384483, rs7402445, rs403084, 
rs11027160, rs12892252, rs1001606, rs10511476, rs347984 and rs12036302) none have previously 
been identified as being involved in the risk of NHL. One, rs17085103 which is found on 
chromosome 6, mapped to two genes: OPRM which is involved in immune function and IPCEF1 
which has previously been identified as being involved with carcinoma. However none of the other 
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top SNPs mapped to genes, and overall there was no strong evidence for the role of the top SNPs in 
lymphomagenesis. 
 All SNPs with a selection probability greater than 0 were then mapped to genes for pathway analysis 
using the methods described previously. To account for the thinning employed before profile 
regression the default settings in the SNP to gene translocation programmes were changed to include 
SNPs 100kb downstream and upstream.  This resulted in a total of 52 genes. Of these 52 genes, only 
one, DAPK1, has previously been associated with lymphoma 241, however this represented a very low 
selection probability. Another gene, E2F3, has been previously associated with Chronic myeloid 
leukaemia, and a large number are associated with other malignancies. Similarly a number of the 
genes, notably ELF1, VTCN1, PTMS and VEGFA are involved in aspects of the immune response. 
However gene enrichment analysis using DAVID and the criteria outlined in the methods section 
(3.4) did not observe significant enrichment of any pathways. When less stringent criteria were 
employed the most important pathways were observed to be those involved in regulation of 
transcription, gene expression and biosynthetic and metabolic processes. One of the selected KEGG 
pathways was ‘pathways in cancer’, but the p-value was non-significant using the defined settings 
(p=7.6x10-3). Additionally no immune related pathways were selected using this methodology.  
Profile regression for prediction 
These findings are not very promising, however the results of the ROC curve analysis did suggest that 
profile regression was able to better identify the SNPs providing the most discrimination between 
cases and controls. To explore this further three models containing different SNPs were created:  
(i) The top 12 SNPs identified using profile regression,  
(ii) The 133 SNPs with a selection probability>0, and 
 (iii) The remaining 867 SNPs with a selection probability of 0.  
A continuous variable was created for each of these sets based on the sum of the rare alleles for the 
included SNPS, (i.e. for each SNP common homozygotes score 0, heterozygotes score 1 and rare 
homozygotes score 2). ROC curve analysis was then performed including the continuous variable as a 
predictor and adjusting for age, sex, country and the significant MDS components.  
All three SNP sets performed better than a random predictor and the AUCs were high (figure 4.3.4d). 
This was expected given that all SNPs were preselected based on an association with NHL in this 
population. However, it is of note that the 133 SNPs selected by profile regression performed 
significantly (p<0.0001) better than the 867 with a selection probability of 0. This is of interest as 
these 133 did not represent the top associations when using the classical analysis. It suggests that 
profile regression is better at selecting the combination of SNPs that are working together. However, 
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it is still dependent on the pre-selection methods. The top 12 SNPs showed no improvement over 
those with a selection probability of 0, but this may just imply that 12 is too small a number to base 
prediction on.  Proper validation of these findings requires replication in an independent cohort.  
Figure 4.3.4d: Receiver Operator Curves and corresponding AUCs for three different SNP sets 
generated using profile regression analyses 
ROC analyses was based on a continuous variable calculated as the sum of the rare alleles for the 
specified SNPs (12, 133 and 867) in each individual 
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4.4 Discussion 
The data utilised in this chapter was generated as part of a larger initiative and alone the number of 
genotyped NHL cases and controls from EPIC was too small to conduct meaningful analyses using 
conventional methodologies. This is a particular problem in the study of NHL given that the few 
associations that have been identified for NHL to date, even amongst large studies, tend to be small in 
magnitude.  This limitation was confirmed by the lack of SNPs reaching genome-wide or even 
suggestive levels of association significance in this population using standard methodologies. 
Additionally of the SNPs which almost reached suggestive significance, there was no strong evidence 
of any biologically plausible associations with NHL indicating these were merely chance findings.  
Profile regression 
A novel clustering approach that uses a Bayesian framework was chosen to investigate these data. 
This resulted in the formation of two distinct clusters, a high risk and a low risk cluster, for which the 
pattern of covariates in the high risk cluster was associated with a more than two-fold increased risk 
of NHL relative to the low risk cluster. As the covariates in this analysis were SNPs, clustering is 
based on genetic profile, with adjustment for potential confounders, and therefore these results 
suggest that the SNPs with high selection probabilities may help inform the genetic basis of NHL. 
However, as with the classical analysis, of the SNPs with the highest selection probabilities according 
to profile regression none had previously been associated with lymphoma.   
 Among the other SNPs, with lower selection probabilities there were potentially more promising 
results. In particular DAPK1 was implicated and reduced expression of this kinase has previously 
been suggested to in part explain the heritable disposition to CLL 241. This is of interest given that 
more than 40% of the cases included in the GWAS are CLL, however it should be noted that the 
selection probability of the mapping SNP was very low (rs3128495, ρ median=0.007). DAPK1 falls in 
chromosome 9, which has previously been identified as of importance in NHL aetiology, along with 
the 6p21.3 chromosomal region 116. Although no association with the specific variants noted in the 
literature are reported, it is of note that 9 associations with SNPs falling in chromosome 9 and seven 
in chromosome 6 were observed. Of these latter SNPs, two (including one mapping to VEGFA) fell in 
the 6p21 region.  
The objective of this chapter was to identify novel SNPs which have not previously been identified in 
the literature. It is hypothesised that they have not been identified either due to their small effect sizes, 
because previous GWAS have not stratified by subtype or because their association with risk can only 
be identified when considered in the context of other interacting SNPs. Therefore it can be argued that 
the fact that the top SNPs identified here have never previously been associated with NHL may well 
have been expected. There is a lack of biological plausibility for the top SNPs. A previous study of 
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GxG in lung cancer utilising profile regression  identified biologically plausible novel SNPs, in 
addition to confirming previously known associations164. However, a lack of biological plausibility for 
SNPs arising in GWAS is not uncommon, and does not necessarily preclude causal associations. 
Pre-selection of SNPs 
Profile regression does not require extremely large datasets and is suited to the analyses of data where 
the number of covariates exceeds the number of observations. In theory it can analyse a few thousand 
covariates (conditional on the number of subjects and number of levels of the categorical covariates). 
However sample size is a concern in this study, stemming from the underlying GWAS analysis that 
the selection of SNPs for profile regression is based on. As mentioned, GWAS invariably do require 
large sample sizes to overcome the issues of multiple testing and false-positive findings. The fact that 
the methodology relies on the pre-selection of a few thousand SNPs out of the whole genome 
represents the main issue with profile regression as a decision must be made on how best to select 
them. In this study the results of the association analyses presented in section 4.3.3 were used to 
obtain the top 5000 SNPs, and then thinned them to a total of 1000 SNPs. However it is known this 
methodology was limited in this population and furthermore that it did not pick up any of the SNPs 
previously associated with NHL in the literature. A recent article 179  identified 15 different SNPs that 
have previously been associated with NHL or its subtypes in GWAS, while the first InterLymph 
GWAS publication subsequently identified a further 7 reaching genome-wide significance for CLL 87. 
Of these SNPs 20 passed QC criteria, but only 1 ranked in the top 5000 associations in the EPIC 
population, and so was eligible for inclusion in the profile regression analysis (rs735665, p=0.0044).  
After thinning, rs735665 was not selected for further analysis. So it is not known whether these SNPs 
identified in the literature would have influenced clustering. Although it should be noted that of the 
SNPs in the region surrounding rs735665 on chromosome 11 that were taken forward for profile 
regression, all had selection probabilities of zero, and there are no known SNPs in LD with rs735665. 
It would be of interest in future analyses to include in the SNP covariates those which have previously 
been associated with NHL in the literature, to determine whether they are also picked up using this 
methodology.  
To counter this, it must also be considered that the role of genetic susceptibility in NHL is ‘modest at 
best’ 171 and overall there are a very small number of known associations for NHL. If working on a 
disorder with a more well-understood genetic basis, and with more confirmed associations there 
would be a greater chance of replicating at least one. Furthermore as the hypothesis was based on the 
ability to pick up joint effects, again these SNPs may not be expected to make it through the pre-
selection stage if they don’t also show a main effect, as standard methodologies are not optimised to 
detect such associations. Finally as mentioned, some argue that for most disorders the ‘missing 
heritability’ can be explained by environmental including epigenetic factors, and there may be no 
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more SNPs to identify 235,236.  Consequently even with a larger dataset the analysis would have been 
limited to pick up the SNPs previously reported in the literature.   
The ability to detect true genetic associations in a GWAS is also dependent on the overall quality of 
the data.  The DNA quality of real samples is usually less than of those used to benchmark the panels, 
and in the context of a GWAS even a small amount of systematic error could result in hundreds of 
false-positive signals 242 , which will then subsequently affect any downstream analysis such as profile 
regression.  Both individual and marker QC were run on the data before initial association analyses 
using the same stringent criteria as employed by the InterLymph GWAS. This resulted in the 
exclusion of three individuals and more than 100,000 markers. Therefore the inability to detect 
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Pathway analysis 
To further explore the findings of this study pathway analysis was applied. The term ‘pathway 
analysis’ can be defined in a variety of ways 239. In general it refers to the practice of assigning genes 
to pathways on the basis of their functions; where a pathway represents a series of events that result in 
a particular end point or function. These end points include metabolic processes, biosynthesis, genetic 
information processing, cell signaling, immune responses and disease. The genes can then be tested in 
aggregate with computational tools and pathway databases to identify the most overrepresented or 
enriched pathways and therefore highlight the biological processes most pertinent to the investigated 
disorder 238. It is also known as gene-enrichment analysis. 
There are a number of benefits associated with performing pathway-based analyses, as compared to 
considering each gene individually. Primarily, the reduction in complexity by reducing dimensionality 
and the increase in explanatory power by incorporating information on the biological processes, 
components, or structures in which individual genes are known to be involved 239. Disruptions in 
different genes may lead to the same disorder, and although affected individuals may share the same 
disrupted pathways, the mutated genes or variants within those pathways are likely to differ and this 
wouldn’t be picked up using standard methods.  Pathway analysis is able to determine if variants are 
working along the same pathway even when there is genetic heterogeneity between individuals 243. By 
allowing for such heterogeneity, pathway analysis also permits the combination of multiple GWAS; 
different GWAS of the same disease often yield different results at the SNP level but the same 
findings at the pathway level, and of different ethnic groups 244. Finally, it has been proven to help 
identify associations that are too weak to pick up under classical analysis 243.  
In this population when all the SNPs with a selection probability greater than zero were mapped to 
genes, no significant enrichment of any pathways was observed. Although it should be noted this was 
based on a very small number of genes. A substantial number of the SNPs on GWAS platforms do not 
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explicitly tag particular genes, while some may map to different splice variants or different genes at 
the same chromosome location or to different genes in a different chromosomal location 226. To 
attenuate this issue somewhat, only genes that were identified using at least two different databases 
were included. Consequently, the 133 selected SNPs only mapped to 52 known genes which could 
then be taken forward for analysis. This is a relatively small number, DAVID recommends ~100 to 
2000 is optimal, as a larger gene list has a higher sensitivity to terms that are only slightly enriched 
and to more specific terms 227. Although DAVID states that it could still be useful for small gene sets, 
the sensitivity in this set is unavoidably decreased towards broader more general terms, and highly 
enriched pathways. So in reality the pathway analysis was under powered to exploit in-depth meaning 
from the results.  Additionally using this methodology it was not possible to assign greater weight to 
those genes mapping to more than one SNP, and the 81 SNPs not mapping to any known genes were 
discarded entirely.  
Advantages and further applications of profile regression 
A further reason for the lack of positive findings may also, yet again, reflect the subtype heterogeneity 
of NHL. All cases of B-cell NHL were considered as a single group to retain power. Genetic 
heterogeneity between subtypes has been proven in tumour based studies 23,109,131. While the emerging 
results from the Interlymph GWAS consortium and other subtype specific GWAS 111,117, suggest there 
is also genetic heterogeneity between the subtypes in terms of susceptibility. Further it has been 
reported that susceptibility loci specific to a single subtype are more common than those relating to 
many 139. The lack of strong findings to date may stem from the inability of previous studies to stratify 
analyses by subtypes, or the limited power due to small sample sizes when stratification was 
performed. The future subtype-specific GWAS papers from InterLymph will be able to better inform 
on this. In theory, you may expect profile regression to be able to pick up this heterogeneity.  There 
was no evidence here of clustering by subtype based on the SNP profiles, but it would be of interest in 
a larger dataset to see whether this method resulted in a number of high risk clusters each representing 
a different subtype. 
Such additional exploratory analyses represent further potential applications for profile regression, 
and despite the lack of success in this population, the available evidence suggests that this is a robust 
methodology which could be well-applied to an alternative dataset. For example the lung cancer 
dataset, where profile regression performed so well 164, was both larger and represented a single well 
defined outcome, unlike the heterogeneity of NHL.  
However, even within the NHL dataset there were some interesting findings; the consistent clustering 
during sensitivity analysis and the consistent selection of the same SNPs contributing to the formation 
of these clusters suggests a genuine partitioning between the groups based on their genetic profile. 
The lack of biological plausibility may be a reflection of the fact that functional SNPs may be lost 
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when performing thinning. Thinning was performed to avoid picking up genetic substructure, as 
during initial runs many clusters based on SNPs in high LD or very close to each other on the genome 
were identified. The thinning script selected one SNP from each region on the basis of the most 
significant p-value, but did not take function into account, and the strongest finding does not 
necessarily represent the most informative. A thinning strategy which is able to take this complexity 
into account may provide more enlightening results. It is possible that the SNPs identified by profile 
regression are in LD or in haplotypes with the biologically important SNP and this hypothesis is 
somewhat supported by the results of the ROC analysis.  
Utility of the identified profile as a susceptibility biomarker 
For the three SNP sets the ROC curves were associated with very high AUCs in excess of 0.8 which 
would commonly rate as very good discriminatory ability.  Rather than comparing against a gold 
standard, which is lacking in this instance, the ROC curves for each SNP set have been compared to 
each other. It is of interest that those with a selection probability>0 performed significantly better than 
those with a selection probability of 0. This is despite the fact that the majority of SNPs in this latter 
group had more significant p-values using the classical analysis. This suggests that further predictive 
ability is imparted through considering the 133 SNPs identified by profile regression in combination. 
Similarly regarding sensitivity and specificity, although not calculated here for this continuous 
biomarker, the relevant improvement in both for the 133 SNP set can be inferred from the ROC curve. 
While the 12 SNP set ultimately performs better at identifying true positives than the 867 SNP set, it 
also identifies more false-positives. Given the similarity in the AUCs careful consideration in this 
context would need to be given to which indices to optimise. Although it should be remembered there 
are also other important considerations and regardless of prediction ability a biomarker requiring 
information on a large number of variants is impractical.  
These findings should be considered with caution. By validating within the same dataset as the results 
were produced there is a risk of overfitting and therefore in an over-inflation of predictive ability. 
Overfitting can occur when large numbers of potential predictors are used to discriminate among a 
small number of outcome events, and the larger the number of predictors the more likely overfitting 
is. The simplest way to check whether overfitting has occurred is to validate the findings in an 
independent dataset.  Validation can be defined as "efforts made to confirm the accuracy, precision, or 
effectiveness of results",  but if results are not reproducible then all other aspects of validity are 
irrelevant 229.  Due to the limited sample size the data could not be split into a training and validation 
set. This strategy means the validity of the multivariable results cannot be proven 229.  However 
although these results are of no use for prediction, they are still of interest to compare the three SNP 
sets to each other.  
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Technical bias was minimal in this study as all samples were genotyped in the same laboratory and 
stringent QC thresholds were applied. There was some potential for selection bias; all cases and 
controls came from the same population, but only a proportion was chosen for genotyping by the 
laboratory, with the selection criteria unknown. This is unlikely to have affected cases and controls 
differentially. There was also the potential for population stratification. Seven European populations 
were included in this study and although the case to control ratio was similar between most countries, 
it differed in Italy, and Italians comprised 76% of the controls in the whole study.  This was accounted 
for this in analysis, by adjusting on both MDS components and country, as well as age and sex. 
Previous studies have shown that the inclusion of MDS correctly adjusts the estimates of risk 
associated with the clusters, and simulation studies prove that profile regression does not induce a 
false association to disease or false clustering based on the disease even in data sets where a genetic 
structure is clearly present. Therefore the possibility that the genetic profile of the cluster is a causal 
factor with regard to the increased risk cannot be ruled out. However, uncertainty remains about the 
effect of differing distributions of case-control status among distinct subpopulations for this 
methodology 164.  
 
In terms of the other biomarker criteria (methods section 3.6) as mentioned many of Bradford Hill’s 
criteria, such as temporality, are inappropriate for a genetics-based study. Among those that can be 
applied there was little evidence of biological plausibility, and related to this, little evidence of 
consistency or coherence with existing knowledge. This also pertains to the Venice and Ransohoff 
criteria regarding replication and amount of evidence.  Again these issues could be addressed if 
replication in an independent cohort was possible. Given the relative weakness of the effect estimate, 
even if could be replicated it would be of virtually no clinical utility.  
Limitations and strengths 
In addition to those discussed there are a number of other limitations to this study including the 
exclusive use of a European Caucasian population which may limit its wider generalisability and 
external validity.  Further, there was an overrepresentation of Italians and this did appear to affect the 
clustering, suggesting that country of origin is an important factor.  As discussed in the results section, 
women were also overrepresented in relation to worldwide incidence, and there was a high proportion 
of overweight participants and of people with a history of smoking, given both of these factors have 
been associated with NHL in some studies 32, this may also have impacted findings.  
Most of the other limitations are common to all genetic studies, for example the possibility that the 
true functional SNP of interest is in LD with that identified by the study.  Allelic loss in cells may 
additionally prevent the genotyping assays from accurately distinguishing between homo- and 
heterozygote states 245.  
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A further common problem in genetic studies, the difficulty of estimating the combined effects of 
genetic polymorphisms, is addressed by the main strength of this study which is the use of profile 
regression, and this also circumvents the problem of multiple testing.  There are now a number of 
methodologies available which aim to deal with this issue of GxG and which utilise clustering, 
including latent class analysis (LCA) and dimensionality reduction methods 246. However, although 
these tools are useful for handling covariates in general, they do not routinely provide effect sizes or 
p-values, or account for possible confounding and in the case of MDR in particular, interpretation 
may be difficult163,164. In contrast profile regression can adjust for specified confounders, and although 
as a Bayesian methodology it doesn’t generate p-values, it calculates a selection probability that 
provides an easily interpretable measures of the importance of each variable 238. 
 
Conclusions 
It has been stated that ‘post-GWAS studies are likely to provide a clearer picture of the true role of 
common variants in common complex disorders’238. Here, a novel post-GWAS methodology in 
combination with pathway analysis, has been applied to attempt to better understand the genetic basis 
of NHL. Although it can be concluded that profile regression is well-suited to such analysis, 
ultimately as GWAS provide the ‘etiological framework’238, this study was underpowered to identify 
the genetic determinants of risk. If the GWAS is unable to accurately identify the top SNPs, then you 
need to be able to include more covariates in the profile regression analysis. However, despite the 
good computational performance and power of profile regression, after multiple sensitivity analysis it 
was not possible to include a larger number of SNPs in this particular analysis.  It is currently not 
computationally possible, but it would be of interest in the future to consider a genuine genome-wide 
analysis using profile regression. Furthermore as profile regression provides a different interpretation 
of the data to logistic regression, ideally the two should be utilised simultaneously, to provide 
maximum information 163.   
The PReMiuM package used to run these analyses can be utilised to make predictions in an 
independent cohort and assess the findings of the analyses 
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. An independent cohort was not 
available in this instance however this could represent possible future work. In theory if the findings 
could be replicated in an independent dataset, and the function of the associated SNPs could be 
ascertained, then the utility would lie in what this could tell us about mechanisms and particularly 
about the variants working in combination to affect risk. It may provide further evidence on the 
underlying genetic susceptibility for NHL, and help to infer how it may be interacting with 
environmental factors or with biomarkers on any stage of the causal pathway.  
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5. BIOMARKERS OF INTERNAL DOSE: EXPOSURE 
TO ENVIRONMENTAL POLLUTANTS AND FUTURE 
RISK OF NHL 
 
BIOMARKER: Body burden of two heavy metals and ten persistent organic pollutants 
BIOMARKER TYPE: Biomarker of internal dose  
POPULATION: B-cell NHL cases and controls from the EnviroGenoMarkers Study 
This chapter is based in part on the publication ‘Blood Erythrocyte Concentrations of Cadmium and 
Lead and the Risk of B-Cell Non-Hodgkin's Lymphoma and Multiple Myeloma: A Nested Case-
Control Study’ by Kelly et al. (2013)216. Tables, figures and text have been modified accordingly. 
5.1 Introduction 
The epidemiological evidence to date suggests a largely environmental component to the aetiology of 
NHL.  The reported increase in incidence of NHL had been noted to mirror the worldwide usage 
trends of a number of suspected chemical risk factors, with the plateauing of the increase observed to 
occur following the banning of many of these substances in much of the world 247. An excess of cases 
has also been reported in those who are occupationally or residentially exposed to the suggested 
environmental risk factors 248. While the relatively higher prevalence of NHL in males has been 
suggested to be related to the occupational nature of many of these environmental risk factors, and 
this is supported by the fact that incidence in women has been noted to rise with the increasing 
emergence of a female workforce in more traditionally male occupations such as industry 15,30. 
However, this argument is countered by the fact that male excesses have also been observed in 
children 15. Nevertheless, there exists a consistent evidence base for an important role of 
environmental factors in the aetiology of NHL.   
 
However, assessing the association between environmental factors and NHL has been hampered by 
the difficulty of measuring exposure, which is often inferred from surrogate or proxy measures. Much 
of the evidence relating to the environmental epidemiology of NHL comes from case-control studies 
which are highly subject to recall bias and selection bias, or from investigations of high level  
accidental  exposure 71. The use of biomarkers of internal dose measured prospectively within a cohort 
study eliminates these issues, and provides an objective, accurate measure which is theoretically free 
from bias. In order to determine whether such a measure could be used to predict the risk of 
developing NHL in healthy persons, within the EnviroGenoMarkers study the body burden of twelve 
potential risk factors including six Polychlorinated biphenyls (PCB) congeners and two heavy metals, 
were measured in prospectively collected blood samples. 
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5.1.1 PCBs and NHL 
PCBs have been commonly cited as NHL risk factors, but the findings have been inconsistent and a 
causal relationship is yet to be defined 
63,70,249-251
. PCBs are a mixture of synthetic chlorinated 
hydrocarbons that are the products and incidental by-products of multiple industrial and agricultural 
processes. A PCB molecule consists of a pair of joined 6-carbon rings, with chlorines substituted at 
any one of the free 10-carbon positions, which can be twisted, relative to each other (non-coplanar), or 
aligned in the same plane (coplanar). There are 209 possible chlorine arrangements, or congeners, 
which display different properties 63 with commercial PCB mixtures typically containing 60 to 90 of 
these congeners 251. PCBs have recently been upgraded to Class 1 carcinogens by IARC 252 and 
although once widely used, concerns about their health effects and toxicity has led to them being 
banned in most countries 66. However, these compounds are exceptionally stable, chemically inert and 
highly soluble in lipids 251. Consequently, they have extensively polluted the environment and are still 
found in all environmental media, including air, water, and soil which has led to bioaccumulation in 
the food chain.  As such, diet represents a primary source of PCB exposure 63. 
The evidence for an association with NHL is based on the observed tumorogenic and carcinogenic 
properties of PCBs and in particular the dioxin-like properties exhibited by the coplanar congeners  
79,253. The dioxin–like congeners share a biological mechanism, based on binding to the Ah-receptor 
193, with 2,3,7,8-TCDD a compound which has previously been associated with an increased risk of 
lymphoid malignancies 254. The relationship is further supported by the known immunosuppressive 
and inflammatory properties of PCBs 255, and by the temporal relationship between the incidence of 
NHL and the worldwide usage of PCBs.  
5.1.2 Persistent Organic Pollutants (POPs) and NHL 
In addition to PCBs, four other POPs hypothesised to have an effect on NHL risk were explored: 
Dichlorodiphenyldichloroethylene (DDE), Dichlorodiphenyltrichloroethane (DDT), 
Hexachlorobenzene (HCB) and 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) 76,78,81,83,86.  The 
biological rationale linking them to NHL is also based on their suspected carcinogenic and 
immunotoxic properties 85 and the literature linking them to NHL is similarly inconsistent. DDT  (and 
DDE its main metabolite) is an insecticide which is now mostly banned in the western world, but due 
to its prolonged half-life and biologic persistence, which may extend over several decades, it remains 
a common contaminant in human adipose tissue 82. HCB is a commonly used fungicide, that has also 
been found to be a contaminant in certain pesticides 82,256. BDE-47 is widely used as a flame retardant 
in thermoplastics, textiles and building materials and its production is on the increase 257.  
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5.1.3 Cadmium, Lead and NHL 
Non-essential metals such as cadmium (Cd) and lead (Pb) are ubiquitous persistent environmental 
toxicants which bioaccumulate in the human body. The global burden of Cd and Pb is high due to 
their widespread usage in industrial and manufacturing processes and through contaminated 
phosphate fertilisers 258-261. Human exposure occurs primarily through the ingestion of contaminated 
food and drinking water, the inhalation of contaminated air and smoking 262-264.  Pb and Cd constitute 
some of the most widespread environmental pollutants and both are highly toxic in trace amounts 263, 
but have no known beneficial physiological role 263,265. Consequently they represent an important 
public health burden 266,267. 
Since 1993, Cd has been classified as a group 1 carcinogen by the International Agency for Research 
on Cancer (IARC) based on sufficient evidence from animal models and increased incidence of breast 
and lung cancer in humans 268.  Pb is classified as a possible human carcinogen (group2b), while its 
inorganic compounds are deemed probable carcinogens (group 2a) 269.  As with the investigated 
POPs, the strongest evidence for an association between Pb and Cd with NHL arises from the 
observation of elevated incidence in populations geographically or occupationally exposed to 
industrial sources 248, and the fact that both agents have been observed to modulate the immune 
system 259,270,271. Furthermore, a primary target of Pb 272 and a secondary target of Cd is the 
hematopoietic system 272,273, making these metals plausible candidate risk factors for NHL.  
 
Despite the available evidence and the numerous studies conducted to date, a causal relationship 
remains to be defined for all the investigated environmental contaminants with NHL.  
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5.2 Methods 
5.2.1 Study subjects and exposure assessment 
This study is based on all 270 incident cases of B-cell NHL and their matched controls from the 
EnviroGenoMarkers project. The study population and the methods used to assess body burden of six 
PCB congeners, DDE, DDT, HCB, BDE-47, Cd and Pb are outlined in the methods chapter (see 
methods chapter 3.1.2, tables 3.1.2a- c and figure 3.1.2 for details of the study population and section 
3.2.1 for assessment of body burden).   
5.2.2 Statistical analysis 
All analyses were conducted on the total population as well as by cohort (EPIC-Italy and NSHDS) 
and by sex where appropriate. The statistical significance of the differences in baseline characteristics 
between cases and controls were determined using the Student’s t-test and the chi-squared test for 
continuous and categorical outcomes respectively. Exposure concentrations were explored using non-
parametric methods due to their typically non-Gaussian distributions. Cohort and sex specific analyses 
used the ranksum test while the case-control status analyses used the Wilcoxon signed rank test. 
Correlation between exposure levels was assessed using Pearson’s correlation coefficient. Each 
pollutant was treated as a separate risk factor.   PCBs mixtures based on the properties of the 
congeners 274 were additionally considered as risk factors: the dioxin-like congeners (118, 156), the 
non-dioxin like congeners (138, 153, 170, 180) and the immunotoxic congeners (118, 138, 156, 170). 
As was the sum total of all PCBs. 
Cases were categorised into ordered quartiles based on the distribution of exposure in the control 
population. A further binary variable was created to assess whether blood concentration exceeding 
‘highly exposed’ levels, defined as being above the 90th percentile of the control exposure 
distribution, was associated with greater risk by comparing it to those in the lowest quartile. For the 
remaining analyses, stratified by subtype, age group, BMI category and time to diagnosis, exposure 
levels were log transformed to normalise the distributions.  
In the basic model, conditional logistic regression analyses were used to calculate odds ratios and 
95% confidence intervals accounting for the matching factors. Tests for trend were performed using 
the Wald test statistic based on the continuous quartiles. Where all controls were included to 
maximise power, unconditional logistic regression adjusting for the matching variables was used. 
Confounding was assessed by additionally running an adjusted model to determine how the results 
differed.  Potential confounders were identified as BMI (kg/m2), height (cm), educational level (as a 
proxy for socioeconomic status), vegetable intake (g/day), dairy intake (g/day), protein intake (g/day), 
total fat intake (g/day) and alcohol consumption (g/day), based on both a significant (p<0.05) 
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association with cumulative POP concentration in the total population and a reported association with 
NHL in the literature 73,101 to ensure biological plausibility for the included confounders. 
Heterogeneity between strata (subtype, time to diagnosis, age group and BMI category) was assessed 
using a meta-analytic model (3.3.4).   
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5.3 Results  
The baseline characteristics of cases and controls are described in the methods section (3.1.2, table 
3.1.2c). NSHDS accounted for 69% of the participants, 51% of participants were female, around 20% 
were current smokers and nearly 60% were overweight or obese according to their BMI. There were 
no significant differences between cases and controls for any of the investigated variables. A total of 
270 incident cases (EPIC-Italy n=84, NSHDS n=186) and 270 matched controls were included. The 
median time from blood collection to diagnosis was 6.6 years in NSHDS and 5.0 in Epic-Italy (Table 
3.1.2b) There was no association between time to NHL diagnosis and body burden for any of the 
pollutants amongst the cases (p-value>0.05). 
The mean, median and range of exposure concentrations in cases and controls for each investigated 
pollutant are shown in table 5.3a. For BDE-47 and DDT more than 80% of the population had levels 
that could not be quantified and therefore these were excluded from further analyses. Additionally, 
one participant, a male control from the NSHDS was excluded from the PCB analyses as an outlier as 
his exposure levels were far above the 99
th
 percentile of the distribution for all congeners.  
There was no significant difference (p<0.05) between cases and controls in median exposure levels 
according to the Wilcoxon signed rank test for any of the investigated exposures (table 5.3a). 
However, stratified analyses by cohort and by sex showed significantly higher concentrations in 
female cases than in female controls for Cd (p=0.046) and PCB118 (p=0.027).  While amongst males, 
PCB118 (p=0.024), PCB138 (p=0.036), PCB153 (p=0.033), PCB156 (p=0.017) and HCB (p=0.011) 
were significantly higher in controls (Appendix: table 5.3i). 
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Table 5.3a; Mean, median and range of exposure concentrations of six PCB congeners, HCB, 
DDT, DDE, BDE-47, Cadmium and Lead in cases and controls from the EnviroGenoMarkers 
study 
Exposure LOQ 
  Cases n=270   Controls n=270   Difference 
 
% <LOQ Median Mean Range 
 
% <LOQ Median Mean Range 
 
p-valuea 
PCB118  5pg/ml 
 
0.00% 134.7 182 (8.5, 901.6) 
 
0.00% 147.7 175.7 (11.6, 832.1) 
 
0.991 
PCB138 5pg/ml 
 
0.00% 530 605.6 (11.0, 1810.1) 
 
0.00% 562.3 636.4 (51.2, 2675.4) 
 
0.276 
PCB153 4pg/ml 
 
0.00% 1007.8 1150.9 (32.5, 3308.0) 
 
0.00% 1086 1205.5 (120.6, 4334.1) 
 
0.239 
PCB156  2pg/ml 
 
0.00% 90.6 102 (19.8, 307.8) 
 
0.00% 95.6 106.7 (15.5, 394.9) 
 
0.186 
PCB170  4pg/ml 
 
0.00% 326.4 375.2 (62.7, 1082.3) 
 
0.00% 357.6 389.4 (50.4, 1291.2) 
 
0.284 
PCB180  3pg/ml 
 
0.00% 696.6 788.8 (139.7, 2708.8) 
 
0.00% 727.8 807.9 (100.1, 2431.5) 
 
0.284 
HCB  25pg/ml 
 
0.00% 257.8 398.1 (62.5, 3604.0) 
 
0.00% 289.2 432.5 (64.5, 3882.2) 
 
0.198 
DDT  200pg/ml 
 
85.90% 
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331.7 (206.6, 825.8) 
 
86.70% 298.2 399.8 (218.8, 1636.9) 
 
0.865 
DDE 5pg/ml 
 
0.00% 2478.7 4038.4 (16.4, 30992.8) 
 
0.00% 2675.3 4200.1 (76.4, 23858.3) 
 
0.374 
BDE-47  15pg/ml 
 
84.10% 23.5 34.2 (15.1, 133.4) 
 
81.10% 25.8 95.1 (15.3, 2063.3) 
 
0.657 
Cadmium 0.02µg/L 
 
0.00% 0.54 0.759 (0.098, 4.113) 
 
0.00% 0.498 0.757 (0.099, 5.224) 
 
0.398 
Lead 0.10µg/L   0.00% 57.679 70.56 (15.423, 400.843)   0.00% 57.597 72.158 (11.199, 672.482)   0.768 
LOQ – Limit of quantification 
aDifferences between median concentrations in cases and controls according to the Wilcoxon signed-rank test for paired samples                            
One participant with exposure levels above the 99th percentile  was excluded from the PCB analysis 
 
There was significant correlation between the various exposure levels in the total population, for all 
except Cd (table 5.3b). As expected, strong correlation amongst the PCBs was observed. Particularly 
amongst those PCBs with similar degrees of chlorination; the Pearson’s ρ between PCB170 and 
PCB180 was 0.973, p<0.0001, which may in part explain the similar results observed for most of the 
PCB congeners in the subsequent analyses. 
Table 5.3b: Pearson correlation coefficients (r
2
) between exposure concentrations of six PCB 
congeners, HCB, DDE, Cadmium and Lead measured in participants from the 
EnviroGenoMarkers Study 
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PCB118 1 
         PCB138 0.7747 1 
        PCB153 0.7681 0.9681 1 
       PCB156 0.6544 0.7938 0.8801 1 
      PCB170 0.5951 0.8259 0.9088 0.9569 1 
     PCB180 0.6346 0.8101 0.9032 0.9282 0.9723 1 
    HCB 0.6881 0.4544 0.4734 0.4199 0.3565 0.4454 1 
   DDE 0.7327 0.6739 0.6336 0.3892 0.3864 0.4843 0.7317 1 
  Cadmium 0.0364NS 0.087 0.095 0.0837NS 0.084NS 0.108 0.116 0.170 1 
 Lead 0.343 0.214 0.231 0.185 0.185 0.288 0.453 0.418 0.190 1 
NS Correlation is not significant (p>0.05)                                                                                                                                                          
r2>0.7 are highlighted in italics to indicate high correlation 
Log transformed exposure levels 
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Table 5.3c shows the association between increasing quartiles of exposure and risk of NHL, both 
under the basic conditional model, and when adjusting for potential confounders. Although under the 
basic model a number of significant inverse associations were observed there was no evidence of a 
dose-response trend. When adjusting on confounders, inverse associations with PCB138 and PCB153 
survived and due to the high correlation so did those with non-dioxin like PCBs.  Some suggestion of 
an inverse trend was also noted for the sum of total PCBs, HCB and DDE. Stratified analyses by 
gender (5.3d) indicated that these inverse associations were heavily influenced by males who 
displayed multiple dose-dependent inverse trends with the investigated POPs. This was not observed 
in females and there was some suggestion of an increased risk with high levels of exposure to Cd 
among women. Analyses stratified by cohort are shown in appendix 5.3ii. For the majority of 
exposures the inconsistent and non-significant results across the total population and in the subgroups 
indicated an essentially null relationship. These relationships were attenuated slightly by adjustment 
for confounders, but the conclusions were unchanged. 
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Table 5.3c: Association between NHL and quartiles of measured body burden of six PCB 
congeners, specified PCB functional groups, HCB, DDE, Cadmium and Lead in participants 
from the EnviroGenoMarkers Study 
Expsoure   
No. 
Ca 
No. 
Co 
  OR 95% CI 
P-
value 
p for 
trend 
  OR(adj) 95% CI 
P-
value 
p for 
trend 
              PCB118 Q1(8.46, 94.05) 80 68 
 
1 
 
   
1 
 
  
 
Q2 (94.25, 148.04) 68 67 
 
0.76 (0.44,1.32) 0.332 
  
0.57 (0.31,1.08) 0.084 
 
 
Q3 (148.37, 219.85) 42 66 
 
0.45 (0.24,0.84) 0.012* 
  
0.35 (0.17,0.72) 0.004* 
 
 
Q4 (219.91, 901.63) 80 67 
 
0.96 (0.49,1.87) 0.909 0.571 
 
0.67 (0.3,1.49) 0.332 0.168 
              PCB138 Q1 (10.97, 396.03) 86 67 
 
1 
 
   
1 
 
  
 
Q2 (399.73, 562.09) 60 67 
 
0.67 (0.41,1.08) 0.102 
  
0.53 (0.31,0.91) 0.021* 
 
 
Q3 (562.64, 778.15) 63 67 
 
0.63 (0.37,1.1) 0.104 
  
0.50 (0.27,0.94) 0.031* 
 
 
Q4 (778.44, 2675.35) 61 67 
 
0.60 (0.33,1.08) 0.089 0.093 
 
0.38 (0.18,0.78) 0.009* 0.010* 
              PCB153 Q1 (32.47, 812.10) 88 68 
 
1 
 
   
1 
 
  
 
Q2 (813.60, 1083.97) 59 66 
 
0.60 (0.36,1.03) 0.064 
  
0.56 (0.31,1.02) 0.058 
 
 
Q3 (1088.49, 1489.97) 60 67 
 
0.54 (0.3,0.98) 0.044* 
  
0.47 (0.24,0.93) 0.031* 
 
 
Q4 (1493.70, 4334.12) 63 67 
 
0.55 (0.3,1.04) 0.066 0.078 
 
0.37 (0.17,0.78) 0.009* 0.011* 
              PCB156 Q1 (15.50, 69.69.62) 75 67 
 
1 
 
   
1 
 
  
 
Q2 (69.95, 95.44) 71 67 
 
0.88 (0.49,1.56) 0.654 
  
0.9 (0.48,1.71) 0.754 
 
 
Q3 (95.76, 126.68) 51 67 
 
0.59 (0.31,1.11) 0.100 
  
0.56 (0.27,1.16) 0.118 
 
 
Q4 (126.87, 394.89) 73 67 
 
0.86 (0.45,1.64) 0.644 0.545 
 
0.69 (0.33,1.45) 0.326 0.228 
              PCB170 Q1 (50.39, 257.50) 73 67 
 
1 
 
   
1 
 
  
 
Q2 (257.62, 358.81) 82 68 
 
0.99 (0.59,1.66) 0.967 
  
0.9 (0.51,1.6) 0.718 
 
 
Q3 (359.10, 468.52) 43 66 
 
0.48 (0.25,0.92) 0.028* 
  
0.37 (0.17,0.79) 0.010* 
 
 
Q4 (468.55, 1291.23) 72 67 
 
0.83 (0.45,1.53) 0.55 0.356 
 
0.59 (0.28,1.23) 0.160 0.091 
              PCB180 Q1 (100.08, 533.51) 72 67 
 
1 
 
   
1 
 
  
 
Q2 (533.84, 730.03) 78 68 
 
1.03 (0.61,1.73) 0.926 
  
1 (0.55,1.81) 0.999 
 
 
Q3 (730.81, 966.02) 46 66 
 
0.57 (0.31,1.05) 0.071 
  
0.45 (0.21,0.95) 0.035* 
 
 
Q4 (966.55, 2708,83) 74 67 
 
0.94 (0.52,1.69) 0.827 0.595 
 
0.68 (0.32,1.42) 0.300 0.168 
              
Dioxin-like 
PCBs        
(118, 156) 
Q1 (36.16, 172.31) 82 67 
 
1 
 
   
1 
 
  Q2 (172.47, 247.91) 70 67 
 
0.72 (0.42,1.22) 0.219 
  
0.7 (0.39,1.27) 0.245 
 Q3 (248.24, 347.34) 39 67 
 
0.41 (0.22,0.75) 0.004* 
  
0.34 (0.17,0.68) 0.002* 
 Q4 (348.22, 1126.82) 79 67 
 
0.82 (0.44,1.53) 0.539 0.340 
 
0.63 (0.30,1.30) 0.209 0.083 
              
Non-Dioxin 
like PCBs                                  
(138, 153, 
170, 180) 
Q1 (245.80, 2027.04) 81 67 
 
1 
 
   
1 
 
  Q2 (2027.72, 2696.84) 65 67 
 
0.73 (0.43,1.23) 0.237 
  
0.66 (0.37,1.17) 0.153 
 Q3 (2719.63, 3727.56) 62 67 
 
0.63 (0.34,1.14) 0.127 
  
0.54 (0.27,1.10) 0.091 
 Q4 (3747.581, 10380.82) 62 67 
 
0.62 (0.34,1.16) 0.138 0.144 
 
0.44 (0.21,0.92) 0.030* 0.033* 
              
Immunotoxic 
PCBs                
(118, 138, 
156, 170)  
Q1 (153.93, 851.71) 76 67 
 
1 
 
   
1 
 
  Q2 (857.09, 1162.29) 68 67 
 
0.85 (0.5,1.44) 0.542 
  
0.73 (0.4,1.32) 0.294 
 Q3 (1164.09, 1598.01) 58 67 
 
0.69 (0.39,1.22) 0.202 
  
0.57 (0.30,1.1) 0.093 
 Q4 (1606.86, 4907.36) 68 67 
 
0.82 (0.44,1.50) 0.512 0.431 
 
0.56 (0.27,1.16) 0.117 0.092 
              ΣPCBs Q1 (329.28, 2192.24) 80 67 
 
1 
 
   
1 
 
  
 
Q2 (2195.17, 3006.59) 72 67 
 
0.82 (0.49,1.39) 0.46 
  
0.73 (0.41,1.31) 0.29 
 
 
Q3 (3018.09, 4016.41) 51 67 
 
0.51 (0.28,0.94) 0.030* 
  
0.43 (0.21,0.87) 0.019* 
   Q4 (4037.42, 11400.98) 67 67   0.68 (0.36,1.27) 0.229 0.143   0.46 (0.22,0.99) 0.047* 0.026* 
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Table 5.3c: continued 
Exposure   
No. 
Ca 
No. 
Co 
  OR 95% CI 
P-
value 
p for 
trend 
  OR(adj) 95% CI 
P-
value 
p for trend 
              HCB Q1 (62.47, 181.87) 85 67 
 
1 
 
   
1 
 
  
 
Q2 (184.78, 288.81) 62 67 
 
0.58 (0.32,1.03) 0.064 
  
0.52 (0.27,1.02) 0.057 
 
 
Q3 (289.49, 474.86) 59 67 
 
0.47 (0.24,0.94) 0.032* 
  
0.28 (0.12,0.65) 0.003* 
 
 
Q4 (477.00, 3882.19) 64 66 
 
0.49 (0.22,1.07) 0.074 0.061 
 
0.35 (0.14,0.87) 0.023* 0.014* 
              DDE Q1 (16.40, 1308.26) 81 67 
 
1 
 
   
1 
 
  
 
Q2 (1310.23, 2666.60) 62 67 
 
0.65 (0.37,1.14) 0.137 
  
0.55 (0.28,1.05) 0.07 
 
 
Q3 (2675.27, 5523.58) 68 68 
 
0.67 (0.37,1.21) 0.186 
  
0.40 (0.20,0.84) 0.015* 
 
 
Q4 (5528.29, 30992.76) 59 66  
0.55 (0.28,1.08) 0.082 0.106 
 
0.34 (0.15,0.77) 0.010* 0.008* 
              
Cadmium Q1 (0.098, 0.308) 70 68 
 
1 
    
1 
   
 
Q2 (0.310, 0.498)  53 67 
 
0.78 (0.46,1.30) 0.341 
  0.82 
(0.46,1.45) 0.490  
 
Q3 (0.490, 0.790) 74 66 
 
1.12 (0.67,1.85) 0.668 
  1.12 
(0.64,1.96) 0.679  
 
Q4 (0.794, 5.224)  73 68 
 
1.06 (0.63,1.77) 0.835 0.487 
 1.06 
(0.59,1.92) 0.836 0.555 
              
Lead Q1 (11.199, 38.598) 70 67 
 
1 
    
1 
   
 
Q2 (38.609, 57.594)  65 67 
 
0.94 (0.56,1.56) 0.800 
  1.00 
(0.55,1.79) 0.992  
 
Q3 (57.597, 83.455)  64 67 
 
0.92 (0.52,1.64) 0.782 
 
 
0.80 (0.41,1.57) 0.522 
   Q4 (83.748, 672.482)  71 68   1.03 (0.53,1.99) 0.93 0.957   0.92 (0.44,1.94) 0.836 0.724 
OR – conditional logistic regression accounting for matching factors                                                                                                                       
OR(adj) – conditional logistic regression additionally adjusting for BMI, height, educational level, vegetables, dairy, protein, total fat, 
alcohol 
*Significant at the 95% confidence leve
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Table 5.3d Association between NHL and quartiles of measured body burden of six PCB congeners, specified PCB functional groups, HCB, DDE, 
Cadmium and Lead stratified by gender 
POP by 
quartile 
  Males   Females 
 
Ca/Co OR 95% CI 
P-
value 
p for 
trend 
 
OR(adj) 95% CI 
P-
value 
p for 
trend 
 
Ca/Co OR 95% CI 
P-
value 
p for 
trend 
 
OR(adj) 95% CI 
P-
value 
p for 
trend 
PCB118 1 
 47/34 
1 
     
1 
    
31/34 1 
    
1 
   
 
2 
 35/32 
0.6 (0.27,1.32) 1.32 0.202 
  
0.69 (0.28,1.72) 0.424 
  
35/34 1.28 (0.59,2.81) 0.534 
  
1.09 (0.46,2.6) 0.846 
 
 
3 
 22/33 
0.32 (0.13,0.78) 0.78 0.013* 
  
0.21 (0.07,0.65) 0.007* 
  
23/34 0.89 (0.37,2.12) 0.793 
  
0.69 (0.24,1.96) 0.487 
 
 
4 
 29/33 
0.39 (0.15,0.98) 0.98 0.045* 0.021* 
 
0.4 (0.13,1.22) 0.109 0.037 
 
48/34 2.41 (0.94,6.22) 0.068 0.138 
 
2.09 (0.67,6.52) 0.203 0.367 
PCB138 1 
 42/33 
1 
     
1 
    
44/34 1 
    
1 
   
 
2 
 36/34 
0.69 (0.34,1.38) 1.38 0.293 
  
0.53 (0.22,1.25) 0.148 
  
24/34 0.58 (0.29,1.13) 0.11 
  
0.38 (0.17,0.87) 0.022 
 
 
3 
 30/32 
0.55 (0.24,1.27) 1.27 0.159 
  
0.55 (0.2,1.54) 0.253 
  
24/34 0.55 (0.25,1.19) 0.13 
  
0.4 (0.16,1.02) 0.056 
 
 
4 
 25/33 
0.41 (0.17,1.03) 1.03 0.057 0.052 
 
0.25 (0.08,0.81) 0.021* 0.033* 
 
45/34 1.19 (0.54,2.63) 0.67 0.848 
 
0.9 (0.33,2.47) 0.845 0.54 
PCB153 1 
 42/34 
1 
     
1 
    
47/34 1 
    
1 
   
 
2 
 38/32 
0.73 (0.32,1.64) 1.64 0.444 
  
0.59 (0.21,1.68) 0.324 
  
19/34 0.39 (0.17,0.86) 0.02 
  
0.4 (0.17,0.97) 0.041 
 
 
3 
 30/33 
0.5 (0.21,1.19) 1.19 0.115 
  
0.52 (0.18,1.55) 0.243 
  
28/34 0.61 (0.28,1.3) 0.198 
  
0.55 (0.23,1.31) 0.175 
 
 
4 
 23/33 
0.35 (0.13,0.92) 0.92 0.034* 0.022* 
 
0.18 (0.05,0.68) 0.011* 0.014* 
 
43/34 0.89 (0.4,1.98) 0.774 1 
 
0.68 (0.26,1.83) 0.45 0.537 
PCB156 1 
 43/33 
1 
     
1 
    
40/34 1 
    
1 
   
 
2 
 39/33 
0.65 (0.31,1.36) 1.36 0.257 
  
0.68 (0.27,1.76) 0.431 
  
27/34 0.72 (0.34,1.51) 0.388 
  
0.94 (0.41,2.18) 0.889 
 
 
3 
 25/34 
0.37 (0.15,0.9) 0.9 0.029* 
  
0.34 (0.11,1.01) 0.053 
  
26/34 0.69 (0.31,1.55) 0.369 
  
0.8 (0.3,2.12) 0.652 
 
 
4 
 26/32 
0.42 (0.17,1.02) 1.02 0.054 0.032* 
 
0.31 (0.1,1) 0.050* 0.021* 
 
44/34 1.15 (0.48,2.75) 0.746 0.627 
 
1.22 (0.42,3.52) 0.717 0.704 
PCB170 1 
 39/34 
1 
     
1 
    
41/34 1 
    
1 
   
 
2 
 38/33 
0.86 (0.41,1.79) 1.79 0.679 
  
0.8 (0.31,2.01) 0.629 
  
28/34 0.71 (0.34,1.46) 0.347 
  
0.87 (0.39,1.96) 0.737 
 
 
3 
 27/33 
0.56 (0.23,1.33) 1.33 0.185 
  
0.55 (0.19,1.61) 0.275 
  
28/34 0.61 (0.25,1.49) 0.283 
  
0.68 (0.23,1.96) 0.473 
 
 
4 
 29/32 
0.64 (0.27,1.54) 1.54 0.321 0.217 
 
0.38 (0.12,1.17) 0.092 0.066 
 
40/34 0.92 (0.4,2.14) 0.854 1 
 
0.94 (0.33,2.68) 0.906 0.905 
PCB180 1 
 34/33 
1 
     
1 
    
38/34 1 
    
1 
   
 
2 
 44/33 
1.21 (0.57,2.55) 2.55 0.616 
  
1.28 (0.47,3.44) 0.632 
  
37/34 0.93 (0.44,1.96) 0.857 
  
1.15 (0.48,2.77) 0.75 
 
 
3 
 30/33 
0.74 (0.31,1.72) 1.72 0.479 
  
0.73 (0.25,2.15) 0.572 
  
20/34 0.42 (0.17,1.06) 0.065 
  
0.32 (0.1,1.03) 0.056 
   4   25/33 0.63 (0.26,1.53) 1.53 0.312 0.15   0.48 (0.16,1.49) 0.205 0.079   42/34 1.1 (0.46,2.66) 0.829 0.889   0.84 (0.25,2.81) 0.779 0.534 
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Table 5.3d continued 
POP by quartile 
  Males   Females 
 
Ca/Co OR 95% CI P-value 
p for 
trend 
 
OR(adj) 95% CI P-value 
p for 
trend 
 
Ca/Co OR 95% CI 
P-
value 
p for 
trend 
 
OR(adj) 95% CI 
P-
value 
p for 
trend 
 
  
 
     
 
    
  
    
 
    
Dioxin-like 
PCBs        
(118, 156) 
1 
 44/33 
1 
     
1 
    
38/34 1 
    
1 
   2 
 42/33 
0.68 (0.31,1.48) 1.478 0.331 
  
0.71 (0.28,1.78) 0.463 
  
29/34 0.67 (0.31,1.42) 0.293 
  
0.58 (0.25,1.37) 0.214 
 3 
 18/33 
0.27 (0.11,0.68) 0.684 0.006* 
  
0.17 (0.05,0.59) 0.005* 
  
20/34 0.49 (0.2,1.19) 0.115 
  
0.29 (0.1,0.89) 0.03 
 
 
4 
 29/33 
0.35 (0.13,0.92) 0.917 0.033* 0.011* 
 
0.29 (0.09,0.94) 0.040* 0.012* 
 
50/34 1.64 (0.69,3.89) 0.265 0.311 
 
1.34 (0.44,4.12) 0.607 0.821 
Non-Dioxin 
like PCBs                                  
(138, 153, 
170, 180) 
1 
 34/33 
1 
     
1 
    
45/34 1 
    
1 
   2 
 47/33 
1.3 (0.55,3.06) 3.062 0.544 
  
1.56 (0.51,4.75) 0.432 
  
24/34 0.51 (0.24,1.1) 0.088 
  
0.42 (0.18,0.98) 0.045 
 3 
 26/33 
0.57 (0.22,1.49) 1.493 0.252 
  
0.72 (0.22,2.37) 0.584 
  
28/34 0.57 (0.25,1.29) 0.178 
  
0.56 (0.22,1.47) 0.24 
 4 
 26/33 
0.65 (0.24,1.77) 1.769 0.396 0.091 
 
0.52 (0.14,1.89) 0.317 0.055 
 
40/34 0.83 (0.36,1.95) 0.674 0.787 
 
0.61 (0.21,1.79) 0.37 0.422 
Immunotoxic 
PCBs                
(118, 138, 
156, 170)  
1 
 33/33 
1 
     
1 
    
42/34 1 
    
1 
   2 
 44/33 
1.24 (0.55,2.84) 2.839 0.602 
  
1.11 (0.4,3.11) 0.842 
  
23/34 0.56 (0.26,1.17) 0.122 
  
0.41 (0.17,0.97) 0.043 
 3 
 30/33 
0.76 (0.31,1.86) 1.859 0.549 
  
0.91 (0.31,2.68) 0.866 
  
27/34 0.65 (0.31,1.36) 0.254 
  
0.48 (0.2,1.19) 0.113 
 
 
4 
 26/33 
0.66 (0.24,1.77) 1.773 0.406 0.173 
 
0.5 (0.14,1.74) 0.274 0.191 
 
45/34 1.29 (0.57,2.9) 0.546 0.613 
 
0.93 (0.34,2.57) 0.892 0.761 
ΣPCBs 1 
 35/33 
1 
     
1 
    
46/34 1 
    
1 
   
 
2 
 46/33 
1.23 (0.53,2.87) 2.872 0.632 
  
1.27 (0.42,3.84) 0.675 
  
23/34 0.5 (0.24,1.05) 0.066 
  
0.42 (0.18,0.96) 0.039* 
 
 
3 
 26/33 
0.55 (0.22,1.39) 1.386 0.203 
  
0.7 (0.22,2.22) 0.54 
  
25/34 0.47 (0.2,1.1) 0.08 
  
0.36 (0.13,1) 0.050* 
 
 
4 
 26/33 
0.57 (0.21,1.54) 1.544 0.271 0.076 
 
0.41 (0.11,1.48) 0.174 0.049* 
 
43/34 0.94 (0.42,2.12) 0.881 0.896 
 
0.64 (0.23,1.8) 0.4 0.35 
HCB 1 
 54/34 
1 
     
1 
    
32/33 1 
    
1 
   
 
2 
 33/33 
0.25 (0.09,0.69) 0.69 0.007* 
  
0.25 (0.08,0.77) 0.016* 
  
31/34 1.06 (0.48,2.3) 0.892 
  
1.17 (0.47,2.93) 0.733 
 
 
3 
 16/33 
0.09 (0.03,0.3) 0.3 <0.001* 
  
0.04 (0.01,0.21) <0.001* 
  
42/34 1.48 (0.6,3.67) 0.398 
  
1.49 (0.48,4.63) 0.488 
 
 
4 
 30/32 
0.16 (0.05,0.54) 0.54 0.003 0.002* 
 
0.07 (0.01,0.35) 0.001* 0.001* 
 
32/34 1.14 (0.38,3.48) 0.812 0.647 
 
1.26 (0.34,4.67) 0.731 0.688 
DDE 1 
 44/33 
1 
     
1 
    
37/34 1 
    
1 
   
 
2 
 37/33 
0.64 (0.29,1.41) 1.41 0.267 
  
0.46 (0.16,1.26) 0.13 
  
33/34 0.82 (0.37,1.83) 0.626 
  
0.53 (0.19,1.45) 0.216 
 
 
3 
 25/34 
0.37 (0.15,0.9) 0.9 0.028* 
  
0.21 (0.07,0.65) 0.007* 
  
35/34 0.83 (0.36,1.93) 0.672 
  
0.4 (0.13,1.22) 0.107 
   4   27/32 0.39 (0.15,1.02) 1.02 0.054 0.031*   0.16 (0.04,0.6) 0.006* 0.003*   32/34 0.74 (0.28,1.96) 0.54 0.591   0.41 (0.11,1.46) 0.167 0.143 
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Table 5.3d continued 
POP by quartile 
  Males   Females 
 
Ca/Co OR 95% CI 
P-
value 
p for 
trend 
 
OR(adj) 95% CI 
P-
value 
p for 
trend 
 
Ca/Co OR 95% CI 
P-
value 
p for 
trend 
 
OR(adj) 95% CI 
P-
value 
p for 
trend 
Cadmium 1 
 39/33 
1 
 
    
1 
    
29/34 1  
   
1 
   
 
2 
 33/33 
0.78 (0.38,1.61) 1.61 0.505 
  
0.76 (0.33,1.74) 0.518 
  
19/35 0.55 (0.24,1.23) 0.143  
 
0.63 (0.26,1.51) 0.296 
 
 
3 
 35/33 
0.93 (0.48,1.81) 1.81 0.837 
  
1.07 (0.49,2.35) 0.867 
  
42/34 1.48 (0.73,3) 0.28  
 
1.39 (0.64,3) 0.406 
 
 
4 
 26/33 
0.57 (0.25,1.31) 1.31 0.188 0.322 
 
0.58 (0.21,1.58) 0.285 0.565 
 
47/34 1.68 (0.87,3.25) 0.125 0.042* 
 
1.75 (0.82,3.7) 0.145 0.074 
Lead 1 
 33/33 
1 
  
   
1 
    
39/35 1  
   
1 
   
 
2 
 29/33 
0.96 (0.46,1.99) 1.99 0.909 
 
 
0.88 (0.38,2.06) 0.772 
  
33/34 0.8 (0.35,1.82) 0.603  
 
0.54 (0.19,1.54) 0.252 
 
 
3 
 40/33 
1.27 (0.59,2.74) 2.74 0.543 
 
 
1.07 (0.44,2.58) 0.885 
  
31/34 0.75 (0.34,1.66) 0.48  
 
0.61 (0.22,1.72) 0.355 
  4   31/33 1.03 (0.43,2.47) 2.47 0.956 0.774  0.79 (0.28,2.27) 0.663 0.805   34/34 0.78 (0.3,2.07) 0.624 0.579  0.6 (0.19,1.94) 0.395 0.487 
OR – conditional logistic regression accounting for matching factors                                                                                                                                                                                                                                                    
OR(adj) – conditional logistic regression additionally adjusting for BMI, height, educational level, vegetables, dairy, protein, total fat, alcohol                                                                                                    
*Significant at the 95% confidence level 
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5.3.1 Subtype-specific results 
Information on histological subtype was available for 225 of 270 cases (83%, for details see Methods 
Figure 3.1.2) and the remaining 45 cases were classified as ‘B-cell NHL, not otherwise specified’.  
The most common subtype was MM, which accounted for 28% of cases. The association between log 
transformed exposure levels and risk for the four largest subgroups are shown in table 5.3.1. There did 
appear to be some differences in risk estimates by subtype, particularly when confounders were taken 
into account. The significant inverse associations were limited to DLBCL. In fact the inverse 
associations with DLBCL, and to some extent MM, were quite striking, although they were based on 
relatively small numbers, and again multiple testing was not taken into account. When a meta-
analyses of each exposure by subtype was conducted, the I2 was 0% for all exposures except PCB170 
(19.1%) and PCB180 (30.1%), and the p values were >0.1, indicating no significant heterogeneity 
between the subtypes. Subtype specific analyses stratified by cohort and sex were based on small 
numbers and no significant associations were revealed (Appendix: tables 5.3.1i and 5.3.1ii). 
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Table 5.3.1: Association between log-transformed body burden of six PCB congeners, specified PCB functional groups, HCB, DDE, Cadmium and 
Lead levels and NHL risk stratified by Subtype 
Exposure 
  CLL (n=42)   DLBCL (n=45) 
 OR 95% CI  p-value   OR(adj) 95% CI  p-value   OR 95% CI  
p-
value 
 
OR
(adj)
 95% CI  
p-
value 
PCB118  
 
0.70 (0.31,1.58) 0.398 
 
5.14 (0.56,47.08) 0.147 
 
0.74 (0.27,2.04) 0.561 
 
0.39 (0.06,2.68) 0.335 
PCB138  
 
0.63 (0.26,1.54) 0.309 
 
1.33 (0.15,11.91) 0.801 
 
0.37 (0.10,1.32) 0.126 
 
0.33 (0.04,2.47) 0.281 
PCB153  
 
0.50 (0.16,1.52) 0.221 
 
0.70 (0.06,7.77) 0.772 
 
0.32 (0.08,1.26) 0.103 
 
0.16 (0.01,1.84) 0.140 
PCB156  
 
0.57 (0.16,2.10) 0.402 
 
1.47 (0.11,19.75) 0.773 
 
0.25 (0.06,0.96) 0.044* 
 
0.01 (0,0.53) 0.023* 
PCB170  
 
0.52 (0.16,1.66) 0.267 
 
0.34 (0.03,3.61) 0.372 
 
0.24 (0.06,1.02) 0.053 
 
0.01 (0,0.47) 0.021* 
PCB180  
 
0.49 (0.14,1.77) 0.278 
 
0.27 (0.02,4.15) 0.351 
 
0.23 (0.05,0.97) 0.045* 
 
0.01 (0,0.50) 0.020* 
Dioxin-like PCBs 
 
0.76 (0.43,1.35) 0.346 
 
2.21 (0.56,8.67) 0.255 
 
0.59 (0.29,1.19) 0.138 
 
0.22 (0.04,1.09) 0.063 
Non-Dioxin like PCBs 
 
0.84 (0.62,1.13) 0.247 
 
0.84 (0.44,1.62) 0.604 
 
0.70 (0.48,1.02) 0.061 
 
0.46 (0.21,1.00) 0.051 
Immunotoxic PCBs 
 
0.85 (0.63,1.14) 0.282 
 
1.17 (0.60,2.29) 0.651 
 
0.71 (0.48,1.04) 0.080 
 
0.46 (0.21,1.01) 0.054 
ΣPCBs 
 
0.89 (0.73,1.09) 0.259 
 
1.02 (0.65,1.60) 0.924 
 
0.79 (0.61,1.02) 0.067 
 
0.58 (0.34,0.99) 0.047* 
HCB 
 
0.42 (0.14,1.26) 0.121 
 
1.12 (0.17,7.40) 0.905 
 
0.90 (0.34,2.39) 0.834 
 
0.41 (0.08,2.00) 0.271 
DDE  
 
0.83 (0.44,1.58) 0.578 
 
1.99 (0.52,7.59) 0.313 
 
0.88 (0.43,1.84) 0.743 
 
1.17 (0.35,3.97) 0.796 
Cadmium 
 
0.88 (0.43,1.83) 0.742 
 
0.60 (0.11,3.32) 0.556 
 
1.15 (0.60,2.18) 0.675 
 
1.85 (0.66,5.13) 0.239 
Lead   0.77 (0.30,1.99) 0.588   0.43 (0.05,3.90) 0.450   0.76 (0.28,2.03) 0.581   0.70 (0.17,2.95) 0.629 
Results for the four largest subtype groups were included                                                                                                                                                                                                     
OR – conditional logistic regression accounting for matching factors                                                                                                                                                                                                                                                    
OR(adj) – conditional logistic regression additionally adjusting for BMI, height, educational level, vegetables, dairy, protein, total fat, alcohol                                                                                                    
*Significant at the 95% confidence level 
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Table 5.3.1: continued 
Exposure  
  FL (n=39)   MM (n=76) 
 OR 95% CI  p-value   ORb(adj) 95% CI  p-value   OR 95% CI  
p-
value 
 
OR
b(adj)
 95% CI  
p-
value 
PCB118  
 
0.95 (0.41,2.21) 0.904 
 
1.04 (0.34,3.13) 0.947 
 
1.06 (0.55,2.07) 0.856 
 
0.62 (0.23,1.63) 0.330 
PCB138  
 
0.91 (0.31,2.67) 0.865 
 
1.17 (0.29,4.77) 0.822 
 
0.74 (0.32,1.70) 0.474 
 
0.45 (0.15,1.32) 0.145 
PCB153  
 
0.94 (0.29,3.04) 0.918 
 
1.20 (0.27,5.31) 0.814 
 
0.73 (0.29,1.85) 0.512 
 
0.41 (0.12,1.42) 0.159 
PCB156  
 
0.99 (0.32,3.01) 0.979 
 
1.12 (0.24,5.36) 0.885 
 
0.77 (0.31,1.88) 0.561 
 
0.47 (0.14,1.62) 0.234 
PCB170  
 
1.39 (0.43,4.51) 0.580 
 
1.65 (0.33,8.24) 0.540 
 
0.77 (0.30,2.00) 0.588 
 
0.42 (0.11,1.66) 0.216 
PCB180  
 
1.43 (0.44,4.63) 0.553 
 
1.52 (0.31,7.41) 0.605 
 
0.90 (0.35,2.31) 0.834 
 
0.56 (0.15,2.10) 0.392 
Dioxin-like PCBs 
 
0.97 (0.56,1.69) 0.927 
 
1.04 (0.51,2.11) 0.914 
 
0.97 (0.63,1.48) 0.871 
 
0.70 (0.39,1.27) 0.244 
Non-Dioxin like PCBs 
 
1.03 (0.77,1.39) 0.825 
 
1.08 (0.74,1.59) 0.688 
 
0.93 (0.73,1.19) 0.570 
 
0.81 (0.58,1.11) 0.192 
Immunotoxic PCBs 
 
1.01 (0.75,1.35) 0.964 
 
1.05 (0.72,1.53) 0.790 
 
0.95 (0.75,1.20) 0.673 
 
0.81 (0.59,1.11) 0.183 
ΣPCBs 
 
1.01 (0.83,1.24) 0.908 
 
1.04 (0.81,1.34) 0.759 
 
0.97 (0.82,1.13) 0.662 
 
0.87 (0.70,1.08) 0.195 
HCB 
 
0.82 (0.36,1.86) 0.633 
 
0.83 (0.25,2.70) 0.752 
 
0.70 (0.30,1.61) 0.394 
 
0.31 (0.08,1.19) 0.089 
DDE  
 
0.77 (0.41,1.48) 0.437 
 
0.93 (0.34,2.55) 0.885 
 
0.66 (0.37,1.15) 0.142 
 
0.52 (0.25,1.10) 0.086 
Cadmium 
 
1.59 (0.74,3.39) 0.235 
 
2.03 (0.69,5.95) 0.199 
 
1.05 (0.69,1.61) 0.814 
 
1.47 (0.82,2.63) 0.199 
Lead   1.37 (0.48,3.93) 0.556   1.17 (0.28,4.93) 0.831   1.12 (0.59,2.12) 0.731   1.20 (0.50,2.85) 0.684 
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5.3.2 Stratification by potential confounders 
In an attempt to explain the unexpected inverse associations noted for many of the POPs, analyses 
were stratified by age group, time to diagnosis and BMI category to determine whether there was 
evidence for confounding or effect modification.  Age at recruitment (and therefore at blood draw; 
table 5.3.2a) did not appear to be modifying the findings, with no trend in risk observed and no 
significant heterogeneity in risk estimates between the age groups. Similarly, there was no evidence of 
an effect of time to diagnosis (table 5.3.2b). This remained true when confounding was taken into 
account. For both the age groups and time to diagnosis stratified analyses results from the meta-
analysis indicated that the percentage of heterogeneity not due to chance (I2) was 0% for all 
exposures, and all p-values were non-significant, when considering both the adjusted and the 
unadjusted models. When sex and cohort specific-analyses were run, the inverse associations were 
mainly confined to males, with females tending to show positive associations for most exposures 
(Appendix: tables 5.3.2i to 5.3.2iv). Nevertheless, none were found to be significant even without 
correction for multiple testing. Stratified analyses by subtype were not run due to small numbers, but 
this would be of interest for the future.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
136 
Table 5.3.2a; Association between log-transformed body burden of six PCB congeners, specified 
PCB functional groups, HCB, DDE, Cadmium and Lead levels and NHL risk stratified by age 
group at recruitment 
Exposure 
  30-44 years                                          
(Cases n=40, Controls n=40)                                 
45-59 years                                             
(Cases n=169, Controls n=158)                                                
60-75 years                                                            
(Cases n=61, Controls n=72)                                       
 OR 
95% CI 
p-
value 
 
OR 
95% CI 
p-
value 
 
OR 
95% CI 
p-
value 
PCB118  
 
0.39 (0.11,1.35) 0.136 
 
0.89 (0.58,1.37) 0.597 
 
1.48 (0.69,3.17) 0.308 
PCB138  
 
0.39 (0.10,1.52) 0.176 
 
0.80 (0.50,1.28) 0.347 
 
0.98 (0.39,2.48) 0.968 
PCB153  
 
0.33 (0.07,1.51) 0.152 
 
0.76 (0.45,1.30) 0.323 
 
0.83 (0.31,2.22) 0.710 
PCB156  
 
0.15 (0.02,0.97) 0.047* 
 
0.81 (0.44,1.52) 0.516 
 
0.85 (0.31,2.33) 0.747 
PCB170  
 
0.31 (0.07,1.42) 0.130 
 
0.85 (0.47,1.55) 0.596 
 
0.79 (0.26,2.45) 0.686 
PCB180  
 
0.36 (0.08,1.64) 0.187 
 
0.93 (0.51,1.70) 0.812 
 
0.79 (0.25,2.48) 0.688 
Dioxin-like 
PCBs 
 
0.37 (0.14,0.99) 0.047* 
 
0.91 (0.68,1.21) 0.516 
 
1.14 (0.70,1.86) 0.600 
Non-Dioxin 
like PCBs 
 
0.75 (0.51,1.11) 0.149 
 
0.95 (0.82,1.09) 0.455 
 
0.96 (0.73,1.25) 0.762 
Immunotoxic 
PCBs 
 
0.64 (0.39,1.05) 0.076 
 
0.95 (0.82,1.09) 0.448 
 
1.02 (0.79,1.33) 0.858 
ΣPCBs 
 
0.77 (0.56,1.05) 0.097 
 
0.96 (0.87,1.06) 0.460 
 
1.00 (0.84,1.20) 0.992 
HCB 
 
0.47 (0.13,1.74) 0.257 
 
0.76 (0.46,1.24) 0.267 
 
0.62 (0.21,1.82) 0.389 
DDE  
 
0.80 (0.28,2.30) 0.685 
 
0.85 (0.63,1.14) 0.270 
 
0.86 (0.50,1.48) 0.579 
Cadmium 
 
0.95 (0.51,1.78) 0.878 
 
1.35 (0.98,1.87) 0.064 
 
0.80 (0.43,1.46) 0.457 
Lead 
 
0.64 (0.28,1.42) 0.272 
 
1.36 (0.75,2.47) 0.304 
 
0.65 (0.24,1.74) 0.394 
             
  
OR
(adj)
 95% CI 
p-
value 
 
OR
(adj)
 95% CI 
p-
value 
 
OR
(adj)
 95% CI 
p-
value 
PCB118  
 
0.36 (0.04,3.04) 0.345 
 
0.72 (0.43,1.23) 0.235 
 
1.10 (0.4,3.01) 0.858 
PCB138  
 
0.43 (0.03,5.67) 0.521 
 
0.59 (0.31,1.13) 0.110 
 
0.70 (0.19,2.54) 0.584 
PCB153  
 
0.44 (0.02,9.11) 0.593 
 
0.55 (0.27,1.15) 0.115 
 
0.71 (0.2,2.53) 0.596 
PCB156  
 
0.21 (0.01,4.22) 0.310 
 
0.70 (0.32,1.55) 0.382 
 
0.90 (0.25,3.29) 0.874 
PCB170  
 
0.63 (0.05,8.89) 0.736 
 
0.67 (0.31,1.44) 0.308 
 
0.82 (0.18,3.77) 0.804 
PCB180  
 
0.97 (0.04,22.46) 0.983 
 
0.76 (0.35,1.64) 0.483 
 
0.87 (0.19,3.99) 0.860 
Dioxin-like 
PCBs 
 
0.34 (0.06,1.85) 0.211 
 
0.81 (0.57,1.15) 0.244 
 
1.01 (0.54,1.9) 0.972 
Non-Dioxin 
like PCBs 
 
0.85 (0.4,1.8) 0.68 
 
0.88 (0.73,1.06) 0.18 
 
0.93 (0.65,1.33) 0.69 
Immunotoxic 
PCBs 
 
0.66 (0.28,1.53) 0.33 
 
0.88 (0.73,1.06) 0.18 
 
0.97 (0.68,1.37) 0.85 
ΣPCBs 
 
0.80 (0.46,1.41) 0.446 
 
0.92 (0.81,1.04) 0.185 
 
0.97 (0.77,1.23) 0.801 
HCB 
 
0.45 (0.04,4.71) 0.506 
 
0.69 (0.39,1.22) 0.198 
 
0.30 (0.06,1.54) 0.150 
DDE  
 
1.16 (0.13,10.58) 0.898 
 
0.65 (0.44,0.98) 0.038* 
 
0.53 (0.24,1.16) 0.114 
Cadmium 
 
17.57 (1.5,205.32) 0.022* 
 
1.25 (0.84,1.85) 0.271 
 
0.95 (0.43,2.08) 0.900 
Lead   0.89 (0.27,2.9) 0.849   1.06 (0.5,2.24) 0.879   0.66 (0.17,2.57) 0.548 
OR – conditional logistic regression accounting for matching factors                                                                                                                       
OR(adj) – conditional logistic regression additionally adjusting for BMI, height, educational level, vegetables, dairy, protein, total fat, 
alcohol 
*Significant at the 95% confidence level 
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Table 5.3.2b; Association between log-transformed body burden of six PCB congeners, specified PCB functional groups, HCB, DDE, Cadmium and 
Lead levels and NHL risk stratified by time to diagnosis 
Exposure  
  ttd< 5 years (n=108)                             ttd> 5 years (n=149)                              ttd< 5 years (n=108)                             ttd> 5 years (n=149)                            
 
OR 95% CI p-value 
 
OR 95% CI p-value 
 
OR
(adj)
 95% CI p-value 
 
OR
(adj)
 95% CI p-value 
PCB118  
 
0.82 (0.52,1.27) 0.368 
 
0.95 (0.64,1.41) 0.808 
 
0.75 (0.47,1.22) 0.253 
 
0.88 (0.55,1.39) 0.576 
PCB138  
 
0.63 (0.39,1.01) 0.056 
 
0.73 (0.46,1.14) 0.166 
 
0.57 (0.34,0.95) 0.032* 
 
0.63 (0.36,1.1) 0.105 
PCB153  
 
0.59 (0.34,1.02) 0.058 
 
0.67 (0.39,1.13) 0.129 
 
0.54 (0.3,0.98) 0.042* 
 
0.58 (0.31,1.08) 0.084 
PCB156  
 
0.67 (0.36,1.27) 0.22 
 
0.7 (0.4,1.22) 0.204 
 
0.68 (0.34,1.33) 0.26 
 
0.65 (0.35,1.23) 0.186 
PCB170  
 
0.61 (0.33,1.15) 0.125 
 
0.71 (0.4,1.28) 0.258 
 
0.59 (0.3,1.16) 0.129 
 
0.62 (0.32,1.22) 0.169 
PCB180  
 
0.62 (0.33,1.17) 0.141 
 
0.77 (0.43,1.39) 0.385 
 
0.59 (0.29,1.18) 0.138 
 
0.7 (0.35,1.39) 0.31 
Dioxin-like PCBs 
 
0.84 (0.63,1.13) 0.247 
 
0.91 (0.7,1.17) 0.454 
 
0.82 (0.6,1.12) 0.211 
 
0.86 (0.65,1.16) 0.33 
Non-Dioxin like PCBs 
 
0.87 (0.75,1.01) 0.068 
 
0.91 (0.79,1.05) 0.187 
 
0.85 (0.73,1) 0.053 
 
0.88 (0.75,1.04) 0.127 
Immunotoxic PCBs 
 
0.89 (0.76,1.03) 0.115 
 
0.93 (0.81,1.06) 0.274 
 
0.87 (0.74,1.02) 0.09 
 
0.9 (0.77,1.05) 0.187 
ΣPCBs 
 
0.92 (0.83,1.02) 0.097 
 
0.95 (0.86,1.04) 0.244 
 
0.91 (0.81,1.01) 0.078 
 
0.93 (0.83,1.03) 0.17 
HCB 
 
0.63 (0.38,1.06) 0.082 
 
0.74 (0.46,1.21) 0.232 
 
0.62 (0.36,1.07) 0.086 
 
0.65 (0.37,1.14) 0.13 
DDE  
 
0.73 (0.54,0.99) 0.045* 
 
0.79 (0.59,1.06) 0.118 
 
0.65 (0.47,0.92) 0.013* 
 
0.71 (0.51,1.01) 0.054 
Cadmium 
 
1.10 (0.81,1.5) 0.551 
 
1.03 (0.78,1.35) 0.846 
 
1.14 (0.8,1.61) 0.471 
 
1.04 (0.76,1.44) 0.788 
Lead  0.68 (0.38,1.21) 0.19  0.91 (0.56,1.46) 0.69  0.75 (0.4,1.39) 0.36  0.8 (0.47,1.39) 0.437 
OR – conditional logistic regression accounting for matching factors                                                                                                                                                                                                                                                   
OR(adj) – conditional logistic regression additionally adjusting for BMI, height, educational level, vegetables, dairy, protein, total fat, alcohol 
*Significant at the 95% confidence level 
ttd-time to diagnosis
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Stratified analyses by BMI (table 5.3.2c), showed that risk estimates tended to decrease with BMI 
category, with the smallest ORs generally noted in obese participants. This was also observed in the 
stratified analyses with patients of normal weight more likely to show a positive association with 
NHL exposure in both cohorts and both genders (Appendix: tables 5.3.2v and 5.3.2vi). Effect 
modification by BMI may also in part explain the observed sex discrepancy, 69.6% of males are 
overweight or obese compared with only 50.2% of females (p<0.0001) and the inverse associations 
tended to be restricted to males.  Although the results of the meta-analysis do not show significant 
heterogeneity between BMI strata, the p-values were much smaller than for subtype or age and the I2 
percentages were greater than 0%. 
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Table 5.3.2c; Association between log-transformed body burden of six PCB congeners, specified 
PCB functional groups, HCB, DDE, Cadmium and Lead levels and NHL risk stratified by BMI 
category 
Exposure 
  Normal                                                 
(Cases n=105, Controls n=109)   
Overweight                                   
(Cases n=121, Controls n=118)   
Obese                                                     
(Cases n=40, Controls n=39) 
 
OR 95% CI p-value 
 
OR 95% CI p-value 
 
OR 95% CI p-value 
PCB118  
 
0.95 (0.43,2.13) 0.906 
 
0.58 (0.28,1.22) 0.152 
 
0.49 (0.06,3.72) 0.488 
PCB138  
 
0.77 (0.36,1.64) 0.497 
 
0.16 (0.05,0.6) 0.006* 
 
0.21 (0.02,2.87) 0.242 
PCB153  
 
0.74 (0.31,1.8) 0.511 
 
0.17 (0.04,0.67) 0.011* 
 
0.07 (0,2.91) 0.16 
PCB156  
 
0.78 (0.29,2.1) 0.621 
 
0.35 (0.1,1.16) 0.085 
 
0.07 (0,3.1) 0.17 
PCB170  
 
0.83 (0.31,2.27) 0.721 
 
0.34 (0.1,1.13) 0.078 
 
3.55E-03 (0,9.16) 0.159 
PCB180  
 
0.83 (0.29,2.34) 0.721 
 
0.31 (0.09,1.04) 0.058 
 
2.24E-03 (0,8.67) 0.148 
Dioxin-like 
PCBs 
 
0.92 (0.55,1.53) 0.739 
 
0.63 (0.38,1.06) 0.083 
 
0.49 (0.14,1.77) 0.278 
Non-Dioxin 
like PCBs 
 
0.94 (0.74,1.18) 0.58 
 
0.66 (0.48,0.93) 0.016* 
 
0.42 (0.13,1.34) 0.141 
Immunotoxic 
PCBs 
 
0.94 (0.73,1.21) 0.632 
 
0.72 (0.53,0.97) 0.029* 
 
0.60 (0.27,1.3) 0.194 
ΣPCBs 
 
0.96 (0.81,1.13) 0.615 
 
0.78 (0.63,0.97) 0.023* 
 
0.65 (0.36,1.19) 0.162 
HCB 
 
1.23 (0.45,3.36) 0.688 
 
0.35 (0.12,1.03) 0.056 
 
2.46E-03 (0,6.06) 0.132 
DDE  
 
0.83 (0.45,1.5) 0.529 
 
0.28 (0.12,0.66) 0.003* 
 
0.42 (0.06,3.23) 0.407 
Cadmium 
 
1.19 (0.7,2.02) 0.53 
 
1.37 (0.76,2.45) 0.297 
 
0.34 (0.02,4.77) 0.424 
Lead 
 
3.10 (0.89,10.8) 0.076 
 
0.71 (0.3,1.65) 0.423 
 
1.23 (0.18,8.44) 0.833 
             
  
OR
(adj)
 95% CI p-value 
 
OR
(adj)
 95% CI p-value 
 
OR
(adj)
 95% CI p-value 
PCB118  
 
0.68 (0.19,2.45) 0.551 
 
0.49 (0.18,1.3) 0.153 
 
∆ 
  PCB138  
 
0.53 (0.12,2.28) 0.393 
 
0.08 (0.01,0.49) 0.007* 
    PCB153  
 
0.62 (0.12,3.25) 0.572 
 
0.12 (0.02,0.68) 0.016* 
    PCB156  
 
1.06 (0.26,4.27) 0.934 
 
0.28 (0.06,1.25) 0.095 
    PCB170  
 
1.44 (0.26,7.94) 0.678 
 
0.22 (0.04,1.12) 0.069 
    PCB180  
 
1.44 (0.24,8.51) 0.685 
 
0.19 (0.04,0.97) 0.046* 
    Dioxin-like 
PCBs 
 
0.88 (0.41,1.91) 0.749 
 
0.56 (0.29,1.09) 0.090 
    Non-Dioxin 
like PCBs 
 
0.95 (0.63,1.45) 0.827 
 
0.58 (0.37,0.91) 0.018* 
    Immunotoxic 
PCBs 
 
0.93 (0.61,1.41) 0.737 
 
0.64 (0.43,0.96) 0.031* 
    ΣPCBs 
 
0.96 (0.72,1.28) 0.79 
 
0.72 (0.55,0.96) 0.026* 
    HCB 
 
1.62 (0.4,6.65) 0.502 
 
0.19 (0.04,0.96) 0.044* 
    DDE  
 
0.54 (0.22,1.35) 0.186 
 
0.11 (0.02,0.53) 0.006* 
    Cadmium 
 
1.29 (0.54,3.09) 0.565 
 
1.66 (0.74,3.71) 0.220 
    Lead   8.08 (1.16,56.44) 0.035*   0.63 (0.2,2.02) 0.438         
OR – conditional logistic regression accounting for matching factors                                                                                                                       
OR(adj) – conditional logistic regression additionally adjusting for BMI, height, educational level, vegetables, dairy, protein, total fat, 
alcohol 
*Significant at the 95% confidence level 
∆ model would not converge 
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5.3.3 Highly exposed individuals 
The inverse associations also disappeared when risk was assessed in ‘highly exposed’ individuals i.e. 
when the risk in those with exposure levels above the 90th percentile of the control distribution was 
compared to those in the lowest quartile of exposure (table 5.3.3). Interestingly though, this was not 
observed for Cd which was found to be significantly associated with risk under almost every other 
model, particularly in females.  
5.3.4 Summary 
These findings have not been corrected for multiple testing. Given the large number of analyses 
explored including multiple strata and subcohorts, overall these results suggest a null association 
between body burden of six PBC congeners, HCB, DDE, Cd or Pb.
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Table 5.3.3: Association between exposure and risk in ‘highly exposed’ individuals 
High exposure is defined as exposure levels above the 90th of the control exposure distribution, the odds of disease are compared with those in the lowest 
quartile of exposure 
  
90th 
percentile 
control 
exposure 
distribution 
Above 90th percentile   
OR 95% CI p-value 
  
OR
(adj)
 95% CI p-value 
Exposure 
n cases 
(%) 
n controls 
(%) 
  PCB118  316.2 35(13.0) 28(10.4) 
 
1.37 (0.76,2.45) 0.294 
 
1.25 (0.65,2.41) 0.500 
PCB138  1112.4 25(9.3) 29(10.7) 
 
0.83 (0.45,1.52) 0.550 
 
0.81 (0.40,1.64) 0.562 
PCB153  1965.7 29(10.7) 29(10.7) 
 
1.01 (0.56,1.81) 0.987 
 
1.15 (0.58,2.26) 0.693 
PCB156  176.4 23(8.5) 28(10.4) 
 
0.79 (0.43,1.45) 0.447 
 
0.89 (0.43,1.81) 0.739 
PCB170  626.6 29(10.7) 29(10.7) 
 
1.00 (0.57,1.78) 0.989 
 
1.07 (0.55,2.06) 0.843 
PCB180  1323.3 29(10.7) 28(10.4) 
 
1.05 (0.58,1.88) 0.872 
 
1.11 (0.57,2.14) 0.763 
Dioxin-like PCBs            478.7 34(12.6) 29(10.7) 
 
1.26 (0.70,2.26) 0.445 
 
1.30 (0.67,2.53) 0.432 
Non-Dioxin like PCBs  4937.2 29(10.7) 29(10.7) 
 
1.00 (0.56,1.80) 0.988 
 
1.18 (0.60,2.30) 0.626 
Immunotoxic PCBs  872.8 33(12.2) 29(10.7) 
 
1.19 (0.67,2.11) 0.549 
 
1.16 (0.60,2.24) 0.665 
ΣPCBs 5438.8 30(11.1) 28(10.4) 
 
1.10 (0.61,1.97) 0.753 
 
1.27 (0.65,2.51) 0.485 
HCB 872.8 25(9.3) 29(10.7) 
 
0.8 (0.41,1.55) 0.506 
 
0.84 (0.42,1.68) 0.624 
DDE  9787.7 27(10) 28(10.4) 
 
0.95 (0.50,1.80) 0.878 
 
1.01 (0.52,1.97) 0.978 
Cadmium 1.7 22(8.1) 27(10.0) 
 
0.79 (0.44,1.44) 0.444 
 
0.77 (0.39,1.52) 0.458 
Lead 125.3 30(11.1) 26(9.60)   1.22 (0.66,2.27) 0.528   1.20 (0.60,2.41) 0.612 
OR – conditional logistic regression accounting for matching factors                                                                                                                                                                                                                                                      
OR(adj) – conditional logistic regression additionally adjusting for BMI, height, educational level, vegetables, dairy, protein, total fat, alcohol 
*Significant at the 95% confidence level 
5.4 Discussion  
In this chapter a prospective design was used to study the risk of NHL associated with internal dose of 
six PCB congeners, HCB, DDE, Cd and Pb under the hypothesis that an elevated body burden may 
increase future risk of this malignancy. This hypothesis was based on a body of epidemiological 
literature and experimental evidence. However these findings could not be replicated and instead a 
number of unexpected inverse associations with certain exposures are reported. Overall, due to non-
correction for multiple testing, the evidence suggests a null relationship between the investigated 
exposures and NHL risk. Consequently it can be concluded that internal dose of these pollutants, as 
assessed by a single spot measurement in this population, has no utility in the prediction of NHL or the 
study of its aetiology.   
Existing evidence from the literature 
Although PCBs have been widely explored in relation to NHL, the evidence has been contradictory. 
While many studies report a positive association with the sum of PCB body burden, PCB mixtures 
(including dioxin-like, non-dioxin like and immunotoxic) and individual congeners 76-80, an equally 
large number have found no association 81-86. Many of the positive findings come from case-control 
studies which are subject to the problems of reverse causation and other bias, or from investigations of 
high  levels of  accidental  exposure 71,  but even among highly exposed occupational cohorts the 
results have not been consistent 250. Of the studies most directly comparable with this chapter, those 
utilising prediagnostic exposure measurements in the general population, two 80,275 reported an 
increased risk with total PCB exposure in both sexes, while a third 77 reported an increase in males. 
Two further studies 81,82 reported no significant associations for any of the investigated congeners. 
Even systematic reviews have been unable to confirm or refute an association. A recent meta-analysis 
reports a weight-adjusted odds ratio for all PCB congeners of 1.43 (95% CI 1.31, 1.55) and concludes 
that the literature supports a causal association between certain congeners and NHL risk 63 . 
Conversely, a separate review 250 states that it is unwarranted to conclude that PCB exposure is related 
to risk of NHL citing methodological limitations, congener-specific discrepancies in results, the lack 
of dose-dependent relationships and the likelihood of spurious associations arising due to multiple 
testing and chance. 
The literature is similarly inconsistent for DDE and for HCB, which showed some of the strongest 
inverse associations in this population. Three case control-studies have reported a positive association 
between NHL and DDE. One was based on adipose tissue concentrations 86 and two measured levels 
in blood 76,78. However, in a study of serum organochlorine levels in participants living near a 
municipal solid waste incinerator the relationship was borderline significant and the OR indicated only 
a marginal increase in risk 76. Additionally a number of both case-control 79,85 and cohort 77,81,82 studies 
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have reported no association. Similarly, for those studies considering HCB; although one 78 observed a 
positive association with risk, two other studies report null findings 76,81. Other work suggests that both 
DDE and HCB may act on risk through an interaction with antibodies to EBV early antigen (EA IgG) 
83,276, but again these findings remain to be validated. 
The putative association between heavy metals and NHL has been much less extensively studied, and 
the biological rationale for a relationship is based largely on animal models. In vitro studies indicate 
that both Cd and Pb have genotoxic properties 277,278 and can induce DNA damage via elevated levels 
of oxidative stress 263. Additionally, there is evidence that, like POPs, they may interact with the 
immune system 259,267,270,271,279,280.  The epidemiological evidence is based mainly on residential 
proximity to sources of exposure such as oil refineries, however these also emit other suspected 
haematological carcinogens including dioxins, which may be confounding the relationship 248,281. Only 
one previous study which directly explored the association with Cd in humans 282 reported an 
association between urinary Cd and NHL in males and an association with leukaemia in both males 
and females, a finding consistent with a case-control study in a Turkish population 272,282. This study is 
the first to report on the risk of any haematological malignancy and internal dose of Pb.  
Exposure assessment 
In this study of a general, non-occupationally exposed cohort, exposure was assessed using 
erythrocyte concentrations of Pb and Cd and blood serum concentrations of eight POPs in samples 
taken from cancer-free individuals at recruitment to the cohort. This provides a point estimate of 
historical exposure free from recall bias. Internal doses of environmental pollutants vary by orders of 
magnitude from individual to individual. This can be attributed to various factors including, age, sex, 
area of residence, calendar year of sampling and route of exposure 283. Global restrictions in the use of 
such pollutants has led to a reported decrease in human body burden over the last decade: for PCBs 
current exposure levels are estimated to be half those of 20-30 years ago283, making it difficult to 
compare between populations and across periods. However, the observed exposure levels for both the 
POPs and the metals were within the range of those reported in studies of similar populations 284-287.  
When considering the total population, most of the investigated exposures were observed at higher 
levels in the Italian cohort; only PCB170 was much higher in NSHDS. PCB118, HCB, DDE and Cd 
were significantly higher in females, while PCB170, PCB180 and Pb were significantly higher in 
males.  
Sex specific effects and the influence of genetic susceptibility 
One of the most striking findings of this study was the sex specific effects which were evident for 
nearly all explored analyses and models. In general, inverse associations were noted for males, while 
females tended to show positive, although non-significant associations, for most exposures. There was 
some evidence for an association between NHL and Cd in females, particularly at high exposure 
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levels. There is little epidemiological evidence reporting on the relationship between metals and NHL 
by sex although other Cd-associated health effects have previously  been observed to be  more 
common  in females 288. 
 
As discussed in the introduction, a number of studies have reported on genetic polymorphisms which 
may influence the uptake, metabolism and storage of these pollutants and which may be affecting the 
results 124,199,234,263,289-291. Crucially a number of these genes have shown sex-specific differences in risk 
194,234,292, and there has been an increasing interest in sex-specific susceptibility to carcinogens 293. Sex-
differences in the expression of xenobiotic metabolising enzymes including the cytochrome P450 
system and the human glutathione S-transferases 294,295, and in candidate transporter genes for 
carcinogen export have all been reported 293.   A growing body of mechanistic, experimental and 
epidemiological evidence suggests that women may be more susceptible to the effect of carcinogens 
than males.  This relates both to baseline differences in exposure levels to putative carcinogens as well 
hormonal, physiological, genetic and epigenetic effects 294,295. Accordingly a number of studies have 
observed greater levels of markers of DNA damage including DNA adduct levels, sister chromatid 
exchanges and micronucleus frequency in female cancer patients compared to similarly exposed male 
cases  293. DNA repair capacity has also been reported to be substantially lower in females, while 
expression of the oncogenic k-ras mutation has been found to be higher. It is thought these effects may 
be regulated by hormonal responses and that oestrogen in particular may play an important role  293-295. 
Such variations may go some way to explaining these findings or alternatively the results may simply 
reflect the lower baseline risk of NHL in unexposed women  293; NHL is 50% more common among 
men 3.  
Potential confounding and effect modification 
The heterogeneous nature of NHL may, in part, explain the differing findings between this study and 
previous work, as it is likely that the risk associated with POPs differs by subtype 86. To take potential 
subtype heterogeneity into account, subtype specific analyses were conducted to the most detailed 
extent allowable by sample size, according to the hierarchies proposed by Morton et al. 19. Despite the 
differing effect estimates observed between subtypes, most were non-significant and there was no 
evidence of subtype heterogeneity.  However it should be noted that due to small numbers the power 
to detect subtype-specific associations was limited and the majority of rarer subtypes could not be 
analysed at all.  
The differing composition of the PCB congeners included in different studies may also account for 
some of the observed discrepancy, particularly where a risk effect for the sum of PCBs has been 
reported.  Individual congeners have been shown to have different biological activity, and therefore 
may produce health effects by different mechanisms 77,296.  In this study six PCB congeners were 
considered, all of which were non-coplanar and highly chlorinated, ranging from five (PCB118) to 
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seven (PCB170 and PCB180) substituted chlorine atoms, and can reasonably be considered as a 
group. Consequently, the sum of these six PCBs as well as dioxin-like congeners, non-dioxin-like 
congeners and immunotoxic congeners were also explored. However, due to the very high correlation 
between the included congeners in the respective groups, the mixtures merely reflected the constituent 
congeners and did not provide any further information on the relationship with NHL in this study.  
In order to try and further disentangle the unexpected results observed, a number of additional 
analyses were performed. Previous studies of NHL and environmental exposures have noted an effect 
of ‘time to diagnosis’ i.e. the time between sample collection and diagnosis date, with stronger 
associations observed closer to diagnosis 81,82,249.  This is thought to be due to the pathophysiologic and 
metabolic changes, such as lipid mobilisation and weight loss, accompanying carcinogenesis which 
may affect the body burden of exposures 297.    To  ensure that pre-diagnostic subclinical changes in 
cases who were diagnosed shortly after blood draw were not modifying the body burden of exogenous 
exposures 297, stratification by the time to diagnosis was performed.  Results appeared consistent 
across strata. No effect of age at diagnosis was determined and adjustment for biologically plausible 
confounders did not alter the conclusions.  
 
There was, however, some evidence of an effect of BMI, with the most strongly inverse associations 
noted in those who were overweight and obese. This may be of interest as organochlorines are stored 
in adipose tissue and therefore PCB levels in the blood have previously been reported to be inversely 
associated with weight gain, and overweight and obese individuals have been observed to have lower 
circulating levels 132,296. In this analysis overweight/obese cases were compared to overweight/obese 
controls at baseline, therefore this would not explain the inverse associations between exposure and 
risk, unless BMI confounds the relationship between PCB levels and NHL through some unknown 
mechanism. Although no association between BMI and NHL was observed in this study it has been 
noted previously by others 99. If BMI does act as a confounder this could explain the high number of 
inverse associations noted in this population which contained a high proportion (60%) of overweight 
and obese individuals. It would also explain why inverse associations were overrepresented in males, 
who had a significantly higher proportion of overweight and obese participants (69.6% compared to 
only 50.2% in females (p<0.001)).  Furthermore it would explain why Cd and Pb which are not known 
to be lipophilic were not affected in the BMI stratified analyses. 
Strengths and Limitations 
The main strength of this study is its prospective design which protects against selection bias and it 
was determined that the case and control populations were similar with respect to baseline factors and 
additional confounders. This design also allows for the determination of a temporal and causal 
relationship between exposure and NHL, lacking in the majority of studies which tend to measure 
post-diagnostic or post-treatment levels.  NHL or its treatment may affect metabolism and blood 
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concentrations of POPs 77,132, and chemotherapy has been observed to decrease PCB levels in the body 
by up to 30% 63. The measures of exposure assessment were also free from recall bias, and were 
conducted using validated methodologies. The use of blood serum measurements has been shown to 
provide a reliable estimate of POP body burden due to their long half-lives 82. Similarly Pb binds to 
erythrocytes and therefore body burden is optimally assessed by blood concentration 298.  Although 
urine is considered to be the best biomaterial to measure biomarkers of lifetime Cd exposure, blood Cd 
has been found to correlate highly with Cd concentrations in both urine and tissue and as such can be 
considered as a good estimate of body burden 267. 
In this study,  lipids were not adjusted for as it has been observed that direct standardisation can 
introduce bias 299 .  Unadjusted volume-based concentrations of POPs, which have been found to 
correlate well with lipid based concentrations, are presented 300. Furthermore, the possibility of 
‘reverse causation’ and disease progression bias 297, which are the main reasons to adjust for lipids, (in 
order to take physiological pre-cancerous changes to normal metabolic process and lipid mobilisation 
into account), have been considered. The findings for BMI suggest that further exploration of these 
results using lipid adjusted concentrations may be of interest.  
 
There were several other limitations to this study. In addition to lipids, information on the blood 
concentrations of beta-HCH and gamma-HCH, or of dioxins was not available. The high correlation 
between exposures, particularly the PCBs, restricted the ability to determine individual effects 301. It is 
possible that there were further unmeasured confounders affecting the results, for example other 
organochlorines, metals or trace elements 275 which may bioaccumulate in parallel with the exposures 
of interest and exert interaction effects on the risk of NHL. Furthermore variables relating to the 
immune system, such as EBV antigens which have been shown to interact with organochlorines in 
NHL risk 83,276 can also not be accounted for. The estimate of body burden is based on a single one 
spot exposure measurement that is not necessarily representative of lifetime exposure. Finally, the 
generalisability of these findings to other populations should also be considered, given the relative 
overrepresentation of females, the excess of MM cases and the relatively high proportion of 
overweight participants and smokers. In particular, these findings should not be extrapolated into an 
occupational setting.  
Conclusions 
In conclusion, in this prospective nested case control study there is no consistent positive association 
with prediagnostic erythrocyte concentrations of Cd or Pb and risk of NHL. In fact significantly 
inverse associations were noted for some PCB congeners. A study in Finland has previously suggested 
that dioxins may act on the risk of soft-tissue sarcoma through a J-shaped dose response curve, and 
there in some support from animal models for such a relationship 302. The results of the ‘high 
exposure’ analysis could considered to be supportive of a J-shaped curve, however again these results 
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were non-significant, and the results from the quartile analysis offer no support. It seems more likely 
the findings arose as a result of multiple testing among strongly correlated congeners or effect 
modification as discussed. Sex-specific susceptibility to xenobiotics and potential carcinogens is also 
likely to play a role in the findings.  For the PCBs and POPs this adds to the existing body of literature 
and is in agreement with those studies which have previously reported a null association between these 
exposures and NHL 250. For the metals, particularly Pb, this study represents among the first evidence 
in the field, and there is some indication that the relationship between NHL and Cd in females is 
worthy of further explorations in a larger cohort. 
 
Overall an essentially null relationship between the investigated exposure and NHL is reported. 
Therefore internal dose of these exposures as measured in serum and erythrocytes cannot be 
considered as a reliable or useful biomarker of NHL, and has no utility in prediction.  
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6. METABOLIC PROFILING OF AN NHL CASE 
CONTROL STUDY TO IDENTIFY PREDICTIVE 
METABOLIC BIOMARKERS 
BIOMARKER: Individual metabolite features or a defined metabolite profile 
BIOMARKER TYPE: Biomarker of biologically effective dose 
POPULATION: B-cell NHL cases and controls from the EnviroGenoMarkers Study 
6.1 Introduction 
Metabolomics is the study of the metabolome, which has been defined as ‘the quantitative 
complement of all of the low molecular weight molecules present in cells in a particular physiological 
or developmental state’ 303. The term metabolomics was coined in 2002 by Fiehn et al. 304. It is often 
used interchangeably with metabonomics which was introduced by Nicholson et al. in 1999 305 Both 
methodologies share similar analytical and modelling procedures. The main difference is that while 
metabonomics measures global systemic change, metabolomics aims to characterise and quantify all 
the small molecules in a biological sample 306,307.   
An individual’s metabolome reflects their exposure experience, including dietary and lifestyle factors, 
as well as their genetics/genomics, and the interactions between these variables 308.  In this way it 
provides a down-stream measure of a whole system’s activity that reflects and measures the genome, 
epigenome, transcriptome and proteome. This metabolic end-point is consequently thought to be more 
closely related to the phenotype than these preceding ‘omes’ and in individuals with disease the 
metabolome has also been shown to be reflective of the disease state. As such it potentially represents 
a rich source for biomarker identification 307,309, particularly in cancer epidemiology  as cancer cells 
are known to possess highly unique metabolic signatures 310. Accordingly, a number of studies have 
shown the ability of metabolomics to distinguish healthy tissue from tumour tissue and healthy 
controls from cases in a variety of cancers 311,312. Particularly promising results concerning the use of 
metabolomics as a potential diagnostic tool have been reported for both prostate and breast cancer 310. 
However, to date the majority of metabolomics studies have been limited to case-control designs, 
resulting in the identification of diagnostic biomarker profiles or biomarkers which assist with the 
classification of tumours by subtype or stage. Very few studies have employed a prospective design in 
an epidemiological context, those that have tend to have been characterised by small participant 
numbers 307 and none have explored NHL. 
There is a strong biological rationale for the identification of prospective biomarkers predictive of 
disease onset from the metabolome 7 as metabolic changes initiated by a disease process precede the 
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overt phenotypic and functional changes, due to the effect of cellular regulation on small-molecule 
substrates 309. Therefore changes in the metabolome should be apparent and detectable before the 
observable onset of clinical disease, allowing a critical window for prediction or early detection.  
This chapter aims to harness this theory and apply metabolomics to the prediction of NHL risk, based 
on the nested case-control design from EGM study. A non-targeted approach and Ultra-high 
performance liquid chromatography Mass Spectrometry (UPLC-MS) were employed to identify 
individual metabolite features, fingerprints, profiles, or signatures that predict risk. Validation of the 
findings is then attempted in an independent cohort. For the purposes of this chapter these profiles are 
considered as biomarkers of biologically effective dose, as metabolomics reflects both the 
environment and the phenotype 310. This represents the first study to report on the feasibility of using 
metabolomics in prospective serum samples to identify biomarkers for risk of NHL. 
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6.2 Methods 
6.2.1 Study subjects 
This chapter is based on the 540 participants from the EGM study (see methods chapter 3.1.2, tables 
3.1.2a- c and figure 3.1.2 for details). For the purposes of validation the cohort was considered as two 
separate populations: NSHDS and EPIC-Italy 
Discovery cohort 
The discovery cohort was composed of the NSHDS component of the EGM study (phase 1 and 2).  
Validation cohort  
The validation cohort was drawn from phase 2 of the EPIC-Italy component of the EGM study. 
Participants from phase 1 of EPIC-Italy were not included as they were processed using a different 
analytical QC and were therefore not comparable.   
 
6.2.2 Metabolic profiling 
Prospectively collected blood samples from each participant underwent metabolic profiling using 
UPLC-MS as described in the methods 3.2.2. Each subpopulation (NSHDS phase 1, NSHDS phase 2 
and EPIC-Italy phase 2) was run separately using the same analytical QCs. Unique metabolite features 
that could be identified in all three populations based on their mass to charge ratio (m/z) and retention 
time (rt) were selected for analysis. 
6.2.3 Statistical analysis 
The Student’s t-test was used to assess differences in average metabolite intensities by sex and by 
cohort. Due to the highly dimensional and collinear nature of MS data, classical univariate, 
unsupervised multivariate and supervised multivariate models were employed to explore the 
relationship between metabolite profiles and risk of disease. All analyses were first performed on the 
discovery cohort then repeated in the validation cohort.  
Classical methods 
Conditional logistic regression was used to determine the association between each metabolite feature 
and disease risk, treating feature intensities as continuous explanatory variables. The strongest 
associations were further explored by considering dose-response relationships: intensities were 
categorised into quartiles based on their distribution in controls. Tests for trend were performed using 
the Wald’s test statistic. Pearson’s correlation coefficient was used to quantify the correlation among 
the metabolite features.   
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Selection of potential confounders 
To account for potential confounding, additional variables were included in the models. These were 
associated both with the metabolite features and with NHL, either in this population or in the 
literature. The associations between each covariate and every metabolite feature were computed using 
univariate linear regression where metabolite intensity was considered as the continuous outcome 
variable.   
Time to diagnosis 
To determine whether metabolite profiles, and potential associations differed as a function of time 
from blood draw to clinical onset, time to diagnosis (ttd) stratification was implemented by ttd <5 and 
ttd>5 years. Stratified analyses included all controls and adjusted for the matching factors: age, sex, 
metabolite batch and phase.  
Multivariate projection methods 
The data was imported into SIMCA-P software (SIMCA-P 12.0, Umetrics, Umeå, Sweden) to run 
both unsupervised and supervised multivariate projection analyses. The data were log-transformed and 
Pareto scaled prior to analysis. PCA was used to describe associations and patterns among the 
variables, considering sex, cohort, phase, age group and metabolomic processing batch in addition to 
case-control status. The QCs were also represented on the score plot to determine if they were evenly 
distributed throughout the samples and check for analytical drift. Strong outliers were identified using 
Hotelling’s T2 range plot and DmodX (distance to model). Once identified, they were excluded from 
further analysis. For each component, R2 was computed to determine the goodness-of-fit of the model 
and Q2 to determine its predictive power. To guard against model over-fitting, a cross validation 
procedure (SIMCA’s default 7-fold internal cross-validation) was implemented.  
Partial least squares (PLS) and Orthogonal-partial least squares projection to latent structures-
discriminant analysis (OPLS-DA) were carried out to discriminate the metabolic patterns between 
NHL cases and controls. The R2 and Q2 measures were inferred using cross validation. As a further 
measure of internal validation, a permutation test was conducted to compare the real Q2 to a generated 
Q2max based on 999 permuted models.  The variable importance in the projection (VIP) values of all the 
metabolite features and the S-plot from the cross-validated OPLS-DA model were used to select those 
which best discriminated cases from controls. The retained features were then taken forward for the 
ROC curve analysis.  
Stratified analyses were also performed for the four largest subtype groups: MM, DLBCL, CLL and 
FL and their matched controls.  
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ROC curve analysis 
The classical and multivariate projection methods resulted in the formation of potentially predictive 
metabolite feature sets which were then taken forward for logistic regression. For each exposure-
disease combination, logistic models using PCA summary of the data subset were run and their 
predictive abilities were assessed by drawing ROC curves, and summarised using the AUC. The 
model with the highest AUC was identified and replication in the validation cohort was attempted. 
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6.3 Results 
6.3.1 Dataset 
After the exclusion of analytical failures (together with their matched pair), of the 186 case-control 
pairs (table 3.1.2a) a total of 183 pairs (366 participants) from the NSHDS component of the EGM 
study were included in the discovery cohort. Of the 34 phase 2 case-control pairs from EPIC-Italy 27 
pairs (54 participants) were eligible for inclusion in the validation cohort (appendix table 6.3.1).  
In this subset of cases from the EnviroGenoMarkers study, there was a higher proportion of NSHDS 
participants (87.1%) than in the total population (68.9%) due to the exclusion of EPIC-Italy phase 1 
participants. There were also slightly more males (51.4% compared to 49.3%) and the average age 
was marginally younger in the subpopulation (52.8 years compared to 53.1 years). There was a 
borderline significant difference in height between cases and controls (171.1cm compared to 169.3cm, 
p=0.046), however there were no other significant differences and the distributions of the other 
investigated characteristics were very similar to the total EnviroGenoMarkers population, therefore 
this subpopulation can be considered representative.  
A total of 2016 metabolite features were identified in NSHDS and 1959 in EPIC-Italy.  In total 902 
unique metabolite features were common between both sets of profiles based on their m/z and rt. Of 
these, 152 were excluded from further analysis as their coefficient of variation (CV) was >30% of the 
cohort-specific QC in at least one of the populations. For the remaining 750 features, 244 (32.5%) had 
a CV less than 15% in both populations and the CV% were similar between NSHDS and EPIC-Italy 
(appendix figure 6.3.1i). There were high levels of correlation between feature intensity (appendix 
figure 6.3.1ii).  The QCs revealed no evidence of analytical drift. According to the test for skewness, 
682 features (90.9%) displayed a non-normal distribution (p<0.001), so all features were log 
transformed to obtain normality.  
A total of 198 (26.4%) features displayed differential intensities by sex (p<0.05), of which the 
majority (n=131) were higher in males. Five hundred and fifteen (68.7%) differed by cohort, with the 
majority of these (n=362) displaying higher intensities in NSHDS. Subsequent principal components 
analysis (PCA) revealed strong discrimination by cohort along the first two components, which 
explained more than 35% of the variation. This also resulted in some clustering by phase and 
processing batch. There was no obvious clustering by sex or age group (appendix figure 6.3.1iii). 
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6.3.2 Association between disease risk and metabolite profile in the discovery dataset 
Classical methods 
Using a conditional logistic regression model (model 1) a total of 13 metabolite features were 
associated with disease risk with a p-value <0.05. Ten were upregulated in cases and three were 
downregulated.  None of these associations would survive any realistic multiple testing correction. 
Potential confounders were identified and two further adjusted models were run (details in appendix 
section 6.3.2i). Using the same arbitrary significance level (0.05) nine associations between metabolite 
features and NHL risk in model 2, and nine in model 3 were found. The number of up and 
downregulated features in the three models and the crossover between them is shown in table 6.3.2. 
There was relatively high overlap between the identified features; 3 were upregulated in all three 
models and 1 was down regulated in all three. In total, 19 unique metabolite features were associated 
with NHL in at least one model.  
For 9 of these 19 strongest metabolite features, an evident dose-response relationship was seen in at 
least one of the models (appendix table 6.3.2ii). While the pairwise correlation coefficients (ρ) tended 
to be significant across the 19x19 pairs, their intensity was relatively low (appendix table 6.3.2.1iii): 
only four pairs showed a ρ >0.5 and none had a ρ >0.7. The comparison of the m/z and rt of these 19 
candidates indicated that they represented distinct features, and their CV% ranged from 11.2 to 29.7% 
(mean; 20.2%, median 18.3%). 
Table 6.3.2: The number metabolite features significantly (p<0.05) associated with NHL risk 
and the direction of their effect using three different modes.   
The number of features that were common between the three models is shown in the columns 
        Model 1   Model 2    Model 3  
Direction of 
effect   
  
 
Conditional 
 
(conditional + 
10 covarsa)  
(conditional 
+ 5 covarsb) 
Upregulated Model 1 (n=10) 
 
10 
    
 
Model 2 (n=5) 
 
4 
 
4 
  
 
Model 3 (n=6) 
 
4 
 
4 
 
6 
         Downregulated Model 1 (n=3) 
 
3 
    
 
Model 2 (n=4) 
 
2 
 
4 
    Model 3 (n=3)   1   2   3 
Associations were determined using a conditional logistic regression model, models 2 and 3 were additionally adjusted for the following 
covariates:                                                                                                                                                                                                                  
aBMI, educational level, alcohol consumption, vegetable consumption, dairy product consumption, protein consumption, total fat 
consumption, energy intake, fruit consumption and fish consumption                                                                                                            
bBMI, educational level, alcohol consumption, total fat and energy consumption 
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Time to diagnosis 
For model 1, 32 associations (p<0.05) between metabolite features and disease risk were identified in 
those who were diagnosed within five years of blood draw (ttd< 5 years n=70 cases), but only 6 in 
those diagnosed more than 5 years later (ttd> 5years n=113 cases). No metabolite features were 
common between the two subgroups. As expected, effect size estimates tended to be larger in the 
group diagnosed closer to blood draw (figure 6.3.2a).   The same pattern was observed for model 2 (< 
5 years n features= 25, ≥5 years n features=8) and model 3 (< 5 years n features=16, ≥5 years n 
features=10). In the ttd<5years subpopulation, across all models 13 unique features were identified. Of 
these, two were common with the 19 selected in the full population.  
Figure 6.3.2a Significant (p<0.05) associations between metabolite features and NHL risk for 
model 1 stratified by time between blood draw and NHL diagnosis <5 years and >5 years) 
The black line represents an OR of 1, and the dashed red line indicates a p-value of 
0.05
 
The Odds ratio represents the increase in odds of incident NHL per unit increase in metabolite feature intensity 
Replication of findings in the Validation cohort 
Analyses for all 750 metabolite features were run in EPIC-Italy. Despite a non-stringent significance 
threshold of p<0.05, none of the 19 putative associations from the NSHDS full population were 
replicated in EPIC-Italy. Linear regression was used to consider the relationship between the p-value 
rankings of the features in the two populations. There was no significant correlation for any of the 
models (p>0.1) and the selected features from NSHDS did not rank among the top 50 in EPIC-Italy in 
156 
 
any case.  In addition to this, under both models more than half of all the metabolite features showed 
discordant directions of effect between the two cohorts.  
Only one of the 13 features identified in the NSHDS ttd<5 years subpopulation was found in EPIC-
Italy (p<0.05), but the direction of effect was discordant and so cannot be considered replicated.  
The mz and r/t of the top selected features from NSHDS and EPIC-Italy were compared. Again there 
was very little evidence that similar features were being identified within the two cohorts (appendix 
figure 6.3.2i)  
Multivariate projection methods 
PCA was applied to the discovery set to identify major trends and any important outliers. This resulted 
in the exclusion of 17 outliers: eight cases and nine controls. These outliers comprised males and 
females, all batches, both phases and a number of different subtypes. The score plot for the first two 
components in the remaining 349 participants is shown in the appendix figure 6.3.2ii.  There was no 
evidence of any discrimination between cases and controls. 
To determine whether the model did have any predictive ability, and to improve interpretation, an 
OPLS-DA model was then built containing one predictive component and one orthogonal component 
(to explain the systematic variation not related to disease status). The model was found to explain 
28.5% of the total variation in metabolite profiles: 7.0% corresponding to disease risk and 21.5% to 
the variation unrelated to risk. The remaining 71.5% can be interpreted as noise. Internal validation of 
this model revealed a negative Q2 (Q2Y=-0.104) indicating the model should not be used for prediction 
purposes. Permutation tests performed on the corresponding PLS model confirmed the lack of 
predictability as the Q2max, exceeded that obtained by the real model. 
 
The score and loadings plots for the OPLS-DA model are shown in figure 6.3.2b. In accordance with 
the lack of predictability of the model these provide little evidence of separation between cases and 
controls from the predictive components. Nevertheless a number of features of potential interest were 
observed in the loadings plot. Their putative association with disease was further supported by the S-
plot and the Variable of Importance in the Projection (VIP) plot (appendix: figure 6.3.2iii). 
Metabolites with VIP scores >1 generally represent those carrying the most information to 
discriminate classes 313. A total of 54 features showed a VIP value >1 and confidence intervals that did 
not include 0 (model 4). Five (9.3%) of these 54 were common with the features identified by the 
classical analysis in the full population (this is defined as model 5).   
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Figure 6.3.2b: Results from the OPLS-Discriminant analysis in the discovery set 
(A) Score Plot; each data point represents a participant. The x-axis describes the between group, or 
predictive, variation and the y axis the within group variation (B) Loadings plot:  each data point 
represents a metabolite feature allowing the identification of those features most influential in the 
formation of the predictive component. 
 
The feature names have been shortened to EN_XXX for the purposes of these figures for easier visualisation 
 
Models were built for each subtype separately: MM, DLBCL, CLL and FL, to account for NHL 
heterogeneity. For each subtype only the matched controls were included to minimise nuisance 
variation from age and sex. Again these models were found to confer no predictive ability (appendix: 
table 6.3.2iv). 
 
Time to diagnosis 
An OLPS-DA model was built in the ttd<5 years subpopulation. The model performed slightly better 
in terms of predictive ability:  8.7% of the total variation in the metabolite profile was attributable to 
disease risk and 17.6% to systematic variation, after the exclusion of nine outliers. Again internal 
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cross-validation revealed a negative Q2 (Q2Y=-0.035), and therefore a lack of utility for prediction 
purposes. 
There was higher overlap in results from the logistic regression analysis for this subgroup. Thirty 
features with a significant VIP value >1 were also selected in the classical analyses (model 6). 
 
6.3.3 Metabolite profile as a predictive biomarker of NHL  
The metabolite features included in each of six the models are shown in the appendix table 6.3.3. 
To evaluate the ability of the metabolite feature sets to discriminate individuals who will develop 
NHL, ROC curves were determined using the scores for the first principal component as a continuous 
predictor. In all models, the first component explained more than 20% of the variation in the data, and 
specifically for model 4, 59% was explained (appendix table 6.3.3). The ROC curves and 
corresponding AUCs for models 1-5 in the full discovery population are shown in figure 6.3.3a.  
Figure 6.3.3a: ROC curves describing the AUC and 95% CI for five different metabolite feature 
sets run in the total discovery cohort 
ROC Curves are shown relative a random predictor (black line). ROC analyses were performed on 
continuous variables computed from principal component analyses of the specified metabolite features 
 
Model 6 is not included here as it pertains only to a subset (ttd<5 years) of the population 
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The AUCs were low for all 5 models, and the confidence intervals provided little evidence that they 
perform better than a random predictor at identifying individuals who will develop NHL. The highest 
AUC was for model 5 (AUC 0.615, 95% CI 0.557, 0.673), which incorporated the findings from both 
the classical and multivariate projection analyses. There was no evidence that this metabolite dataset 
could predict risk in an independent population, as there was no association between the computed 
PCA score and risk for these metabolite features in EPIC-Italy (OR: 0.95, 95% CI 0.54, 1.53). This 
was also true of the other models. 
In model 6 (ttd<5 years subpopulation) the AUC was 0.679 (95%CI 0.603, 0.754), but results could 
not be replicated in EPIC-Italy. For both model 5 (as the ‘best’ performing model in the full 
population) and model 6 (representing the ttd<5 years subpopulation) there was significant 
heterogeneity in the effect estimates between the discovery and validation cohorts, and the pooled 
estimate suggested no significant effect (Figure 6.3.3b). These findings are perhaps not surprising, as 
even in the two best performing models, the AUCs of <0.7 and associated confidence intervals would 
not generally be considered to have strong predictive ability.  
Figure 6.3.3b: Forest plot showing significant heterogeneity in the effect estimates between the 
discovery (NSHDS) and the validation (EPIC-Italy) cohorts for the first principal component 
score and disease risk 
The results for the top performing models; model 5 and model 6, are shown. 
 
ES – Odds Ratio 
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6.4 Discussion 
Metabolomics is an interdisciplinary “omics” science that combines pattern recognition approaches 
and bioinformatics with epidemiology, analytical biochemistry and biology to provide a global 
quantitative assessment of endogenous metabolites within a biological system 310.  Metabolomic 
profiling is now being increasingly used in cancer biomarker development, owing to its down-stream 
nature and consequent close relationship to disease phenotype 307. Accordingly, it is most commonly 
applied to the classification of diseased individuals, and there is increasing evidence that the diagnosis 
of a large number of cancer types can be assisted through the use of metabolomic profiles. The 
strongest findings to date relate to breast, prostate, brain 310 and colorectal cancer 314, with a large 
number of other cancer sites also investigated 307. Such tests are most commonly used on tumour 
tissue, but a role for other biological samples is currently developing, probably most successfully for 
blood serum and ovarian cancer 315. It is cheaper and easier to perform metabolic profiling on bodily 
fluids and consequently this opens up the potential for the use of metabolomics as a predictive 
screening tool 310.  As part of the EnviroGenoMarkers study, the feasibility of using prediagnostic 
blood samples to predict future risk of NHL, based on metabolite profiles characterised using mass 
spectrometry was investigated.  
Summary of findings 
Using logistic regression models, a total of 19 metabolite features were significantly associated with 
risk of NHL. This represented less than 5% of all the metabolite features explored, and therefore there 
is a strong possibility of spurious findings in this population, which is supported by the fact that none 
of the associations were robust to correction for multiple testing. Confounding was also an issue given 
the known influence of external lifestyle and dietary factors on metabolite profiles 316. However, a 
number of the strongest associations were consistent across the various models and additionally 
showed evidence of a dose-response relationship. This hints at a true association for these features, 
and therefore a possible role in prediction. Encouragingly when stratification by time to diagnosis was 
performed, a larger number of significant associations of greater magnitude were observed in the 
subgroup of cases diagnosed closer to blood draw. This provides some evidence of a biological 
plausibility as it would be expected that the metabolite profile in blood samples extracted closer to 
diagnosis would more accurately reflect the disease phenotype.  
The multivariate projection methods did not show strong results and internal validation suggested no 
predictive utility. More promising results were found when the analysis was restricted to those cases 
diagnosed within five years of blood draw, and there was also greater overlap in the features identified 
by the two analytical strategies in this subgroup. Overall, however, due to fact that the findings were 
not robust to correction for multiple testing, the poor performance using the multivariate methods and 
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the lack of replication in an independent cohort, no definitive conclusions about the utility of 
metabolomic profiles as predictors of future risk of NHL can be made. 
 
The lack of strong and replicated positive findings are perhaps not unexpected. To date no studies 
have identified predictive cancer biomarkers from the metabolome through the use of mass 
spectrometry and a prospective cohort design 307. Although a small study within EPIC utilising NMR 
did identify eight spectral regions which were associated with future colon cancer risk over an average 
follow up time of seven years 224. The feasibility of conducting metabolomics studies using a 
prospective design has been additionally proven in prognostic studies, successful metabolomics based 
classifications for recurrence of both hepatocellular carcinoma 317 and breast cancer 318 have been 
developed. However such studies are not really comparable to this one, and operate on a much shorter 
time scale. Therefore, the question remains as to whether it is possible to predict the risk of developing 
a malignancy up to fifteen years later using an individual’s metabolic profile.    
Assessment of methodologies 
In this study, 750 metabolite features representing potential biomarkers, or constituents of a biomarker 
profile were investigated. These features represent only a fraction of the possible metabolites that 
could have been detected. The precise numbers of human metabolites is unknown, although it is 
estimated to lie within the range of 104 to 105, and is somewhat dependent on the different analytical 
and detection methods used 307. To date, the Human Metabolome Database contains about 15,000 
entries 319. Unfortunately, there is not a single analytical methodology that can, even closely, cover the 
whole range of the metabolome.  The number of features measured in this study is within the range of 
what may be expected using our methods 320. These are currently unannotated, and typically one or 
more of these features may represent the same metabolite, or its adduct, isotope or fragment. This was 
explored through the plots of m/z versus rt for the significant associations in the classical analyses, and 
there were some groupings identified. However, further inferences cannot be made without annotation.  
The correct annotation of the identified metabolomic features represents one of the biggest challenges 
in mass spectrometry-based metabolomics. Although retention time or ion mobility can be descriptive 
of the physical and chemical properties of a molecule, putative annotation, absolute identification and 
quantification can only be made in the presence of an authentic standard, and unambiguous annotation 
from database searches is not currently possible 310,321-323. This is more of an issue for MS than for the 
other most commonly used methodology, Nuclear magnetic resonance spectroscopy (1H-NMR).  
Furthermore, MS will only work on ionisable molecules and it is biased towards those that ionise most 
efficiently. In this study only the positive ionisation mode was used, potentially missing metabolites 
that only ionise in the negative mode. Ion suppression can also be a problem with MS as can adduct 
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formation and the more intensive sample preparation required, which can increase sample-to-sample 
variability 307,310,321,322.  
 
UPLC-MS was chosen on the basis of its increased sensitivity to the order of 10 μmol/L which leads 
to wider class detection 307, its robustness, high resolution and ability to identify multiple metabolites 
at low concentrations with high specificity 160,310,321. Due to its increased sensitivity, LC-MS analysis 
was feasible with the limited sample volume available for the current study, (50 μL), for which  1H-
NMR analysis would have been impossible. Liquid chromatography (LC) was chosen over gas 
chromatography (GC) mainly due to the fact that as there is no limit on molecular weight a larger 
number of metabolites can be detected 307. Due to the hypothesis-free nature of this study an 
untargeted approach, analogous to a GWAS, was taken to pick up as many metabolites as possible, 
rather than a targeted approach to identify a few pre-defined metabolite subsets or pathways 307.  
Sample variability 
Sample handling can influence metabolite profiles.  Metabolic pathways are highly susceptible to the 
exogenous environment so within the same study method standardisation is vital 310. This may in part 
explain the dramatic differences seen between EPIC-Italy and NSHDS in this study. Although the 
metabolic profiling was carried out under controlled standardised conditions for all samples, the 
original sample extraction was conducted differently in the two cohorts. Previous work within the 
EGM cohort has found the anticoagulants used and the time between blood collection and freezing 
(benchtime) may both affect the metabolome 324. This nuisance variation should not affect our final 
analyses however: benchtime was only observed to have an effect if greater than 8 hours and although 
exact benchtimes are not available for NSHDS, it was <1 hour for all samples. For all EPIC-Italy 
samples it was <6 hours. Within the cohorts the same anticoagulant was used for all samples. However 
the anticoagulant induced variation may have been a further factor in the inability to replicate between 
cohorts. 
It could also be argued that the difference between the cohorts represents a batch effect. Although 
given the strong within-cohort batch concordance observed this seems unlikely. It seems more 
probable that exogenous differences including the sample collection as well as diet and environmental 
exposures between Italy and Sweden explain the metabolic distinction between the cohorts 308. In 
accordance with the literature 325, multiple strong associations between baseline characteristics and 
metabolite features were observed. It has also been shown that there is a genetic component to the 
metabolome 326 which could further explain the geographical differences observed. 
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Statistical techniques and prediction 
Regardless of the laboratory techniques used, complex analytical methods are required to deal with the 
multivariate, highly collinear noisy datasets produced 224,306. Multiple testing is a particular problem: in 
this study none of the candidate associations would survive any realistic multiple testing correction. 
Commonly metabolomics employs pattern recognition or clustering techniques to determine 
differences between cases and controls 310.  Unsupervised methods, such as PCA, measure the innate 
variation in data sets, whereas supervised methodologies, including OPLS-DA are also able to take the 
outcome into account in the formation of the clusters, and to analyse systematic (orthogonal) variation 
that is not related to the outcome separately, thereby improving interpretability 310. This is particularly 
important in metabolomics where variation may arise from environmental influences or from 
experimental variation 325 disturbing the multivariate modelling and causing imprecise predictions and 
lower model robustness 327. As these methodologies cannot naturally account for the effect of 
confounders, they are therefore considered in combination with classical logistic regression. Within 
this project neither methodology provided reproducible predictive metabolite features.  
Additionally results from OPLS-DA showed poor predictive power for the orthogonal component, 
explaining only a small proportion of such variation, and it was noted that the discriminant analyses 
were highly sensitive to the selection of outliers for exclusion.  This may suggest more refined 
analyses are required to identify the true sources of variation in this dataset. One possibility is the use 
of a lower CV% cut-off for feature inclusion. A threshold of <15% has been suggested in the literature 
230. However under this more stringent threshold a large number of the features included in models 1-6 
would have been excluded from the discovery set. Although again, the ttd<5 years group performed 
better in this respect.  
The ability to stratify by time to diagnosis is one of the major strengths of this study, as was the 
existence of a validation cohort. A recent review reported that only 17% of published MS-based 
studies even attempted to replicate their findings in an independent cohort, so it is difficult to estimate 
the number of spurious associations that may be reported in the literature 307. The lack of internal 
validation was a cause for concern. To ensure that the data were meaningful, an OPLS-DA was built 
for sex. This showed good separation by sex and decent predictive ability for epidemiological data (R2 
0.283, Q2 0.257) as expected, suggesting the low Q2 for the disease model was not due to data quality. 
An obvious limitation of the study was the lack of annotation for the features, which means that 
biological plausibility of the putative markers cannot currently be explored. To make the most of the 
data, existing literature can be used to suggest a number of possible metabolites that the unannotated 
candidates may represent if they do indeed lie on the carcinogenesis pathway. 
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Potential pathways 
Two NHL metabolomics case-control studies have been conducted on human subjects to date. One 
reported an inverse association with hypoxanthine (HX) 328 measured in urine, the other found 
increased pyruvate and glutamate and decreased isoleucine concentrations in the serum of CLL 
patients compared to controls 329. These findings may help inform on the metabolite features identified 
in this study. However, it should be noted in addition to their case control design and the use of urine 
by one, the studied populations were not entirely comparable to the population investigated here. In 
contrast to this population both contained more males than females (>60%).The populations were 
older on average; the mean age was 57 years in Yoo et al.’s 328 study and 71 years in the population 
studied by MacIntyre et al. 329. Both papers were also much more homogeneous in terms of subtypes; 
MacIntyre 329 included only CLL cases, and Yoo et al.’s population 328 was predominantly (73%) 
DLBCL. In addition both papers had information on stage which was lacking from this study, 
although they reported no information on height, weight, BMI, smoking status, or any other variables 
which may be affecting the metabolite profile and which were available for the EGM population. 
Studies of lymphoma in mice additionally suggest a role for altered levels of xanthine, adenosine and 
xanthosine monophosphate (XMP), together with higher levels of inosine and inosine monophosphate 
(IMP). Work in cell lines suggests decreased tryptophan and proline levels may also be expected 330. 
To date the strongest findings in metabolomics tend to be related to those malignancies which are 
intricately involved in metabolism, such as pancreatic cancer. However cell line studies have shown 
that neoplastic lymphoma cells exhibit distinct metabolic profiles compared to normal lymphoctyes 
330, and that a 1H-NMR-based metabolomic approach can better identify patients with poor prognosis 
on the basis of their metabolic profile 329. Therefore the evidence suggests we may well be able to 
obtain biologically meaningful results regarding lymphoma from the findings. 
Only annotation of the identified metabolites will allow the further exploration of these hypotheses, 
and the determination of whether statistical significance translates to biological significance in this 
population. In particular the use of enrichment set analysis could be employed, which may 
additionally allow for the better comparison of the two datasets. Annotation of these features is 
ongoing. 
Subtype specific results 
Interrogation of the PCA score plots did not reveal any clustering by subtype (appendix figure 6.3.1ii) 
and this was supported by the negative predictive value of the OPLS-DA subtype specific models. 
However it has been suggested that the complexity of the genetic and epigenetic interplay in the 
various subtypes is likely to be translated to metabolic regulation 331.  As mentioned the positive 
findings from both MacIntyre et al. 329 and from Yoo et al. 328 pertained largely or completely to single 
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subtypes. Therefore it is suggested that subtype should also be considered further in future, larger 
studies. 
Potential biomarker utility 
For an annotated set of features these findings may be able to impart important mechanistic 
information, and there may indeed be some potential for validation of the findings once the true 
metabolites are known. This would allow consideration of a number of the biomarker criteria 
discussed in methods 3.5: biological plausibility, coherence with existing knowledge and amount of 
evidence. In common with the biomarkers discussed in the previous chapters it is possible to 
determine a temporal relationship, and in this chapter a number of associations of relatively high 
magnitude with a dose-response effect were observed. However careful thought must be given to 
practicality vs. prediction when measuring multiple metabolites.  Furthermore, given the low AUCs 
reported and the current lack of replication, with its subsequent risk of overfitting, at present there is 
no utility for metabolomics profiles in the assessment of future NHL risk based on these findings. In 
common with all MS-based metabolomics studies there is also potential for bias, particularly through 
the pre-processing steps, including the import and conversion of raw data files, the detection of signals 
(peak picking), the assignment of single ions to the same metabolite (deconvolution) and the 
integration and alignment of the chromatographic peaks. Currently no standards exist for these 
different steps; a recent review of mass-spectrometry based metabolomics in cancer research found 
more than 10 different software programs were used for pre-processing in just over 100 studies 307, and 
there is no single methodology which is currently able to measure all the metabolites in a sample 
316,323.  Agreement on the optimal protocol to maximise reproducibility, reliability and sensitivity and 
to minimise analytical drift in order to make the existing methodologies comparable is urgently 
required 323. 
 
The generalizability of this cohort to the wider population is also an important consideration for 
potential biomarker utility. Although, the gender ratio has been slightly shifted towards males, in all 
other respects is it essentially the same as the population discussed in chapter five, and therefore 
subject to the same generalisability issues. Further, this population is even more heavily dominated by 
Swedish participants.  
 
Conclusions 
With the advancement of high-throughput technologies, metabolomics is emerging as a powerful tool 
that has the ability to sub-classify cancer phenotypes and to separate cases from controls on a large 
scale 309,316,323. It was hypothesised that this may also be possible in pre-diagnostic blood samples. The 
results displayed little predictive ability on the basis of the logistic regression, and none when 
multivariate methods were employed. However, given that carcinogenesis represents a continuous 
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spectrum rather than a discrete separation between healthy and diseased 7 this is perhaps not 
surprising; the cases developed cancer at different times after blood sample extraction, so were at 
different stages of the carcinogenesis continuum at enrolment. Therefore given the dynamic nature of 
the metabolome one would perhaps not expect them all to exhibit a profile so similar it could be used 
to distinguish them from controls. This hypothesis is further supported by the fact that stronger 
associations were seen in the subgroup of cases diagnosed closer to blood draw.  An interesting facet 
of the findings was the strong discrimination between two geographically distinct cohorts, as well as 
by sex.  
Here differences in metabolite intensities between cases and controls have been utilised to attempt to 
disentangle the mechanistic underpinnings of disease. These differences can either be considered as a 
reflection of changes in the environment or in the genome, epigenome, transcriptome, or proteome, or 
alternatively as the drivers behind pathogenesis. These questions can begin to be answered by 
integrating other information into the study of the metabolome and this is explored further in chapter 8 
utilising the EGM exposure data and the ‘meet-in-the-middle’ approach. 
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7. t(14;18) TRANSLOCATION: A PREDICTIVE BLOOD 
BIOMARKER FOR FOLLICULAR LYMPHOMA 
BIOMARKER: Prevalence and frequency of the t(14:18) translocation 
BIOMARKER TYPE: Biomarker of early biological effect   
POPULATION: Incident Follicular Lymphoma cases and control from the EPIC cohort 
This chapter is based in part on the publication‘t(14;18) Translocation: A predictive blood biomarker 
for Follicular Lymphoma’ by Roulland S, Kelly RS et al.332 Tables, figures and text have been modified 
accordingly. 
7.1 Introduction 
Follicular Lymphoma (FL), a lymphoma of follicle centre B-cells, represents a particularly attractive 
model to study early biological effects in lymphomagenesis as it is characterised by an indolent 
asympotomatic course and up to 90% of cases share the same genetic hallmark, the t(14;18) (q32;q21)  
translocation 333. The t(14;18) translocation juxtaposes the BCL2 (B-Cell leukaemia/Lymphoma 2) 
proto-oncogene on chromosome 18q21 near to the immunoglobulin heavy chain (IGH) locus on 
chromosome 14q32. This rearrangement subjects BCL2 to the control of the IGH-E enhancer leading 
to overexpression of BCL2 protein, which inhibits apoptosis, thereby increasing cell survival and 
uncontrolled cell proliferation in the germinal centres 147. This effectively ‘immortalises’ the 
lymphocyte, so although with this translocation alone they are not neoplastic, any t(14;18)+ cells1 that 
develop subsequent oncogenic mutations are unlikely to be eliminated through routine apoptotic 
mechanisms 334.  
A large proportion (50-70%) of healthy individuals also harbour low levels of circulating t(14;18)+ 
cells 335,336, yet will never develop FL and the relationship between the translocation and progression 
to disease remains unclear. In rare cases, apparently tumour-free “healthy” individuals carry unusually 
high frequencies (10-100 times greater than the average population) 337. It has previously been 
demonstrated that a high frequency of cells carrying the translocation constitute an expanding clonal 
population of atypical B-cells, which are issued from the germinal centre, and share genotypic and 
phenotypic features exclusively seen in FL 338,339. Nevertheless, a key gap in understanding is whether 
such t(14;18)+ cells with “FL-like” features in healthy individuals constitute clonally-related FL 
precursors, and if high t(14;18) frequencies in blood represent a suitable predictive biomarker of FL 
development.   
 
                                                     
1 From here on t(14;18)+ will be used to denote prevalence/positivity of the translocation (more than 1 cell bearing the translocation per 
1,000,000 circulating lymphocytes (≥1x10-6)) 
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7.2 Methods 
7.2.1 Study population  
Discovery cohort 
The study population was drawn from the EPIC cohort (methods 3.1.1 and table 3.1.2c). Eligible cases 
were those participants who were diagnosed with FL during follow-up, according to the ICOD-3 
(9690/3, 9691/3, 9695/3, 9698/3) and who had an archived cryopreserved buffy coat sample collected 
at enrolment. Each case had two matched controls (methods 3.1.2.7).  Cases and controls with 
insufficient DNA quality or equivocal ICD03 codes were excluded (the number of FL cases are 
smaller than reported in table 3.1.1.7 as no Scandinavian cases were eligible for inclusion in the 
discovery cohort). 
Validation cohort  
The validation cohort was drawn from the NSHDS (methods 3.1.2) according to the eligibility criteria 
used for the EPIC cohort. 
The baseline characteristics of the discovery and validation cohorts are shown in table 7.3.1a. 
7.2.2 Assessment of t(14;18) prevalence and frequency 
Details in the methods section 3.2.3. 
7.2.3 Statistical analysis 
Frequency analyses were conducted on both the total population and within the t(14;18)+  subgroup to 
obtain effect estimates both for a general population and for a population known to be positive for the 
translocation. Differences in  t(14;18)  prevalence  and  frequency  were  analysed  using  the chi-
squared   and  Mann–Whitney  U  tests,  respectively.  Correlations between frequency and time-to-
diagnosis were performed using Spearman’s rank tests.  Unconditional  logistic  regression  was  
applied  to determine  the  association  between  t(14;18)  frequency  and  FL,  adjusting  for  the 
matching factors: age,  sex,  time-since-blood-draw  and  country  of  residence.  An unconditional 
model was used to maximize power, as after exclusion of poor quality DNA samples, there was no 
longer a 1:2 ratio for all cases and controls, and therefore utilizing matched analysis would have 
resulted in further exclusions. Frequency was then dichotomized based on six pre-defined thresholds 
(5x10-6, 1x10-5, 5x10-5, 1x10-4, 5x10-4, 1x10-3), and the risk of FL associated with a frequency above 
these thresholds calculated. These thresholds were chosen to be equally spaced on the basis of the 
frequency distribution in t(14;18)+ participants. ROC curve analysis was used to test the overall ability 
of t(14;18) frequency to predict FL. An optimal predictive t(14;18)  frequency  threshold was 
determined based on a context-specific trade-off between the AUC calculated from the ROC curve 
analysis, sensitivity, positive predictive value (PPV) and negative predictive value (NPV).   
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This optimal (in the context of this biomarker) threshold  was  then  applied  to  the validation  cohort  
to  confirm  its  ability  to  predict  FL  risk  in  an  independent  cohort.  Meta-analysis  of  the  two  
cohorts  was  used  to  assess  heterogeneity  and  provide  a  summary  risk estimate.  Stratified  
analyses  by  time  to  diagnosis  were  performed  on  the  pooled  dataset. Cases were categorized 
into four groups based on the time between blood draw and diagnosis: <5 years, 5-10 years, 10-15 
years and >15 years. For each strata unconditional logistic regression was run adjusting for the 
matching factors using all controls as baseline.  Heterogeneity between the strata was assessed using 
meta-analyses.   
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7.3 Results 
The baseline characteristics of cases and controls in the discovery and validation cohort are shown in 
table 7.3.1a. For the discovery cohort, a total of 100 incident cases of FL with good-quality archived 
prediagnostic blood collected at enrolment were identified. Time to FL diagnosis ranged from 2 
months to 13 years (mean: 6.4 years). The control population comprised 218 participants who did not 
develop lymphoma during follow-up (from the date of their blood draw to the present time).  The 
mean age at diagnosis was 61.6 years in the combined cohort, which is in line with the reported 
median age of 60 years at diagnosis for this malignancy 340. As with the previous chapters, females 
were over-represented, particularly in the discovery cohort, however it has previously been reported 
that FL may not exhibit the same male-bias as other lymphoma subtypes 15. 
7.3.1 t(14;18) Prevalence and Frequency in cases compared to controls  
Overall, the prevalence of t(14;18)+ was significantly higher in incident FL cases compared to the 
controls (56.0% vs. 28.9%, p<10-3) in the discovery cohort. Similarly, the mean and median 
frequencies were significantly higher, both when considering the total population and the t(14;18)+ 
participants only, and this was evident in both sexes (Table 7.3.1b and Figure 7.3.1). Although 
t(14;18) frequencies varied over a 4-log range (from undetectable to one every 50 cells), the highest 
frequency quartile in prediagnostic FL reached levels unseen in the EPIC control group and never 
observed previously in large screenings of healthy subjects  in other studies 337.  
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Table 7.3.1a. Demographic Characteristics and t(14;18) Analysis According to Study Cohort 
    EPIC discovery Cohort   NSHDS Validation Cohort   Total Cohort 
Demographic and 
clinical characteristics 
 
Subjects who did 
not develop FL 
(controls) 
Subjects who 
developed FL 
(incident FL)  
P value^ 
 
Subjects who did 
not develop FL 
(controls) 
Subjects who 
developed FL                
(incident FL)  
P value^ 
 
Subjects who did 
not develop FL 
(controls) 
Subjects who 
developed FL 
(incident FL)  
P value^ 
N 
 
218 100 
  
128 65 
  
346 165 
 Age at blood draw in 
yrs, mean (range)  
 
54.8 (27.3 - 77.7) 54.1 (27.2 - 77.2) NS 
 
55.8 (30.0 - 73.70) 52.9 (30.3 - 72.0) 0.030 
 
55.2 (27.3 - 77.6) 53.6 (27.2-772) NS 
Age at FL diagnosis in 
yrs, mean (range)  
 
n.a 60.3 (37.7 - 79.2) 
  
n.a 63.1 (38.4 - 81.7) 
  
n.a 61.6 (37.7 -81.7) 
 Sex - no (%)      Male 
 
66 (30.3) 32 (32.0) NS 
 
65 (50.8) 32 (49.2) NS 
 
131 (37.9) 64 (38.8) NS 
Female 
 
152 (69.7) 68 (68.0) 
  
63 (49.2) 33 (50.8) 
  
215 (62.1) 101 (61.2) 
 Calendar years of 
enrolment 
 
1993-2002 1993-2002 
  
1990-2010 1990-2010 
  
1990-2010 1993-2010 
 Calendar years of FL 
diagnosis 
 
n.a 1995 - 2007 
  
n.a 1994-2013 
  
n.a 1994-2013 
 Time from blood 
collection to diagnosis 
in months, mean 
(range)    n.a 76.9 (2.7 - 161.3)     n.a 124.0 (5.9 - 244.5)     n.a 91 (2.7-244.5)   
 NS - non-significant at the 5% confidence level                                                                                                                                                                                                                                                                             
^p-value for difference between controls and incident cases; t-test for age at blood draw, chi-squared test for sex  
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Table 7.3.1b t(14;18) Characteristics according to Study cohort and gender 
Population t(14;18) characteristics 
  EPIC discovery Cohort   NSHDS Validation Cohort   Total Cohort 
 
Subjects 
who did not 
develop FL 
(controls) 
Subjects 
who 
developed 
FL (incident 
FL)  P value^ 
 
Subjects 
who did not 
develop FL 
(controls) 
Subjects 
who 
developed 
FL 
(incident 
FL)  P value^ 
 
Subjects who 
did not 
develop FL 
(controls) 
Subjects who 
developed FL 
(incident FL)  
P 
value^ 
 
  
           Total Prevalence (%) 
 
63/218 (28.9) 56/100 (56.0) <0.0001 
 
52/128 (40.6) 46/65 (70.8) <0.0001 
 
115/346 (33.2) 102/165 (61.8) <0.0001 
 
Range  (per 10-5) 
 
0.1 - 45.6 0.1 - 1860 
  
0.1-6.7 0.1 - 2129.5 
  
 0.1 - 45.6 0.1 - 2129.5 
 
 
Mean frequency  (per 10-5) 
 
0.7 91.9 <0.0001 
 
0.4 98.3 0.003 
 
0.6 94.1 <0.0001 
 
Mean frequency in t(14;18)+ 
samples   (per 10-5)  2.3  162.1 <0.01 
 
0.9 138.9 0.026 
 
1.7 151.5 0.0001 
 
Median frequency   (x10-5) 
 
0.1 0.2 <0.0001 
 
0.1 0.3 <0.0001 
 
0.1 0.2 <0.0001 
 
Median frequency in  
t(14;18)+ samples  (per 10-5) 
 
0.2 3.8 <0.0001 
 
0.2 1.6 <0.0001 
 
0.2 1.8 <0.0001 
 
Prevalence of samples above 
10-4 (%) 
 
4/218 (1.8) 21/100 (21) <0.0001 
 
0/128 (0) 12/65 (18.5) <0.0001 
 
4/346 (1.2) 33/165 (20.4) <0.0001 
              Males Prevalence (%) 
 
15/66 (22.7) 21/32 (65.6) <0.0001 
 
30/65 (46.2) 22/32 (68.8) 0.036 
 
45/131 (34.4) 43/64 (67.2) <0.0001 
 
Range - 10-5 
 
0.1 - 13.4 0.1 -1860 
  
0.1 - 4.8 0.1 - 1069.4 
  
0.1 - 13.4 0.1 - 1860 
 
 
Mean frequency  (per 10-5) 
 
0.4 134 0.005 
 
0.5 62.4 0.017 
 
0.4 98.2 0.0003 
 
Mean frequency in t(14;18)+ 
samples   (per 10-5) 
 
1.4 204.2 0.098NS 
 
0.9 90.8 0.05 
 
1.1 146.2 0.0094 
 
Median frequency  (per 10-5) 
 
0.1 0.5 <0.0001 
 
0.1 0.3 0.002 
 
0.1 0.3 <0.0001 
 
Median frequency in  
t(14;18)+ samples  (per 10-5) 
 
0.2 5.8 0.002 
 
0.2 1.3 0.01 
 
0.2 2.7 <0.0001 
 
Prevalence of samples above 
10-4 (%) 
 
1/66 (1.5) 10/32 (31.3) <0.0001 
 
0/63 (0.0) 7/32 (21.9) 0.001 
 
1/131 (0.8) 17/64 (26.6) <0.0001 
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Table 7.3.1b continued 
Population t(14;18) characteristics 
  EPIC discovery Cohort   NSHDS Validation Cohort   Total Cohort 
 
Subjects 
who did not 
develop FL 
(controls) 
Subjects 
who 
developed 
FL 
(incident 
FL)  P value^ 
 
Subjects 
who did 
not develop 
FL 
(controls) 
Subjects 
who 
developed 
FL 
(incident 
FL)  P value^ 
 
Subjects 
who did not 
develop FL 
(controls) 
Subjects 
who 
developed 
FL (incident 
FL)  P value^ 
              Females Prevalence (%) 
 
48/152 (31.6) 35/68 (51.5) 0.005 
 
22/63 (34.9) 24/33 (72.7) <0.0001 
 
70/215 (32.6) 59/101 (58.4) <0.0001 
 
Range  (per 10-5) 
 
0.1 - 45.6 0.1 - 1810 
  
0.1 - 6.7 0.1 - 2129.5 
  
0.1 - 45.6 0.1 - 2129.5 
 
 
Mean frequency (per 10-5) 
 
0.9 71.2 0.001 
 
0.4 133 0.032 
 
0.8 92 0.0002 
 
Mean frequency in t(14;18)+ 
samples   (per 10-5) 
 
2.6 136 0.0112 
 
0.1 183 0.137NS 
 
2.1 155.5 0.005 
 
Median frequency   (x10-5) 
 
0.1 0.2 0.0005 
 
1 0.6 <0.0001 
 
0.1 0.2 <0.0001 
 
Median frequency in  
t(14;18)+ samples  (per 10-5) 
 
0.3 1.3 0.0098 
 
2 2 0.002 
 
0.2 1.4 0.0001 
  
Prevalence of samples above 
10-4 (%)   3/152 (2.0) 11/68 (16.2) <0.0001   0/63 (0.0) 5/33 (15.2) <0.0001   3/215 (3.4) 16/101 (15.8) <0.0001 
NS - non-significant at the 5% confidence level                                                                                                                                                                                                                                                                             
^p-value for difference between controls and incident cases; t-test for mean frequency, chi-squared test for prevalence, Mann-Whitney U test for median frequency 
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Figure 7.3.1. t(14;18) frequency distribution in incident cases and healthy controls from in the 
discovery and validation cohorts 
(Adapted from Roulland et al. 332) this figure shows t(14;18) frequencies in blood from healthy  
individuals  who  subsequently  developed  FL  (incident  FL  cases)  as  compared  to healthy  
individuals  who  did  not  (controls)  in  the  EPIC  discovery  cohort  and  the  NSHDS  validation  
cohort.  The dashed horizontal lines indicate the cutoff value of 1x10-4. The dashed blue line 
represents the median frequency. The negative threshold value was defined as half the detection limit 
of the Q-PCR assay (e.g. 1x10-6).  
 
7.3.2 t(14;18) frequency as a predictive biomarker of NHL  
To evaluate the potential of t(14;18) frequency to discriminate individuals who will develop FL, a 
ROC curve was determined from the logistic model. The AUC was computed to be 0.744 (95% CI 
0.654, 0.834) when carried-out on t(14;18)+ samples, indicating that t(14;18) frequency constitutes a 
good predictive marker, allowing the discrimination of individuals who will develop FL from controls 
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(Figure 7.3.2). Considering the AUC together with sensitivity, specificity, PPV and NPV it was found 
that the optimal cut-off frequency value to obtain good predictive ability for the risk of FL 
development (OR: 9.88, sensitivity: 93.7%, PPV: 84.0%), whilst maintaining a reasonable specificity 
(38.2%) was 10-4  (table 7.3.2). Unconditional logistic regression adjusting for the matching factors 
suggested an almost ten-fold increase in risk of NHL associated with being above this threshold in 
t(14;18)+ individuals (OR; 9.88; 95% CI, 2.98-32.70; P=1.77x10-4). If this threshold was applied to all 
individuals regardless of t(14;18) prevalence, the risk increased by more than 15-fold (OR; 15.52; 
95% CI, 5.12-47.11; P=1.29x10-6 ). 
Figure 7.3.2: The receiver-operating-characteristic (ROC) curves for t(14;18) frequency in the 
discovery cohort (t(14;18)
 +
 samples) 
The solid diagonal line shows the performance of a random predictor.    
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Table 7.3.2: Ability of varying thresholds of t(14;18) frequency to predict risk of FL among 
t(14;18)
+
 individuals in the discovery cohort 
t(14;18) frequency 
threshold 
Sensitivity Specificity PPV NPV 
      OR≠ (95% CI) 
5x10
-6
 67.3% 60.3% 59.7% 67.9% 2.97 (1.36, 6.45) 
1x10
-5
 60.0% 74.6% 67.3% 68.1% 4.35 (1.94, 9.77) 
5x10
-5
 43.6% 90.5% 80.0% 64.8% 7.43 (2.66, 20.73) 
1x10
-4
 38.2% 93.7% 84.0% 63.4% 9.88 (2.98, 32.70) 
5x10
-4
 23.6% 100.0% 100.0% 60.0% ł 
1x10
-3
 20.0% 100.0% 100.0% 58.9% ł 
Continuous variable 
    
1.01 (1.00, 1.01) 
≠ OR adjusting for age at screening, sex, country and days between blood draw and frequency screening                                   
ł No controls were above this threshold so an odds ratio could not be computed 
 
7.3.3 Validating the utility of t(14;18) frequency as a predictive biomarker   
These initial findings were confirmed in an independent validation cohort. In this cohort t(14;18)+ 
prevalence and mean and median frequency were all significantly higher (P<0.05) in those 
participants who went on to develop FL (Table 7.3.1). The AUC in this population was 0.796 (0.708-
0.883), and those participants with a frequency above 5x10-5 had a greater than forty fold increase in 
risk of FL (OR 41.82 95%CI 4.25, 411.75, p=0.001) (appendix table 7.3.3 and figure 7.3.3). No 
controls displayed a frequency >1x10-4 , so an odds ratio could not be computed. However, using this 
threshold 12 out of 65 participants (18.5%) who went on to develop FL were correctly identified.  
Meta-analysis of the discovery and validation phases found no heterogeneity in the effect estimates 
between the two cohorts at the thresholds where an odds ratio could be computed in both cohorts; at 
5x10-6 the p-value for heterogeneity was 0.509, at 1x10-5  p=0.631 and at 5x10-5 p=0.177 (figure 
7.3.3i).  
When both  the discovery  and the validation  cohorts  were  combined,  the  AUC  was  0.764  
(0.700-0.827) (Fig. 7.3.3b).  Table 7.3.3 describes the predictive ability of the varying thresholds in 
the pooled cohort and confirms that a threshold of 1x10-4 is associated with a high predictive ability, 
in terms of odds ratio, sensitivity and PPV, whilst maintaining a specificity greater than 30%.  
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Figure 7.3.3: The receiver-operating-characteristic (ROC) curves for t(14;18) frequency in the 
validation cohort (t(14;18)
+
 samples) 
The solid diagonal line shows the performance of a random predictor.    
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Table 7.3.3: Ability of varying thresholds of t(14;18) frequency to predict risk of FL among 
t(14;18)
+
 individuals in the pooled cohort (discovery and validation cohorts combined) 
t(14;18) frequency 
threshold 
Sensitivity Specificity PPV NPV OR
≠ 
(95% CI) 
5x10-6 68.3% 61.7% 61.1% 68.9% 3.48 (1.96, 6.02) 
1x10-5 60.4% 73.9% 67.0% 68.0% 4.84 (2.64, 8.90) 
5x10-5 40.6% 93.9% 85.4% 64.3% 11.53 (4.74, 28.05) 
1x10-4 32.7% 96.5% 89.2% 62.0% 14.95 (4.94, 45.25) 
5x10-4 20.8% 100.0% 100.0% 59.0% Ł 
1x10-3 16.8% 100.0% 100.0% 57.8% Ł 
 
Continuous variable         1.01 (1.00, 1.01) 
PPV – positive predictive value                                                                                                                                                                 
NPV – Negative predictive value                                                                                                                                                         
AUC – area under the curve                                                                                                                                                            
≠ OR adjusting for age at screening, sex, country and days between blood draw and frequency screening                                        
Ł No controls were above this threshold so an odds ratio could not be computed 
 
Overall,  within the pooled cohort a t(14;18) frequency >1x10-4 was associated with a 15-fold increase 
in risk among t(14;18)+  individuals (OR: 14.95; 95% CI, 4.94-45.25; P=1.7x10-6) and a 23 fold 
increase in risk when considering both t(14;18)+ and t(14;18)- participants2 together (OR: 23.17; 95% 
CI, 9.98-67.31; P=7.7x10-9) . 
7.3.4 Stratification by time to diagnosis 
To determine whether increased t(14;18) frequency might be preferentially observed in pre-diagnostic 
samples collected close to diagnosis, analysis on the pooled cohort (n=511) was additionally stratified 
by time to diagnosis which ranged from 2 months to 20 years (mean 7.9 years)
3
. Overall, median time 
to diagnosis did not differ according to t(14;18)+ prevalence  (p=0.48). Among t(14;18)+ cases, there 
was no significant correlation between t(14;18) frequency and time to diagnosis (rs=-0.06, p=0.563).  
When analysis was stratified by 5-year ttd intervals, the risk of NHL associated with a frequency   
>10-4 was significant in all intervals in the total population, but not in cases diagnosed >15 years after 
enrolment (Table 7.3.4). There was no heterogeneity of effect estimates across ttd strata.  
                                                     
2 From here on t(14;18)- is defined as participants with no cells carrying the translocation 
3 Time to diagnosis (ttd) was different in the pooled cohort as compared to the discovery cohort, due to the inclusion of extra participants 
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Table 7.3.4; Risk of FL associated with a frequency >1x10
-4
 stratified by time to diagnosis in the 
pooled cohort (discovery and validation cohorts combined) 
Results for the total population and for t(14;18)+ participants are shown separately  
    
All participants (n=511)                                                                                              
p for heterogeneity= 0.837
NS
   
t(14;18)
+
participants (n=217)                                                                 
p for heterogeneity= 0.665
NS
 
Time to 
diagnosis 
 
No. 
cases 
No. 
controls OR
≠ 
(95% CI) p-value 
 
No. 
cases 
No. 
controls OR
≠ 
(95% CI) p-value 
< 5 years 
 
49 346 23.84 (7.06, 80.51) 3.26x10-07 
 
30 115 17.17 (4.48, 65.81) 3.35x10-05 
5-10 years 
 
63 346 30.11 (9.58, 94.68) 5.70x10-09 
 
36 115 22.87 (6.70, 78.08) 5.89x10-07 
10 - 15 years 
 
38 346 15.34 (3.68, 63.91) 1.77x10-04 
 
25 115 8.40 (1.92, 36.73) 4.68x10-03 
>15 years  15 346 16.07 (1.24, 208.67) 0.034   11 115 5.85 (0.42, 80.94) 0.187
NS 
≠ OR adjusting for age at screening, sex, country and days between blood draw and frequency screening                                       
p for heterogeneity assess whether there was a significant difference between time strata                                                              
NS – non significant at the 95% level 
 
7.3.5 t(14;18)
+
 clones as disease precursors 
To confirm that t(14;18)+ clones present in the prediagnostic samples constituted the precursors which 
progressed to overt FL, biopsy samples for all included cases were requested from the corresponding 
EPIC centres. Due to centre-specific ethical restrictions and the logistical difficulties of obtaining 
tumours samples stored in various non-centralised locations, only 3 good-quality archival formalin 
fixed paraffin embedded FL biopsies from EPIC subjects were recovered. Their t(14;18) clonotypic 
breakpoints were determined, and compared to the ones found in the corresponding prediagnostic 
samples. All FL biopsies were found to be t(14;18) +, including one mcr variant, and corresponded to 
the t(14;18)+  prediagnostic samples. In all cases, the same t(14;18) breakpoint was found before and 
after FL outcome, demonstrating that t(14;18)+ clones in blood from these healthy individuals 
constituted bona-fide precursors, subsequently progressing to FL. These findings were independent of 
frequency, as one of the precursor clones was detected in a case with a very low t(14;18) frequency 
(1/500.000 cells), and of time to diagnosis, which ranged from 4.9-10.6 years in the three participants 
with biopsy samples.  
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7.4 Discussion 
The strong association between FL and high frequencies of t(14;18) is well documented, and the 
presence at low frequency of t(14;18)+ clones in the blood from healthy individuals is equally well 
known 333,336,337,341. What is not understood is the relationship between the two and if, and how, those 
t(14;18)+ individuals who go on to develop FL can be distinguished from those who don’t. The 
timeline for disease progression still remains poorly characterized 341-343. However a recent report of 
synchronous FL development, occurring from the same t(14;18)+ precursor 9 years after bone marrow 
transplantation in both the donor and the recipient 343, demonstrated that commitment to malignant 
transformation can occur nearly a decade before disease onset.  
The literature suggests that this translocation may represent a useful biomarker in the study of NHL. 
The prospective design of the EPIC cohort provides a valuable opportunity to investigate the 
association of this chromosomal aberration with FL onset. In this study it was demonstrated that 
t(14;18)+ prevalence was significantly associated with future risk of FL in a cohort of people who 
were healthy at blood sampling, and that there is a  dose-dependent relationship between translocation 
frequency and risk.  These findings were used to identify a frequency threshold that had strong 
predictive ability in terms of specificity and positive predictive value, but that maintained reasonable 
sensitivity. The utility of this threshold was then confirmed in an independent cohort.  Above this 
threshold, t(14;18) frequencies reaching one in every 10,000 blood cells, a greater than 23-fold greater 
risk of FL was observed in this population.  
7.4.1 Assessment of t(14;18) threshold as a predictive biomarker of FL risk 
As discussed, the presence of the translocation is insufficient as a biomarker. Similarly a continuous 
frequency distribution is not appropriate for clinical usage and a cut-off point somewhere along this 
distribution must be chosen. This is by its nature somewhat abitrary, and indeed the investigated cut-
off points chosen here, were selected to be equally spaced throughout the distribution in this specific 
population. This raises questions regarding the validity of using these particular thresholds. Of the 
thresholds, one was then chosen as ‘optimal’ based on its ability to maximise the indices of interest in 
this population. These are discussed in more detail below. However, despite the arbitrary nature of the 
chosen threshold, it was possible to demonstrate that it performed equally well in an independent 
population.  
ROC curves 
In both the discovery and pooled cohorts AUCs in excess of 0.7 were observed with confidence 
intervals ranging from at least 0.65 at the lower bound to greater than 0.8 at the upper bound. As this 
constitutes the first predictive biomarker of FL there is no gold standard for comparison. However 
these AUCs would be ranked as fair to good under most commonly accepted definitions.   
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The ROC curves and corresponding AUCs were presented for  t(14;18)+ individuals, rather than for 
the total population to demonstrate what the specific frequency cut-off identified in this study 
provides in terms of predictive ability above and beyond classifying participants as positive or 
negative for the translocation. The odds ratios have also been presented for the t(14;18)+ individuals 
only as including t(14;18)-  individuals would inflate the effect estimates. Instead the presented effect 
estimate provides a conservative, but still strong, estimate of the association of this specific threshold 
with the outcome of interest.  
 
Sensitivity and Specificity 
Due to the heterogeneous nature of most cancers, it is unlikely a single biomarker will be able to 
detect all cases of a particular subtype with high sensitivity and specificity 344. There does exist a 
measure called the Youden index, which can be used to determine the point on the ROC curve that 
maximises both sensitivity and specificity. The drawback of this index is that it affords equal weight 
to sensitivity and specificity, which in a real world setting is rarely appropriate. Rather in most 
instances a trade off must be made between sensitivity and specificity, that is optimal for the usage of 
the that particular biomarker. In this study for the defined threshold, lower sensitivity is accepted as a 
trade-off for increased specificity. This is optimal for the potential usage of this biomarker, that is, to 
predict progression to disease in a target population with the aim of administering preventative 
therapy to those at highest risk. Although this biomarker performs poorly at predicting all cases of FL 
that eventually developed within these cohorts, with sensitivities in the two populations below 40%, it 
is very good at identifying a certain subgroup of those who will go on to develop disease. Furthermore 
its false-positive rate is extremely low, hence its high positive predictive value.   
 
Within a population-wide setting even a low false-positive rate would translate to vast numbers of 
wrongly diagnosed people. Given the monetary and emotional costs of chemotherapy, and the fact 
that there are other ways of diagnosing FL in its latent state, it is better to avoid unnecessary or 
overtreatment in individuals for whom there is a high degree of certainty they will not develop the 
disease.  Hence a high specificity was favoured.  
 
Bradford Hill Causation Criteria 
In terms of Bradford Hill’s causation criteria the biomarker performed well. A strong association that 
displayed a biological gradient was observed. This finding is coherent and consistent with the current 
literature and with independent analyses of different populations conducted in Bertrand Nadal’s lab.  
Additionally the nature of the nested case-control design allowed the determination of temporality of 
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association. It is known that t(14;18)+ prevalence is not specific, as these translocations have been 
observed both in other NHL subtypes  and more importantly in healthy individuals. Within this study 
the chosen frequency threshold showed specificity for FL development of 94% in the discovery 
cohort and 97% in the pooled cohort. Additional experiments in healthy populations and in those who 
go on to develop other malignancies associated with this translocation, such as DLBCL, would be 
necessary to further define the specificity of this threshold for risk of FL.  It should also be noted that 
the absence of specificity does not negate a causal relationship.  
Biological plausibility of the association has been discussed in detail. This is further strengthened by 
the finding that in three participants for whom post-diagnosis biopsy samples were available, the 
t(14;18)+ cells in the biopsy sample were clonally related to those in the prediagnostic blood sample in 
the same individual 332. Funding is available to collect biopsy samples from more of the included 
cases in order to expand upon these findings and offer further support. Negotiations with the sites to 
obtain these biopsies are ongoing. The fact progression to disease was observed in some people below 
the threshold may argue against plausibility, but it is not unsurprising, since it is known there are also 
a proportion of FL cases, who display only low frequencies of the translocation or lack it altogether. 
This may suggest differing pathways of development and favour further subdivision of the subtypes.  
Potential confounders such as age and country of residence were controlled for in this study – but the 
possibility that a further factor, such an environmental exposure may be causing both the clonal 
expansion of the translocation as well as lymphomagenesis through an unrelated mechanism cannot 
be ruled out.  What also remains to be fully determined is Bradford Hill’s eighth criteria ‘experiment’: 
whether the condition can be prevented or altered with intervention to the causal factor. Studies have 
shown decreasing frequencies of t(14;18) in some but not all patients following treatment with the 
drug Rituximab 345.  This needs to be further clarified but could potentially have a significant 
implication for usage of this biomarker.  
Venice-Criteria 
In terms of the Venice criteria, this biomarker would score well. Although a sample size of over 1000 
(cases and controls combined assuming a 1:1 ratio) is recommended to achieve large scale-evidence, 
this generally refers to genetic studies which have issues of power and multiple testing not relevant in 
this study of a single biomarker. Furthermore, although this represents the first prospective study, 
there is already a large amount of data confirming a strong association between t(14;18) frequency 
and FL.  
Almost uniquely, this biomarker has been replicated in an independent cohort. To date cancer 
biomarker research has been characterised by ‘inflated expectations, followed by disappointment 
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when the results cannot be reproduced’ 229. Within this study meta-analysis of the two independent 
cohorts found no significant heterogeneity.  
The third Venice Criteria is protection from bias. Bias was minimal in this study: the biomarker was 
measured in an objective manner using a recognised and proven screening assay in the same lab under 
the same conditions using prediagnostic blood samples.  All participants came from the same cohort 
and were healthy at recruitment. There is some potential for selection bias as participants were 
excluded on the basis of unavailable or poor DNA quality DNA samples, but this is unlikely to be 
related to disease status. Cases and controls were adjusted for potential confounding factors such as 
age which may be related to t(14;18) frequency and it can be concluded that bias is unlikely to be 
affecting the presence of an association, although it may have some effect on its magnitude 
7.4.2 Strengths and Limitations 
The main strength of this study, resides in its nested-case control design within an established cohort 
which allows the establishment of a temporal relationship and eliminates recall and selection bias. 
This design is in accordance with the PRoBE (prospective-specimen-collection-blinded-evaluation) 
design, which has been proposed to optimize the biomarker validation studies 346.  The cases and 
controls are from the same at-risk population and fulfil the same eligibility criteria.  
The ability to investigate t(14;18) frequency by time to diagnosis represents a further strength.  
Interestingly, no association between frequency and time to diagnosis was observed and it was 
determined that the threshold showed high predictive ability both close to and up to 15 years before 
diagnosis. This is particularly important for translation to a clinical setting 344. The main limitation of 
this study, when considering the usage of a biomarker in a population-wide setting, is its relatively 
small sample size which led to wide confidence intervals and a consequent lack of precision in the 
estimates of effect size. Further the European Caucasian population may limit its wider 
generalizability and external validity.    However, as discussed in the results section, the baseline 
characteristics were in keeping with what may be expected in terms of gender and age at diagnosis. 
Furthermore it is of note that the findings were replicated in an independent, geographically distinct 
cohort. 
The lack of information on grade of disease represents a limitation that may be particularly important 
in the context of FL. A close relationship between grade 3 FLs and progression to the more aggressive 
DLBCL lymphoma has been observed 340, while it has been noted that the prevalence of the 
translocation may be uncommon among such high grade cases 17 . This would have important 
implications for the clinical relevance of this biomarker.  
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7.4.3 Clinical utility 
Based on these performance indices, the translation of the biomarker into clinical practice can be 
considered. The ultimate goal of biomarker discovery is to create a predictive model with optimal 
sensitivity and specificity that can be utilized in clinical practice, most commonly in the form of a 
screening test. The criteria for a useful screening test are outlined in the methods section 3.5 and 
appendix box 3.5. This biomarker would perform well against a number of these criteria including the 
testing method; translocation frequency is detectable in blood using a simple, reproducible, low-cost 
assay. 
However, any screening test for FL would fail to meet all these criteria, particularly those regarding 
the disease itself. The natural history is not well understood and although NHL as a collective group 
represent an important health problem, the relative risk of FL remains low and population wide-
screening would not be cost-effective. Furthermore, despite the advent of effective therapies which 
have significantly improved clinical outcome, FL remains incurable and patients continue to die from 
the disease following resistance to treatments or transformation into a more aggressive DLBCL 347. 
When considering the economics of the potential clinical translocation of this biomarker it must also 
be noted that, in comparison to many malignancies, the survival estimates for FL are good. For those 
with limited disease median survival is 19 years, and up to 80% of FL cases survive for ten years or 
more 340. Nevertheless, the majority of cases have advanced disease at diagnosis, and as mentioned FL 
often transforms into the more lethal DLBCL 340, meaning that there is an argument for investing in 
early detection. 
 
The findings suggest that this biomarker could be considered a pre-disease condition analogous to 
monoclonal B-cell lymphocytosis, which has been shown to be a precursor for CLL 348, or 
monoclonal gammopathy of undetermined significance which is a precursor for MM 349. The 
identification of such a condition would enable the identification of high risk groups for monitoring. It 
has also been suggested that such in situ disease can be used as an intermediate outcome to increase 
sample size in future studies 
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7.4.4 Biomarker as a tool for understanding biological processes  
One of the major failings of this biomarker as a clinical tool is that, as observed in this cohort, a large 
proportion of individuals who will develop FL do not display elevated t(14;18) levels before FL onset, 
and thus cannot be detected. This ‘failing’ in fact suggests two possible diverse pathways of 
lymphomageneis in FL: one in which progression to FL systematically occurs from clonally-related 
t(14;18)+ bona fide lymphoma precursors (as confirmed in the study of prediagnostic/tumour sample 
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pairs, details in 332), and one in which there is no clonal expansion of this precursor, or it is absent 
altogether. The literature support the existence of different molecular subtypes 350, and the utility of 
this biomarker may lie in its ability to distinguish between these two forms of FL. In other words it 
can be argued that this biomarker does not predict risk of FL, but rather predicts risk of a certain 
subset of FL associated with a very high frequency of t(14;18) and which may be aetiologically, 
clinically, pathologically and genetically different from other FL subtypes. This adds further support 
for calls in the literature to reclassify FL based on translocation status as more clinical, 
epidemiological and genetic data become available 17.   
 
Alternatively the findings may suggest a greater than previously suspected role for alternative BCL2 
breakpoints in aetiology. Among the t(14;18)- participants who went on to develop FL, to exclude the 
possibility that they represented false-negatives, a refined nested PCR assay was run to screen for 
three additional breakpoint clusters in a subset of participants  (details in 332). These alternative 
breakpoints are each involved in <10% of FL cases and together with the initial screen cover ~70% of 
BCL2 breakpoints 350,351.  Among 30 screened t(14;18)- EPIC participants who subsequently 
developed FL, 4 were identified with alternative BCL2/JH translocations (two mcr/JH and two 
3’MBR/JH) and frequency distributions similar to cases with MBR/JH junctions.   
Either way, the identification of committed FL precursors in prediagnostic blood samples suggests a 
mechanistic continuum between pre-clinical and clinical phases of FL progression in t(14;18) 
associated lymphomagenesis 352. The identification of these cells is the first step in their isolation and 
geno-phenotypic characterisation. This will provide important insights into the factors driving FL 
progression 353,354, suggest future therapeutic avenues, and help to target the identification of future 
biomarkers which could be utilized together with this frequency threshold in a multivariate model.  
This finding is important in the wider field of biomarker discovery. It has recently been stated that 
current design of using diagnostic samples for discovery and then attempting to validate the findings 
in prediagnostic samples, has been unsuccessful and that such markers have little value for early 
detection 355. Here, the findings from numerous case-control studies of translocations and NHL were 
validated using a cohort design, suggesting that this method can be successful and potentially paving 
the way for future similar studies. 
7.4.5 Conclusion  
In conclusion there is a strong association between the defined t(14;18) frequency threshold (>1x10-4) 
and risk of FL, which is apparent up to 15 years before diagnosis.  Crucially these findings have been 
validated in an independent cohort, achieving consistent results. In this way this threshold fulfils most 
of the ‘Rules of Evidence’ for molecular markers proposed by Ransohoff 229. Although tailored to 
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high through-put discovery based –omics studies, these rules can also be considered in the context of 
this study. The investigation of a single biomarker is free-from many of the problems of an –omics 
based approach, most notably the dangers of overfitting and multiple testing. However by validating 
the findings in an independent cohort, the possibility of such issues influencing the results have been 
eliminated anyway. Similarly, the possibility of residual bias and confounding is minimised meeting 
two more of Ransohoff’ rules. Although generalisability is an important issue, sufficient evidence is 
presented to warrant the further investigation of this biomarker in larger and more diverse 
populations. 
Ransohoff’s final rules pertain to clinical usefulness in terms of benefit, harm, cost and effort 229.  Due 
to the relatively low prevalence of FL in the population and the lack of effective preventative or 
curative therapies for those in whom FL could be predicted there is currently no direct clinical 
application for such a biomarker.  
The biomarker is useful in a number of other ways. First it provides information on mechanisms of 
lymphomagenesis. Second, given its known association with a number of risk factors, it can help to 
establish or refute their causal relationship with NHL. Smoking 148, UV radiation 356 and exposure to 
both pesticides and dioxins 357 have all been associated with translocation frequency or prevalence. If 
such associations can be established, then this biomarker may be of use in a screening capacity in high 
risk exposed populations, such as farmers working with certain pesticides. Third, it may represent a 
precursor condition that can be managed accordingly. Finally it may provide further insights to enable 
the division of FL into more appropriate subtypes.  It could build upon the proposed subdivision 
between t(14;18)+ and t(14;18)- 334, introducing a further group:  t(14;18)HF(high frequency), which may 
more accurately allow the discrimination of committed precursors from otherwise inoffensive 
t(14;18)+ clones. Given the lack of rationale for population wide screening for FL such insights into 
etiology and mechanisms are arguably more useful than prediction in this instance. As such this 
frequency threshold can be described as a useful biomarker of early biological effect.  
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PART 2: INTEGRATING BIOMARKERS 
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8. INTEGRATING BIOMARKERS: THE “MEET-IN-
THE-MIDDLE”APPROACH 
POPULATION: B-cell NHL cases and controls from the EnviroGenoMarkers Study 
8.1 Introduction 
One way of integrating biomarkers is to use the MITM approach. This concept relies on two important 
findings that have emerged from the development of the field of molecular epidemiology. First, the 
fact that exposure to certain pollutants can be directly correlated to biomarkers of biologically 
effective dose and early biological effect 7. For example styrene and DNA adducts 358. Second, that 
cancer risk has been associated with the levels of such biomarkers 359. Therefore, the identification of 
elevated biomarkers levels both in those who are exposed to certain pollutants and in those who 
develop disease has the two-fold benefit of strengthening the causal link with the exposure, while also 
providing information on the causal pathway and the potential mechanisms through which this 
exposure may be acting 7.  
The application of this theory to NHL is problematic as biomarkers related to exposure and those 
related to disease tend to have been studied separately (see chapter one; Introduction). More 
importantly, none of the biomarkers identified to-date are specific to either NHL (with the possible 
exception of the translocation threshold) or its putative risk factors, making the definition of a causal 
pathway difficult. The aim of the MITM approach is to search on the same human biosample (i)- 
prospectively for biomarkers of past environmental exposures, and (ii)- retrospectively for biomarkers 
associated with future disease risk. 
Figure 8.1 Schematic describing the “meet-in-the-middle” approach for molecular epidemiology 
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In this way the MITM approach can identify intermediate biomarkers that lie along the causal pathway 
7 i.e. a biomarker from any of the categories falling between exposure to a risk factor and disease as 
outlined in figure 1 (chapter 1). Here this principle is applied to the metabolite profiles from the EGM 
study in order to search for intermediate biomarkers associated with both environmental pollutants 
and with NHL (figure 8.1).  
Omics are particularly well suited to this approach as their methods are hypothesis-free and they allow 
biological and mechanistic interpretation. This allows for the identification of novel candidates that do 
not necessarily have a biologically plausible  a priori relationship 7. There is a particularly  strong 
rationale for the link between a metabolite profile and disease (see chapter 6) 310, and there is  wealth 
of data in preclinical models that demonstrate the effect of exogenous exposures on metabolite levels 
320. Furthermore the concept has already been shown to provide very promising results in a 
metabolomics profiling study of dietary fibre intake and risk of colon cancer 224.  
This chapter represents the first study to report on metabolomics profiles following exposure to PCBs. 
The results are of particular interest, given the number of unexpected inverse associations reported in 
chapter 5 for these pollutants with risk of NHL. 
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8.2 Methods 
8.2.1 Study subjects, exposure assessment and metabolite profiling 
This chapter is based on the same EGM discovery and validation cohorts described in chapter 6 (table 
3.1.2c, appendix table 6.3.1). All participants had information on the body burden of six PCB 
congeners, DDE, DDT, HCB, BDE-47, Cd and Pb, as described in methods 3.2.1. Metabolomic 
profiling of cases and controls was performed as described in methods 3.2.2 and chapter 6.  
8.2.2 Disease vs. metabolite profile 
The identification of individual metabolites and metabolite profiles associated with NHL is described 
in chapter 6.  
8.2.3 Exposure vs. metabolite profile 
Linear regression was used to assess the relationship between log-transformed exposure levels and 
metabolite intensities in the discovery cohort. The model was adjusted for the EGM matching factors: 
age, sex, phase, as well as metabolite batch (matched pairs underwent profiling in the same batch) and 
fasting status (>95% cases had the same fasting status as their matched control). 
8.2.4 Identification of potential MITM candidates 
The parallel analyses conducted in 8.2.2 and 8.2.3 resulted in two lists of the metabolite features most 
strongly associated with disease risk and exposure concentration, respectively. These features were 
selected on the basis of their strength of association (as measured by their p-value) and cut-off was 
arbitrarily set to 0.05. The resulting lists were subsequently considered as potential MITM biomarkers. 
Biological plausibility was explored by considering the direction of effect. Validation of the 
candidates was attempted by replicating the findings in EPIC-Italy. 
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8.3 Results 
8.3.1 Disease vs. metabolite profile 
Within the discovery cohort, six potentially predictive metabolite sets were selected, representing a 
total of 90 different metabolite features (chapter 6, results and appendix 6.3.3). Of these, 60 were 
unique to the total population (models 1-5), 22 were unique to the ttd <5 years subpopulation (model 
6), and 8 overlapping features were found irrespective of the model used. The candidates from models 
1-5 and from model 6 will be considered separately.  
8.3.2 Exposure vs. metabolite profile 
In keeping with previous analyses, metabolite features with a CV>30% in either the discovery or the 
validation cohorts were excluded, as were exposures with >10% of samples below the LOQ. 
Consequently, 750 metabolite features and 10 exposures were included in the analyses. The 
associations between the POPs, PCBs and metals with metabolite features are summarised in figure 
8.3.2. At the stringent Bonferroni level, a large number of associations were observed for the more 
highly chlorinated PCB congeners and for HCB, which is also highly chlorinated. Fewer associations 
were found for metals and DDE. Figure 8.3.2 plots the correlation between the p-values obtained for 
each exposure-metabolite feature combination. It shows clear clustering across both metals as 
compared to the POPs, and a cluster among PCB170, 180 and 156 within the POPs. There is also 
evidence of clustering by metabolite feature suggesting the existence of related features.  
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Figure 8.3.2: Associations between measured body burden of six PCB congeners, HCB, DDE, 
Cadmium and Lead with intensity levels of 750 metabolite features in the discovery cohort 
according to significance level 
Significance was computed using univariate linear regression for each exposure-metabolite pair. In the heat 
map the p-value for every exposure-metabolite association is presented coloured according to p-value (see 
colour key) the y-axis dendogram shows the clustering between the exposures and the x-axis dendogram the 
clustering between metabolite features. The metabolite feature names are represented along the bottom x-axis 
 
 
 
 
 
 
 
p-value 
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8.3.3 Potential “Meet-in-the-Middle” Candidates 
Figure 8.3.3a shows the effect size estimate as a function of the p-value for each of the 90 disease-
related metabolite features defined in section 8.3.1. All PCBs showed high numbers of low p-value 
associations, particularly PCB153, 156, 170 and 180 which also tended to show the stronger effect 
sizes. HCB was again observed to show similar results to these more highly chlorinated congeners, 
whilst very few associations were noted for DDE.  
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Figure 8.3.3a: Association between exposure and metabolite feature intensity for 90 metabolite 
features identified as being associated with NHL 
The β coefficients and p-values from the linear regression model are plotted to determine the strength and the 
significance of the association. The dashed red line indicates a p-value of 0.05. The 90 features were identified 
as being associated with disease risk in chapter six. They are plotted as different series depending on which 
disease-metabolite model they were originally identified in. full details of these models are given in appendix 
table 6.3.3) 
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Figure 8.3.3a continued 
 
To explore these results further, the direction of effect was determined for those metabolites found to 
be associated with the investigated pollutants and with disease (table 8.3.3). The β coefficients and p-
values from the linear regression model for each of the 90 features are plotted. This provides a 
measure of the correlation between features intensity and pollutant concentration. Interestingly for the 
POPs, the intensity levels of all the MITM candidates were positively associated with both exposure 
and disease. For the heavy metals, intensity was negatively associated with exposure levels but 
positively associated with disease risk. There was a strong overlap between the candidates found for 
POPs and between the metals. In total, 62 different metabolite features can be considered as potential 
MITM candidates: 46 that were unique to the pooled population, 11 that were unique to the ttd<5 
years subpopulation, and five that were common to both.   
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Table 8.3.3 Direction of the association with exposure concentration and with disease risk for 
the metabolite features identified as potential MITM middle candidates  
Feature-disease associations selected in models 1-5 (associated (p<0.05) with disease in the total 
population) and model 6 (associated with disease in ttd<5 years) were considered separately. The 
MITM candidates were stratified into (i) those for which feature intensity was positively associated 
with disease and with exposure to the investigated pollutant (ii) those for which feature intensity was 
negatively associated with disease and with exposure to the investigated pollutant and (iii) where 
direction of effect was discordant between exposure and disease 
Model Exposure 
n. metabolite features associated with disease and exposure 
Total 
(i) Positive association 
with disease and 
exposure 
(ii) Negative 
association with 
disease and exposure 
(iii) Discordant 
direction of 
effect 
 
1- 5  
(associated 
with disease in 
total 
population) 
 
PCB118 23 23 0 0 
PCB138 24 24 0 0 
PCB153 45 45 0 0 
PCB156 46 46 0 0 
PCB170 43 43 0 0 
PCB180 47 47 0 0 
HCB 28 28 0 0 
DDE 6 6 0 0 
Cadmium 6 0 0 6 
Lead 0 0 0 0 
      6 
(associated 
with disease in 
those 
diagnosed 
within 5 years 
of blood draw) 
PCB118 3 3 0 0 
PCB138 4 4 0 0 
PCB153 12 12 0 0 
PCB156 12 12 0 0 
PCB170 10 10 0 0 
PCB180 12 12 0 0 
HCB 7 7 0 0 
DDE 1 1 0 0 
Cadmium 5 0 0 5 
Lead 2 0 0 2 
One feature EPIC_NSHDS_244 was excluded from the model because the direction of effect with NHL was discordant among models 1-5 
 
For these 62 features, for validation purposes, the analyses were repeated in EPIC-Italy. It comprised 
a much smaller sample size, and there were fewer significant associations for all the exposures. 
Specifically, none reached the Bonferroni threshold (appendix figure 8.3.3), as detailed in chapter six, 
and there was no overlap with the NSHDS results.  Due to this, the replication criteria were loosened, 
and only the direction of effect (both with the exposure and disease) considered as an indication of 
consistency across both populations. These consistent features are listed in Figure 8.3.3b. For clarity, 
and due to the strong overlap in results across PCBs, these were considered as a single group. All 
POPS (PCBs, DDE, HCB) and metals were considered as two further groups. The largest number of 
potential candidates (n=9) are for the putative relationship between PCBs and NHL. This figure 
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indicates that increased intensity for the features is associated with both higher levels of PCBs and an 
increased risk of future disease. For the metals the results suggest that increased intensity is associated 
with a decreased metal erythrocyte concentration, but an increased risk of future disease.   
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Figure 8.3.3b: Metabolite features identified as potential “Meet-in-the-Middle” Candidates in the Discovery Cohort and which could be Validated in 
EPIC cohort 
 
For the total model only cadmium is included as there were no candidates associated with lead and disease 
None of the associations were significant in EPIC-Italy ‘validation’ was based on concordance of direction of effect
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8.4 Discussion 
Introduction 
Metabolite profiles can reasonably be considered as either biomarkers of biologically effective dose or 
of early biological effect relating to certain exposures or to particular diseases, depending on the 
particular metabolites observed 224. As such, these profiles may provide candidates for intermediate 
biomarkers lying on the causal pathway between the exposure and disease that could inform on 
mechanisms.  Here this “meet-in-the-middle” approach has been applied to the previously explored 
PCB/POP/metal relationship with NHL (chapter 5) to determine if it can gain biological/mechanistic 
information on these results, and potentially draw conclusions on putative casual pathways.  
 
MITM candidates 
The metabolite profiles showing the strongest association with future risk of NHL risk were presented 
in chapter six. These findings lacked replication and the significance levels were not sufficiently 
strong to rule out false-positive findings. It was speculated that this failure to identify definitive 
associations may relate to the time-lag between blood draw and disease diagnosis, and stronger 
findings were observed in the population restricted to those diagnosed closer to blood draw. 
Accordingly, a much larger number of associations were observed for the exposure-metabolite 
relationships, even using stringent multiple testing correction strategies.  This was to be expected, 
given that the exposure levels and the metabolite profile represent the same time frame, and the 
metabolome is known to reflect current experience. There was high concordance between the PCBs in 
terms of the metabolite feature associations, and for PCB170 and 180 an almost identical set were 
selected.  Fewer associations were noted for the metals, possibly suggesting that they interact with 
metabolism to a lesser extent (or through a more complex mechanism) than the organochlorines. 
There was an overlap of 62 biomarker features (table 8.3.3) that were associated with both exposure 
to one the investigated pollutants and disease. Of these, 15 features were considered to be validated in 
EPIC-Italy (11 from total population and 4 from ttd<5 yrs) using a loose criterion (due to the smaller 
sample size in EPIC-Italy). Although, this represents less than half, potential biological plausibility is 
strengthened by the fact that there were clear differences between the PCBs as compared to the 
metals. In summary, the results suggested that increased POP (PCBs, HCB, DDE) exposure levels 
were associated with an increased intensity of metabolite features that were also associated with an 
increased risk of disease. Conversely, an increased body burden of Cd and Pb appeared to be 
associated with decreased intensity in NHL associated metabolite features.  
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The causal pathway 
These results are intriguing given the findings reported in Chapter 5. There was no evidence of a 
positive association between exposure and disease, and for PCBs, some evidence of an inverse 
association was observed. Therefore the positive associations between the ‘MITM candidates’ with 
both exposure and disease seem somewhat counter-intuitive. There are a number of possible 
explanations for these findings: 
 Either the metabolite-disease or the metabolite-exposure relationships represent chance 
associations.  
 The disease associated metabolite profiles may be associated with another unmeasured NHL 
risk factor rather than exposure to environmental pollutants.  
 The exposure-associated metabolite profiles could relate to a different health outcome not 
investigated here (or not to any outcome at all). 
 There is no association between POPs and NHL, and the apparent disease-metabolite 
relationship may actually result from confounding by a further factor associated with both 
POPs and disease which may be reflected in the metabolome 
 There is a strong positive association between POPs and NHL, but this was not identified in 
chapter 5 because body burden is a sub-optimal measure of exposure history. Changes to the 
metabolome are more sensitive to the effects of PCBs, so can act as an intermediate step 
linking them to the disease. This would be supported by the body of literature which has 
reported a positive association between PCBs and risk of NHL.  
 The inverse association with metals could be explained if the observed metabolite profiles 
represent early stages in the causal pathway. Metal exposure may, through interaction or 
negative feedback, lead to an up regulation of later stage biomarkers, which are associated 
with an increased risk of disease.  
To determine which, if any, of these hypotheses may explain the results, annotation of the metabolite 
features is required in order to identify the pathways and mechanisms involved.  
Potential mechanisms 
A number of studies have investigated metabolic profiles following PCB exposure in animal models 
360,361. Lipid metabolism has been shown to be particularly affected with lysophosphatidylcholine 
(16:0), tyrosine, PC(18:4/18:1) and lysoPE(18:2/0:0), all found to be significantly altered. Tryptophan 
metabolism and phenylalanine metabolism are also thought to be affected and interestingly sex-
specific differences in results have been noted. This is the first study to consider perturbations to the 
metabolome with PCB exposure in humans and the first in any medium for HCB and DDE. A recent 
publication has reported that the early effects of Cd exposure in humans can be detected by metabolic 
profiling using NMR and urine samples 362. They found a positive association between citrate levels 
and Cd exposure but an inverse association with 3-hydroxyisovalerate, dimethylglycine, creatinine, 
creatine and 4-deoxy-erythronic acid, which may be of particular interest. Animal studies of the 
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metabolite profiles following Cd exposure have reported a role for carboxylic acids, amines, sulfated 
compounds, glucuronides, and glycosides in addition to citrate 363.  Encouragingly, a number of the 
pathways in which these metabolites are involved have been previously implicated in NHL and other 
haematological malignancies 364-366. Therefore, if such metabolites were included in the annotated 
findings this would considerably strengthen the evidence for a relationship with disease.  
 
Strengths and limitations 
Currently the biological pathways relating to these results can only be speculated upon. As in chapter 
six, the lack of annotation, represents a significant limitation of this study. This study was also limited 
by the factors stated in chapter five relating to the reliance on a single spot measure as an assessment 
of body burden. This is even more pertinent in this context as the metabolome is also known to 
fluctuate over time, suggesting this study could be considerably improved by the use of repeat 
measurements 7. Only classical, rather than multivariate projection methods such as PLS were utilised 
in this study. This strategy was chosen is in accordance with the previous MITM colon cancer study 
224, and to allow for the easy and intuitive adjustment of matching factors.  
 
Subtype heterogeneity was not assessed in this chapter despite the fact that, as discussed in chapter 
six, metabolite profiles may be subtype specific. This issue is magnified with the use of the ‘meet-in-
the-middle’ approach, as the potential for the association between the disease and the exposure to also 
vary by subtype was observed in chapter five.  Nevertheless, this study was underpowered to run 
subtype specific analyses and therefore, given a lack of association between the exposure and the 
disease had already been demonstrated; these analyses were conducted as a proof of principal of the 
approach. 
 
There were also a number of strengths specific to this study, mainly stemming from its novelty, and 
the variety of pollutants included. This generated particularly interesting findings regarding the 
differences in the metabolomics profile with exposure to POPs compared to metals. The clustering of 
PCBs by degrees of chlorination and the similarity of findings for HCB with the lower chlorinated 
congeners are also of interest. This study additionally overcomes one of the challenges discussed in 
the introduction regarding the identification of NHL biomarkers, as it links the risk factor and the 
disease to potential intermediate biomarkers on the same biosample.  Further, the prospective design 
allows the assessment of both the POPs and the metabolite profile free from the influence of inherent 
metabolic changes due to the disease itself 224. Unlike in studies observing positive associations 
between PCBs and NHL 249, it was not possible to adjust on lipids in EGM. Since these studies 
indicated lipid metabolism was affected by PCB exposure 360,361, it may be worthy of further 
exploration within EGM. Finally, given that metabolomics has been stated to be at a developmental 
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stage with respect to cancer epidemiology, with the majority of studies including <100 patients 307, 
this analysis represents one of the largest to-date. 
As discussed in chapters five and six, the generalisability of this population must be considered in the 
analysis of these findings. Given that the source of exposure to POPs and metals are likely to vary 
between populations and by geography, the excess of Swedish participants in this population must be 
taken into account. This is especially pertinent as a strong division by geographical cohort was 
observed in the PCA analysis in chapter six.  
Biomarker utility 
There is little clinical or predictive utility that can be garnered from this study. However the 
preliminary findings suggest that metabolite profiles may represent useful biomarkers to assess 
exposure to or experience of suggested NHL risk factors. This rests on the association between 
disease and the risk factor. If true, this indicates that the methods used in chapter five were inadequate 
to assess lifetime exposure such as would be expected to increase NHL risk. It may be that the 
metabolome provides a better measure.   
If the exposure-metabolite profile associations are assumed to be true then the metabolome would 
fulfil a substantial proportion of criteria for a ‘good’ biomarker, including importantly replication in 
an independent cohort. Despite the high correlation between the PCBs the differences between the 
similar structural groups, such as the more highly chlorinated PCB congeners as well as the metals, 
suggests some specificity. There is also coherence with existing knowledge in terms of the well-
known perturbations to metabolite profiles caused by exogenous exposures. The most common use of 
metabolomics to date has probably been in the field of toxicology. Consequently in future analyses it 
would be of interest to attempt building predictive exposure models similar to those illustrated in 
chapter six. These may have utility as biomarkers in biomonitoring studies or environmental risk 
assessment 367. 
Regarding the other biomarker criteria, coherence cannot be considered until the annotations are 
complete, and this will also inform on biological plausibility. Bias cannot be ruled out for the 
exposure-metabolite associations, only the matching factors have been adjusted for, although an 
attempt has been made to control for laboratory or sample induced ‘nuisance variation’ by adjusting 
on processing batch and fasting status.  If lipid adjustment was in some way biasing the results 
between PCBs and disease, it may also be expected to affect the association between PCBs and 
metabolite profiles. Furthermore, as with the subtypes-specific analyses, sex-stratified analyses were 
not run to retain power, to avoid issues of multiple testing and because, these analyses were conducted 
as a proof of principal.  However, the results of chapter five suggest sex-stratified analyses may be of 
interest, as do the findings from the metabolomics and PCB exposure studies in animal models 360,361.   
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Nevertheless there is sufficient evidence to warrant the further exploration of the highlighted 
candidates as a means of gaining a better biological understanding of both PCB exposure and 
lymphomagenesis, and the potential relationship between them. In this way, the MITM approach 
provides a promising strategy to which the agnostic –omics methodology, which is able to 
simultaneously and objectively measure many hundreds of potential biomarkers, is particularly well 
suited.  These biomarkers can then be considered as a profile or set, allowing better consideration of 
pathways than is available with the more traditionally employed exploration of single biomarkers. 
Finally these profiles may represent any stage of disease pathogenesis 367. If intervention is the goal 
then it may be of more interest to search for biomarkers in those diagnosed more than five years after 
blood draw, as these will have the potential to represent early stage disease biomarkers. This was not 
possible here as very few features were identified for the ttd>5 years group and none were validated 
as MITM candidates.  
Conclusions 
This is the first study to attempt to gain insight into the biology underlying suspected relationship 
between POPs and NHL through the identification of intermediate biomarkers in the potential causal 
pathway using the MITM approach. This was a hypothesis-generating study and these primary results, 
once annotated and validated in a new dataset, will provide the starting point for future analyses.  
Metabolomic profiles are particularly useful as they directly mirror a cell’s function 307 and 
consequently provide considerable insight into dysregulated metabolic pathways, inherent disease 
development, and pathophysiological alterations caused by external stressors 367. Therefore, it was 
hypothesised metabolomics may provide a rich resource for biomarkers lying between a risk factor 
and disease. The benefits of identifying such biomarkers would be three-fold: the identification of 
biomarkers of (i)- POPs, (ii)- and of NHL, and (iii)- the improved characterisation of their uncertain 
association. Based on these results, the strongest utility for metabolic profiling in this context 
probably lies in the first of these three. While these results are only suggestive, the number of 
common metabolites between the PCBs, POPs and the metals, also suggest potential common 
pathways associated with exposure that are worthy of further investigation. Although not conclusive, 
the results do go some way to providing a more comprehensive understanding of the pathways of 
NHL.  A number of MITM biomarkers have been identified, however whether they belong to the 
causal pathway between exposure and disease can only be determined with further studies.  
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9 DISCUSSION 
B-cell Non-Hodgkin lymphomas represent the most frequent hematopoietic cancers of adulthood, and 
an increase in incidence has been reported in most countries during the past 30 years, which is now 
beginning to abate. Although a proportion of this increase can be attributed to changes in 
classification and reporting of NHL within this time period, the evidence suggests these findings 
represent more than a mere data artefact. However, the risk factors driving the incidence trend of 
NHL over the last decades remain elusive and the mechanisms of malignancy poorly understood. The 
more that is known about this malignancy, the greater the importance of subtype heterogeneity is 
revealed to be, further complicating its study. The aim of this thesis was to identify novel biomarkers 
of the pathways of lymphomagenesis which could provide further insights into the aetiology of NHL. 
The generation of such biomarkers could have multi-faceted benefits for research including: improved 
risk factor assessment, determination of biologically important dosage of exposure, identification of 
individuals at high risk, and improved mechanistic insights into the lymphomagenesis pathway. This 
would subsequently impart translational potential to provide novel targets for prediction, prevention 
and therapy, and ultimately to advance the control of NHL.  
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9.1 Rationale and Aims 
The rationale behind these aims was that novel approaches for the study of both NHL risk factors and 
NHL biomarkers were required, necessary as a means to try and address the relative lack of success 
achieved with the currently adopted strategies, as discussed in the introduction. As well as to further 
inform on the reported increases in NHL incidence over the previous decades. It has been stated that 
only if the underlying disease patterns are understood can hypotheses regarding aetiology and 
pathogenesis be accurately tested 15.  
 
The thesis was split into two parts, the first of which investigated and attempted to validate four 
different types of biomarkers occurring at different stages along the causal pathway: biomarkers of 
susceptibility, internal dose, biologically effective dose and early biological effect. These were chosen 
on the basis of a known or suspected relationship with NHL. In the second part of the thesis the 
additional utility which could be conferred by integrating different biomarker types using the MITM 
approach was explored.  The included population was based on a number of different studies which 
contained a subpopulation of EPIC NHL cases and controls. Not all EPIC NHL cases were included 
in the thesis, although exploration of the various subpopulations in each chapter suggested they were 
representative of EPIC overall. As the original projects for which these subpopulations were selected  
were not planned around the aims of this thesis there were some sample size limitations. 
Consequently a largely hypothesis-free approach was taken to determine the potential role of the 
biomarkers in NHL research and the feasibility of integrating them.  
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9.2 Summary of findings  
This thesis employed novel techniques and methods and represents a number of firsts in the study of 
NHL. These include the potential causal relationship with Cd and Pb exposure and the determination 
of the predictive ability of metabolomic profiles in prediagnostic blood samples. It is additionally the 
first to determine a predictive threshold for the t(14;18) translocation in Follicular lymphoma risk. 
Finally it is among the initial few studies considering the use of the ‘meet-in-the-middle’ approach and 
the utility of profile regression for GWAS data in any malignancy. The findings have been discussed 
in detail in the relevant chapters and are summarised below.  
Biomarkers of susceptibility to NHL were explored using EPIC NHL cases and controls, genotyped as 
part of the InterLymph NHL GWAS consortium, which has reported exciting findings and novel 
susceptibility loci for a number of NHL subtypes, including those involved in apoptosis with CLL 87. 
These findings were not replicated in the EPIC subpopulation, nor were any novel genetic variants 
identified. However this was not unexpected and it can be concluded that this was a function of a 
sample size rather than the novel statistical methodology, profile regression, which was used. In fact 
profile regression was found to outperform the conventional association analyses in terms of 
predictive ability in this population, and there was some weak evidence for the identification of 
biologically plausible genes such as DAPK1. These findings are therefore supportive of the benefits of 
this methodology for analysing highly dimensional, complex data 164, and pave the way for future 
studies.  
 
Prediagnostic concentrations of PCBs, POPs and metals were considered as biomarkers of exposure. 
Intriguing results regarding the role of gender and obesity, and for the DLBCL subtype are worthy of 
exploration in future studies. However, overall the evidence suggested a null association between 
POPs and NHL, reflecting the ambiguity in the existing literature. A possible explanation for the null 
findings with POPs, metals and NHL risk may be that the blood measures used do not accurately 
reflect long-term exposure. There was some support for this theory on the basis of the metabolomics 
results, and the findings indicate that metabolomic profiles may be a useful method of exposure 
assessment or environmental monitoring. The tentative evidence that metabolomics may additionally 
have a role in disease prediction means that a metabolic profile can reasonably be considered as an 
intermediate biomarker along the causal pathway between risk factors and disease, using the theory of 
the MITM approach. In general the metabolomics results were promising. Within the discovery cohort 
there was evidence of biological plausibility for an association with disease risk including dose-
response, robustness to adjustment for confounding, and the fact that the strongest associations were 
identified in those diagnosed closest to blood draw.  It was not possible to replicate these findings in a 
validation cohort, although this may relate to underlying differences between the cohorts primarily 
due to anti-coagulant induced bias. Conversely for the POPs analysis coherence of results between 
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structurally similar pollutants supported biological plausibility and a large number of findings were 
replicated.  
Finally the most compelling results were those related to frequency of the t(14;18) translocation as a 
biomarker of risk for FL. The strength, and crucially the replication, of this finding suggests an 
exciting potential for eventual translation into a predictive methodology. Consequently a patent based 
on these results has been applied for.   
9.2.1 t(14;18) frequency as a candidate biomarker for risk prediction  
The ultimate goal of biomarker discovery is the translation into a clinical setting. The most likely 
candidate in this study is the t(14;18) translocation. The results suggest that the identified high 
frequency threshold actually represents a previously unknown pre-disease state that will progress into 
overt malignancy. This would comprise the third such condition for NHL after chronic lymphocytic 
leukaemia/monoclonal B-cell lymphocytosis (CLL/MBL), and multiple myeloma/monoclonal 
gammopathy of undetermined significance (MM/MGUS) 348,349. Both MBL and MGUS have been 
found to confer significant benefit in the identification of patients at high risk of CLL and MM, 
respectively, who can then be managed accordingly 368-370. It can be hoped that as the first example of 
a pre-disease condition for FL, it may confer similar utility in the management of this subtype. 
Alternatively it may allow further subdivision of FL on the basis of t(14;18) frequency, which could 
ultimately prove useful in determining aetiology or clinical management. However, any application of 
this biomarker can only be speculated at presently. Further studies in larger and more diverse 
populations and with additional validation are needed before any kind of clinical translation can be 
considered.  
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9.3 Strengths and Weaknesses 
Some caution must be applied when considering the findings in this thesis, due to the limitations 
discussed in the relevant chapters, which stem mainly from sample size.  Power was computed at the 
outset of the EGM study, although the strength of the emerging findings now suggest the sample size 
chosen may have been insufficient. For this reason, and due to the hypothesis generating nature of this 
thesis, power has not been calculated here for the individual chapters.  The power of the individual 
analyses was further limited where subtype-specific analyses were conducted. In fact, subtype 
heterogeneity represents an important limitation of any study considering NHL as a group. This is 
discussed further in section 9.5 below.  
 
There were a number of other limitations, misclassification of disease or subtype status can often 
represent a significant issue in studies of NHL. This can be a particular problem in prospective 
cohorts which encompass a number of the different classification systems used over the years 26, 
however within the EPIC cohort procedures have been implemented to address this 215. With regards 
to the EPIC NHL data, there was a lack of information on grading and staging of disease with only 
21% of cases having this information available, and no information on family history. However the 
fact that this population arose from a large well-characterised cohort with inbuilt quality control, 
calibration and validation procedures represents one of the major strengths of this thesis and 
minimises many of the potential problems inherent in epidemiological studies.   
 
As a cohort study the baseline characteristics of the participants are free of the recall bias which has 
plagued many of the case-control studies comprising the majority of the epidemiological literature for 
NHL. Nevertheless although the information was collected at baseline, it still relies on self-reported 
data. In fact, as discussed, the inconsistencies in the NHL literature may well arise from the inaccurate 
measurement of many risk factors which have been based on self-reported data. In this study the use 
of self-reported information for smoking status, physical activity index and education level could have 
introduced bias. For all these variables what is of interest is lifetime experience, which may be 
particularly difficult for people to report accurately.    
 
There was a possibility of selection bias, as analyses were performed on the available data, rather than 
specifically selected populations. However, again such bias was likely to be minimal as the majority 
of the analyses were on matched case-control pairs. The nesting within EPIC raises issues of the 
generalisability of the findings, both in terms the genetic and metabolomic data and also the data on 
the suspected risk factors which are subject to geographical preferences and regulations. Consequently 
this may need to be addressed in the forward translation of these findings.  
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Nevertheless, the underlying focus of this thesis was to generate hypotheses and assess the feasibility 
of novel strategies for biomarker development. Therefore its main strengths lie in the inferences 
which can be gleaned from these analyses and the way in which they can inform future work. These 
are discussed in further detail below.  
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9.4 Recommendations and implications for biomarker research 
Prospective cohort studies are vital for the study of risk factors and predictive biomarkers 
Although a number of the Bradford Hill criteria have been rendered redundant in this era of molecular 
epidemiology, what remains true is that to establish a causal relationship exposure to, or experience 
of, a risk factor must precede disease. Similarly a predictive biomarker must be shown to be present 
and measurable before disease onset so it can be determined that is not influenced by the 
pathophysiological changes due to the disease itself 224. Indeed, as mentioned, the prospective design 
employed represents one of the main strengths of this thesis. Although case-control studies may 
provide useful hypotheses, the comparison of the results presented here to the existing case-control 
based literature and the consideration of the inherent bias associated with such studies leads to the 
conclusion that a predictive biomarker can only be accurately assessed in the context of a cohort 
study. To date there has been a failure to address this in the NHL literature. There is still a lack of 
large-scale population based cohort studies. They are hampered by cost and the relative rarity of the 
individual subtypes. More are needed and, crucially, they must be constructed in a way that allows for 
molecular epidemiological analysis. 
Accurate measurement of exposure is vital 
Given the suspected environmental component to NHL aetiology, one of the biggest challenges in its 
study is accurately measuring the risk factor. Even for data that is based on measurements rather than 
self-report current, methods for measuring external exposure, such as through residential proxies, 
JEM or measure from the surrounding environment, tend to lack accuracy. Consequently they may 
not be reflective of the dosage actually experienced by an individual. This underlines the need for 
internal molecular biomarkers with increased validity. 
Here, blood concentration was used as a proxy for lifetime exposure, but the results suggest that the 
metabolomic profiles may represent a more accurate picture of the effect of such exposures. The 
effect of exposure can then be better correlated with actual disease risk. This is in agreement with the 
literature which observes that omics technologies provide a theoretically objective and informative 
measure of the long-term exposure to environmental pollutants based on the resulting perturbations of 
cellular pathways and networks 224,367. Other omics technologies, such as epigenetics, are likely to be 
better suited for this purpose than metabolomics and should play a pivotal role in future studies  
Factors occurring in the early stages of the causal pathway may be too far removed from the 
disease to act as biomarkers in diseases with long latency; the most promising biomarkers are 
late stage biomarkers   
Early stage biomarkers may be too far upstream of the event of interest to act in a predictive manner. 
This was evidenced by the fact that within this thesis the strongest associations by far were noted for a 
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late stage biomarker - translocation frequency. For early stage biomarkers the relationship with 
disease, which may not occur for many years, is likely to be distorted by the intervening stages and 
pathways and the potential bias and confounding these may introduce into the association. This could 
again explain the null relationship with the POPs/metals and is also supported by the fact that for the 
metabolomics markers the strength of the associations increase closer to diagnosis. This suggests that 
metabolomics profiles can act as both early and late stage biomarkers, with the utility of the early 
stage biomarkers lying in their improved assessment of risk factors and in the inferences they can 
provide on mechanisms. Annotation of the metabolite profiles will help disentangle this further. 
Integrating biomarkers provides increased utility and interpretability 
It can be concluded that additional utility was imparted through the integration of different biomarker 
categories to provide a more global view of the disease process using the MITM approach.  
The results of chapter five, when considered in isolation, may lead to the conclusion that PCB 
exposure was protective against NHL. The inclusion of the metabolic profile enables the 
consideration of the alternative hypotheses that the blood-based measure of POPs does not provide an 
accurate assessment of exposure. Further work may consider gene-environment interaction. Similarly 
the profile regression analyses emphasised the importance of not considering genetics in isolation 
given the differences in profile regression results when environmental factors were included in the 
analysis. Furthermore, integrating additional biomarkers such as genetic variants or environmental 
exposures into the consideration of t(14;18) translocation frequency helps to improve the 
understanding of the causes and drivers of this translocation and consider its translation into a 
clinically useful screening strategy in high risk groups.  However, within this thesis the numbers are 
too small to draw definitive conclusions. 
The role of a priori hypotheses should not be overlooked  
In order to integrate biomarkers in a biologically meaningful way it is vital to choose them carefully, 
based on known biology, pathways and mechanisms. In an era where there is a general trend to focus 
on the use of large scale hypothesis-free studies using next generational high throughput techniques, 
the findings from this study suggest that hypothesis-driven analyses should not be overlooked,  even 
though they have been criticised by some 169,371. The most successful analysis was that conducted with 
a biological a priori, namely the translocation study. The GWAS approach did not yield biologically 
meaningful findings, and it is difficult to draw definitive inferences on the metabolic profiling without 
annotation and validation. Candidate studies may be particularly appropriate when, as in this thesis, 
sample size is limited.  
Omics focussed studies are likely to play an increasingly important role  
If a population is large and contains a sufficient number of cases then omics, which tend to be 
hypothesis-free, can provide almost unprecedented opportunity to search for biomarkers of exposure 
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or disease at a population-wide level. By considering many hundreds or thousands of variables 
simultaneously a temporal picture of disease evolution can be constructed based on the interacting 
pathways and networks identified 
367
.  
In addition to metabolomics, other omics technologies were conducted within the EGM cohort (figure 
10.4) of which the transcriptomic analyses produced particularly interesting results. Over 700 
candidate genes showing altered expression years before clinical onset were observed for Chronic 
Lymphocytic Leukaemia. These genes were involved in cell signalling networks and immune system 
regulation pathways, providing plausible new mechanistic insights 372. Encouragingly, like the 
metabolomics results, they also showed a clear distinction in findings by time to diagnosis. 
Consequently, the results to date suggest an important future role for omics technologies, which as has 
been shown, can be complemented by the MITM approach. This has also been applied to the 
transcriptomics data with very encouraging results (Castagne and Kelly et al. under preparation4). As 
for the more traditional biomarkers, it should also be noted that the greatest utility will likely be 
garnered by integrating the different hierarchical omics levels (figure 9.4) to potentially allow the 
characterisation of the entire malignant phenotype 310.  
Figure 9.4 Methodologies and ‘-omics’ technologies included in the EnviroGenoMarkers Study 
 
 
Novel Statistical methodologies are vital 
Such developments also introduce new challenges which are only just beginning to be addressed. 
Most omics markers have not yet been validated, few longitudinal studies have been conducted, 
standardized protocols are lacking  and uncertainty surrounds their applicability and role in the causal 
paradigm 367. In addition their highly dimensional nature raises major challenges in terms of statistics 
                                                     
4 Castagné  R,  Kelly RS, Vineis P, Kyrtopoulos S, Vermeulen R,  Chadeau-Hyam  on behalf of the EnviroGenoMarkers project consortium 
Integration of gene expression profiling and meet-in-the-middle strategies to dissect transcriptomic changes after environmental pollutant 
exposures in a B-Cell Chronic Lymphocytic leukaemia cohort study (under preparation) 
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and study design, with complex biostatistical methodologies and high computing capabilities required 
to deal with these issues 238. These challenges extend even beyond those facing researchers when they 
first tried to characterise the human genome, due to the additional temporal component of these 
downstream –omes as well as issues regarding their stability, variation, plasticity and the ways in 
which they relate to an individual’s lifecourse 367.  Large changes in the philosophies and methods of 
statistical analyses applied to epidemiological data are required to cope with these issues and keep 
pace with the technological advances 169. 
It is vital to make biological as well as statistical meaning from such data 239. This requires a multi-
disciplinary systems biology approach incorporating pre-existing knowledge and taking the multistage 
evolution of disease into account 168,367. In fact it has been argued that the as the field develops the 
focus should be on approaches that improve the understanding of the biology rather than on the 
development of new statistical methods 238. Pathway analysis is the most popular method for 
converting high throughput data into biologically meaningful results 239, as demonstrated in chapters 4 
and 8, and there additionally exist similar methods for metabolomics which could be applied to 
annotated data 230. However pathway analysis is also entirely reliant on the underlying databases 
utilized. The existing databases are not completely comparable in terms of nomenclature and most are 
in varying stages of completion; a large number of genes remain unannotated and for those that are, 
many annotations are of a low quality and potentially inaccurate.  Consequently a further required 
development is improved mapping techniques and high resolution annotation knowledge bases which 
are specific to the methodologies and technologies used 169,239. Only this can allow the understanding 
of whether the identified biomarker does in fact belong to the causal pathway, and the role it plays. 
Replication holds the key  
Throughout the thesis three criteria sets were used to assess the explored biomarkers: Bradford-Hill, 
Ransohof and the Venice criteria, with ROC curves, sensitivity and specificity additionally presented 
where appropriate. In fact, it is argued by Ransohof, that the most important of the biomarker criteria 
is replication, and without this the other factors are meaningless 373. This is well illustrated by the 
contrast in the confidence that can be placed in the findings of the metabolomics analysis relative to 
those of the translocations where near identical results were observed in the discovery and validation 
cohorts. It should also be noted that it is possible that the failure to replicate the findings in the 
metabolomics validation cohort stemmed from the comparability of the samples which were 
processed with a different anti-coagulant introducing substantial nuisance variation into the results. 
Therefore this underlines the importance, not only of validating, but of validating in a suitable 
population.  
In addition to ‘epidemiological validation’ of a finding through replication in an independent cohort, 
is it also vital to show that a proposed biomarker displays ‘technical validation’ in terms of  intrinsic 
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measurement error and analytic sensitivity which can arise from within subject variability. The best 
way to minimise such variability is through the use of repeat samples 7.  These would be of particular 
value for all the biomarkers explored here by allowing the visualisation of the temporal progression of 
the disease pathway, and potentially of ‘critical windows’ of exposure. Therefore, although not 
available in EPIC, where possible repeat sampling should always be built into such studies 
Clinical prediction is still not a reality in most instances 
In the introduction to this thesis, it was stated that biomarkers that could help to identify individuals at 
an increased risk of NHL would be sought, with a view to eventual translation into clinical practice, 
such as screening strategies. Currently however, despite the strong findings reported here as well as 
very promising findings from the EGM transcriptomics study, translating their potential predictive 
ability into a clinical capacity is currently not feasible. In fact much of this stems from the nature of 
lymphoma itself rather than from failings with the predictive test. With reference to the discussion on 
FL in chapter 7 (7.3.4) NHL in general is not well suited to population-wide screening regardless of 
the strength of the association with the identified biomarker.  
In fact very few conditions do meet all these criteria, and the number of population-wide screening 
programs, in any nation or health system is incredibly small. More common are targeted screening 
tests in certain sub-populations, such as those exposed to known causal agents. For NHL this may 
include measuring translocation frequency in groups such as pesticide sprayers or workers exposed to 
particular chemical, although definitive validation of such risk factors would first be required.  
Ethical implications must be taken into account 
Thus the search for biomarkers will generate vast amounts of new information, some of which may 
represent plausible candidates for forward translation into clinical practice, and some of which will 
represent incidental findings. Both have important ethical, legal, financial and physiological 
implications 374,375. Genetic screening for cancer susceptibility has become an accepted part of 
oncologic care particularly for individuals with an inherited disposition to cancers of the breast, ovary, 
colon, stomach and uterus 
376
. However current guidelines are less than definitive and only pertain to 
high penetrance mutations. The identification of predictive biomarkers from other technologies, 
particularly as incidental findings, potentially opens ‘Pandora’s box’ regarding issues of ownership, 
dissemination, regulation and informed consent 374-376. This may prove particularly problematic for 
omics as there are still so many unknowns in these types of analyses and the development of new 
biomarker criteria must reflect this.  
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9.5 NHL and Subtype Heterogeneity 
The points discussed here can well be applied to the study of NHL and indeed the lessons learnt are 
already beginning to be assimilated into ongoing studies. However NHL remains a challenging 
malignancy to study. The single biggest factor behind this is its heterogeneity. In fact it could be 
argued that NHL doesn’t represent one disease at all, but multiple. Unfortunately due to small sample 
sizes, subtype specific analyses were limited here. Although as a group NHL represents the eighth 
most common malignancy in Western Europe, each individual subtype has relatively low incidence 22. 
Among a cohort of more than half a million people even the most common subtype - Multiple 
myeloma (MM) - comprised only 452 cases. The two subtypes generally reported as being the most 
common among the NHLs, DLBCL and FL comprised 284 and 243 cases respectively, and in total 
1757 incident cases of NHL have been identified in the EPIC cohort to date (This total does not 
include French cases as France was not involved in the Lymphoma working group). In fact MM is 
often considered a distinct entity from the other B-cell NHL due to its pathophysiological differences, 
and is excluded from analyses. However under the most commonly used classifications scheme today 
17,19 MM is classed as a B-cell NHL (hierarchical group 4) and therefore was considered with the other 
B-cell subtypes here. 
 
Here, there was no evidence of statistically significant heterogeneity by subtype for either the 
PCB/POP/Metals analysis or the metabolomics. Conversely, the most promising findings were those 
restricted to one subtype, FL, and similarly the aforementioned EGM transcriptomics findings pertain 
only to CLL 372. Therefore when exploring aetiology and biomarkers these results support the utility 
of considering NHL both as a cohesive group and by subtype, numbers permitting, particularly when 
taking a hypothesis free approach, as was done in this thesis.  Furthermore to reflect the gender-
disparities by subtype, ideally subtype analyses should also be gender specific 23. Finally, the 
additional subclassification of the subtypes based on the findings emerging from genetic and 
epigenetic studies also needs to be considered 18. The high risk biomarker for FL identified here, adds 
to this discussion. 
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9.6 Concluding comments 
In conclusion, through addressing the aims set out in the introduction a number of interesting results 
have emerged, as well as a number of challenges. It was stated that in the introduction that NHL was a 
prime candidate for biomarker development. Although this remains true, the results suggest that 
obtaining biomarkers that are accurate and of utility for all subtypes may not be feasible. One of the 
major conclusions of this thesis is the increasingly important role that subtype heterogeneity plays in 
all aspects of NHL research. 
 
 In terms of the results, a novel biomarker to inform on the risk of one of the most common NHL 
subtypes, FL, in the form of a t(14;18) translocation frequency threshold has been identified. 
Although currently unsuitable for clinical usage, it allows further insights into the mechanisms of this 
malignancy, and additionally represents a previously unknown pre-disease state.   
 
The results also emphasise again the relevance of gene-environment interactions in the aetiology of 
NHL and suggest that future work should also consider gene-biomarker interactions and the 
importance of the interacting omics levels including the genome. If undiscovered risk factors for NHL 
do in fact exist, it may be that such integrated analyses are the only way to identify them. Integration 
of different technologies was shown to improve utility and encouraging proof of principle results are 
presented for the MITM approach, suggesting that it is a feasible methodology that could reasonably 
be applied to the other omics technologies. Similarly profile regression could well play an important 
role in the future of molecular epidemiology.   Finally this thesis confirms the importance of omics 
technologies in the future of NHL research but also underlines the continued importance of targeted 
studies and suggest the most fruitful identification of biomarkers and the most complete picture of the 
disease process is likely to be achieved through the integration of the two. The subsequent translation 
of such biomarkers into clinical practice could have huge implications for this highly prevalent 
malignancy.  
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3. METHODS 
Table 3.1.1; Baseline characteristics of the 1757 incident B-cell NHL cases identified in the 
EPIC cohort during follow-up stratified by eligibility for the case-control analyses 
Eligibility was determined by the availability of a baseline blood sample and two suitable matched 
controls who were cancer free at the time of diagnosis in the corresponding case 
    
Eligible 
Participants 
(n=1524)   
Non-eligible 
Participants 
(n=233)   
Difference 
(p-value) 
Sex Males (%) 759 (49.8) 
 
59 (25.3) 
 
  
 
Females (%)  765 (50.2) 
 
174 (74.7) 
 
<0.001 
Age Mean yrs (range) 57.01 (22 -79) 
 
55.70 (24 - 94) 
 
0.028 
Country France (%)  0 (0) 
 
5 (2.1) 
  
 
Italy (%) 173 (11.4) 
 
9 (3.9) 
  
 
Spain (%) 128 (8.4) 
 
6 (2.6) 
  
 
UK (%) 216 (14.2) 
 
126 (5.4) 
  
 
Netherlands (%) 119 (7.8) 
 
8 (3.4) 
  
 
Greece (%) 49 (3.2) 
 
0 (0.0) 
  
 
Germany (%) 156 (0.2) 
 
10 (4.3) 
  
 
Sweden (%) 309 (20.3) 
 
1 (4.3) 
  
 
Denmark (%) 358 (23.5) 
 
2 (8.6) 
    Norway (%) 16 (1.0)   66 (28.3)   <0.001 
Figure 3.1.1 Subtype Classification of Incident Cases in Eligible and Non-eligible Participants  
Percentage of the total cases classified into each subtype. Chi-squared p-value refers to the differences 
across the subtype categories between the two groups   
BALL- B-cell Acute Lymphatic Leukemia , BCLL- B-cell Chronic Lymphocytic Leukaemia, BNOS - B-cell NHL Not 
Otherwise Specified, BO – BCLL NHL, other, DLBCL - Diffuse Large B-cell Lymphoma, FL – Follicular Lymphoma, HCL - 
Hairy Cell Leukaemia, LPL - Lymphoplasmacytic Lymphoma, ML - Marginal Zone B-cell Lymphoma, MM- Multiple 
Myeloma 
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R script to run Profile Regression for chapter 4 (4.3.4) and in chapter 8 (8.3.1.1.1)  
The sections in italics represent variable indices that were altered to run the sensitivity analysis, and 
the GxE analysis. Code is developed from the R package PReMiuM 223. 
library(PReMiuM)                                                                                                                                                 
gxgmatrix<-read.table(file.choose(),header=T,sep="\t")                                                                              
inputs_yModel<-"Bernoulli"                                                                                                                      
inputs_xModel<-"Discrete"                                                                                                                   
inputs_covnames<-names(gxgmatrix[c(2:1001)])                                                                             
inputs_fixedeffectsnames<-names(gxgmatrix[c(1002:1014)])                                                                                         
inputs<-list(yModel=inputs_yModel, xModel=inputs_xModel, inputData=gxgmatrix, 
covNames=inputs_covnames, fixedEffectsNames=inputs_fixedeffectsnames) 
runInfoObj<-profRegr(covNames=inputs$covNames, fixedEffectsNames=inputs$fixedEffectsNames, 
outcome="outcome", data=inputs$inputData, output="output", nSweeps=285000, nBurn=285000, 
nClusInit=5, yModel=inputs$yModel, xModel=inputs$xModel, nProgress=1, nFilter=100, 
varSelectType="BinaryCluster", seed=1) 
dissimObj<-calcDissimilarityMatrix(runInfoObj) 
clusObj<-calcOptimalClustering(dissimObj,maxNClusters=20) 
riskProfileObj<-calcAvgRiskAndProfile(clusObj, includeFixedEffects=T) 
 
rho<-summariseVarSelectRho(runInfoObj) 
clusObj 
rho$rhoMedian 
whichcovariates<-which(rho$rhoMedian>0.45) 
clusterOrderObj<-plotRiskProfile(riskProfileObj, "summary.png", showRelativeRisk=F, 
orderBy=NULL, whichCovariates=whichcovariates,  useProfileStar=T) 
 
 
 
 
Box 3.5: Criteria for a population-based screening test 
(modified from Wilson & Junger, 1968 
233
) 
1. The condition should represent an important public health problem 
2. The natural history of the condition should be well understood 
3. There should be a recognizable latent or early sympotomatic stage 
4. There should be a test that is easy to perform and interpret and which in addition is acceptable, accurate, reliable, 
sensitive and specific 
5. There should be an accepted treatment for the condition, which is more effective if started early 
6. There should be an accepted policy on who should be treated 
7. Diagnosis and treatment should be cost effective 
8. Case-finding should be a continuous process 
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4.PROFILE REGRESSION AS A TOOL FOR 
IDENTIFYING SUSCEPTIBILTY BIOMARKERS 
FROM GENETIC PROFILES  
4.2.4 R script to thin the list of top 5000 SNPs found to be significantly associated with NHL 
When the top 5000 SNPs are ordered by chromosome and then base-pair position, this code picks up 
the top SNPs for each region, according to p-value, by assuming that SNPs within 100kb of each other 
are in the same region and those more than 100kb apart are independent.  
minp<-1 
        data<-read.table("preGC-top1k4s.txt",header=F) 
        for(i in 1:dim(data)[1]){                                                                                                                                                                  
 if(i==1){ 
                if(data[i,4]<minp){ 
                        minp<-data[i,4] 
                        minpRow<- i 
                }else{ 
                        print("!!!") 
                }                                                                                                                                                                                                                                                    
…………….}else{                                                                                                                                                                               
                if(data[i,4]<minp && data[i,2]<data[i-1,2]+100000 && data[i,3]==data[i-1,3]){ 
                        minp<-data[i,4] 
                        minpRow<- i 
                }                                                                                                                                                    
                        if(data[i,2]>data[i-1,2]+100000 || data[i,3]!=data[i-1,3]){ 
          write.table(data[minpRow,],file="selectedSNP",quote=F,row.names=F,col.names=F,append=T) 
                        minp<-data[i,4] 
                         minpRow<- i 
                } 
            } 
        } 
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Table 4.3.4: Sensitivity analyses exploring the number of iterations (nSweep) of the sampler 
required to obtain consistent clustering in the profile regression analysis 
nBurn, nSweep, and nFilter refer to the script in appendix 3.4.4. nClusInit=5 and maxNClusters=20 
were kept consistent throughout. which(rho$rhoMedian>xx) varied dependent on the preceding 
results 
nBurn nSweep nFilter Outcome 
Cluster 
No. 
clusters 
Significant 
Covariates 
(β) 1 2 3 4 
1000 1000 40 Cluster sizes 408 30 
 
 
2 Spain; 1.40, 
Greece; 1.43, 
Age; -0.02    
Empirical risk 0.355 1 
 
  
   
Profile regression risk 0.358 0.941 
   1500 1500 40 Cluster sizes 407 31 
  
2 
Italy; -2.97, 
Age; -0.04    
Empirical risk 0.350 1 
   
   
Profile regression risk 0.360 0.930 
   3000 3000 40 Cluster sizes 415 23 
  
2 
Italy; -2.52, 
UK; 0.66    
Empirical risk 0.366 1 
   
   
Profile regression risk 0.369 0.915 
   5000 5000 40 Cluster sizes 407 17 10 4 4 Italy; -2.28, 
UK; 1.78, 
Age; -0.02    
Empirical risk 0.354 1 1 1 
 
   
Profile regression risk 0.369 0.601 0.632 0.919 
 10000 10000 40 Cluster sizes 418 20 
  
2 
Italy; -2.54, 
Age; -0.03    
Empirical risk 0.371 1 
   
   
Profile regression risk 0.374 0.917 
   50000 50000 40 Cluster sizes 414 24 
   Italy; -2.16,                        
UK; 1.72    
Empirical risk 0.365 1 
   
   
Profile regression risk 0.370 0.861 
   250000 250000 100 Cluster sizes 413 25 
  
2 
Italy; -2.31    
Empirical risk 0.363 1 
   
   
Profile regression risk 0.370 0.870 
   275000 275000 100 Cluster sizes 412 26 
  
2 
Italy; 2.05    
Empirical risk 0.362 1 
   
   
Profile regression risk 0.371 0.816 
   285000 285000 100 Cluster sizes 413 25 
  
2 
Italy; -2.09, 
UK; 1.71    
Empirical risk 0.363 1 
         Profile regression risk 0.371 0.850       
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5. BIOMARKERS OF INTERNAL DOSE: EXPOSURE 
TO ENVIRONMENTAL POLLUTANTS AND FUTURE 
RISK OF NHL 
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Table 5.3i; Mean, median and range of six PCB congeners, HCB, DDE, Cadmium and 
Lead concentrations in cases and controls from the EnviroGenoMarkers Study 
stratified by cohort and by gender 
Exposure Population 
  Cases   Controls   Difference 
 
Median Mean Range 
 
Median Mean Range 
 
p-value
a
 
PCB118  Sweden  121.1 161.2 (8.5,901.6) 
 
129.0 153.7 (11.6,832.1)  0.890 
 
Italy 
 180.1 228.1 (50,882.9) 
 
201.9 224.8 (52.4,578.1) 
 
0.885 
 
Men  
 109.9 140.7 (8.5,708) 
 
133.7 166.4 (11.6,832.1) 
 
0.0244* 
 
Women 
 171.5 222.1 (12.6,901.6) 
 
162.8 184.7 (16.5,753.3) 
 
0.0267* 
PCB138  Sweden  530.0 608.1 (11,1770.9) 
 
562.6 652.1 (51.2,2675.4) 
 
0.279 
 
Italy 
 519.0 600.1 (186.8,1810.1) 
 
562.0 601.4 (220.5,1768.6) 
 
0.647 
 
Men  
 499.5 580.1 (11,1770.9) 
 
576.3 669.0 (51.2,2675.4) 
 
0.036* 
 
Women 
 562.1 630.5 (15.1,1810.1) 
 
555.1 604.8 (66.7,1603.9) 
 
0.581 
PCB153  Sweden  1036.0 1142.8 (32.5,2698.4) 
 
1083.5 1210.4 (120.6,4334.1) 
 
0.364 
 
Italy 
 981.2 1169.0 (368.2,3308) 
 
1100.1 1194.5 (472.4,3010) 
 
0.448 
 
Men  
 974.9 1110.0 (32.5,2698.4) 
 
1116.1 1256.9 (120.6,4334.1) 
 
0.0333* 
 
Women 
 1032.0 1190.7 (69.1,3308) 
 
1013.2 1155.6 (139,2860.4) 
 
0.670 
PCB156  Sweden  92.2 104.0 (19.8,307.8) 
 
101.3 109.0 (15.5,394.9) 
 
0.309 
 
Italy 
 83.9 97.5 (22.6,243.9) 
 
90.8 101.7 (32.6,326.7) 
 
0.391 
 
Men  
 89.8 100.9 (31.4,307.8) 
 
102.2 114.2 (24.5,394.9) 
 
0.0168* 
 
Women 
 91.8 103.0 (19.8,243.9) 
 
90.8 99.4 (15.5,326.7) 
 
0.614 
PCB170  Sweden  343.3 384.1 (62.7,1082.3) 
 
375.7 399.1 (50.4,1211.8) 
 
0.384 
 
Italy 
 303.3 355.4 (98.6,934.3) 
 
306.1 367.7 (127.5,1291.2) 
 
0.465 
 
Men  
 341.3 384.6 (62.7,1082.3) 
 
383.5 421.1 (84,1211.8) 
 
0.088 
 
Women 
 309.0 366.0 (89.5,934.3) 
 
311.5 358.6 (50.4,1291.2) 
 
0.842 
PCB180  Sweden  677.9 753.1 (139.7,2111.6) 
 
733.2 784.0 (100.1,2159.5) 
 
0.367 
 
Italy 
 712.3 868.0 (279.9,2708.8) 
 
720.0 861.2 (349.2,2431.5) 
 
0.525 
 
Men  
 718.2 800.0 (139.7,2708.8) 
 
782.3 860.2 (180.3,2159.5) 
 
0.134 
 
Women 
 625.4 778.0 (177.4,2430.6) 
 
678.9 757.1 (100.1,2431.5) 
 
0.984 
HCB Sweden  201.8 243.0 (62.5,659.7) 
 
218.1 248.9 (64.5,1098.8) 
 
0.696 
 
Italy 
 568.7 741.5 (115.8,3604) 
 
628.5 841.7 (106.9,3882.2) 
 
0.274 
 
Men  
 199.7 298.2 (62.5,2011.4) 
 
257.9 378.2 (64.5,3661.2) 
 
0.0113* 
 
Women 
 332.8 495.1 (82.9,3604) 
 
309.4 486.0 (83.3,3882.2) 
 
0.597 
DDE  Sweden  1595.3 2223.6 (16.4,13776.1) 
 
1992.8 2706.3 (76.4,18041.6) 
 
0.084 
 
Italy 
 5946.1 8056.7 (1052.1,30992.8) 
 
5579.2 7547.6 (1098.7,23858.3) 
 
0.490 
 
Men  
 1919.7 3299.0 (16.4,30992.8) 
 
2374.1 3617.0 (76.4,22536.8) 
 
0.230 
 
Women 
 3305.3 4756.1 (78.6,30124.3) 
 
3408.7 4770.4 (321,23858.3) 
 
0.854 
Cadmium Sweden  
0.41 0.72 (0.10, 4.11) 
 
0.41 0.78 (0.10, 5.22) 
 
0.998 
 
Italy 
 
0.63 0.86 (0.22, 3.59) 
 
0.59 0.71 (0.18, 2.76) 
 
0.112 
 
Men  
 
0.36 0.61 (0.13, 3.78) 
 
0.38 0.73 (0.10, 5.22) 
 
0.315 
  Women   0.64 0.91 (0.10, 4.11)   0.54 0.79 (0.18, 4.32)   0.046* 
Lead Sweden  
44.5 55.2 (15.4, 342.8) 
 
45.5 54.7 (11.2, 672.5) 
 
0.633 
 
Italy 
 
92.8 104.6 (48.5, 400.8) 
 
89.6 110.5 (39.3, 378.9) 
 
0.287 
 
Men  
 
64.1 78.5 (15.4, 342.8) 
 
60.9 85.2 (24.3, 672.5) 
 
0.794 
 
Women 
 
51.9 62.9 (16.8, 400.8) 
 
53.4 59.6 (11.2, 220.94) 
 
0.823 
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aDifferences between median concentrations in cases and controls according to the Wilcoxon signed-rank test for paired samples                                                  
One participant with exposure levels above the 99th percentile  was excluded from the PCB analysis 
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Table 5.3ii Association between NHL and quartiles of exposure to persistent organic pollutants and metals stratified by cohort 
POP by 
quartile 
 
NSHDS 
 
EPIC-Italy 
 
Ca/Co 
OR 95% CI 
P-
value 
p for 
trend 
 
OR(adj) 95% CI 
P-
value 
p for 
trend  Ca/Co 
OR 95% CI 
P-
value 
p for 
trend 
 
OR(adj) 95% CI 
P-
value 
p for 
trend 
                        PCB118 1 
 
68/54 1 
    
1 
    
29/20 1 
    
1 
   
 
2 
 
53/47 0.84 (0.48,1.48) 0.551 
  
1.14 (0.58,2.23) 0.701 
  
16/22 0.48 (0.19,1.23) 0.126 
  
0.61 (0.21,1.8) 0.372 
 
 
3 
 
32/47 0.45 (0.23,0.88) 0.019* 
  
0.36 (0.16,0.82) 0.014* 
  
14/21 0.46 (0.17,1.27) 0.133 
  
0.5 (0.17,1.5) 0.216 
 
 
4 
 
33/37 0.61 (0.32,1.17) 0.14 0.047* 
 
0.4 (0.16,0.99) 0.047* 0.012* 
 25/20 
1.08 (0.37,3.16) 0.895 0.672 
 
1.12 (0.31,4.01) 0.864 0.754 
PCB138 1 
 
53/46 1 
    
1 
    
34/21 1 
    
1 
   
 
2 
 
48/47 0.85 (0.48,1.52) 0.579 
  
0.67 (0.33,1.36) 0.268 
  
11/20 0.28 (0.09,0.81) 0.020* 
  
0.17 (0.05,0.63) 0.008* 
 
 
3 
 
41/46 0.68 (0.35,1.33) 0.262 
  
0.48 (0.21,1.1) 0.082 
  
18/22 0.38 (0.13,1.14) 0.084 
  
0.27 (0.07,0.98) 0.046* 
 
 
4 
 
44/46 0.75 (0.38,1.5) 0.418 0.344 
 
0.47 (0.2,1.15) 0.097 0.064 
 21/20 
0.44 (0.13,1.47) 0.181 0.198 
 
0.32 (0.07,1.47) 0.143 0.136 
PCB153 1 
 
54/46 1 
    
1 
    
29/21 1 
    
1 
   
 
2 
 
46/47 0.75 (0.39,1.42) 0.376 
  
0.76 (0.36,1.61) 0.48 
  
19/21 0.57 (0.22,1.48) 0.245 
  
0.46 (0.15,1.38) 0.166 
 
 
3 
 
44/47 0.66 (0.32,1.35) 0.251 
  
0.62 (0.25,1.51) 0.294 
  
13/20 0.31 (0.09,1.08) 0.066 
  
0.22 (0.05,0.95) 0.043* 
 
 
4 
 
42/45 0.66 (0.31,1.39) 0.276 0.282 
 
0.39 (0.15,1) 0.05 0.048* 
 23/21 
0.5 (0.15,1.71) 0.272 0.33 
 
0.46 (0.11,1.93) 0.285 0.361 
PCB156 1 
 
46/46 1 
    
1 
    
28/21 1 
    
1 
   
 
2 
 
59/47 1.16 (0.59,2.28) 0.666 
  
1.46 (0.67,3.17) 0.343 
  
21/20 0.67 (0.23,1.9) 0.448 
  
0.46 (0.13,1.61) 0.227 
 
 
3 
 
32/47 0.62 (0.28,1.35) 0.23 
  
0.56 (0.21,1.47) 0.242 
  
11/22 0.3 (0.09,0.99) 0.049* 
  
0.16 (0.03,0.72) 0.017* 
 
 
4 
 
49/45 1 (0.47,2.14) 0.995 0.638 
 
0.75 (0.3,1.89) 0.544 0.241 
 24/20 
0.61 (0.16,2.26) 0.458 0.377 
 
0.42 (0.08,2.11) 0.291 0.294 
PCB170 1 
 
45/47 1 
    
1 
    
27/21 1 
    
1 
   
 
2 
 
61/46 1.31 (0.7,2.44) 0.403 
  
1.22 (0.59,2.51) 0.595 
  
19/20 0.6 (0.21,1.7) 0.336 
  
0.4 (0.12,1.36) 0.141 
 
 
3 
 
34/46 0.73 (0.36,1.51) 0.403 
  
0.5 (0.2,1.3) 0.155 
  
17/21 0.45 (0.13,1.49) 0.19 
  
0.34 (0.08,1.38) 0.13 
 
 
4 
 
46/46 0.96 (0.47,1.96) 0.92 0.529 
 
0.64 (0.25,1.6) 0.339 0.16 
 21/21 
0.51 (0.14,1.82) 0.299 0.368 
 
0.41 (0.09,1.83) 0.241 0.382 
PCB180 1 
 
45/47 1 
    
1 
    
26/21 1 
    
1 
   
 
2 
 
59/46 1.34 (0.71,2.56) 0.367 
  
1.41 (0.65,3.05) 0.382 
  
19/20 0.74 (0.3,1.81) 0.504 
  
0.48 (0.16,1.43) 0.187 
 
 
3 
 
35/46 0.76 (0.37,1.55) 0.444 
  
0.48 (0.19,1.26) 0.139 
  
20/22 0.6 (0.19,1.87) 0.378 
  
0.44 (0.11,1.68) 0.23 
   4   47/46 1 (0.5,2.01) 0.996 0.651   0.63 (0.24,1.64) 0.342 0.168   19/20 0.62 (0.2,1.96) 0.414 0.447   0.45 (0.11,1.89) 0.274 0.336 
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Table 5.3ii continued 
POP by quartile 
  NSHDS   EPIC-Italy 
 
Ca/Co 
OR 95% CI 
P-
value 
p for 
trend 
 
OR(adj) 95% CI 
P-
value 
p for 
trend  Ca/Co 
OR 95% CI 
P-
value 
p for 
trend 
 
OR(adj) 95% CI 
P-
value 
p for 
trend 
 
 
  
    
 
     
 
    
 
    
Dioxin-like 
PCBs        
(118, 156) 
1 
 
51/47 1 
    
1 
    
25/21 1 
    
1 
   2 
 
48/46 0.87 (0.45,1.68) 0.674 
  
0.94 (0.44,2.03) 0.878 
  
20/21 0.83 (0.35,1.94) 0.666 
  
1.02 (0.36,2.85) 0.974 
 3 
 
36/46 0.64 (0.3,1.36) 0.249 
  
0.52 (0.22,1.26) 0.149 
  
16/21 0.67 (0.25,1.79) 0.422 
  
0.66 (0.22,1.96) 0.451 
 
 
4 
 
51/46 0.9 (0.42,1.95) 0.794 0.711 
 
0.65 (0.25,1.67) 0.367 0.234 
 23/20 
1.07 (0.32,3.54) 0.918 0.846 
 
1.12 (0.28,4.55) 0.871 0.871 
Non-Dioxin 
like PCBs                                  
(138, 153, 
170, 180) 
1 
 
56/47 1 
    
1 
    
26/21 1 
    
1 
   2 
 
43/46 0.72 (0.39,1.34) 0.301 
  
0.66 (0.33,1.34) 0.254 
  
21/21 0.73 (0.29,1.86) 0.511 
  
0.6 (0.21,1.69) 0.33 
 3 
 
44/46 0.68 (0.34,1.37) 0.28 
  
0.61 (0.25,1.49) 0.281 
  
15/21 0.43 (0.13,1.45) 0.174 
  
0.28 (0.07,1.17) 0.081 
 4 
 
43/46 0.67 (0.32,1.37) 0.272 0.294 
 
0.41 (0.16,1.04) 0.061 0.072 
 22/20 
0.66 (0.2,2.2) 0.498 0.553 
 
0.57 (0.14,2.33) 0.433 0.497 
Immunotoxic 
PCBs                
(118, 138, 
156, 170)  
1 
 
51/47 1 
    
1 
    
25/21 1 
    
1 
   2 
 
48/46 0.92 (0.5,1.72) 0.797 
  
0.76 (0.36,1.6) 0.47 
  
21/21 0.81 (0.3,2.18) 0.682 
  
0.59 (0.2,1.78) 0.353 
 3 
 
41/46 0.75 (0.38,1.47) 0.397 
  
0.56 (0.25,1.28) 0.173 
  
14/21 0.54 (0.18,1.63) 0.273 
  
0.39 (0.11,1.4) 0.151 
 
 
4 
 
46/46 0.86 (0.43,1.72) 0.663 0.572 
 
0.51 (0.21,1.25) 0.139 0.107 
 24/20 
0.94 (0.28,3.18) 0.922 0.843 
 
0.83 (0.2,3.46) 0.801 0.753 
ΣPCBs 1 
 
54/47 1 
    
1 
    
27/21 1 
    
1 
   
 
2 
 
48/46 0.82 (0.44,1.54) 0.54 
  
0.76 (0.37,1.56) 0.45 
  
22/21 0.69 (0.25,1.84) 0.454 
  
0.51 (0.17,1.54) 0.233 
 
 
3 
 
40/46 0.62 (0.3,1.28) 0.195 
  
0.52 (0.21,1.27) 0.152 
  
12/21 0.32 (0.1,1.1) 0.07 
  
0.2 (0.04,0.85) 0.030* 
 
 
4 
 
44/46 0.7 (0.34,1.46) 0.343 0.289 
 
0.41 (0.16,1.05) 0.064 0.048* 
 23/20 
0.62 (0.18,2.1) 0.441 0.435 
 
0.46 (0.11,2.05) 0.31 0.386 
HCB 1 
 
53/46 1 
    
1 
    
27/21 1 
    
1 
   
 
2 
 
49/46 0.80 (0.42,1.53) 0.496 
  
0.90 (0.42,1.9) 0.774 
  
18/20 0.64 (0.27,1.51) 0.305 
  
0.68 (0.27,1.73) 0.419 
 
 
3 
 
36/46 0.53 (0.24,1.2) 0.129 
  
0.51 (0.18,1.4) 0.19 
  
20/22 0.61 (0.23,1.64) 0.329 
  
0.69 (0.24,2) 0.489 
 
 
4 
 
48/46 0.71 (0.31,1.6) 0.408 0.424 
 
0.5 (0.18,1.4) 0.189 0.156 
 19/20 
0.6 (0.2,1.85) 0.377 0.368 
 
0.59 (0.17,2.07) 0.414 0.411 
DDE 1 
 
68/47 1 
    
1 
    
20/21 1 
    
1 
   
 
2 
 
41/46 0.50 (0.26,0.95) 0.035* 
  
0.39 (0.18,0.86) 0.020* 
  
19/20 1.01 (0.38,2.66) 0.984 
  
1.18 (0.42,3.34) 0.753 
 
 
3 
 
39/46 0.45 (0.23,0.89) 0.022* 
  
0.33 (0.14,0.78) 0.011* 
  
22/22 1.05 (0.41,2.7) 0.915 
  
1.25 (0.44,3.53) 0.672 
   4   38/46 0.46 (0.24,0.89) 0.022* 0.026*   0.19 (0.07,0.48) 0.001* <0.001*  23/20 1.34 (0.46,3.86) 0.589 0.607   1.44 (0.43,4.79) 0.551 0.555 
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Table 5.3ii continued 
POP by 
quartile 
  NSHDS   EPIC-Italy 
 
Ca/Co 
OR 95% CI 
P-
value 
p for 
trend 
 
OR(adj) 95% CI 
P-
value 
p for 
trend  Ca/Co 
OR 95% CI 
P-
value 
p for 
trend 
 
OR(adj) 95% CI 
P-
value 
p for 
trend 
 
 
  
    
 
     
 
    
 
    
Cadmium 1 
 
46/46 1  
   
1 
    
16/21 1  
   
1 
   
 
2 
 
48/47 1.04 (0.58,1.88) 0.886  
 
1.12 (0.57,2.21) 0.741 
  
17/21 1.00 (0.43,2.33) 0.994  
 
1.06 (0.42,2.67) 0.896 
 
 
3 
 
47/46 1.05 (0.57,1.91) 0.882  
 
1.09 (0.54,2.23) 0.802 
  
24/21 1.49 (0.64,3.5) 0.357  
 
1.68 (0.68,4.14) 0.263 
 
 
4 
 
45/46 1.00 (0.54,1.86) 0.992 0.999 
 
1.10 (0.51,2.39) 0.806 0.837 
 27/21 
1.91 (0.75,4.86) 0.177 0.168 
 
2.11 (0.75,5.91) 0.157 0.106 
Lead 1 
 
59/47 1  
   
1 
    
23/21 1  
   
1 
   
 
2 
 
36/45 0.57 (0.29,1.11) 0.097  
 
0.61 (0.28,1.32) 0.211 
  
16/21 0.71 (0.3,1.71) 0.449  
 
0.77 (0.31,1.91) 0.573 
 
 
3 
 
37/46 0.59 (0.3,1.14) 0.115  
 
0.53 (0.23,1.2) 0.126 
  
26/21 1.16 (0.49,2.7) 0.738  
 
1.17 (0.48,2.87) 0.724 
  4  54/47 0.83 (0.44,1.58) 0.574 0.755  0.80 (0.37,1.75) 0.58 0.648  19/21 0.79 (0.31,2.05) 0.636 0.945  0.88 (0.3,2.53) 0.809 0.921 
OR – conditional logistic regression accounting for matching factors                                                                                                                                                                                                                                                    
OR(adj) – conditional logistic regression additionally adjusting for BMI, height, educational level, vegetables, dairy, protein, total fat, alcohol                                                                                                    
*Significant at the 95% confidence level 
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Table 5.3.1i: Association between log-transformed exposure levels and NHL risk by Subtype; 
stratified by cohort 
Exposure  
CLL  DLBCL FL  MM  
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
             Sweden n=31 
  
n=34 
  
n=19 
  
n=55 
  PCB118  0.64 (0.26,1.56) 0.324 0.66 (0.23,1.93) 0.451 0.68 (0.23,1.98) 0.48 1.64 (0.75,3.6) 0.215 
PCB138  0.61 (0.23,1.6) 0.313 0.47 (0.12,1.88) 0.286 0.63 (0.16,2.56) 0.519 0.87 (0.36,2.1) 0.764 
PCB153  0.56 (0.17,1.82) 0.336 0.46 (0.1,2.01) 0.299 0.61 (0.12,3.03) 0.548 0.88 (0.32,2.38) 0.795 
PCB156  0.61 (0.14,2.74) 0.52 0.34 (0.08,1.39) 0.133 0.64 (0.15,2.67) 0.541 0.99 (0.37,2.64) 0.978 
PCB170  0.62 (0.17,2.32) 0.481 0.37 (0.08,1.6) 0.182 0.82 (0.16,4.27) 0.811 0.92 (0.32,2.62) 0.873 
PCB180  0.62 (0.15,2.49) 0.496 0.37 (0.08,1.59) 0.18 0.89 (0.15,5.19) 0.892 0.93 (0.32,2.68) 0.893 
HCB 0.20 (0.03,1.29) 0.091 0.60 (0.12,2.94) 0.526 0.37 (0.06,2.28) 0.286 1.21 (0.44,3.34) 0.712 
DDE  0.64 (0.29,1.4) 0.265 0.77 (0.35,1.71) 0.523 0.73 (0.32,1.67) 0.46 0.69 (0.39,1.24) 0.216 
Dioxin-like 
PCBs 
0.74 (0.39,1.39) 0.344 0.62 (0.3,1.29) 0.201 0.76 (0.38,1.53) 0.446 1.22 (0.74,1.99) 0.435 
Non-Dioxin 
like PCBs 
0.87 (0.63,1.18) 0.367 0.78 (0.53,1.15) 0.207 0.91 (0.61,1.37) 0.661 0.97 (0.75,1.26) 0.818 
Immunotoxic 
PCBs 
0.85 (0.62,1.18) 0.332 0.76 (0.51,1.13) 0.179 0.88 (0.6,1.29) 0.513 1.04 (0.8,1.34) 0.772 
ΣPCBs 0.9 (0.72,1.12) 0.344 0.83 (0.64,1.09) 0.183 0.92 (0.71,1.21) 0.561 1.01 (0.85,1.21) 0.897 
Cadmium 0.94 (0.42,2.11) 0.884 1.14 (0.56,2.29) 0.722 1.1 (0.35,3.47) 0.872 0.96 (0.61,1.52) 0.87 
Lead 1.61 (0.47,5.55) 0.45 0.62 (0.21,1.83) 0.39 1.46 (0.28,7.76) 0.655 1.32 (0.66,2.63) 0.428 
             Italy  n=11 
  
n=11 
  
n=20 
  
n=21 
  PCB118  1.27 (0.15,11.01) 0.827 2.57 (0.07,96.51) 0.609 1.94 (0.4,9.33) 0.408 0.22 (0.04,1.21) 0.082 
PCB138  0.82 (0.06,10.79) 0.878 0.11 (0,3.7) 0.22 1.64 (0.28,9.75) 0.585 0.18 (0.01,2.68) 0.214 
PCB153  0.28 (0.02,4.17) 0.357 0.04 (0,2.74) 0.135 1.63 (0.26,10.07) 0.599 0.27 (0.02,3.32) 0.304 
PCB156  0.48 (0.04,6.15) 0.574 0.02 (0,2.53) 0.111 2.22 (0.3,16.39) 0.433 0.21 (0.02,2.32) 0.203 
PCB170  0.28 (0.02,3.64) 0.331 0 (0,1.92) 0.08 2.48 (0.41,14.82) 0.321 0.32 (0.03,3.62) 0.361 
PCB180  0.21 (0.01,4.2) 0.31 0.01 (0,1.31) 0.062 2.11 (0.41,10.89) 0.374 0.82 (0.11,6.24) 0.845 
Dioxin-like 
PCBs  
0.88 (0.22,3.5) 0.861 0.30 (0.02,3.76) 0.353 1.63 (0.57,4.65) 0.36 0.38 (0.12,1.18) 0.093 
Non-Dioxin 
like PCBs 
0.72 (0.35,1.5) 0.384 0.32 (0.08,1.28) 0.107 1.20 (0.76,1.91) 0.432 0.76 (0.41,1.41) 0.386 
Immunotoxic 
PCBs 
0.84 (0.41,1.74) 0.636 0.38 (0.1,1.46) 0.16 1.27 (0.75,2.16) 0.365 0.62 (0.33,1.17) 0.14 
ΣPCBs 0.84 (0.52,1.37) 0.496 0.47 (0.18,1.23) 0.124 1.16 (0.83,1.62) 0.39 0.77 (0.51,1.17) 0.216 
HCB 0.69 (0.19,2.5) 0.571 1.17 (0.33,4.08) 0.809 1.05 (0.41,2.69) 0.92 0.17 (0.03,1.16) 0.07 
DDE  2.50 (0.44,14.14) 0.299 2.52 (0.24,26.58) 0.441 0.85 (0.29,2.46) 0.763 0.39 (0.06,2.49) 0.321 
Cadmium 0.68 (0.13,3.67) 0.652 1.21 (0.24,5.98) 0.817 2.12 (0.71,6.29) 0.178 1.79 (0.56,5.71) 0.322 
Lead 0.13 (0.01,1.76) 0.126 5.08 (0.16,159.28) 0.355 1.31 (0.34,5.08) 0.692 0.25 (0.03,2.16) 0.21 
OR – conditional logistic regression accounting for matching factors                                                                                                                                                                                                                                                    
*Significant at the 95% confidence level 
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Table 5.3.1ii: Association between log-transformed exposure levels and NHL risk by Subtype; 
stratified by gender 
Exposure                 
CLL  DLBCL FL  MM  
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
             Males n=25 
  
n=24 
  
n=19 
  
n=34 
  PCB118  0.58 (0.21,1.64) 0.305 0.51 (0.13,2.01) 0.335 0.31 (0.07,1.28) 0.105 0.74 (0.25,2.23) 0.596 
PCB138  0.29 (0.06,1.46) 0.135 0.69 (0.14,3.37) 0.645 0.38 (0.09,1.6) 0.186 0.48 (0.12,1.9) 0.296 
PCB153  0.20 (0.03,1.48) 0.115 0.56 (0.1,3.12) 0.508 0.38 (0.08,1.89) 0.237 0.54 (0.13,2.35) 0.415 
PCB156  0.16 (0.02,1.53) 0.11 0.38 (0.07,2.02) 0.258 0.38 (0.07,1.99) 0.253 0.57 (0.14,2.3) 0.426 
PCB170  0.14 (0.01,1.41) 0.097 0.51 (0.09,2.85) 0.44 0.56 (0.1,3.11) 0.51 0.59 (0.15,2.35) 0.457 
PCB180  0.15 (0.01,1.63) 0.119 0.51 (0.09,2.96) 0.453 0.61 (0.11,3.47) 0.575 0.79 (0.21,2.99) 0.732 
Dioxin-like 
PCBs  
0.58 (0.26,1.28) 0.178 0.56 (0.23,1.41) 0.22 0.51 (0.22,1.18) 0.116 0.76 (0.38,1.55) 0.458 
Non-Dioxin 
like PCBs 
0.62 (0.35,1.11) 0.106 0.85 (0.55,1.34) 0.488 0.81 (0.53,1.23) 0.316 0.86 (0.6,1.25) 0.433 
Immunotoxic 
PCBs 
0.68 (0.42,1.11) 0.127 0.79 (0.49,1.26) 0.324 0.74 (0.48,1.13) 0.168 0.84 (0.58,1.23) 0.377 
ΣPCBs 0.75 (0.53,1.07) 0.118 0.86 (0.63,1.18) 0.362 0.83 (0.63,1.11) 0.209 0.90 (0.7,1.16) 0.424 
HCB 0.27 (0.06,1.22) 0.089 0.42 (0.09,2.02) 0.28 0.70 (0.21,2.34) 0.565 0.52 (0.17,1.57) 0.248 
DDE  0.73 (0.31,1.76) 0.487 0.9 (0.36,2.29) 0.832 0.59 (0.25,1.37) 0.22 0.67 (0.28,1.59) 0.36 
Cadmium 0.43 (0.14,1.27) 0.125 0.84 (0.38,1.89) 0.681 1.51 (0.57,3.98) 0.404 0.77 (0.36,1.62) 0.489 
Lead 0.66 (0.23,1.92) 0.448 0.65 (0.22,1.97) 0.45 1.13 (0.23,5.62) 0.885 1.11 (0.45,2.7) 0.822 
             Females n=17 
  
n=21 
  
n=20 
  
n=42 
  PCB118  1.00 (0.26,3.88) 0.999 1.23 (0.26,5.86) 0.795 11.12 (0.88,140.92) 0.063 1.32 (0.56,3.07) 0.523 
PCB138  1.00 (0.35,2.79) 0.993 0.14 (0.01,1.29) 0.083 6.54 (0.69,61.6) 0.101 0.97 (0.33,2.8) 0.951 
PCB153  0.87 (0.25,3.11) 0.836 0.12 (0.01,1.37) 0.089 5.61 (0.55,57.19) 0.145 0.90 (0.27,2.99) 0.866 
PCB156  1.87 (0.27,12.8) 0.525 0.12 (0.01,1.22) 0.073 3.85 (0.51,29) 0.191 0.96 (0.29,3.15) 0.945 
PCB170  0.97 (0.24,3.9) 0.971 0.05 (0,0.94) 0.045* 3.81 (0.55,26.44) 0.176 0.99 (0.26,3.8) 0.988 
PCB180  0.94 (0.2,4.33) 0.936 0.06 (0,0.86) 0.038* 3.29 (0.53,20.56) 0.202 1.03 (0.27,3.92) 0.961 
HCB 1.16 (0.46,2.96) 0.753 0.62 (0.21,1.88) 0.399 4.15 (1,17.26) 0.05 1.11 (0.64,1.92) 0.702 
DDE  0.99 (0.7,1.38) 0.932 0.5 (0.25,0.98) 0.045 1.51 (0.87,2.6) 0.14 0.99 (0.72,1.37) 0.956 
Dioxin-like 
PCBs 
1.02 (0.69,1.51) 0.905 0.6 (0.31,1.14) 0.118 1.86 (0.98,3.54) 0.059 1.03 (0.76,1.39) 0.848 
Non-Dioxin 
like PCBs 
1.00 (0.78,1.29) 0.982 0.67 (0.43,1.04) 0.077 1.44 (0.96,2.15) 0.08 1.01 (0.82,1.25) 0.912 
Immunotoxic 
PCBs 
1.16 (0.15,9.07) 0.885 2.11 (0.44,9.99) 0.348 0.94 (0.3,2.92) 0.918 1.12 (0.28,4.44) 0.875 
ΣPCBs 0.99 (0.37,2.65) 0.985 0.85 (0.26,2.81) 0.795 1.36 (0.42,4.36) 0.609 0.65 (0.31,1.36) 0.251 
Cadmium 4.10 (0.69,24.28) 0.12 2.06 (0.62,6.81) 0.235 1.71 (0.5,5.81) 0.389 1.23 (0.73,2.08) 0.443 
Lead 1.57 (0.15,15.83) 0.704 1.69 (0.13,21.7) 0.686 1.59 (0.39,6.55) 0.52 1.13 (0.45,2.82) 0.793 
OR – conditional logistic regression accounting for matching factors                                                                                                                                                                                                                                                    
*Significant at the 95% confidence level 
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Table 5.3.2i; Association between log-transformed exposure levels and risk stratified by age 
group in NSHDS and EPIC-Italy 
Exposure  
  30-44 years       45-59 years                60-75 years            
 
OR 95% CI p-value 
 
OR 95% CI p-value 
 
OR 95% CI p-value 
              Sweden 
 
n cases=30, n controls=30 
 
n cases=119, n controls=109 
  
n cases=37, n controls=47 
 
 
PCB118  
 
0.34 (0.08,1.44) 0.145 
 
0.90 (0.56,1.47) 0.685 
 
2.08 (0.77,5.58) 0.146 
 
PCB138  
 
0.66 (0.22,1.98) 0.461 
 
0.77 (0.46,1.3) 0.334 
 
1.04 (0.34,3.16) 0.941 
 
PCB153  
 
0.62 (0.17,2.27) 0.471 
 
0.76 (0.42,1.39) 0.378 
 
0.88 (0.25,3.12) 0.841 
 
PCB156  
 
0.36 (0.06,2.31) 0.282 
 
0.85 (0.4,1.79) 0.666 
 
1.01 (0.27,3.68) 0.994 
 
PCB170  
 
0.58 (0.14,2.48) 0.464 
 
0.86 (0.41,1.77) 0.677 
 
0.83 (0.19,3.66) 0.802 
 
PCB180  
 
0.66 (0.15,2.93) 0.582 
 
0.87 (0.41,1.84) 0.711 
 
0.72 (0.15,3.44) 0.678 
 
Dioxin-like 
PCBs 
 
0.46 (0.17,1.27) 0.134 
 
0.93 (0.67,1.28) 0.642 
 
1.39 (0.74,2.64) 0.309 
 
Non-Dioxin 
like PCBs 
 
0.88 (0.63,1.24) 0.474 
 
0.94 (0.8,1.11) 0.460 
 
0.97 (0.69,1.37) 0.855 
 
Immunotoxic 
PCBs 
 
0.78 (0.5,1.21) 0.267 
 
0.95 (0.8,1.12) 0.513 
 
1.10 (0.78,1.53) 0.593 
 
ΣPCBs 
 
0.87 (0.66,1.15) 0.334 
 
0.96 (0.86,1.08) 0.503 
 
1.03 (0.82,1.3) 0.781 
 
HCB 
 
0.19 (0.02,1.94) 0.160 
 
0.65 (0.3,1.42) 0.280 
 
1.38 (0.27,7.08) 0.701 
 
DDE  
 
0.96 (0.32,2.91) 0.943 
 
0.76 (0.55,1.06) 0.111 
 
0.78 (0.39,1.56) 0.482 
 
Cadmium 
 
0.93 (0.48,1.79) 0.824 
 
1.19 (0.83,1.7) 0.346 
 
0.81 (0.41,1.58) 0.536 
 
Lead 
 
0.64 (0.26,1.53) 0.314 
 
1.65 (0.81,3.35) 0.169 
 
0.65 (0.17,2.41) 0.516 
              Italy  
 
n cases=10, n controls=10 
 
n cases=50, n controls=49 
  
n cases=24, n controls=25 
 
 
PCB118  
 
∆ 
   
0.83 (0.31,2.21) 0.709 
 
0.72 (0.18,2.89) 0.643 
 
PCB138  
     
0.93 (0.29,2.95) 0.904 
 
0.85 (0.16,4.6) 0.854 
 
PCB153  
     
0.76 (0.23,2.52) 0.655 
 
0.76 (0.16,3.62) 0.732 
 
PCB156  
     
0.73 (0.23,2.31) 0.599 
 
0.65 (0.13,3.32) 0.602 
 
PCB170  
     
0.84 (0.3,2.39) 0.742 
 
0.75 (0.13,4.27) 0.742 
 
PCB180  
     
1.05 (0.38,2.92) 0.919 
 
0.89 (0.17,4.74) 0.887 
 
Dioxin-like 
PCBs 
     
0.86 (0.47,1.56) 0.617 
 
0.79 (0.33,1.84) 0.579 
 
Non-Dioxin 
like PCBs 
     
0.97 (0.72,1.3) 0.839 
 
0.95 (0.62,1.44) 0.799 
 
Immunotoxic 
PCBs 
     
0.94 (0.69,1.28) 0.698 
 
0.91 (0.58,1.42) 0.669 
 
ΣPCBs 
     
0.97 (0.79,1.19) 0.755 
 
0.95 (0.71,1.27) 0.713 
 
HCB 
     
0.84 (0.45,1.57) 0.582 
 
0.33 (0.07,1.54) 0.158 
 
DDE  
     
1.42 (0.69,2.95) 0.344 
 
1.01 (0.41,2.5) 0.978 
 
Cadmium 
     
2.14 (1.03,4.42) 0.041* 
 
0.74 (0.19,2.93) 0.667 
  Lead           0.84 (0.27,2.6) 0.767   0.66 (0.15,2.9) 0.580 
∆ model would not  converge 
OR – conditional logistic regression accounting for matching factors                                                                                                                                                                                                                                                    
*Significant at the 95% confidence level 
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Table 5.3.2ii; Association between log-transformed levels and risk stratified by age group in 
males and females 
Exposure  
  30-44 years       45-59 years                60-75 years            
 
OR 95% CI p-value 
 
OR 95% CI p-value 
 
OR 95% CI p-value 
              Males 
 
n cases=25, n controls=25 
 
n cases=89, n controls=78 
  
n cases=19, n controls=30 
 
 
PCB118  
 
0.16 (0.02,1.19) 0.073 
 
0.59 (0.33,1.07) 0.082 
 
0.94 (0.28,3.08) 0.913 
 
PCB138  
 
0.16 (0.02,1.45) 0.103 
 
0.59 (0.3,1.18) 0.135 
 
0.75 (0.19,2.92) 0.677 
 
PCB153  
 
0.21 (0.02,1.99) 0.175 
 
0.52 (0.23,1.19) 0.123 
 
0.64 (0.15,2.8) 0.558 
 
PCB156  
 
0.14 (0.01,1.61) 0.113 
 
0.45 (0.17,1.14) 0.092 
 
0.74 (0.18,3.08) 0.679 
 
PCB170  
 
0.29 (0.04,2.19) 0.230 
 
0.56 (0.23,1.35) 0.196 
 
0.59 (0.11,3.14) 0.539 
 
PCB180  
 
0.46 (0.07,3.25) 0.436 
 
0.63 (0.26,1.49) 0.292 
 
0.56 (0.1,3.21) 0.516 
 
Dioxin-like 
PCBs 
 
0.21 (0.05,0.91) 0.037 
 
0.67 (0.45,1.01) 0.057 
 
0.90 (0.43,1.87) 0.779 
 
Non-Dioxin 
like PCBs 
 
0.68 (0.39,1.21) 0.191 
 
0.86 (0.69,1.06) 0.150 
 
0.89 (0.6,1.33) 0.566 
 
Immunotoxic 
PCBs 
 
0.49 (0.23,1.02) 0.056 
 
0.83 (0.67,1.02) 0.081 
 
0.92 (0.63,1.36) 0.683 
 
ΣPCBs 
 
0.68 (0.43,1.07) 0.095 
 
0.89 (0.77,1.02) 0.100 
 
0.94 (0.72,1.22) 0.630 
 
HCB 
 
0.05 (0,0.79) 0.033 
 
0.57 (0.29,1.12) 0.103 
 
0.48 (0.1,2.36) 0.363 
 
DDE  
 
0.57 (0.12,2.66) 0.472 
 
0.83 (0.57,1.2) 0.315 
 
0.59 (0.23,1.5) 0.268 
 
Cadmium 
 
0.82 (0.33,2.06) 0.674 
 
1.13 (0.76,1.68) 0.550 
 
0.23 (0.04,1.23) 0.086 
 
Lead 
 
0.53 (0.2,1.38) 0.194 
 
2.00 (0.89,4.52) 0.094 
 
0.19 (0.03,1.45) 0.110 
              Females 
 
n cases=15, n controls=15 
 
n cases=80, n controls=80 
  
n cases=42, n controls=42 
 
 
PCB118  
 
0.91 (0.18,4.55) 0.907 
 
1.75 (0.83,3.71) 0.142 
 
2.03 (0.73,5.63) 0.176 
 
PCB138  
 
0.65 (0.18,2.34) 0.513 
 
1.22 (0.57,2.59) 0.613 
 
1.27 (0.34,4.71) 0.718 
 
PCB153  
 
0.47 (0.08,2.79) 0.410 
 
1.22 (0.53,2.83) 0.644 
 
1.04 (0.27,4.1) 0.951 
 
PCB156  
 
0.17 (0.01,3.05) 0.227 
 
1.42 (0.59,3.45) 0.435 
 
0.97 (0.23,4.17) 0.972 
 
PCB170  
 
0.34 (0.03,3.26) 0.347 
 
1.31 (0.55,3.11) 0.544 
 
1.03 (0.21,5) 0.966 
 
PCB180  
 
0.25 (0.02,3.44) 0.303 
 
1.41 (0.58,3.41) 0.444 
 
1.05 (0.22,4.92) 0.953 
 
Dioxin-like 
PCBs 
 
0.68 (0.21,2.17) 0.512 
 
1.37 (0.86,2.18) 0.188 
 
1.39 (0.7,2.74) 0.342 
 
Non-Dioxin 
like PCBs 
 
0.81 (0.5,1.31) 0.400 
 
1.07 (0.86,1.34) 0.539 
 
1.03 (0.71,1.49) 0.885 
 
Immunotoxic 
PCBs 
 
0.82 (0.49,1.38) 0.456 
 
1.12 (0.89,1.41) 0.328 
 
1.13 (0.78,1.65) 0.512 
 
ΣPCBs 
 
0.86 (0.6,1.23) 0.417 
 
1.07 (0.92,1.25) 0.384 
 
1.06 (0.82,1.37) 0.639 
 
HCB 
 
2.18 (0.31,15.15) 0.430 
 
1.09 (0.52,2.27) 0.824 
 
0.80 (0.18,3.55) 0.771 
 
DDE  
 
1.09 (0.26,4.58) 0.903 
 
0.89 (0.55,1.43) 0.619 
 
1.15 (0.54,2.43) 0.722 
 
Cadmium 
 
1.09 (0.46,2.58) 0.851 
 
1.87 (1.06,3.27) 0.030 
 
1.39 (0.61,3.14) 0.432 
  Lead   1.37 (0.21,8.86) 0.742   0.81 (0.32,2.04) 0.660   1.19 (0.35,4.07) 0.785 
OR – conditional logistic regression accounting for matching factors                                                                                                                                                                                                                                                    
*Significant at the 95% confidence level 
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Table 5.3.2iii Association between log transformed exposure levels and NHL risk stratified by 
time to diagnosis in NSHDS and EPIC-Italy 
Exposure (log 
pg/ml) 
  <5 years        ≥ 5 years      
 
OR 95% CI p-value 
 
OR 95% CI p-value 
          Sweden 
 
n cases=70, n controls=186 
 
n cases=116, n controls=186 
 
PCB118  
 
1.08 (0.65,1.78) 0.766 
 
0.91 (0.6,1.39) 0.662 
 
PCB138  
 
0.66 (0.39,1.12) 0.123 
 
0.74 (0.45,1.19) 0.214 
 
PCB153  
 
0.63 (0.33,1.17) 0.144 
 
0.71 (0.4,1.27) 0.253 
 
PCB156  
 
0.77 (0.35,1.69) 0.51 
 
0.79 (0.41,1.5) 0.467 
 
PCB170  
 
0.62 (0.28,1.36) 0.23 
 
0.84 (0.43,1.67) 0.627 
 
PCB180  
 
0.56 (0.25,1.27) 0.167 
 
0.84 (0.42,1.69) 0.623 
 
Dioxin-like 
PCBs 
 
0.99 (0.7,1.39) 0.933 
 
0.91 (0.69,1.22) 0.536 
 
Non-Dioxin like 
PCBs 
 
0.88 (0.73,1.04) 0.137 
 
0.93 (0.79,1.09) 0.346 
 
Immunotoxic 
PCBs 
 
0.93 (0.78,1.1) 0.4 
 
0.94 (0.8,1.09) 0.404 
 
ΣPCBs 
 
0.94 (0.83,1.06) 0.287 
 
0.95 (0.86,1.06) 0.389 
 
HCB 
 
1.26 (0.56,2.84) 0.579 
 
0.56 (0.28,1.12) 0.103 
 
DDE  
 
0.74 (0.52,1.05) 0.089 
 
0.66 (0.48,0.91) 0.012* 
 
Cadmium 
 
0.92 (0.63, 1.33) 0.652 
 
0.99 (0.74, 1.33) 0.939 
 
Lead 
 
0.68 (0.36, 1.28) 0.23 
 
0.98 (0.58, 1.65) 0.941 
          Italy  
 
n cases=38, n controls=84 
 
n cases=33, n controls=84 
 
PCB118  
 
0.35 (0.12,1) 0.050* 
 
1.38 (0.46,4.19) 0.566 
 
PCB138  
 
0.53 (0.16,1.77) 0.3 
 
0.56 (0.15,2.11) 0.39 
 
PCB153  
 
0.50 (0.14,1.77) 0.285 
 
0.38 (0.1,1.48) 0.162 
 
PCB156  
 
0.58 (0.18,1.89) 0.368 
 
0.32 (0.08,1.24) 0.099 
 
PCB170  
 
0.65 (0.2,2.09) 0.468 
 
0.28 (0.07,1.18) 0.084 
 
PCB180  
 
0.81 (0.26,2.57) 0.723 
 
0.50 (0.14,1.79) 0.286 
 
Dioxin-like 
PCBs 
 
0.59 (0.32,1.11) 0.1 
 
0.83 (0.42,1.63) 0.589 
 
Non-Dioxin like 
PCBs 
 
0.88 (0.64,1.2) 0.407 
 
0.79 (0.55,1.12) 0.182 
 
Immunotoxic 
PCBs 
 
0.80 (0.58,1.11) 0.179 
 
0.83 (0.58,1.2) 0.32 
 
ΣPCBs 
 
0.88 (0.71,1.09) 0.253 
 
0.87 (0.69,1.11) 0.269 
 
HCB 
 
0.41 (0.19,0.9) 0.025* 
 
0.77 (0.36,1.64) 0.495 
 
DDE  
 
0.78 (0.39,1.55) 0.474 
 
1.72 (0.85,3.47) 0.13 
 
Cadmium 
 
0.40 (0.12, 1.31) 0.132 
 
1.56 (0.68, 3.58) 0.292 
 Lead  1.56 (0.79, 3.08) 0.204  0.59 (0.17, 2.07) 0.41 
OR – conditional logistic regression accounting for matching factors                                                                                                                                                                                                                                                    
*Significant at the 95% confidence level 
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Table 5.3.2iv Association between log transformed exposure levels and NHL risk stratified by 
time to diagnosis in Males and females 
Exposure (log pg/ml) 
  <5 years        ≥ 5 years      
 
OR 95% CI p-value 
 
OR 95% CI p-value 
          Males 
 
 
n cases=60, n controls=133 
 
n cases=71, n controls=133 
 
PCB118  
 
0.59 (0.32,1.07) 0.083 
 
0.54 (0.3,0.95) 0.034* 
 
PCB138  
 
0.57 (0.3,1.07) 0.082 
 
0.47 (0.23,0.95) 0.036* 
 
PCB153  
 
0.46 (0.21,1.01) 0.054* 
 
0.4 (0.17,0.92) 0.031* 
 
PCB156  
 
0.50 (0.2,1.28) 0.148 
 
0.32 (0.13,0.8) 0.015* 
 
PCB170  
 
0.42 (0.17,1.06) 0.066 
 
0.42 (0.16,1.1) 0.078 
 
PCB180  
 
0.44 (0.17,1.13) 0.088 
 
0.49 (0.18,1.29) 0.149 
 
Dioxin-like 
PCBs 
 
0.69 (0.46,1.04) 0.075 
 
0.61 (0.41,0.9) 0.013* 
 
Non-Dioxin 
like PCBs 
 
0.82 (0.66,1.01) 0.059 
 
0.79 (0.63,1) 0.047* 
 
Immunotoxic 
PCBs 
 
0.82 (0.66,1.01) 0.057 
 
0.77 (0.62,0.96) 0.018* 
 
ΣPCBs 
 
0.87 (0.75,1) 0.055 
 
0.84 (0.72,0.98) 0.024* 
 
HCB 
 
0.46 (0.22,0.96) 0.039* 
 
0.48 (0.23,0.98) 0.045* 
 
DDE  
 
0.75 (0.5,1.13) 0.174 
 
0.71 (0.46,1.08) 0.111 
 
Cadmium 
 
0.78 (0.50, 1.20) 0.26 
 
1.63 (0.99, 2.68) 0.055 
 
Lead 
 
0.38  (0.17, 0.83) 0.016* 
 
1.02  (0.54, 1.92) 0.947 
          Females 
 
 
n cases=48, n controls=137 
 
n cases=78, n controls=137 
 
PCB118  
 
1.38 (0.68,2.8) 0.369 
 
1.61 (0.91,2.85) 0.099 
 
PCB138  
 
0.83 (0.39,1.81) 0.647 
 
0.94 (0.51,1.72) 0.829 
 
PCB153  
 
0.96 (0.39,2.34) 0.925 
 
0.87 (0.43,1.78) 0.71 
 
PCB156  
 
1.10 (0.43,2.82) 0.85 
 
1.11 (0.51,2.41) 0.796 
 
PCB170  
 
1.12 (0.44,2.89) 0.808 
 
0.92 (0.42,2.01) 0.833 
 
PCB180  
 
1.12 (0.42,2.94) 0.825 
 
0.94 (0.43,2.08) 0.884 
 
Dioxin-like 
PCBs 
 
1.17 (0.74,1.86) 0.496 
 
1.26 (0.87,1.83) 0.222 
 
Non-Dioxin 
like PCBs 
 
0.99 (0.78,1.26) 0.961 
 
0.98 (0.81,1.18) 0.8 
 
Immunotoxic 
PCBs 
 
1.03 (0.81,1.31) 0.781 
 
1.05 (0.87,1.28) 0.602 
 
ΣPCBs 
 
1.02 (0.86,1.2) 0.835 
 
1.02 (0.89,1.16) 0.794 
 
HCB 
 
0.99 (0.43,2.24) 0.973 
 
1.04 (0.49,2.21) 0.917 
 
DDE  
 
0.73 (0.46,1.16) 0.186 
 
0.86 (0.57,1.28) 0.452 
 
Cadmium 
 
1.66 (1.01, 2.73) 0.046* 
 
1.20 (0.80, 1.81) 0.376  
 Lead  0.89 (0.39, 2.06) 0.79  0.75 (0.35, 1.60) 0.456 
OR – conditional logistic regression accounting for matching factors                                                                                                                                                                                                                                                    
*Significant at the 95% confidence level 
 
 
 
254 
 
Table 5.3.2v Association between log-transformed levels and risk stratified by BMI category in 
NSHDS and EPIC-Italy 
Exposure             
(log pg/ml) 
  Normal   Overweight   Obese 
 
OR 95% CI p-value 
 
OR 95% CI p-value 
 
OR 95% CI p-value 
              Sweden 
 
n cases=73, n controls=79 
  
n cases=83, n controls=76 
  
n cases=26, n controls=27 
 
PCB118  
 
0.96 (0.41,2.22) 0.919 
 
0.77 (0.35,1.72) 0.526 
 
0.69 (0.09,5.47) 0.723 
 
PCB138  
 
0.71 (0.32,1.59) 0.406 
 
0.24 (0.06,0.96) 0.044* 
 
0.31 (0.02,5.24) 0.415 
 
PCB153  
 
0.64 (0.25,1.67) 0.363 
 
0.26 (0.06,1.17) 0.079 
 
0.10 (0,5.30) 0.252 
 
PCB156  
 
0.55 (0.19,1.64) 0.285 
 
0.53 (0.13,2.13) 0.374 
 
0.09 (0,5.17) 0.242 
 
PCB170  
 
0.61 (0.2,1.87) 0.390 
 
0.51 (0.12,2.13) 0.359 
 
0.00 (0,11.1) 0.171 
 
PCB180  
 
0.59 (0.18,1.9) 0.373 
 
0.39 (0.09,1.78) 0.226 
 
0.00 (0,13.48) 0.174 
 
Dioxin-like 
PCBs 
 
0.85 (0.5,1.44) 0.542 
 
0.78 (0.44,1.4) 0.407 
 
0.61 (0.15,2.47) 0.488 
 
Non-Dioxin 
like PCBs 
 
0.89 (0.69,1.15) 0.371 
 
0.73 (0.5,1.06) 0.096 
 
0.45 (0.13,1.52) 0.198 
 
Immunotoxic 
PCBs 
 
0.90 (0.69,1.17) 0.438 
 
0.80 (0.57,1.11) 0.185 
 
0.65 (0.28,1.53) 0.328 
 
ΣPCBs 
 
0.93 (0.78,1.11) 0.406 
 
0.84 (0.66,1.07) 0.151 
 
0.69 (0.36,1.31) 0.258 
 
HCB 
 
1.02 (0.26,3.94) 0.982 
 
0.47 (0.11,2.01) 0.307 
 
0.00 (0,6.08) 0.132 
 
DDE  
 
0.82 (0.43,1.55) 0.546 
 
0.28 (0.1,0.76) 0.013* 
 
0.74 (0.06,9.35) 0.818 
 
Cadmium 
 
0.94 (0.53,1.68) 0.846 
 
2.24 (1.03,4.88) 0.043* 
 
0.33 (0.02,4.84) 0.421 
 
Lead 
 
3.66 (0.93,14.4) 0.063 
 
0.96 (0.34,2.67) 0.932 
 
1.31 (0.19,9.14) 0.785 
              Italy  
 
n cases=32, n controls=30 
  
n cases=38, n controls=42 
  
n cases=14, n controls=12 
 
PCB118  
 
0.90 (0.06,14.73) 0.942 
 
0.17 (0.02,1.2) 0.075 
 
∆ 
  
 
PCB138  
 
2.23 (0.11,44.39) 0.599 
 
0.03 (0,1.51) 0.079 
    
 
PCB153  
 
4.34 (0.14,135.04) 0.403 
 
0.03 (0,1.61) 0.085 
    
 
PCB156  
 
39.77 (0.37,4280.14) 0.123 
 
0.09 (0,1.85) 0.119 
    
 
PCB170  
 
8.10 (0.26,250.69) 0.232 
 
0.12 (0.01,1.84) 0.126 
    
 
PCB180  
 
6.62 (0.26,166.65) 0.251 
 
0.19 (0.02,1.79) 0.147 
    
 
Dioxin-like 
PCBs 
 
12.96 (0.19,887.66) 0.235 
 
0.32 (0.09,1.12) 0.074 
    
 
Non-Dioxin 
like PCBs 
 
1.60 (0.65,3.91) 0.303 
 
0.50 (0.22,1.13) 0.097 
    
 
Immunotoxic 
PCBs 
 
2.56 (0.58,11.3) 0.214 
 
0.49 (0.22,1.09) 0.082 
    
 
ΣPCBs 
 
1.65 (0.73,3.72) 0.231 
 
0.61 (0.35,1.08) 0.089 
    
 
HCB 
 
1.55 (0.34,7.19) 0.573 
 
0.26 (0.05,1.4) 0.117 
    
 
DDE  
 
0.85 (0.14,5.01) 0.856 
 
0.30 (0.06,1.36) 0.118 
    
 
Cadmium 
 
6.09 (0.7,52.63) 0.101 
 
0.26 (0.05,1.39) 0.115 
      Lead   1.02 (0.03,31.01) 0.991   0.38 (0.08,1.83) 0.228         
∆ model would not  converge 
OR – conditional logistic regression accounting for matching factors                                                                                                                                                                                                                                                    
*Significant at the 95% confidence level 
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Table 5.3.2vi Association between log-transformed exposure levels and risk stratified by BMI 
category in males and females 
Exposure (log 
pg/ml) 
  Normal   Overweight   Obese 
 
OR 95% CI p-value 
 
OR 95% CI p-value 
 
OR 95% CI p-value 
              Males 
 
n cases=41, n controls=39 
  
n cases=73, n controls=73 
  
n cases=18, n controls=19 
 
PCB118  
 
0.74 (0.16,3.4) 0.695 
 
0.48 (0.18,1.23) 0.127 
 
∆ 
  
 
PCB138  
 
1.61 (0.16,16.34) 0.689 
 
0.15 (0.03,0.73) 0.019* 
    
 
PCB153  
 
2.13 (0.15,30.8) 0.580 
 
0.14 (0.03,0.78) 0.024* 
    
 
PCB156  
 
1.08 (0.2,5.87) 0.925 
 
0.28 (0.06,1.22) 0.090 
    
 
PCB170  
 
2.22 (0.22,22.17) 0.497 
 
0.28 (0.07,1.17) 0.081 
    
 
PCB180  
 
3.18 (0.25,41.12) 0.375 
 
0.30 (0.07,1.23) 0.095 
    
 
Dioxin-like 
PCBs 
 
0.90 (0.33,2.46) 0.838 
 
0.56 (0.29,1.06) 0.076 
    
 
Non-Dioxin 
like PCBs 
 
1.26 (0.65,2.45) 0.495 
 
0.65 (0.43,0.97) 0.037* 
    
 
Immunotoxic 
PCBs 
 
1.05 (0.58,1.92) 0.866 
 
0.67 (0.46,0.99) 0.043* 
    
 
ΣPCBs 
 
1.09 (0.71,1.67) 0.708 
 
0.76 (0.58,0.99) 0.040* 
    
 
HCB 
 
0.46 (0.05,3.84) 0.472 
 
0.24 (0.06,0.92) 0.037* 
    
 
DDE  
 
1.13 (0.14,9) 0.908 
 
0.39 (0.16,0.94) 0.037* 
    
 
Cadmium 
 
1.97 (0.55,7.12) 0.299 
 
0.94 (0.44,2.01) 0.873 
    
 
Lead 
 
3.46 (0.43,27.64) 0.242 
 
0.81 (0.3,2.2) 0.674 
    
              Females 
 
n cases=64, n controls=70 
  
n cases=48, n controls=45 
  
n cases=22, n controls=20 
 
PCB118  
 
1.05 (0.41,2.74) 0.913 
 
0.82 (0.25,2.75) 0.753 
 
0.76 (0.1,5.68) 0.793 
 
PCB138  
 
0.70 (0.31,1.61) 0.402 
 
0.20 (0.02,1.78) 0.150 
 
0.31 (0.02,4.66) 0.394 
 
PCB153  
 
0.65 (0.24,1.71) 0.380 
 
0.25 (0.03,2.35) 0.223 
 
0.14 (0,5.93) 0.307 
 
PCB156  
 
0.65 (0.19,2.25) 0.501 
 
0.60 (0.06,5.71) 0.653 
 
0.17 (0.01,5.82) 0.326 
 
PCB170  
 
0.64 (0.2,2.06) 0.457 
 
0.60 (0.06,5.92) 0.659 
 
0.01 (0,37.71) 0.270 
 
PCB180  
 
0.60 (0.18,1.99) 0.400 
 
0.33 (0.03,3.84) 0.376 
 
0.01 (0,28.84) 0.235 
 
Dioxin-like 
PCBs 
 
0.92 (0.51,1.68) 0.790 
 
0.83 (0.34,2.02) 0.682 
 
0.66 (0.19,2.31) 0.520 
 
Non-Dioxin 
like PCBs 
 
0.89 (0.69,1.16) 0.395 
 
0.70 (0.39,1.25) 0.226 
 
0.53 (0.17,1.64) 0.268 
 
Immunotoxic 
PCBs 
 
0.92 (0.7,1.21) 0.549 
 
0.80 (0.5,1.31) 0.380 
 
0.71 (0.33,1.53) 0.385 
 
ΣPCBs 
 
0.94 (0.78,1.13) 0.484 
 
0.84 (0.59,1.19) 0.324 
 
0.75 (0.42,1.35) 0.332 
 
HCB 
 
1.73 (0.52,5.78) 0.371 
 
0.97 (0.15,6.35) 0.971 
 
0.01 (0,23.08) 0.240 
 
DDE  
 
0.80 (0.43,1.5) 0.491 
 
0.05 (0,1.14) 0.061 
 
0.26 (0.02,3.42) 0.304 
 
Cadmium 
 
1.04 (0.57,1.88) 0.895 
 
2.54 (0.81,7.95) 0.109 
 
1.09 (0.01,92.54) 0.969 
  Lead   2.91 (0.61,13.91) 0.181   0.52 (0.11,2.56) 0.422   0.50 (0.01,42.85) 0.761 
∆ model would not  converge 
OR – conditional logistic regression accounting for matching factors                                                                                                                                                                                                                                                    
*Significant at the 95% confidence level 
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6. METABOLIC PROFILING OF AN NHL CASE 
CONTROL STUDY TO IDENTIFY PREDICTIVE 
METABOLIC BIOMARKERS 
 
Table 6.3.1: Baseline characteristics of cases and controls in the EnviroGenoMarkers study 
Baseline variable 
Case (n=210) Control (n=210) 
Difference 
(p-value) [no. (%)] [no. (%)] 
Cohort Epic-Italy 27 (12.9) 27 (12.9) 
 
 
NSHDS 183 (87.1) 183 (87.1) 
 
Sex Male 108 (51.4) 108 (51.4) 
 
 
Female 102 (48.6) 102 (48.6) 
 
Mean Age (yrs) 52.75 52.75 0.997 
Mean Height (cm) 171.10 169.30 0.046* 
Mean Weight (kg) 77.78 76.25 0.283 
BMI Underweight 1 (0.5) 0 (0.0) 
 
 
Normal 82 (39.0) 84 (40.0) 
 
 
Overweight 94 (44.8) 91 (43.3) 
 
 
Obese 29 (13.8) 31 (14.8) 
 
 
nk 4 (1.9) 4 (1.9) 0.768 
Smoking 
status Never 87 (41.4) 101 (48.1) 
 
 
Former 73 (34.8) 55 (26.2) 
 
 
Current 48 (22.9) 44 (21.0) 
 
 
nk 2 (1.0) 10 (4.8) 0.166 
Highest 
educational 
level None 2 (1.0) 1 (0.5) 
 
 
Primary 65 (31.0) 64 (30.5) 
 
 
Technical/professional 56 (26.7) 49 (23.3) 
 
 
Secondary 42 (20.0) 51 (24.3) 
 
 
University/college 40 (19.1) 34 (16.2) 
 
 
nk 5 (2.4) 11 (5.2) 0.722 
Cambridge 
physical 
activity index Inactive 64 (30.5) 58 (27.6) 
 
 
Moderately inactive 82 (39.1) 76 (36.2) 
 
 
Moderately active 53 (25.2) 60 (28.6) 
 
 
Active 10 (4.8) 15 (7.1) 
 
  nk 1 (0.5) 1 (0.5) 0.581 
 
 
257 
 
Figure 6.3.1i: Percentage Coefficient of Variance (CV%) of feature intensity for the 750 
included metabolite features in the discovery cohort and validation cohorts of the 
EnviroGenoMarkers Study 
(A) Correlation between CV% in NSHDS (NS) and EPIC-ITALY (EPIC), (B) Histogram of CV% in 
EPIC-Italy, (C) Histogram of CV% in NSHDS 
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Figure 6.3.1ii: Correlation matrix describing the correlation between feature intensity for the 
750 metabolite features in the discovery cohort and validation cohorts of the 
EnviroGenoMarkers Study 
Computed using Spearman’s rank correlation coefficient and raw intensity values 
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Figure 6.3.1iii: Score plot of the first two components following principal components analysis 
of 750 metabolite features in the discovery cohort and validation cohorts of the 
EnviroGenoMarkers Study 
Coloured by sex, cohort, study phase and metabolomics processing batch 
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Table 6.3.2i: Number of metabolite features associated with lifestyle, anthropometric and 
lifestyle covariates at differing levels of statistical significance 
Covariate 
n Significant Associations (p) 
<0.05 <0.01 
 <6.67x10
-4
 
(bonferroni) 
BMI (kg/m2)2,3 196 138 59 
Height (cm) 214 149 39 
Weight (kg) 59 23 2 
Educational levela,2,3 99 49 4 
Smoking statusb 37 13 0 
Cambridge physical activity indexc 24 1 0 
Alcohol (g/day)2,3 67 26 6 
Vegetable intake (g/day)2 46 11 0 
Dairy products (g/day)2 50 10 0 
Protein (g/day)2 94 17 0 
Total fats (g/day)2,3 192 89 4 
Energy (kcal/day)2,3 147 36 2 
Fish (g/day)2 65 12 1 
Fruit (g/day)2 42 12 0 
Computed using linear regression where log transformed metabolite feature intensity levels were considered as the outcome variable, and 
the covariate was considered as a continuous explanatory variable. aEducational level; 0-None, 1-primary, 2-Technical/professional, 3-
secondary, 4-university/college. bSmoking status 0-never, 1-former, 2-current. cPhysical activity 0-inactive, 1-moderately inactive, 2-
moderately active, 3-active.                                                                                                                                                                                                
2 variables included in model 2                                                                                                                                                                                         
3variables included in model 3 
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Table 6.3.2ii: Association between NHL risk and metabolite feature intensity quartiles for 19 
selected features 
Metabolite 
Feature 
Conditional Model1 (conditional + 10 covars) Model2 (conditional + 5 covars) 
OR 95% CI p-value p-trend OR 95% CI p-value p-trend OR 95% CI p-value 
p-
trend 
EPIC_NSHDS_15 
            1 1 
   
1 
   
1 
   2 1.66 (0.86,3.21) 0.134 
 
3.93 (1.53,10.1) 0.004* 
 
2.68 (1.19,6.03) 0.018* 
 3 2.29 (1.08,4.84) 0.031* 
 
5.72 (1.98,16.53) 0.001* 
 
3.77 (1.47,9.65) 0.006* 
 4 2.21 (0.99,4.95) 0.054* 0.058 4.85 (1.58,14.94) 0.006* 0.013* 3.18 (1.17,8.6) 0.023* 0.037* 
EPIC_NSHDS_172 
           1 1 
   
1 
   
1 
   2 1.35 (0.7,2.61) 0.366 
 
1.19 (0.55,2.59) 0.662 
 
1.12 (0.54,2.32) 0.754 
 3 1.50 (0.76,2.97) 0.246 
 
1.80 (0.82,3.97) 0.145 
 
1.80 (0.84,3.88) 0.13 
 4 1.93 (1,3.72) 0.051* 0.050* 1.87 (0.86,4.07) 0.112 0.07 1.72 (0.83,3.59) 0.146 0.089 
EPIC_NSHDS_231 
           1 1 
   
1 
   
1 
   2 0.95 (0.52,1.75) 0.867 
 
0.81 (0.39,1.71) 0.581 
 
0.71 (0.35,1.44) 0.349 
 3 0.76 (0.39,1.48) 0.419 
 
0.59 (0.26,1.34) 0.209 
 
0.60 (0.27,1.31) 0.196 
 4 1.57 (0.69,3.53) 0.281 0.612 1.37 (0.5,3.77) 0.544 0.936 1.41 (0.54,3.67) 0.484 0.988 
EPIC_NSHDS_286 
           1 1 
   
1 
   
1 
   2 1.17 (0.54,2.53) 0.686 
 
1.24 (0.52,2.96) 0.626 
 
1.37 (0.59,3.19) 0.46 
 3 1.29 (0.54,3.12) 0.567 
 
1.55 (0.55,4.4) 0.408 
 
1.39 (0.52,3.71) 0.511 
 4 2.93 (0.98,8.73) 0.054* 0.079 4.13 (1.07,15.98) 0.040* 0.063 3.97 (1.07,14.78) 0.040* 0.078 
EPIC_NSHDS_375 
           1 1 
   
1 
   
1 
   2 1.52 (0.82,2.84) 0.186 
 
1.79 (0.87,3.7) 0.115 
 
1.64 (0.82,3.28) 0.166 
 3 1.47 (0.76,2.84) 0.255 
 
2.17 (0.98,4.81) 0.055* 
 
1.88 (0.88,4) 0.102 
 4 1.42 (0.73,2.75) 0.304 0.437 1.15 (0.51,2.58) 0.735 0.749 1.16 (0.54,2.49) 0.707 0.765 
EPIC_NSHDS_482# 
           1 1 
   
1 
   
1 
   
2 1.82 (0.94,3.53) 0.074 
 
1.31 (0.58,2.95) 0.514 
 
1.42 (0.65,3.11) 0.379 
 3 1.97 (1.08,3.61) 0.027* 
 
1.45 (0.7,2.99) 0.32 
 
1.59 (0.79,3.19) 0.197 
 4 2.57 (1.32,5.01) 0.005* 0.007* 2.13 (0.96,4.72) 0.064 0.053* 2.20 (1.03,4.69) 0.042* 0.035* 
EPIC_NSHDS_513 
           1 1 
   
1 
   
1 
   2 1.17 (0.65,2.13) 0.603 
 
1.20 (0.59,2.45) 0.609 
 
1.12 (0.57,2.21) 0.742 
 3 1.49 (0.79,2.78) 0.215 
 
1.39 (0.65,2.96) 0.395 
 
1.63 (0.79,3.37) 0.182 
 4 1.54 (0.77,3.08) 0.224 0.166 1.38 (0.6,3.14) 0.446 0.388 1.46 (0.66,3.26) 0.353 0.225 
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Table 6.3.2ii continued 
Metabolite 
Feature 
Conditional Model1 (conditional + 10 covars) Model2 (conditional + 5 covars) 
OR 95% CI p-value p-trend OR 95% CI p-value p-trend OR 95% CI p-value p-trend 
EPIC_NSHDS_514# 
           1 1 
   
1 
   
1 
   2 0.88 (0.46,1.68) 0.693 
 
0.77 (0.35,1.67) 0.508 
 
0.85 (0.41,1.79) 0.673 
 3 1.52 (0.81,2.86) 0.191 
 
1.11 (0.5,2.48) 0.799 
 
1.34 (0.63,2.87) 0.447 
 4 1.99 (1.05,3.79) 0.035* 0.013* 2.55 (1.16,5.58) 0.019* 0.011* 2.93 (1.37,6.27) 0.005* 0.003* 
EPIC_NSHDS_516 
           
1 1 
   
1 
   
1 
   2 1.33 (0.69,2.54) 0.392 
 
1.35 (0.59,3.06) 0.474 
 
1.20 (0.54,2.64) 0.656 
 3 1.13 (0.59,2.15) 0.708 
 
1.16 (0.53,2.56) 0.712 
 
1.17 (0.55,2.49) 0.685 
 4 1.33 (0.68,2.62) 0.407 0.554 1.38 (0.6,3.18) 0.455 0.603 1.32 (0.59,2.95) 0.503 0.557 
EPIC_NSHDS_523 
           1 1 
   
1 
   
1 
   2 1.45 (0.76,2.77) 0.257 
 
1.42 (0.65,3.1) 0.385 
 
1.51 (0.72,3.2) 0.277 
 3 1.38 (0.73,2.6) 0.322 
 
1.29 (0.6,2.8) 0.516 
 
1.50 (0.71,3.17) 0.291 
 4 2.78 (1.31,5.91) 0.008* 0.016* 2.56 (1.02,6.42) 0.045* 0.081 2.6 (1.08,6.29) 0.034* 0.051* 
EPIC_NSHDS_558 
           1 1 
   
1 
   
1 
   2 1.40 (0.49,4.03) 0.533 
 
1.71 (0.45,6.46) 0.429 
 
1.43 (0.4,5.15) 0.583 
 3 1.56 (0.51,4.77) 0.436 
 
2.11 (0.51,8.81) 0.305 
 
1.65 (0.42,6.49) 0.474 
 4 2.18 (0.73,6.51) 0.162 0.105 2.89 (0.72,11.65) 0.136 0.105 2.48 (0.65,9.43) 0.183 0.102 
EPIC_NSHDS_587# 
           1 1 
   
1 
   
1 
   2 0.93 (0.49,1.77) 0.833 
 
1.01 (0.48,2.14) 0.975 
 
0.96 (0.47,1.99) 0.923 
 3 1.32 (0.72,2.44) 0.371 
 
1.39 (0.68,2.85) 0.365 
 
1.31 (0.66,2.62) 0.442 
 4 1.86 (1,3.45) 0.048* 0.019* 2.10 (1.01,4.37) 0.048* 0.034* 1.94 (0.97,3.87) 0.061 0.042* 
EPIC_NSHDS_61 
           1 1 
   
1 
   
1 
   2 4.40 (2.08,9.29) <0.001* 
 
4.09 (1.76,9.52) 0.001* 
 
4.21 (1.86,9.53) 0.001* 
 3 2.92 (1.36,6.29) 0.006* 
 
2.47 (1.03,5.93) 0.043* 
 
2.27 (0.98,5.27) 0.056 
 4 3.37 (1.6,7.11) 0.001* 0.038* 2.89 (1.16,7.22) 0.023* 0.144 2.38 (1.01,5.59) 0.047* 0.299 
EPIC_NSHDS_781 
           1 1 
   
1 
   
1 
   2 0.86 (0.44,1.68) 0.661 
 
0.93 (0.45,1.92) 0.836 
 
0.97 (0.48,1.99) 0.942 
 3 0.41 (0.15,1.15) 0.092 
 
0.36 (0.11,1.17) 0.09 
 
0.39 (0.13,1.22) 0.107 
 4 0.36 (0.1,1.35) 0.13 0.119 0.36 (0.07,1.81) 0.216 0.172 0.39 (0.09,1.78) 0.225 0.182 
EPIC_NSHDS_796 
           1 1 
   
1 
   
1 
   2 0.92 (0.52,1.65) 0.791 
 
0.82 (0.39,1.69) 0.585 
 
0.84 (0.42,1.66) 0.612 
 3 1.08 (0.6,1.96) 0.788 
 
1.08 (0.53,2.2) 0.84 
 
1.12 (0.57,2.2) 0.743 
 4 0.60 (0.31,1.17) 0.135 0.264 0.47 (0.21,1.06) 0.069 0.173 0.51 (0.24,1.09) 0.085 0.219 
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Table 6.3.2ii continued 
Metabolite 
Feature 
Conditional Model1 (conditional + 10 covars) Model2 (conditional + 5 covars) 
OR 95% CI p-value p-trend OR 95% CI p-value p-trend OR 95% CI p-value p-trend 
             EPIC_NSHDS_803 
           1 1 
   
1 
   
1 
   2 1.04 (0.62,1.77) 0.874 
 
0.86 (0.47,1.6) 0.644 
 
0.98 (0.55,1.78) 0.959 
 3 0.52 (0.28,0.98) 0.041* 
 
0.45 (0.21,0.97) 0.040* 
 
0.53 (0.26,1.09) 0.084 
 4 0.59 (0.3,1.16) 0.127 0.038* 0.55 (0.24,1.28) 0.167 0.064 0.61 (0.28,1.36) 0.231 0.103 
EPIC_NSHDS_861 
 
          1 1 
   
1 
   
1 
   2 0.71 (0.39,1.27) 0.248 
 
0.85 (0.42,1.73) 0.654 
 
0.82 (0.42,1.64) 0.581 
 3 0.74 (0.38,1.45) 0.388 
 
0.91 (0.41,2.02) 0.819 
 
0.87 (0.4,1.87) 0.713 
 4 0.73 (0.38,1.42) 0.357 0.35 0.90 (0.41,1.99) 0.8 0.802 0.91 (0.42,1.95) 0.807 0.788 
EPIC_NSHDS_871 
 
          1 1 
   
1 
   
1 
   2 1.00 (0.55,1.82) 0.99 
 
0.69 (0.32,1.51) 0.355 
 
0.63 (0.3,1.33) 0.228 
 3 0.95 (0.5,1.81) 0.872 
 
0.54 (0.23,1.26) 0.157 
 
0.52 (0.24,1.14) 0.102 
 4 1.29 (0.65,2.53) 0.467 0.505 1.10 (0.46,2.66) 0.83 0.787 0.89 (0.4,2.01) 0.787 0.837 
EPIC_NSHDS_888# 
 
          1 1 
   
1 
   
1 
   2 2.10 (0.98,4.51) 0.057* 
 
2.48 (0.99,6.23) 0.053 
 
2.68 (1.09,6.56) 0.032* 
 3 2.30 (1.01,5.24) 0.046* 
 
2.56 (0.95,6.85) 0.062 
 
2.77 (1.07,7.16) 0.035* 
 4 2.79 (1.17,6.66) 0.021* 0.035* 4.56 (1.55,13.38) 0.006* 0.010* 3.77 (1.37,10.36) 0.010* 0.022* 
Ordered quartile intensities were computed based on the distribution in the controls 
The Odds ratio represents the increase in odds of incident NHL in each quartile of intensity                                                                      
*Significant at the 95% confidence level                                                                                                                                                                     
Model 1 included BMI, educational level, alcohol consumption, vegetable consumption, dairy product consumption, protein consumption, 
total fat consumption, energy intake, fruit consumption and fish consumption                                                                                                           
Model 2 included BMI, educational level, alcohol consumption, total fat and energy consumption 
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Table 6.3.2iii Pearson’s correlation coefficient between the 19 top metabolite features identified in the discovery set 
selected on the basis of a significant (p<0.05) association with NHL under at least one of the logistic regression models in the discovery set 
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EPIC_NSHDS_15 1.000 
                  EPIC_NSHDS_61 0.207* 1.000 
                 EPIC_NSHDS_172 0.141* 0.188* 1.000 
                EPIC_NSHDS_231 0.101 -0.009 0.137* 1.000 
               EPIC_NSHDS_286 -0.004 0.051 0.316* 0.254* 1.000 
              EPIC_NSHDS_375 0.093 0.037 0.045 0.091 -0.054 1.000 
             EPIC_NSHDS_482 0.072 0.076 0.150* 0.142* 0.036 0.208* 1.000 
            EPIC_NSHDS_513 0.088 0.003 0.095 0.172* -0.016 0.149* 0.426* 1.000 
           EPIC_NSHDS_514 0.009 -0.003 0.157* 0.172* 0.158* 0.091 0.335* 0.347* 1.000 
          EPIC_NSHDS_516 0.039 0.118* 0.155* -0.005 0.078 -0.010 0.137* 0.233* 0.324* 1.000 
         EPIC_NSHDS_523 0.160* 0.094 0.087 0.172* -0.203* 0.214* 0.437* 0.462* 0.170* 0.182* 1.000 
        EPIC_NSHDS_558 -0.062 -0.051 0.125* 0.157* 0.508* 0.024 0.059 -0.093 0.115* -0.040 -0.271* 1.000 
       EPIC_NSHDS_587 0.000 0.105* 0.092 0.167* 0.105* 0.228* 0.563* 0.269* 0.334* 0.030* 0.219* 0.361* 1.000 
      EPIC_NSHDS_781 -0.016 -0.010 0.077 0.350* 0.535* -0.077 -0.217* -0.143* 0.074 0.013 -0.354* 0.463* 0.067 1.000 
     EPIC_NSHDS_796 0.169* 0.134* 0.036 0.140* 0.059 0.047 0.320* 0.201* 0.119* 0.029 0.225* 0.011 0.216* 0.016 1.000 
    EPIC_NSHDS_803 0.215* 0.057 0.192* 0.135* -0.046 0.028 0.031 0.127* 0.032 0.031 0.203* -0.105* 0.086 0.063 0.238* 1.000 
   EPIC_NSHDS_861 -0.014 0.006 -0.080 0.067 -0.099 0.037 0.039 0.079 0.058 0.043 0.054 0.010 0.104* 0.011 0.017 0.028 1.000 
  EPIC_NSHDS_871 0.023 0.080 0.014 -0.015 -0.166* 0.105* 0.064 0.138* 0.017 0.023 0.131* -0.137* 0.048 -0.183* 0.076 -0.035 0.060 1.000 
 EPIC_NSHDS_888 0.045 0.012 -0.003 0.143* 0.393* -0.071 -0.107* -0.119* 0.075 0.093 -0.271* 0.404* 0.149* 0.527* 0.199* 0.079 -0.007 -0.047 1.000 
*Significant at the 95% confidence level                                                                                                                                                                                                                                                                                            
metabolite features pairs with a rho median>0.5 are highlighted in bold 
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Figure 6.3.2i: Significant features in NSHDS (discovery set, blue) and EPIC-Italy (validation set, 
red) plotted according to rt (x-axis) and m/z (y-axis) 
Where two features (one from EPIC-Italy and one from NSHDS) appear to have similar m/z and rt 
(highlighted by a dashed red box) the OR and p-value associated with each feature is shown in order 
to explore whether the metabolite features are related 
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Figure 6.3.2ii Score Plot of the PCA Model in the discovery cohort 
Coloured according to case-control status 
 
 
Figure 6.3.2iii: S-Plot of the OPLS-DA Model in the Discovery cohort 
 
The S-plot shows the covariance (p) versus the correlation p(corr) of the metabolite features for the 
discriminating component of the OPLS-DA model. In theory features in the bottom left and top right 
of the plot represent reliable discriminators between cases and controls 
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Table 6.3.2iv: Predictive ability of the subtype specific OPLS-DA models based on the discovery 
cohort 
The negative Q2 for every subtype suggests none of these models have any predictive ability 
Subtype N. 
N. excluded 
outliers R
2
 P1 O1 Q
2
 
Follicular lymphoma 36 2 0.299 0.065 0.234 -0.436 
BCLL 62 3 0.329 0.046 0.280 -1.180 
DLBCL 68 2 0.251 0.045 0.132 -1.040 
MM 108 5 0.259 0.063 0.196 -0.469 
R2-Goodness of model fit; measure of the variance explained                                                                                                                                      
P1-Proprtion of the explained variance due to disease risk                                                                                                                                              
O1 –Proportion of the explained variance not due to disease risk (orthogonal variation)                                                                                           
Q2 – goodness of prediction of the model  
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Table 6.3.3: Description of the metabolite feature models considered in the ROC analyses 
 
Model 
 
Description 
 
n 
features 
Percentage of 
variation 
explained by 
the first 
component 
 
Included features 
 
1 
 
Significant (p<0.05) 
features from the 
conditional logistic 
regression model1 in the 
discovery cohort 
 
13 
 
20.4% 
 
EPIC_NSHDS_61 EPIC_NSHDS_172 EPIC_NSHDS_286 
EPIC_NSHDS_375 EPIC_NSHDS_482 EPIC_NSHDS_513  
EPIC_NSHDS_516 EPIC_NSHDS_523 EPIC_NSHDS_587   
EPIC_NSHDS_781  EPIC_NSHDS_803   EPIC_NSHDS_861 
EPIC_NSHDS_888    
 
2 
 
Significant (p<0.05) 
features from conditional 
logistic regression 
model2 in the discovery 
cohort 
 
9 
 
 
24.5% 
 
EPIC_NSHDS_15 EPIC_NSHDS_61 EPIC_NSHDS_231 
EPIC_NSHDS_286 EPIC_NSHDS_375 EPIC_NSHDS_781  
EPIC_NSHDS_796 EPIC_NSHDS_803 EPIC_NSHDS_888   
 
3 
 
Significant (p<0.05) 
features from conditional 
logistic regression 
model3 in the discovery  
cohort 
 
9 
 
29.3% 
 
EPIC_NSHDS_61 EPIC_NSHDS_231 EPIC_NSHDS_286 
EPIC_NSHDS_375 EPIC_NSHDS_514 EPIC_NSHDS_558  
EPIC_NSHDS_781  EPIC_NSHDS_871 EPIC_NSHDS_888 
 
4 
 
Features with a VIP 
value>1 and jack-knifed 
confidence intervals that 
do not include one from 
the OPLS-DA model in 
the discovery cohort 
 
54 
 
59.4% 
 
EPIC_NSHDS_6 EPIC_NSHDS_61 EPIC_NSHDS_213 
EPIC_NSHDS_215 EPIC_NSHDS_244 EPIC_NSHDS_248 
EPIC_NSHDS_256 EPIC_NSHDS_266 EPIC_NSHDS_316 
EPIC_NSHDS_326 EPIC_NSHDS_347 EPIC_NSHDS_357 
EPIC_NSHDS_417 EPIC_NSHDS_421 EPIC_NSHDS_422 
EPIC_NSHDS_431 EPIC_NSHDS_445 EPIC_NSHDS_450 
EPIC_NSHDS_461 EPIC_NSHDS_463 EPIC_NSHDS_464 
EPIC_NSHDS_465 EPIC_NSHDS_466 EPIC_NSHDS_467 
EPIC_NSHDS_468 EPIC_NSHDS_470 EPIC_NSHDS_472 
EPIC_NSHDS_473 EPIC_NSHDS_475 EPIC_NSHDS_476 
EPIC_NSHDS_482 EPIC_NSHDS_483 EPIC_NSHDS_484 
EPIC_NSHDS_485 EPIC_NSHDS_486 EPIC_NSHDS_490 
EPIC_NSHDS_493 EPIC_NSHDS_499 EPIC_NSHDS_500 
EPIC_NSHDS_502 EPIC_NSHDS_505 EPIC_NSHDS_514 
EPIC_NSHDS_515 EPIC_NSHDS_516 EPIC_NSHDS_518 
EPIC_NSHDS_557 EPIC_NSHDS_560 EPIC_NSHDS_579 
EPIC_NSHDS_582 EPIC_NSHDS_583 EPIC_NSHDS_585 
EPIC_NSHDS_587 EPIC_NSHDS_589 EPIC_NSHDS_598 
 
5 
 
Features identified in 
models 1,2 or 3 AND in 
model 4 
 
5 
 
38.6% 
 
EPIC_NSHDS_61 EPIC_NSHDS_482 EPIC_NSHDS_514 
EPIC_NSHDS_516 EPIC_NSHDS_587 
 
6 
 
 Features identified in 
models 1,2 or 3 AND in 
model 4 when these 
models were run only in 
those participants who 
were diagnosed within 
five years of blood draw 
 
30 
 
36.1% 
 
EPIC_NSHDS_62 EPIC_NSHDS_87 EPIC_NSHDS_120 
EPIC_NSHDS_172 EPIC_NSHDS_202 EPIC_NSHDS_231 
EPIC_NSHDS_252 EPIC_NSHDS_256 EPIC_NSHDS_257 
EPIC_NSHDS_265 EPIC_NSHDS_266 EPIC_NSHDS_267 
EPIC_NSHDS_269 EPIC_NSHDS_270 EPIC_NSHDS_271 
EPIC_NSHDS_272 EPIC_NSHDS_273 EPIC_NSHDS_274 
EPIC_NSHDS_290 EPIC_NSHDS_325 EPIC_NSHDS_450 
EPIC_NSHDS_457 EPIC_NSHDS_482 EPIC_NSHDS_495 
EPIC_NSHDS_518 EPIC_NSHDS_521 EPIC_NSHDS_525 
EPIC_NSHDS_767 EPIC_NSHDS_803 EPIC_NSHDS_887 
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7. t(14;18) TRANSLOCATION: A PREDICTIVE 
BLOOD BIOMARKER FOR FOLLICULAR 
LYMPHOMA 
 
Table 7.3.3: Ability of varying thresholds of t(14;18) frequency to predict risk of FL among 
t(14;18)
+
 individuals in the validation cohort 
t(14;18) 
frequency 
threshold 
Sensitivity Specificity PPV NPV OR≠ (95% CI) 
5x10
-6
 69.57% 63.46% 62.75% 70.21% 4.43 (1.79, 10.94) 
1x10
-5
 60.87% 73.08% 66.67% 67.86% 5.93 (2.25, 15.60) 
5x10
-5
 
36.96% 98.08% 94.44% 63.75% 
41.82 (4.25, 
411.75) 
1x10
-4
 26.09% 100.00% 100.00% 60.47% ł 
5x10
-4
 17.39% 100.00% 100.00% 57.78% ł 
1x10
-3
 13.04% 100.00% 100.00% 56.52% ł 
Continuous 
variable         1.04 (1.01, 1.07) 
≠ OR adjusting for age at screening, sex, country and days between blood draw and frequency screening                                   
ł No controls were above this threshold so an odds ratio could not be computed 
 
Figure 7.3.3: The receiver-operating-characteristic (ROC) curves for t(14;18) frequency in the 
discovery cohort (t(14;18)
+
 samples) 
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8. INTEGRATING BIOMARKERS: THE “MEET-IN-
THE-MIDDLE”APPROACH 
 
Figure 8.3.3: Associations between ten environmental polluants and 750 metabolite features in 
the validation cohort (EPIC-Italy) according to significance level 
 
 
 
 
 
 
 
p-value 
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